



© Kirby Institute, UNSW Sydney

**ISSN 1448-5915**

This publication is available at: <http://www.kirby.unsw.edu.au>

Kirby Institute  
UNSW Sydney  
Sydney NSW 2052  
Australia

Telephone: **02 9385 0900** Facsimile: **02 6100 2860** International prefix: **612** Email: [info@kirby.unsw.edu.au](mailto:info@kirby.unsw.edu.au)

**AUSTRALIAN NSP SURVEY**  
Prevalence of HIV, HCV and injecting and  
sexual behaviour among NSP attendees

NATIONAL DATA REPORT  
2016 - 2020

**Report prepared by**

**Sue Heard, Jenny Iversen and Lisa Maher**

**Kirby Institute**

UNSW Sydney  
Sydney NSW 2052  
Australia

**July 2021**

Any presentation of these data should include acknowledgement of the Australian Needle Syringe Program Survey, Kirby Institute, UNSW Sydney.

Citation: Heard, S; Iversen, J & Maher, L. (2021). Australian Needle Syringe Program Survey National Data Report 2016-2020: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: Kirby Institute, UNSW Sydney.

The Australian Needle Syringe Program Survey is funded by the Australian Government Department of Health. Kirby Institute, Faculty of Medicine & Health, UNSW Sydney.

## **ACKNOWLEDGEMENTS**

We would like to acknowledge the many people who assist each year in the development and conduct of the Australian NSP Survey (ANSPS), particularly the clients, staff and managers at participating NSP services. We also appreciate the dedication and vision of the founding members of the project and the late Dr Margaret MacDonald who was responsible for the development and conduct of the ANSPS from 1995 until 2003.

Special thanks go to Mr Philip Cunningham, Senior Scientist and Operations Manager, Ms Beth Catlett, DBS Coordinator and Mr Mitchell Starr, Senior Hospital Scientist at the NSW State Reference Laboratory for HIV at St Vincent's Hospital and St Vincent's Centre for Applied Medical Research. We also appreciate the assistance provided by Ms Louise Geddes and Ms Rachel McCleave from the Kirby Institute.

In 2020, the project received support and input from the following members of the ANSPS National Advisory Group: Ms Jennifer Taleski (ACT); Ms Elisabeth Morgan (NSW); Mr David Decolongon (NT); Mr Stephen Lymb, Mr Bruce Surman and Mr Rob Gerrie (SA); Ms Myf Briggs (TAS); Mr Gary Morris and Ms Terrie Spall (VIC); Ms Jude Bevan (WA); Ms Melanie Walker (Australian Injecting and Illicit Drug Users League); and Ms Sue Heard, Dr Jenny Iversen and Professor Lisa Maher (Kirby Institute). We would particularly like to thank Mr Robert Kemp (QLD) for chairing the National Advisory Group.

Ethical approvals were obtained from institutional ethics committees associated with the investigators and participating NSP sites. The Australian Needle Syringe Program Survey is funded by the Australian Government Department of Health.

## ABBREVIATIONS

ACT	Australian Capital Territory
ANSPS	Australian Needle Syringe Program Survey
DAA	Direct acting antiviral
DBS	Dried blood spot
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
NSP	Needle syringe program
NSW	New South Wales
NT	Northern Territory
OAT	Opioid agonist therapy
PIEDs	Performance and image-enhancing drugs
PWID	People who inject drugs
PBS	Pharmaceutical Benefits Scheme
QLD	Queensland
RNA	Ribonucleic acid
SA	South Australia
TAS	Tasmania
VIC	Victoria
WA	Western Australia

## TABLE OF CONTENTS

### Summary

Key Findings.....	i
Introduction.....	1
COVID-19 .....	1
Demographic characteristics .....	2
Injection behaviour .....	3
Sexual behaviour.....	5
Drug treatment .....	6
HIV and HCV diagnostic testing .....	6
HIV antibody prevalence .....	6
HCV antibody prevalence.....	8
HCV RNA prevalence.....	9
HCV treatment.....	11
References .....	13

### Tables

1. National .....	14
2. Australian Capital Territory.....	42
3. New South Wales.....	62
4. Northern Territory .....	90
5. Queensland .....	110
6. South Australia.....	138
7. Tasmania.....	166
8. Victoria .....	186
9. Western Australia .....	214

### Appendix

A. Participating NSP services .....	242
B. Methodological notes .....	244
C. List of tables .....	246

## KEY FINDINGS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor blood borne viral infections and injecting and sexual behaviour among people who inject drugs.
- In 2020, 38 Needle Syringe Programs (NSPs) throughout Australia participated in the ANSPS and 1,324 NSP attendees completed the survey. The response rate was 35%.
- The number of participating NSPs, number of respondents and the response rate in 2020 were lower than in previous years due to public health responses to the COVID-19 pandemic. Further, Victorian NSP services were not in a position to implement the ANSPS in 2020 due to a range of restrictions designed to reduce community transmission of COVID-19 during the ANSPS data collection period.

## COVID-19

- As a sentinel surveillance system with the capacity to respond to emerging issues, the 2020 ANSPS included a module about COVID-19-related impacts.
- The majority (78%) of respondents reported that it was not more difficult to access needles and syringes during the pandemic, while one in two reported no change to their illicit drug use.
- Almost one in three respondents reported they had been tested for COVID-19, with the majority (96%) reporting a negative result. Among the remaining respondents, four reported a positive test result, six were unsure of the result, and five did not report their test result.

## Demographic characteristics

- Over the period 2016 to 2020, the median age of survey respondents was stable (range 42 to 43 years), with the proportion of young injectors (aged <25 years) also stable (range 3% to 5%).
- The median time since first injection was stable between 2016 and 2020 (range 21 to 22 years), and the proportion of new initiates (those injecting for less than three years) was also stable between 2016 and 2020 (range 5% to 6%).
- The proportion of respondents from an Indigenous Australian background increased, from 18% in 2016 to 22% in 2020.
- The proportion of respondents reporting incarceration in the 12 months prior to survey completion was stable over the five-year period 2016 to 2020 (range 12% to 13%).
- While the proportion of respondents reporting sex work in the month prior to the survey remained low and stable at 5% to 6% over the last five years, condom use at last paid sex declined from 68% in 2016 to 44% in 2020.

## Injection behaviour

- One in two respondents reported injecting daily or more frequently in all survey years between 2016 and 2020.
- The proportion of respondents reporting methamphetamine as the last drug injected increased from 43% in 2016 to 47% in 2020. Methamphetamine was the most commonly reported drug last injected nationally in all years 2016 to 2020.
- While the proportion of respondents reporting heroin as the last drug injected declined from 28% in 2016 to 22% in 2020, this decline was not evident when data from Victoria were excluded.
- Pharmaceutical opioids were the third most commonly reported class of drugs last injected in all years 2016 to 2020, and prevalence declined from 8% to 6% over this period.

- The proportion of respondents who reported last injecting performance and image enhancing drugs (PIEDs) was low and stable between 2016 to 2020 (range 4% to 6%).
- There was a decline in the proportion of respondents reporting receptive sharing of needles and syringes in the last month, from 19% in 2016 to 16% in 2020. The proportion reporting recent (last month) reuse of needles and syringes (including reuse of one's own syringes) also declined, from 27% in 2016 to 23% in 2020, while prevalence of recent receptive sharing of drug preparation equipment remained stable at between 25% and 30% over the same period.
- The prevalence of self-reported drug overdose in the past 12 months declined, from 18% in 2016 to 13% in 2020.

### **Drug treatment**

- Engagement with drug treatment services remained high, with two thirds (65%) of respondents reporting a lifetime history of drug treatment in 2020.
- Although there was a decline in the overall proportion of respondents who reported current engagement in opioid agonist therapy (OAT) between 2016 and 2020, engagement in OAT remained stable among respondents who reported last injecting an opioid (range 44% to 53%).

### **HIV antibody prevalence**

- Although HIV antibody prevalence remained low nationally over the five-year period (2016 to 2020), HIV prevalence increased from 1.4% in 2016 to 2.5% in 2020.
- In all years 2016 to 2020 HIV antibody prevalence was higher among homosexual men compared to bisexual or heterosexual men and compared to women.

### **HCV antibody prevalence**

- Hepatitis C virus (HCV) antibody prevalence declined nationally from 51% in 2016 to 39% in 2020. This is the fourth consecutive year that less than half of respondents had been exposed to HCV, following two decades of HCV antibody prevalence  $\geq 50\%$  (all years 1999 to 2016).
- Across all survey years 2016 to 2020, prevalence of HCV antibody was higher among older than among younger respondents and among those with longer injection histories.

### **HCV RNA prevalence**

- Among respondents who were tested for HCV RNA and after applying weightings, the proportion with detectable HCV RNA (active infection) declined from 33% in 2016 to 16% in 2020. HCV RNA prevalence declined among both males (37% in 2016 to 17% in 2020) and females (26% in 2016 to 15% in 2020).

### **HCV treatment uptake**

- Among respondents assessed as eligible for HCV treatment, the proportion who reported a lifetime history of HCV treatment increased, from 29% in 2016 to 62% in 2020.
- Similarly, among respondents assessed as eligible, the proportion who reported recent (last 12 months) HCV treatment increased from 22% in 2016 to 32% in 2020.
- Notwithstanding this overall increase, there was a decline in the proportion of respondents who reported recent HCV treatment in 2020 (32%) compared to 2019 (44%). There was also a decline in the proportion of respondents who reported a recent HCV diagnostic test in 2020 (48%) compared to 2019 (54%).



## INTRODUCTION

The Australian Needle Syringe Program Survey (ANSPS) provides serial point prevalence estimates of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) antibody prevalence, HCV ribonucleic acid (RNA) prevalence and sexual and injecting risk behaviour among people who inject drugs (PWID) in Australia. Conducted annually over a one-two week period in October, all clients attending participating Needle Syringe Program (NSP) services are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV testing (see methodological notes [Appendix B] for further details on the ANSPS design and implementation). Commencing in 2015, HCV RNA testing has also been conducted among respondents with sufficient dried blood spot (DBS) samples. This report presents national and state/territory findings for the period 2016 to 2020.

## COVID-19

In Australia, a range of public health measures have been implemented since COVID-19 was declared a global pandemic by the World Health Organisation in March 2020. All Australian states and territories have experienced COVID-19-related travel restrictions, while most have restricted public and private gatherings, and some have introduced full or partial lockdowns during the pandemic. In order to provide flexibility and to accommodate jurisdictional differences in the pandemic response, the 2020 ANSPS was implemented in several phases rather than the usual mid-October time frame nationally. Four jurisdictions with little or no community transmission (WA, ACT, TAS, QLD) implemented the survey early (in September), while two jurisdictions (NSW and NT) implemented the ANSPS in the usual October timeframe. One jurisdiction (SA) implemented the ANSPS later than usual (in December), however SA experienced a snap lockdown the week before survey was due to be implemented and the ANSPS was completed off site (surveys taken away for completion) rather than on site. These factors resulted in a significantly reduced number of ANSPS respondents in this jurisdiction. Between June and November 2020 Victoria experienced outbreaks of community transmission of COVID-19 that necessitated the implementation of public health measures to reduce transmission and no Victorian NSP services were in a position to participate in the 2020 ANSPS.

Due to the impacts of the COVID-19 pandemic, a reduced number of NSP services participated in the 2020 ANSPS compared to previous years (38 sites in 2020 compared to 54 sites in 2019). Further, the number of ANSPS respondents halved from ~2,600 in 2019 to 1,324 in 2020 due to the limited participation of SA and the non-participation of Victoria. The response rate was also lower at 35% in 2020, compared to >40% between 2016 and 2019 (Table 1.1.1). Of the 1,324 ANSPS respondents in 2020, the majority (90%) were recruited from NSP services (n=31) that participated in the ANSPS in each of the past five years (2016 to 2020). Appendix A provides details of participating NSP services over the period 2016 to 2020.

As a sentinel surveillance system with the capacity to respond to emerging issues, the 2020 ANSPS included a module about the impacts of COVID-19. Among the overall 1,324 ANSPS respondents in 2020, 1,224 (92%) completed the ANSPS COVID-19 module that comprised a set of eight questions. The following discussion and data analysis excludes the 100 ANSPS respondents who declined to complete the COVID-19 module.

As a testament to NSP services' commitment to ensure service delivery during the COVID-19 pandemic, the majority of ANSPS respondents (n=960, 78%) reported that it was not more difficult to access needles and syringes during the pandemic. However, around one in ten respondents (n=144, 12%) reported that it was more difficult to access needles and syringes since the pandemic commenced, and 9% (n=113) reported they had not attempted to access needles and syringes since March 2020.

A total of fifty respondents (4%) reported they had commenced depot buprenorphine (Buvidal® or Sublocade®) since March 2020, while 116 respondents (10%) reported they had commenced takeaway doses of their OAT and 145 respondents (11%) reported they had injected their own OAT since the pandemic commenced. Among respondents who reported OAT prescription at the time of ANSPS participation (n=334), 8% had commenced depot buprenorphine, 30% had commenced takeaway doses of their OAT and 28% reported they had injected their own OAT since March 2020.

Since the pandemic commenced a total of 202 respondents (17%) reported accessing take-home Naloxone (an opioid agonist used to reverse the effects of opioid overdose). Among respondents who reported last injecting an opioid, one in four (n=129, 27%) reported accessing take-home Naloxone since March 2020.

Just over half of respondents (n=643, 54%) reported no change in their illicit drug use since the pandemic commenced, while one in ten (n=125, 11%) reported that their illicit drug use had increased and one in three (n=416, 35%) reported their illicit drug use had decreased.

Almost one in three ANSPS respondents (n=337, 28%) reported that they had a COVID-19 test in 2020. Of these, four respondents (1%) reported a positive COVID-19 test. The majority of respondents tested for COVID-19 reported a negative result (n=322, 96%), while six respondents (2%) were unsure of their result and five respondents (1%) did not report their test result.

## Demographic characteristics

Approximately two thirds of survey respondents were male across all years 2016 to 2020. In 2020, the majority (79%) of respondents identified as heterosexual, while 10% identified as bisexual and 4% as homosexual (Table 1.1.1). Women were significantly more likely to identify as bisexual than men in each of the past five years (18% vs 5% respectively in 2020,  $p < 0.001$ ).

Over the period 2016 to 2020 the proportion of respondents from an Indigenous Australian background increased significantly, from 18% to 22% ( $\chi^2$  trend  $p < 0.001$ )<sup>1,2</sup>. In all years 2016 to 2020, the majority of respondents were born in Australia (range 86% to 88%), with the United Kingdom/Ireland (4%) and New Zealand (3%) the predominant countries of birth outside Australia in 2020. Most respondents also reported that their parents spoke English at home (range 92% to 95%) over the period 2016 to 2020.

Over the period 2016 to 2020, the median age at survey completion ranged from 42 to 43 years and the proportion of respondents aged <25 years (3% in 2020) was also stable ( $\chi^2$  trend  $p = 0.167$ , Table 1.1.1). The median time since first injection ranged from 21 to 22 years and the proportion of new initiates (those injecting for less than 3 years) was stable, ranging from 5% in 2016 to 6%


in 2020 ( $\chi^2$  trend  $p=0.200$ ). The median age at first drug injection was stable across the period 2016 to 2020, ranging from 18 to 19 years of age. Among new initiates to injection drug use, the median age at first drug injection increased from 28 years in 2016 to 30 years in 2020.

The proportion of respondents reporting incarceration in the 12 months prior to survey completion remained stable, ranging from 12% to 13% over the five-year period 2016 to 2020 ( $\chi^2$  trend  $p=0.472$ ). Among respondents with a history of recent incarceration, approximately one in three reported injecting while in prison and this proportion was stable over the period 2016 to 2020 ( $\chi^2$  trend  $p=0.647$ , Table 1.1.1).

### Injection behaviour

Methamphetamine was the most commonly reported drug last injected nationally in all years 2016 to 2020 (Table 1.1.2). Reports of methamphetamine injection increased significantly over the five-year period, from 43% in 2016 to 47% in 2020 ( $\chi^2$  trend  $p<0.001$ , Figure 1). The significant increase in reports of methamphetamine injection over the five-year period (2016 to 2020) was also observed when data from Victoria were excluded ( $\chi^2$  trend  $p=0.002$ ).

**Figure 1. Proportion of respondents (%) reporting last injecting heroin, methamphetamine, and all other drugs, 2016–2020**



Heroin was the second most commonly reported drug last injected nationally in 2020, with a significant decline in prevalence observed between 2016 (28%) and 2020 (22%,  $\chi^2$  trend  $p<0.001$ ). However, this decline was not significant when data from Victoria (where opioids are the predominant drug last injected) were excluded ( $\chi^2$  trend  $p=0.576$ ).

The third most commonly reported class of drugs last injected nationally was pharmaceutical opioids<sup>3,4</sup> (8%, including morphine, oxycodone and fentanyl), with a significant decline observed over the period 2016 to 2020 ( $\chi^2$  trend  $p=0.041$ , Figure 2). The significant decline in pharmaceutical


opioids as the last drug injected was also observed over the five-year period 2016 to 2020, when data from Victoria were excluded ( $\chi^2$  trend  $p=0.004$ ).

Methadone was reported as the last drug injected by less than ten percent of ANSPS respondents in all years 2016 to 2020 (range 6% to 4%) with prevalence stable over this period ( $\chi^2$  trend  $p=0.804$ ). Buprenorphine and buprenorphine-naloxone injection were reported by a minority of survey respondents. The prevalence of both buprenorphine-naloxone injection (2% to 1%,  $\chi^2$  trend  $p=0.089$ ), and buprenorphine injection (2% to 3%,  $\chi^2$  trend  $p=0.839$ ) was stable over the period 2016 to 2020.

A minority of survey respondents (1% across all survey years) reported cocaine as the last drug injected. The prevalence of performance and image enhancing drugs (PIEDs) as the last drug injected was stable over the period 2016 to 2020 ( $\chi^2$  trend  $p=0.098$ , Figure 2).

In all years 2016 to 2020, methamphetamine was the most commonly reported last drug injected among new initiates (less than 3 years since first injection), with a stable prevalence observed between 2016 and 2020 (range 48% to 63%,  $\chi^2$  trend  $p=0.402$ ).


**Figure 2. Proportion of respondents (%) reporting last injecting pharmaceutical opioids, methadone, and performance and image enhancing drugs, 2016–2020**



Daily or more frequent injection was reported by approximately half of respondents in each of the past five years (Table 1.1.2). Prevalence of at least one public injection (injection in a car, beach, park, street or squat) in the month prior to survey completion was stable between 2016 to 2020 (range 42% to 47%,  $\chi^2$  trend  $p=0.782$ , Table 1.1.3). In 2020, almost one in eight respondents reported they had experienced a drug overdose in the previous 12 months ( $n=171$ , 13%, Table 1.1.2), and reports of overdose declined significantly over the period 2016 (18%) to 2020 (13%) ( $\chi^2$  trend  $p=0.001$ ), including when data from Victoria were excluded ( $\chi^2$  trend  $p=0.005$ ).

As shown in Figure 3, there was a significant decline in two of the three key injecting risk behaviours over the five-year period 2016 to 2020. The proportion of respondents who reported reuse of needles and syringes (including one's own) in the month preceding the survey declined, from 27% in 2016 to 23% in 2020 ( $\chi^2$  trend  $p=0.010$ ). There was also a significant decline in the reports of receptive sharing of needles and syringes in the month prior to survey completion, from 19% in 2016 to 16% in 2020 ( $\chi^2$  trend  $p=0.023$ ). Receptive sharing of ancillary equipment remained stable over the period 2016 to 2020 (range 25% to 30%,  $\chi^2$  trend  $p=0.381$ ). As in previous years, spoons and water were the most commonly identified receptively shared ancillary items in 2020 (Table 1.1.3).

**Figure 3. Proportion of respondents (%) reporting reuse and receptive sharing of needles and syringes and receptive sharing of ancillary equipment in the last month, 2016–2020**



**Sexual behaviour**

In all years 2016 to 2020 approximately half of respondents reported sex with a regular partner in the month prior to survey completion (range 43% to 47%, Table 1.1.6). Of these, the majority (72% to 77%) reported that they did not use condoms with their regular sex partner. A smaller proportion of respondents (13% to 15%) reported sex with other partners in the month preceding survey participation. Condom use was higher among this group, with 22% reporting always using condoms and 28% reporting some condom use with non-regular partners in 2020. While the proportion of respondents reporting sex work in the month prior to the survey remained low and stable at 5% to 6% over the last five years ( $\chi^2$  trend  $p=0.391$ ), condom use at last paid sex declined from 68% in 2016 to 44% in 2020 ( $\chi^2$  trend  $p<0.001$ , Table 1.1.6). Of the respondents who reported sex work in the previous month in 2020 ( $n=61$ ), 52% were women, 44% were men, and 3% identified their sex as other.

## Drug treatment

Engagement with drug treatment services was high (Table 1.1.4), with two thirds (65%) of respondents reporting a lifetime history of drug treatment in 2020. Nonetheless, there was a significant decline in the overall proportion of respondents reporting current OAT from 33% in 2016 to 26% in 2020 ( $\chi^2$  trend  $p < 0.001$ ). This decline was also observed when data from Victoria were excluded ( $\chi^2$  trend  $p = 0.012$ ). This may reflect the significant increase in the proportion of respondents reporting methamphetamine as the last drug injected, with OAT not indicated for methamphetamine dependence. Further, among respondents who reported last injecting opioids, current OAT was stable over the period 2016 to 2020 (range 44% to 53%,  $\chi^2$  trend  $p = 0.965$ ). In 2020, current methadone treatment was reported by 18% of respondents, with current buprenorphine treatment reported by 8% of respondents and buprenorphine-naloxone treatment by 5% of respondents.

## HIV and HCV diagnostic testing

Prevalence of HIV diagnostic screening among ANSPS respondents over the period 2016 to 2020 was high, with 79% to 83% reporting a lifetime history of HIV diagnostic testing (Table 1.1.5). In 2020, 45% of respondents reported an HIV diagnostic test in the previous 12 months. Among the  $n = 32$  respondents who tested HIV antibody positive, the majority (88%,  $n = 28$ ) were aware of their HIV positive status. A minority (6%,  $n = 2$ ) of respondents who tested HIV positive reported that they were HIV negative, and 6% ( $n = 2$ ) did not report their HIV status.

Respondents also reported high prevalence of lifetime HCV diagnostic screening over the period 2016 to 2020 (range 80% to 83%). In 2020, almost half (48%) of respondents reported an HCV diagnostic test in the previous 12 months, however a significant decline in recent (last 12 months) HCV diagnostic testing was observed over the period 2016 to 2020 ( $\chi^2$  trend  $p = 0.002$ ).


## HIV antibody prevalence

HIV antibody prevalence remained low nationally over the period 2016 to 2020 (range 1.4% to 2.5%), however a significant increase was observed over this 5-year period ( $\chi^2$  trend  $p = 0.029$ , Table 1.2.1). The increase in HIV antibody prevalence was also observed when data from Victoria were excluded ( $\chi^2$  trend  $p = 0.030$ ).


HIV prevalence was low and stable in all jurisdictions (Figure 4). No respondents in the Australian Capital Territory, and no women in South Australia or Tasmania tested positive to HIV antibodies in any of the previous five years, 2016 to 2020.

Nationally, HIV antibody prevalence was consistently higher among homosexual male respondents than among bisexual and heterosexual male or female respondents in all years, (Table 1.2.2 and Figure 5)<sup>5</sup>. HIV prevalence was also higher among men who reported methamphetamine as the last drug injected (5.4% in 2020) compared to men who reported last injecting all other drugs (1.2% in 2020, Table 1.2.4). In 2020, HIV prevalence was significantly higher among men who reported sex work in the month preceding the survey compared to men who did not report recent sex work (15.4% vs 2.9% respectively,  $p = 0.008$ , Table 1.2.10).

**Figure 4. HIV antibody prevalence (%) by jurisdiction, 2016–2020**



**Figure 5. HIV antibody prevalence (%) by gender and sexual identity, 2016–2020**



In all years 2016 to 2019, respondents from an Aboriginal and/or Torres Strait Islander background were significantly more likely to test HIV antibody positive than non-Indigenous respondents ( $p < 0.05$ ). However, no significant difference in HIV prevalence was observed between Indigenous and non-Indigenous respondents in 2020. In addition, prevalence of HIV infection among Aboriginal and Torres Strait Islander respondents remained stable between 2016 and 2020 (range 2.8% to 3.6%,  $\chi^2$  trend  $p = 0.886$ ). Of the eight Indigenous respondents who tested HIV antibody positive in 2020, half ( $n = 4$ ) identified as heterosexual.


In 2020, the median age of respondents living with HIV was 50 years (range 24 to 64 years) and the median time since first injection was 16.5 years (range 2 to 46 years). In 2020, and comparable to previous years, 75% of respondents living with HIV reported they were on antiretroviral treatment.

### HCV antibody prevalence

HCV antibody prevalence declined significantly nationally, from 51% in 2016 to 39% in 2020 ( $\chi^2$  trend  $p < 0.001$ , Table 1.3.1), with a similar significant decline observed when data from Victoria were excluded ( $\chi^2$  trend  $p < 0.001$ ). Over the five-year period 2016 to 2020, HCV antibody prevalence declined among both men (from 52% in 2016 to 39% in 2020,  $\chi^2$  trend  $p < 0.001$ ) and women (from 47% in 2016 to 40% in 2020,  $\chi^2$  trend  $p = 0.006$ ).

At the jurisdictional level (Figure 6), declines in HCV antibody prevalence were observed in most jurisdictions. Across all five years of the survey, HCV antibody prevalence was significantly higher among older respondents and those with longer injection histories (Table 1.3.3 and 1.3.4). Figure 7 illustrates the relationship between exposure to HCV and time since first injection among respondents in 2020.


**Figure 6. HCV antibody prevalence (%) by jurisdiction, 2016–2020**




In all survey years, prevalence of HCV was also higher among respondents reporting heroin or other opioids as the last drug injected compared to respondents who last injected methamphetamine (Figure 8). HCV antibody prevalence was also consistently higher among respondents who reported imprisonment in the year preceding survey completion compared to those who did not ( $p < 0.010$  in all years 2016 to 2020) and among respondents who reported an Indigenous background ( $p \leq 0.001$  in all years 2017 to 2020).



**Figure 7. HCV antibody prevalence (%) by time since first injection, 2020**



**Figure 8. HCV antibody prevalence (%) by drug last injected and gender, 2016–2020**




**HCV RNA prevalence**


HCV direct acting antiviral (DAA) therapies have been available through the Australian Government’s Pharmaceutical Benefits Scheme (PBS) since March 2016. To determine HCV viraemic prevalence the ANSPS commenced HCV RNA testing in 2015. While 89% of the sample had sufficient DBS for HCV RNA in 2020, less than half of respondents were tested for HCV RNA in 2016. To adjust for potential sample bias in the RNA tested sub-sample, weightings were applied to HCV RNA data for all years (2016 to 2020) to adjust for gender (given higher rates of spontaneous clearance among women) and HCV antibody status. Results with small sample sizes, particularly at the jurisdictional level, should therefore be interpreted with caution.

As previously stated, HCV antibody prevalence declined significantly (from 51% in 2016 to 39% in 2020,  $\chi^2$  trend  $p < 0.001$ ) and lifetime HCV treatment increased significantly (from 29% in 2016 to 62% in 2020,  $\chi^2$  trend  $p < 0.001$ ). Among respondents who were tested for HCV RNA and after applying weightings, the proportion with detectable HCV RNA (active infection) also declined significantly, from 33% in 2016 to 16% in 2020 ( $\chi^2$  trend  $p < 0.001$ ). As shown in Figure 9, HCV RNA prevalence declined significantly among both males (37% in 2016 to 17% in 2020,  $\chi^2$  trend  $p < 0.001$ ) and females (26% in 2016 to 15% in 2020,  $\chi^2$  trend  $p < 0.001$ ).

**Figure 9. Proportion of respondents (%) with detectable HCV RNA\* by gender and survey year**




**Figure 10. HCV viraemic status (%) by survey year**



Results of HCV antibody and RNA testing can be combined to provide an estimate of viraemic prevalence among respondents<sup>6</sup>. As shown in Figure 10, the proportion of respondents with no evidence of exposure to HCV (HCV antibody negative) increased from 49% in 2016 to 61% in 2020 and the proportion with cleared infection (HCV antibody positive and HCV RNA negative) increased from 18% in 2016 to 23% in 2020, resulting in a 52% decline in the proportion of respondents with active HCV infection over the five-year period, 2016 to 2020.


**Figure 11. HCV viraemic status (%) nationally and by jurisdiction in 2020**



### HCV treatment


Among respondents who tested HCV antibody positive and after excluding those who reported spontaneous HCV clearance, the proportion who reported a lifetime history of HCV treatment increased significantly, from 29% in 2016 to 62% in 2020 ( $\chi^2$  trend  $p < 0.001$ , Figure 12). Similarly, among respondents who tested HCV antibody positive and after excluding those who reported spontaneous or treatment-induced clearance more than 12 months previously, the proportion who reported recent (last 12 months) HCV treatment increased significantly, from 22% in 2016 to 32% in 2020, ( $\chi^2$  trend  $p < 0.001$ , Figure 12). These trends were observed among both men and women. However, the increasing trend in lifetime HCV treatment uptake that occurred between 2016 and 2019<sup>6</sup> was not maintained between 2019 (64%) and 2020 (62%,  $p = 0.628$ ) and there was a significant decline in the proportion of people who reported recent HCV treatment between 2019 (44%) and 2020 (32%,  $p = 0.002$ ). The decline in recent HCV treatment uptake between 2019 and 2020 was observed among men (47% vs 31% respectively,  $p = 0.002$ ) but not among women (39% vs 32% respectively,  $p = 0.345$ ).

**Figure 12. Proportion of respondents (%) reporting lifetime and recent\* HCV treatment among HCV antibody positive respondents who did not report spontaneous clearance by survey year**



\* The denominator for recent HCV treatment excludes those who reported prior HCV treatment induced clearance.

**Figure 13. Lifetime history of HCV treatment (%) nationally and by jurisdiction, 2016-2020**



## References

1. Doyle M, Maher L, Graham S, Wand H, Iversen J. Hepatitis C virus prevalence and associated risk factors among Indigenous Australians who inject drugs. *Aust N Z J Public Health* 2018;42(1):52-6.
2. Graham S, Maher L, Wand H, Doyle M, Iversen J. Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015. *Int J Drug Policy* 2017;47:69-76.
3. Iversen J, Dertadian G, Geddes L, Maher L. High risk injecting behaviour among people who inject pharmaceutical opioids in Australia. *Int J Drug Policy* 2017;42:1-6.
4. Geddes L, Iversen J, Memedovic S, Maher L. Intravenous fentanyl use among people who inject drugs in Australia. *Drug Alcohol Rev* 2018;37 Suppl 1:S314-S22.
5. Iversen J, Wand H, Topp L, Kaldor J, Maher L. Extremely low and sustained HIV incidence among people who inject drugs in a setting of harm reduction. *AIDS* 2014;28(2):275-8.
6. Iversen J, Dore G, Catlett B, Cunningham P, Grebely J, Maher L. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. *Journal of Hepatology* 2019;70(1):33-39.

## National

Table 1.1.1 Number (percentage) of respondents by demographic characteristics and survey year

National	2016	2017	2018	2019	2020*
<b>Number of sites</b>	50	52	53	54	38
<b>N° surveyed</b>	N=2210	N=2600	N=2742	N=2609	N=1324
<b>Response rate (%)</b>	41%	41%	45%	45%	35%
<b>Gender (%)</b>					
Male	1449 (66)	1721 (66)	1828 (67)	1722 (66)	902 (68)
Female	740 (33)	848 (33)	899 (33)	861 (33)	413 (31)
Other	15 (1)	24 (1)	13 (<1)	18 (1)	8 (1)
Not reported	6 (<1)	7 (<1)	2 (<1)	8 (<1)	1 (<1)
<b>Sexual identity (%)</b>					
Heterosexual	1727 (78)	2019 (78)	2133 (78)	1969 (75)	1045 (79)
Bisexual	220 (10)	233 (9)	259 (9)	262 (10)	128 (10)
Gay/Lesbian	93 (4)	132 (5)	122 (4)	119 (5)	50 (4)
Other	-- --	-- --	-- --	-- --	35 (3)
Not reported	170 (8)	216 (8)	228 (8)	259 (10)	66 (5)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	1738 (79)	2081 (80)	2135 (78)	1994 (76)	982 (74)
Yes	395 (18)	460 (18)	533 (19)	568 (22)	290 (22)
Not reported	77 (3)	59 (2)	74 (3)	47 (2)	52 (4)
<b>Region/country of birth (%)</b>					
Australia	1904 (86)	2257 (87)	2347 (86)	2302 (88)	1142 (86)
Other Oceania	74 (3)	81 (3)	83 (3)	67 (3)	42 (3)
Asia	25 (1)	31 (1)	31 (1)	26 (1)	18 (1)
UK & Ireland	81 (4)	111 (4)	122 (4)	87 (3)	52 (4)
Other	76 (3)	86 (3)	120 (4)	102 (4)	49 (4)
Not reported	50 (2)	34 (1)	39 (1)	25 (1)	21 (2)
<b>Main language spoken at home by parents (%)</b>					
English	2036 (92)	2455 (94)	2538 (93)	2465 (94)	1253 (95)
Non-English	133 (6)	130 (5)	168 (6)	128 (5)	59 (4)
Not reported	41 (2)	15 (1)	36 (1)	16 (1)	12 (1)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	42	42	42	42	43
<i>Age range</i>	17-76	16-76	14-78	15-73	18-74
<i>Age group (%)</i>					
<25 years	86 (4)	122 (5)	116 (4)	95 (4)	44 (3)
25+ years	2119 (96)	2466 (95)	2617 (95)	2502 (96)	1279 (97)
Not reported	5 (<1)	12 (<1)	9 (<1)	12 (<1)	1 (<1)
<i>Median age first injection</i>					
	18	19	19	19	19
<i>Age range</i>	10-76	10-76	10-64	10-67	10-60
N° not reported	83	127	128	135	33
<i>Median yrs since first injection</i>					
	21	21	22	22	22
<i>Range</i>	<1-53	<1-59	<1-53	<1-59	<1-53
<i>Years since first injection</i>					
<3 years	110 (5)	149 (6)	137 (5)	149 (6)	82 (6)
3+ years	2016 (91)	2324 (89)	2475 (90)	2321 (89)	1208 (91)
Not reported	84 (4)	127 (5)	130 (5)	139 (5)	34 (3)
<b>Imprisonment last year (%)</b>					
No	1821 (82)	2105 (81)	2208 (81)	2106 (81)	1095 (83)
Yes	269 (12)	316 (12)	346 (13)	350 (13)	158 (12)
Not reported	120 (5)	179 (7)	188 (7)	153 (6)	71 (5)
<b>N° in prison</b>					
	N=269	N=316	N=346	N=350	N=158
Injected in prison	89 (33)	100 (32)	116 (34)	111 (32)	48 (30)

\* Implementation of the 2020 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

**Table 1.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

<b>National</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° surveyed</b>	<b>N=2210</b>	<b>N=2600</b>	<b>N=2742</b>	<b>N=2609</b>	<b>N=1324</b>
<b>Drug last injected (%)</b>					
Cocaine	17 (1)	27 (1)	28 (1)	20 (1)	7 (1)
Methamphetamine	953 (43)	1070 (41)	1314 (48)	1269 (49)	619 (47)
Heroin	608 (28)	778 (30)	714 (26)	707 (27)	286 (22)
Pharm. opioids	176 (8)	227 (9)	204 (7)	153 (6)	109 (8)
Methadone	121 (5)	130 (5)	112 (4)	124 (5)	77 (6)
Buprenorphine	52 (2)	51 (2)	63 (2)	43 (2)	39 (3)
Buprenorphine/naloxone	38 (2)	30 (1)	39 (1)	23 (1)	17 (1)
PIEDs	86 (4)	117 (5)	100 (4)	93 (4)	84 (6)
More than one	129 (6)	120 (5)	137 (5)	119 (5)	64 (5)
Other	30 (1)	25 (1)	18 (1)	37 (1)	5 (<1)
Not reported	0 (0)	25 (1)	13 (<1)	21 (1)	17 (1)
<b>Ever injected opioids</b>					
No	445 (20)	573 (22)	627 (23)	603 (23)	377 (28)
Yes	1757 (80)	2013 (77)	2078 (76)	1989 (76)	946 (71)
Not reported	8 (<1)	14 (1)	37 (1)	17 (1)	1 (<1)
<b>Frequency of injection last month (%)</b>					
Not last month	170 (8)	249 (10)	228 (8)	235 (9)	138 (10)
Less than weekly	338 (15)	387 (15)	387 (14)	371 (14)	228 (17)
Weekly not daily	545 (25)	593 (23)	669 (24)	586 (22)	300 (23)
Daily or more	1110 (50)	1334 (51)	1396 (51)	1376 (53)	645 (49)
Not reported	47 (2)	37 (1)	62 (2)	41 (2)	13 (1)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
No	1771 (80)	2048 (79)	2157 (79)	2056 (79)	1088 (82)
Yes	382 (17)	452 (17)	475 (17)	448 (17)	206 (16)
Not reported	57 (3)	100 (4)	110 (4)	105 (4)	30 (2)
<b>Overdosed in last 12 months</b>					
No	1739 (79)	2029 (78)	2106 (77)	2060 (79)	1120 (85)
Yes	403 (18)	463 (18)	520 (19)	438 (17)	171 (13)
Not reported	68 (3)	108 (4)	116 (4)	111 (4)	33 (2)

**Table 1.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>National</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° injected last month</b>	<b>N=1993</b>	<b>N=2314</b>	<b>N=2452</b>	<b>N=2333</b>	<b>N=1173</b>
<b>Places injected last month (%)</b>					
All private	1067 (54)	1275 (55)	1307 (53)	1214 (52)	673 (57)
Any public	915 (46)	1022 (44)	1129 (46)	1105 (47)	496 (42)
Not reported	11 (1)	17 (1)	16 (1)	14 (1)	4 (<1)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	1424 (71)	1734 (75)	1795 (73)	1746 (75)	891 (76)
Most of the time	442 (22)	457 (20)	502 (20)	449 (19)	220 (19)
Half of the time	49 (2)	46 (2)	60 (2)	53 (2)	23 (2)
Some of the time	33 (2)	30 (1)	44 (2)	39 (2)	19 (2)
Not last month	19 (1)	12 (1)	20 (1)	13 (1)	4 (<1)
Not reported	26 (1)	35 (2)	31 (1)	33 (1)	16 (1)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	1597 (80)	1890 (82)	1977 (81)	1924 (82)	980 (84)
Once	114 (6)	126 (5)	164 (7)	126 (5)	66 (6)
Twice	111 (6)	115 (5)	92 (4)	113 (5)	40 (3)
3-5 times	78 (4)	87 (4)	104 (4)	82 (4)	51 (4)
>5 times	73 (4)	61 (3)	89 (4)	57 (2)	28 (2)
Not reported	20 (1)	35 (2)	26 (1)	31 (1)	8 (1)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	1597 (80)	1890 (82)	1977 (81)	1924 (82)	980 (84)
One	152 (8)	158 (7)	194 (8)	168 (7)	73 (6)
Two	37 (2)	39 (2)	36 (1)	38 (2)	20 (2)
Three to five	31 (2)	24 (1)	34 (1)	27 (1)	14 (1)
More than five	22 (1)	17 (1)	31 (1)	17 (1)	10 (1)
Don't know	76 (4)	101 (4)	85 (3)	79 (3)	46 (4)
Not reported	78 (4)	85 (4)	95 (4)	80 (3)	30 (3)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	155 (8)	131 (6)	172 (7)	147 (6)	73 (6)
Casual sex partner	16 (1)	21 (1)	21 (1)	18 (1)	14 (1)
Close friend	98 (5)	115 (5)	131 (5)	82 (4)	48 (4)
Acquaintance	52 (3)	54 (2)	55 (2)	58 (2)	30 (3)
Other	20 (1)	40 (2)	38 (2)	47 (2)	19 (2)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	428 (21)	506 (22)	513 (21)	482 (21)	182 (16)
Water	379 (19)	435 (19)	484 (20)	451 (19)	191 (16)
Filter	195 (10)	251 (11)	243 (10)	221 (9)	71 (6)
Drug mix	191 (10)	210 (9)	251 (10)	234 (10)	89 (8)
None	1354 (68)	1541 (67)	1644 (67)	1555 (67)	836 (71)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	1638 (82)	1905 (82)	1980 (81)	1939 (83)	1005 (86)
Yes	329 (17)	377 (16)	431 (18)	369 (16)	159 (14)
Not reported	26 (1)	32 (1)	41 (2)	25 (1)	9 (1)
<b>Source of needle acquisition</b>					
Needle Syringe Program	1757 (88)	2019 (87)	2140 (87)	2032 (87)	1001 (85)
Chemist/Pharmacy	495 (25)	539 (23)	588 (24)	572 (25)	319 (27)
Personal sources	268 (13)	272 (12)	306 (12)	325 (14)	130 (11)
Dispensing/Vending Machine	324 (16)	351 (15)	400 (16)	441 (19)	172 (15)
Other sources	49 (2)	71 (3)	100 (4)	69 (3)	37 (3)



**Table 1.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

National	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=2210	N=2600	N=2742	N=2609	N=1324
<b>Ever any treatment/therapy for drug use (%)</b>					
No	608 (28)	745 (29)	810 (30)	809 (31)	460 (35)
Yes	1566 (71)	1837 (71)	1901 (69)	1789 (69)	862 (65)
Not reported	36 (2)	18 (1)	31 (1)	11 (<1)	2 (<1)
<b>History of methadone maintenance treatment (%)</b>					
Currently	538 (24)	617 (24)	583 (21)	634 (24)	235 (18)
Previously	522 (24)	575 (22)	645 (24)	522 (20)	236 (18)
Never	1048 (47)	1343 (52)	1411 (51)	1395 (53)	809 (61)
Not reported	102 (5)	65 (3)	103 (4)	58 (2)	44 (3)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	143 (6)	184 (7)	196 (7)	169 (6)	105 (8)
Previously	575 (26)	638 (25)	703 (26)	640 (25)	278 (21)
Never	1408 (64)	1715 (66)	1759 (64)	1759 (67)	903 (68)
Not reported	84 (4)	63 (2)	84 (3)	41 (2)	38 (3)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	164 (7)	196 (8)	212 (8)	173 (7)	70 (5)
Previously	482 (22)	568 (22)	645 (24)	596 (23)	258 (19)
Never	1487 (67)	1775 (68)	1799 (66)	1795 (69)	987 (75)
Not reported	77 (3)	61 (2)	86 (3)	45 (2)	9 (1)

**Table 1.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

National	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=2210	N=2600	N=2742	N=2609	N=1324
<b>Previous HIV test (%)</b>					
Yes, ever	1840 (83)	2097 (81)	2211 (81)	2105 (81)	1042 (79)
Yes, last year	1120 (51)	1273 (49)	1363 (50)	1271 (49)	601 (45)
>1 year ago	720 (33)	824 (32)	848 (31)	834 (32)	441 (33)
Never tested	293 (13)	369 (14)	390 (14)	381 (15)	232 (18)
Not reported	77 (3)	134 (5)	141 (5)	123 (5)	50 (4)
<b>Previous HCV test (%)</b>					
Yes, ever	1825 (83)	2099 (81)	2201 (80)	2101 (81)	1087 (82)
Yes, last year	1203 (54)	1420 (55)	1455 (53)	1409 (54)	631 (48)
>1 year ago	622 (28)	679 (26)	746 (27)	692 (27)	456 (34)
Never tested	185 (8)	253 (10)	251 (9)	257 (10)	128 (10)
Not reported	200 (9)	248 (10)	290 (11)	251 (10)	109 (8)
<b>Lifetime treatment for HCV (%)#</b>					
<b>N° self-reported HCV diagnosis</b>	N=643	N=697	N=738	N=667	N=289
Antiviral treatment	184 (29)	314 (45)	409 (55)	428 (64)	180 (62)
No antiviral treatment	454 (71)	376 (54)	322 (44)	237 (36)	107 (37)
Not reported	5 (1)	7 (1)	7 (1)	2 (<1)	2 (1)
<b>Treatment for HCV in past 12 months (%)**</b>					
<b>N° self-reported HCV diagnosis</b>	N=617	N=639	N=603	N=502	N=196
Antiviral treatment	137 (22)	227 (36)	236 (39)	222 (44)	62 (32)
No antiviral treatment	475 (77)	405 (63)	360 (60)	278 (55)	132 (67)
Not reported	5 (1)	7 (1)	7 (1)	2 (<1)	2 (1)

# among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 1.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

<b>National</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° surveyed</b>	N=2210	N=2600	N=2742	N=2609	N=1324
<b>Sex with a regular partner last month (%)</b>					
No	1089 (49)	1329 (51)	1374 (50)	1345 (52)	684 (52)
Yes	1039 (47)	1129 (43)	1228 (45)	1124 (43)	584 (44)
Not reported	82 (4)	142 (5)	140 (5)	140 (5)	56 (4)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=1039	N=1129	N=1228	N=1124	N=584
Never	746 (72)	822 (73)	924 (75)	808 (72)	450 (77)
Sometimes	135 (13)	136 (12)	137 (11)	150 (13)	55 (9)
Every time	105 (10)	126 (11)	95 (8)	110 (10)	51 (9)
Not reported	53 (5)	45 (4)	72 (6)	56 (5)	28 (5)
<b>Sex with other partner(s) last month (%)</b>					
No	1777 (80)	2074 (80)	2137 (78)	2040 (78)	1063 (80)
Yes	331 (15)	349 (13)	420 (15)	399 (15)	190 (14)
Not reported	102 (5)	177 (7)	185 (7)	170 (7)	71 (5)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=331	N=349	N=420	N=399	N=190
Never	124 (37)	126 (36)	179 (43)	184 (46)	90 (47)
Sometimes	105 (32)	123 (35)	117 (28)	100 (25)	54 (28)
Every time	95 (29)	84 (24)	105 (25)	89 (22)	41 (22)
Not reported	7 (2)	16 (5)	19 (5)	26 (7)	5 (3)
<b>Sex work last month (%)</b>					
No	1969 (89)	2274 (87)	2394 (87)	2276 (87)	1190 (90)
Yes	121 (5)	133 (5)	154 (6)	134 (5)	61 (5)
Not reported	120 (5)	193 (7)	194 (7)	199 (8)	73 (6)
<b>Condom used at last sex work (%)</b>					
Yes	82 (68)	94 (71)	100 (65)	78 (58)	27 (44)

**Table 1.1.7 Number (percentage) of respondents by COVID-19 related behaviours in 2020**

<b>National</b>			
<b>N° surveyed</b>		<b>N=1324</b>	
<b>More difficult to access sterile needles and syringes</b>		<b>Start or increase takeaway dose of methadone/bupe/suboxone</b>	
Yes	144 (11)	Yes	116 (9)
No	960 (73)	No	688 (52)
Not applicable	113 (9)	Not applicable	382 (29)
Not reported	107 (8)	Not reported	138 (10)
<b>Start depot buprenorphine</b>		<b>Inject own methadone/bupe/suboxone</b>	
Yes	50 (4)	Yes	145 (11)
No	803 (61)	No	688 (52)
Not applicable	339 (26)	Not applicable	364 (27)
Not reported	132 (10)	Not reported	127 (10)
<b>Access take home naloxone</b>		<b>COVID-19 test</b>	
Yes	202 (15)	Yes	337 (25)
No	667 (50)	No	802 (61)
Not applicable	315 (24)	Don't know	60 (5)
Not reported	140 (11)	Not reported	125 (9)
<b>Change illicit drug use</b>		<b>If YES, what was result (N=337)</b>	
Yes, increased	125 (9)	Positive	4 (1)
Yes, decreased	416 (31)	Negative	322 (96)
No change	643 (49)	Don't know	6 (2)
Not reported	140 (11)	Not reported	5 (1)

## HIV antibody prevalence

Table 1.2.1 HIV antibody prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2016	1412	24 (1.7)	727	5 (0.7)	2160	31 (1.4)
2017	1641	45 (2.7)	820	7 (0.9)	2492	53 (2.1)
2018	1784	37 (2.1)	888	8 (0.9)	2686	46 (1.7)
2019	1675	51 (3.0)	841	6 (0.7)	2542	59 (2.3)
2020	877	27 (3.1)	406	3 (0.7)	1292	32 (2.5)
X <sup>2</sup> p trend		0.029		0.986		0.029

Table 1.2.2 HIV antibody prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Heterosexual	1193	6 (0.5)	492	3 (0.6)	1691	9 (0.5)
Bisexual	61	3 (4.9)	148	1 (0.7)	214	5 (2.3)
Homosexual	58	14 (24.1)	27	0 (0.0)	90	15 (16.7)
p value		<0.001		1.000		<0.001
<b>2017</b>						
Heterosexual	1352	12 (0.9)	577	3 (0.5)	1934	16 (0.8)
Bisexual	82	6 (7.3)	135	3 (2.2)	227	9 (4.0)
Homosexual	68	24 (35.3)	44	0 (0.0)	122	24 (19.7)
p value		<0.001		0.165		<0.001
<b>2018</b>						
Heterosexual	1473	12 (0.8)	611	6 (1.0)	2086	18 (0.9)
Bisexual	90	6 (6.7)	162	2 (1.2)	255	8 (3.1)
Homosexual	80	16 (20.0)	35	0 (0.0)	120	17 (14.2)
p value		<0.001		0.773		<0.001
<b>2019</b>						
Heterosexual	1355	13 (1.0)	560	5 (0.9)	1919	18 (0.9)
Bisexual	92	13 (14.1)	148	0 (0.0)	253	14 (5.5)
Homosexual	79	25 (31.7)	36	0 (0.0)	117	26 (22.2)
p value		<0.001		0.680		<0.001
<b>2020</b>						
Heterosexual	746	5 (0.7)	276	3 (1.1)	1023	8 (0.8)
Bisexual	43	4 (9.3)	72	0 (0.0)	120	5 (4.2)
Homosexual	38	17 (44.7)	10	0 (0.0)	49	18 (36.7)
p value		<0.001		1.000		<0.001

**Table 1.2.3 HIV antibody prevalence by age group, gender and survey year**

National Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
<25 years	51	1 (2.0)	32	0 (0.0)	86	1 (1.2)
25-34 years	262	7 (2.7)	169	1 (0.6)	433	8 (1.9)
35-44 years	528	3 (0.6)	274	1 (0.4)	808	4 (0.5)
45+ years	568	13 (2.3)	251	3 (1.2)	829	18 (2.2)
p value		0.039		0.640		0.016
<b>2017</b>						
<25 years	76	1 (1.3)	40	0 (0.0)	118	1 (0.9)
25-34 years	275	7 (2.6)	166	0 (0.0)	454	8 (1.8)
35-44 years	587	14 (2.4)	302	2 (0.7)	894	16 (1.8)
45+ years	695	23 (3.3)	308	5 (1.6)	1014	28 (2.8)
p value		0.716		0.329		0.390
<b>2018</b>						
<25 years	60	1 (1.7)	49	0 (0.0)	111	1 (0.9)
25-34 years	284	12 (4.2)	194	2 (1.0)	480	14 (2.9)
35-44 years	643	6 (0.9)	338	1 (0.3)	987	7 (0.7)
45+ years	791	18 (2.3)	304	5 (1.6)	1099	24 (2.2)
p value		0.013		0.313		0.005
<b>2019</b>						
<25 years	51	0 (0.0)	39	0 (0.0)	91	0 (0.0)
25-34 years	254	8 (3.2)	175	0 (0.0)	436	9 (2.1)
35-44 years	605	11 (1.8)	332	2 (0.6)	943	13 (1.4)
45+ years	757	31 (4.1)	294	4 (1.4)	1062	36 (3.4)
p value		0.062		0.457		0.011
<b>2020</b>						
<25 years	23	0 (0.0)	18	1 (5.6)	42	1 (2.4)
25-34 years	145	4 (2.8)	78	1 (1.3)	225	5 (2.2)
35-44 years	288	6 (2.1)	160	0 (0.0)	449	6 (1.3)
45+ years	420	17 (4.1)	150	1 (0.7)	575	20 (3.5)
p value		0.487		0.054		0.151

**Table 1.2.4 HIV antibody prevalence by last drug injected, gender and survey year**

National Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Heroin	384	5 (1.3)	207	4 (1.9)	595	9 (1.5)
Methamphetamine	582	16 (2.8)	339	1 (0.3)	929	19 (2.1)
Other opioids	254	0 (0.0)	125	0 (0.0)	381	0 (0.0)
PIEDs	80	1 (1.3)	0	0 (0.0)	82	1 (1.2)
Other drugs	112	2 (1.8)	56	0 (0.0)	173	2 (1.2)
p value		0.035		0.146		0.028
<b>2017</b>						
Heroin	468	7 (1.5)	274	3 (1.1)	751	10 (1.3)
Methamphetamine	651	31 (4.8)	356	3 (0.8)	1016	35 (3.4)
Other opioids	292	3 (1.0)	131	0 (0.0)	428	3 (0.7)
PIEDs	99	0 (0.0)	3	0 (0.0)	105	0 (0.0)
Other drugs	131	4 (3.1)	56	1 (1.8)	192	5 (2.6)
p value		0.001		0.479		0.001
<b>2018</b>						
Heroin	460	8 (1.7)	238	2 (0.8)	701	10 (1.4)
Methamphetamine	828	25 (3.0)	452	6 (1.3)	1287	32 (2.5)
Other opioids	274	1 (0.4)	137	0 (0.0)	412	1 (0.2)
PIEDs	90	0 (0.0)	5	0 (0.0)	96	0 (0.0)
Other drugs	126	3 (2.4)	53	0 (0.0)	181	3 (1.7)
p value		0.035		0.671		0.012
<b>2019</b>						
Heroin	429	9 (2.1)	249	2 (0.8)	689	12 (1.7)
Methamphetamine	794	37 (4.7)	427	3 (0.7)	1231	41 (3.3)
Other opioids	241	4 (1.7)	96	0 (0.0)	339	4 (1.2)
PIEDs	88	0 (0.0)	5	0 (0.0)	93	0 (0.0)
Other drugs	114	1 (0.9)	55	1 (1.8)	170	2 (1.2)
p value		0.008		0.565		0.030
<b>2020</b>						
Heroin	191	2 (1.1)	88	1 (1.1)	280	3 (1.1)
Methamphetamine	391	21 (5.4)	207	2 (1.0)	603	24 (4.0)
Other opioids	161	2 (1.2)	78	0 (0.0)	241	2 (0.8)
PIEDs	77	0 (0.0)	3	0 (0.0)	80	0 (0.0)
Other drugs	50	1 (2.0)	27	0 (0.0)	78	2 (2.6)
p value		0.008		1.000		0.013

**Table 1.2.5 HIV antibody prevalence by years of injection, gender and survey year**

National Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
<3 years	67	0 (0.0)	39	0 (0.0)	108	0 (0.0)
3 to 10 years	191	10 (5.2)	102	1 (1.0)	296	11 (3.7)
11+ years	1097	12 (1.1)	564	4 (0.7)	1676	18 (1.1)
p value		0.001		0.673		0.003
<b>2017</b>						
<3 years	97	1 (1.0)	44	0 (0.0)	143	1 (0.7)
3 to 10 years	212	10 (4.7)	122	0 (0.0)	339	11 (3.2)
11+ years	1332	34 (2.6)	654	7 (1.1)	2010	41 (2.0)
p value		0.129		0.731		0.215
<b>2018</b>						
<3 years	83	3 (3.6)	46	0 (0.0)	129	3 (2.3)
3 to 10 years	235	9 (3.8)	148	0 (0.0)	384	9 (2.3)
11+ years	1466	25 (1.7)	694	8 (1.2)	2173	34 (1.6)
p value		0.046		0.584		0.420
<b>2019</b>						
<3 years	97	3 (3.1)	49	0 (0.0)	146	3 (2.1)
3 to 10 years	210	12 (5.7)	145	1 (0.7)	361	14 (3.9)
11+ years	1278	35 (2.7)	608	5 (0.8)	1091	41 (2.2)
p value		0.076		1.000		0.165
<b>2020</b>						
<3 years	56	1 (1.8)	26	0 (0.0)	82	1 (1.2)
3 to 10 years	134	8 (6.0)	61	2 (3.3)	197	10 (5.1)
11+ years	665	18 (2.7)	309	1 (0.3)	981	21 (2.1)
p value		0.131		0.123		0.055

**Table 1.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year**

National Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
No receptive sharing	1018	18 (1.8)	527	4 (0.8)	1559	23 (1.5)
Receptive sharing	243	4 (1.7)	124	0 (0.0)	370	4 (1.1)
p value		1.000		1.000		0.805
<b>2017</b>						
No receptive sharing	1190	31 (2.6)	603	5 (0.8)	1817	36 (2.0)
Receptive sharing	250	7 (2.8)	119	2 (1.7)	372	10 (2.7)
p value		0.861		0.325		0.386
<b>2018</b>						
No receptive sharing	1309	29 (2.2)	637	6 (0.9)	1951	35 (1.8)
Receptive sharing	293	5 (1.7)	148	0 (0.0)	444	5 (1.1)
p value		0.390		0.601		0.414
<b>2019</b>						
No receptive sharing	1235	41 (3.3)	625	3 (0.5)	1877	46 (2.5)
Receptive sharing	247	6 (2.4)	115	2 (1.7)	366	8 (2.2)
p value		0.466		0.174		0.762
<b>2020</b>						
No receptive sharing	663	20 (3.0)	284	3 (1.1)	955	25 (2.6)
Receptive sharing	107	2 (1.9)	75	0 (0.0)	182	2 (1.1)
p value		0.756		0.494		0.293

**Table 1.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year**

National Frequency of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
Less than daily	559	12 (2.2)	300	1 (0.3)	868	14 (1.6)
Daily or more	715	10 (1.4)	358	3 (0.8)	1081	13 (1.2)
Not last month	110	1 (0.9)	54	1 (1.9)	166	2 (1.2)
p value		0.581		0.347		0.712
<b>2017</b>						
Less than daily	643	22 (3.4)	292	3 (1.0)	944	25 (2.7)
Daily or more	817	17 (2.1)	440	4 (0.9)	1276	22 (1.7)
Not last month	153	5 (3.3)	81	0 (0.0)	236	5 (2.1)
p value		0.240		1.000		0.310
<b>2018</b>						
Less than daily	717	13 (1.8)	324	4 (1.2)	1044	17 (1.6)
Daily or more	899	21 (2.3)	472	3 (0.6)	1376	24 (1.7)
Not last month	137	3 (2.2)	82	1 (1.2)	223	5 (2.2)
p value		0.760		0.466		0.817
<b>2019</b>						
Less than daily	643	26 (4.0)	291	2 (0.7)	941	28 (3.0)
Daily or more	856	21 (2.5)	461	4 (0.9)	1331	27 (2.0)
Not last month	149	3 (2.0)	78	0 (0.0)	230	3 (1.3)
p value		0.172		1.000		0.204
<b>2020</b>						
Less than daily	350	11 (3.1)	159	2 (1.3)	514	13 (2.5)
Daily or more	425	11 (2.6)	202	1 (0.5)	630	14 (2.2)
Not last month	93	5 (5.4)	42	0 (0.0)	136	5 (3.7)
p value		0.373		0.702		0.615

**Table 1.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year**

National Imprisonment last year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
No imprisonment	1135	16 (1.4)	632	1 (0.2)	1781	18 (1.0)
Imprisonment	200	6 (3.0)	59	2 (3.4)	261	8 (3.1)
p value		0.125		0.020		0.013
<b>2017</b>						
No imprisonment	1300	40 (3.1)	698	5 (0.7)	2023	46 (2.3)
Imprisonment	229	2 (0.9)	67	1 (1.5)	299	3 (1.0)
p value		0.076		0.424		0.196
<b>2018</b>						
No imprisonment	1421	30 (2.1)	748	7 (0.9)	2179	38 (1.7)
Imprisonment	249	7 (2.8)	92	0 (0.0)	343	7 (2.0)
p value		0.489		1.000		0.699
<b>2019</b>						
No imprisonment	1322	43 (3.3)	708	5 (0.7)	2049	50 (2.4)
Imprisonment	250	3 (1.2)	89	1 (1.1)	344	4 (1.2)
p value		0.099		0.510		0.170
<b>2020</b>						
No imprisonment	711	23 (3.2)	349	3 (0.9)	1069	28 (2.6)
Imprisonment	118	4 (3.4)	38	0 (0.0)	156	4 (2.6)
p value		1.000		1.000		0.614



**Table 1.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year**

National Condom use at last sex	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
No condom use	429	10 (2.3)	289	1 (0.4)	724	11 (1.5)
Condom use	151	2 (1.3)	83	1 (1.2)	237	4 (1.7)
p value		0.740		0.397		0.771
<b>2017</b>						
No condom use	462	17 (3.7)	319	2 (0.6)	786	19 (2.4)
Condom use	170	7 (4.1)	81	1 (1.2)	254	8 (3.2)
p value		0.798		0.494		0.523
<b>2018</b>						
No condom use	545	11 (2.0)	369	1 (0.3)	917	12 (1.3)
Condom use	154	7 (4.6)	67	0 (0.0)	226	7 (3.1)
p value		0.080		1.000		0.060
<b>2019</b>						
No condom use	469	18 (3.8)	317	0 (0.0)	790	18 (2.3)
Condom use	159	1 (0.6)	89	3 (3.4)	253	4 (1.6)
p value		0.056		0.010		0.621
<b>2020</b>						
No condom use	278	13 (4.7)	159	1 (0.6)	439	15 (3.4)
Condom use	75	3 (4.0)	29	0 (0.0)	104	3 (2.9)
p value		1.000		1.000		1.000

**Table 1.2.10 HIV antibody prevalence by sex work last month, gender and survey year**

National Sex work last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
No sex work	1286	18 (1.4)	621	3 (0.5)	1921	23 (1.2)
Sex work	50	3 (6.0)	65	1 (1.5)	121	4 (3.3)
p value		0.041		0.329		0.072
<b>2017</b>						
No sex work	1464	39 (2.7)	696	6 (0.9)	2182	45 (2.1)
Sex work	57	4 (7.0)	61	0 (0.0)	126	5 (4.0)
p value		0.074		1.000		0.192
<b>2018</b>						
No sex work	1614	31 (1.9)	740	6 (0.8)	2363	38 (1.6)
Sex work	65	2 (3.1)	81	0 (0.0)	150	2 (1.3)
p value		0.368		1.000		1.000
<b>2019</b>						
No sex work	1490	44 (3.0)	717	5 (0.7)	2226	51 (2.3)
Sex work	60	4 (6.7)	64	1 (1.6)	129	5 (3.9)
p value		0.111		0.402		0.251
<b>2020</b>						
No sex work	807	23 (2.9)	352	2 (0.6)	1166	26 (2.2)
Sex work	26	4 (15.4)	30	1 (3.3)	58	6 (10.3)
p value		0.008		0.218		<0.001

**Table 1.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Non Indigenous	1127	14 (1.2)	555	2 (0.4)	1696	17 (1.0)
Indigenous	233	9 (3.9)	152	2 (1.3)	391	11 (2.8)
p value		0.010		0.204		0.012
<b>2017</b>						
Non Indigenous	1341	33 (2.5)	627	3 (0.5)	1991	37 (1.9)
Indigenous	266	12 (4.5)	172	4 (2.3)	446	16 (3.6)
p value		0.064		0.042		0.024
<b>2018</b>						
Non Indigenous	1439	20 (1.4)	662	3 (0.5)	2111	23 (1.1)
Indigenous	311	15 (4.8)	209	3 (1.4)	523	19 (3.6)
p value		<0.001		0.153		<0.001
<b>2019</b>						
Non Indigenous	1314	37 (2.8)	615	1 (0.2)	1947	39 (2.0)
Indigenous	331	14 (4.2)	215	5 (2.3)	552	20 (3.6)
p value		0.185		0.005		0.027
<b>2020</b>						
Non Indigenous	675	20 (3.0)	278	2 (0.7)	958	23 (2.4)
Indigenous	168	6 (3.6)	115	1 (0.9)	285	8 (2.8)
p value		0.683		1.000		0.699

**Table 1.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year**

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
English speaking	1283	22 (1.7)	688	4 (0.6)	1990	28 (1.4)
Non-English speaking	102	1 (1.0)	26	0 (0.0)	130	1 (0.8)
p value		1.000		1.000		1.000
<b>2017</b>						
English speaking	1534	43 (2.8)	790	7 (0.9)	2352	51 (2.2)
Non-English speaking	96	2 (2.1)	27	0 (0.0)	126	2 (1.6)
p value		1.000		1.000		1.000
<b>2018</b>						
English speaking	1653	36 (2.2)	846	4 (0.5)	2508	41 (1.6)
Non-English speaking	120	1 (0.8)	39	2 (5.1)	164	3 (1.8)
p value		0.511		0.025		0.750
<b>2019</b>						
English speaking	1566	48 (3.1)	817	5 (0.6)	2405	55 (2.3)
Non-English speaking	100	3 (3.0)	22	1 (4.6)	125	4 (3.2)
p value		1.000		0.148		0.534
<b>2020</b>						
English speaking	824	26 (3.2)	392	3 (0.8)	1225	31 (2.5)
Non-English speaking	48	1 (2.1)	10	0 (0.0)	58	1 (1.7)
p value		1.000		1.000		1.000

**Table 1.2.13 HIV antibody prevalence by region/country of birth, gender and survey year**

National Region/country of birth	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Australia	1216	22 (1.8)	632	4 (0.6)	1864	27 (1.5)
Other Oceania	46	0 (0.0)	24	0 (0.0)	72	1 (1.4)
Asia	21	0 (0.0)	2	0 (0.0)	24	0 (0.0)
UK & Ireland	47	0 (0.0)	30	0 (0.0)	78	0 (0.0)
Other	50	1 (2.0)	23	0 (0.0)	74	1 (1.4)
p value		0.947		1.000		0.890
<b>2017</b>						
Australia	1415	39 (2.8)	729	6 (0.8)	2167	46 (2.1)
Other Oceania	43	1 (2.3)	31	0 (0.0)	77	1 (1.3)
Asia	18	1 (5.6)	9	0 (0.0)	27	1 (3.7)
UK & Ireland	73	1 (1.4)	33	0 (0.0)	107	1 (0.9)
Other	68	1 (1.5)	10	0 (0.0)	82	1 (1.2)
p value		0.740		1.000		0.820
<b>2018</b>						
Australia	1518	33 (2.2)	793	6 (0.8)	2320	39 (1.7)
Other Oceania	57	1 (1.8)	23	0 (0.0)	82	2 (2.4)
Asia	26	0 (0.0)	4	0 (0.0)	30	0 (0.0)
UK & Ireland	83	2 (2.4)	38	0 (0.0)	121	2 (1.7)
Other	90	1 (1.1)	24	0 (0.0)	117	1 (0.9)
p value		0.964		1.000		0.936
<b>2019</b>						
Australia	1467	45 (3.1)	763	6 (0.8)	2248	53 (2.4)
Other Oceania	38	1 (2.6)	23	0 (0.0)	66	1 (1.5)
Asia	22	3 (13.6)	3	0 (0.0)	25	3 (12.0)
UK & Ireland	55	0 (0.0)	28	0 (0.0)	83	0 (0.0)
Other	77	2 (2.6)	22	0 (0.0)	100	2 (2.0)
p value		0.085		1.000		0.055
<b>2020</b>						
Australia	740	22 (3.0)	365	3 (0.8)	1113	26 (2.3)
Other Oceania	33	1 (3.0)	9	0 (0.0)	42	1 (2.4)
Asia	16	1 (6.3)	2	0 (0.0)	18	1 (5.6)
UK & Ireland	34	1 (2.9)	17	0 (0.0)	51	1 (2.0)
Other	39	1 (2.6)	10	0 (0.0)	49	1 (2.0)
p value		0.722		1.000		0.652

## HCV antibody prevalence

Table 1.3.1 HCV antibody prevalence by gender and survey year

National Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2016	1326	695 (52)	672	315 (47)	2016	1019 (51)
2017	1577	786 (50)	799	381 (48)	2404	1178 (49)
2018	1770	817 (46)	884	376 (43)	2668	1200 (45)
2019	1670	781 (47)	835	360 (43)	2531	1151 (45)
2020	877	342 (39)	405	163 (40)	1291	507 (39)
X <sup>2</sup> p trend		<0.001		0.006		<0.001

Table 1.3.2 HCV antibody prevalence by sexual identity, gender and survey year

National Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heterosexual	1115	597 (54)	451	207 (46)	1570	806 (51)
Bisexual	58	24 (41)	145	76 (52)	208	103 (50)
Homosexual	57	22 (39)	23	6 (26)	84	30 (36)
p value		0.021		0.051		0.020
<b>2017</b>						
Heterosexual	1292	657 (51)	560	265 (47)	1856	923 (50)
Bisexual	80	40 (50)	132	66 (50)	221	109 (49)
Homosexual	70	15 (21)	45	16 (36)	125	36 (29)
p value		<0.001		0.239		<0.001
<b>2018</b>						
Heterosexual	1462	690 (47)	610	264 (43)	2074	955 (46)
Bisexual	89	34 (38)	161	64 (40)	253	101 (40)
Homosexual	80	28 (35)	35	15 (43)	120	44 (37)
p value		0.032		0.723		0.031
<b>2019</b>						
Heterosexual	1351	645 (48)	554	239 (43)	1909	887 (46)
Bisexual	91	38 (42)	149	61 (41)	253	104 (41)
Homosexual	79	15 (19)	36	15 (42)	117	30 (26)
p value		<0.001		0.894		<0.001
<b>2020</b>						
Heterosexual	746	297 (40)	275	106 (39)	1022	404 (40)
Bisexual	43	16 (37)	72	40 (56)	120	56 (47)
Homosexual	38	6 (16)	10	3 (30)	49	9 (18)
p value		0.024		0.027		0.004

**Table 1.3.3 HCV antibody prevalence by age group, gender and survey year**

National Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	50	10 (20)	29	12 (41)	82	24 (29)
25-34 years	248	92 (37)	159	67 (42)	408	160 (39)
35-44 years	502	286 (57)	254	123 (48)	761	410 (54)
45+ years	523	306 (59)	229	113 (49)	761	424 (56)
p value		<0.001		0.459		<0.001
<b>2017</b>						
<25 years	73	6 (8)	40	9 (23)	115	15 (13)
25-34 years	264	104 (39)	163	72 (44)	438	180 (41)
35-44 years	558	278 (50)	296	143 (48)	859	422 (49)
45+ years	674	394 (58)	296	155 (52)	980	555 (57)
p value		<0.001		0.003		<0.001
<b>2018</b>						
<25 years	58	10 (17)	49	10 (20)	109	21 (19)
25-34 years	283	96 (34)	192	75 (39)	477	172 (36)
35-44 years	638	296 (46)	337	150 (45)	981	449 (46)
45+ years	785	411 (52)	303	140 (46)	1092	553 (51)
p value		<0.001		0.005		<0.001
<b>2019</b>						
<25 years	51	13 (25)	40	8 (20)	92	21 (23)
25-34 years	254	66 (26)	175	74 (42)	436	141 (32)
35-44 years	601	275 (46)	331	137 (41)	938	416 (44)
45+ years	756	424 (56)	288	141 (49)	1055	569 (54)
p value		<0.001		0.004		<0.001
<b>2020</b>						
<25 years	23	3 (13)	18	7 (39)	42	10 (24)
25-34 years	145	30 (21)	78	26 (33)	225	56 (25)
35-44 years	289	118 (41)	159	70 (44)	449	188 (42)
45+ years	419	190 (45)	150	60 (40)	574	252 (44)
p value		<0.001		0.473		<0.001

**Table 1.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

National Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	67	5 (7)	38	8 (21)	107	14 (13)
3 to 10 years	184	55 (30)	93	34 (37)	280	91 (33)
11+ years	1022	601 (59)	522	265 (51)	1556	872 (56)
p value		<0.001		<0.001		<0.001
<b>2017</b>						
<3 years	96	4 (4)	44	5 (11)	142	9 (6)
3 to 10 years	207	55 (27)	122	37 (30)	333	93 (28)
11+ years	1199	684 (57)	594	323 (54)	1813	1016 (56)
p value		<0.001		<0.001		<0.001
<b>2018</b>						
<3 years	83	9 (11)	46	2 (4)	129	11 (9)
3 to 10 years	233	51 (22)	146	47 (32)	380	99 (26)
11+ years	1373	713 (52)	659	312 (47)	2043	1031 (50)
p value		<0.001		<0.001		<0.001
<b>2019</b>						
<3 years	96	8 (8)	50	0 (0)	146	8 (5)
3 to 10 years	210	46 (22)	145	48 (33)	361	96 (27)
11+ years	1273	683 (54)	601	294 (49)	1889	982 (52)
p value		<0.001		<0.001		<0.001
<b>2020</b>						
<3 years	56	5 (9)	26	0 (0)	82	5 (6)
3 to 10 years	135	21 (16)	61	22 (36)	198	43 (22)
11+ years	663	305 (46)	308	136 (44)	978	443 (45)
p value		<0.001		<0.001		<0.001

**Table 1.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

National Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	75	10 (13)	1341	699 (52)	1460	736 (50)
Receptive sharing	18	2 (11)	318	177 (56)	347	187 (54)
p value		1.000		0.256		0.244
<b>2017</b>						
No receptive sharing	106	6 (6)	1580	801 (51)	1747	841 (48)
Receptive sharing	18	2 (11)	317	188 (59)	359	204 (57)
p value		0.328		0.005		0.003
<b>2018</b>						
No receptive sharing	86	6 (7)	1787	813 (46)	1935	849 (44)
Receptive sharing	23	4 (17)	391	219 (56)	442	244 (55)
p value		0.214		<0.001		<0.001
<b>2019</b>						
No receptive sharing	113	5 (4)	1683	803 (48)	1870	853 (46)
Receptive sharing	15	1 (7)	318	170 (53)	362	185 (51)
p value		0.534		0.060		0.055
<b>2020</b>						
No receptive sharing	65	4 (6)	872	352 (40)	953	364 (38)
Receptive sharing	5	0 (0)	171	88 (51)	182	93 (51)
p value		1.000		0.007		0.001

**Table 1.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

National Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	7	2 (29)	518	346 (67)	539	354 (66)
Methamphetamine	59	8 (14)	783	336 (43)	870	362 (42)
Other opioids	5	3 (60)	326	192 (59)	340	202 (59)
PIEDs	26	0 (0)	46	0 (0)	75	0 (0)
Other drugs	7	1 (14)	130	68 (52)	152	78 (51)
p value		0.005		<0.001		<0.001
<b>2017</b>						
Heroin	16	4 (25)	653	442 (68)	703	473 (67)
Methamphetamine	70	4 (6)	883	343 (39)	987	363 (37)
Other opioids	8	1 (13)	380	229 (60)	412	240 (58)
PIEDs	36	0 (0)	64	2 (3)	103	2 (2)
Other drugs	12	0 (0)	144	80 (56)	166	84 (51)
p value		0.010		<0.001		<0.001
<b>2018</b>						
Heroin	12	2 (17)	650	381 (59)	685	399 (58)
Methamphetamine	82	7 (9)	1127	433 (38)	1260	463 (37)
Other opioids	3	1 (33)	385	212 (55)	404	223 (55)
PIEDs	20	0 (0)	68	1 (1)	95	1 (1)
Other drugs	11	1 (9)	149	81 (55)	172	88 (51)
p value		0.266		<0.001		<0.001
<b>2019</b>						
Heroin	14	2 (14)	632	415 (66)	677	441 (65)
Methamphetamine	90	4 (4)	1058	385 (36)	1210	415 (34)
Other opioids	7	1 (14)	319	171 (54)	334	178 (53)
PIEDs	27	0 (0)	59	1 (2)	91	1 (1)
Other drugs	5	1 (20)	148	89 (60)	168	97 (58)
p value		0.147		<0.001		<0.001
<b>2020</b>						
Heroin	6	1 (17)	267	160 (60)	278	164 (59)
Methamphetamine	42	4 (10)	546	162 (30)	599	173 (29)
Other opioids	5	0 (0)	230	116 (50)	238	119 (50)
PIEDs	23	0 (0)	49	2 (4)	79	2 (3)
Other drugs	4	0 (0)	69	40 (58)	76	42 (55)
p value		0.404		<0.001		<0.001

**Table 1.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

National Frequency of injection last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	56	7 (13)	743	391 (53)	815	407 (50)
Daily or more	37	5 (14)	933	498 (53)	1010	529 (52)
Not last month	11	2 (18)	127	53 (42)	151	60 (40)
p value		0.840		0.046		0.014
<b>2017</b>						
Less than daily	66	4 (6)	815	398 (49)	913	416 (46)
Daily or more	59	4 (7)	1107	607 (55)	1223	647 (53)
Not last month	17	1 (6)	202	91 (45)	235	99 (42)
p value		1.000		0.005		<0.001
<b>2018</b>						
Less than daily	60	6 (10)	948	432 (46)	1040	453 (44)
Daily or more	50	4 (8)	1253	611 (49)	1362	652 (48)
Not last month	18	1 (6)	185	68 (37)	223	74 (33)
p value		0.914		0.007		<0.001
<b>2019</b>						
Less than daily	65	4 (6)	835	365 (44)	935	389 (41)
Daily or more	66	3 (5)	1190	617 (52)	1326	660 (50)
Not last month	15	1 (7)	195	82 (42)	231	86 (37)
p value		0.772		<0.001		<0.001
<b>2020</b>						
Less than daily	38	2 (5)	469	170 (36)	516	176 (34)
Daily or more	32	2 (6)	581	273 (47)	626	284 (45)
Not last month	12	1 (8)	116	38 (33)	137	41 (30)
p value		1.000		<0.001		<0.001

**Table 1.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

National Imprisonment last year	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	87	9 (10)	1519	760 (50)	1663	801 (48)
Imprisonment	11	2 (18)	222	151 (68)	245	160 (65)
p value		0.607		<0.001		<0.001
<b>2017</b>						
No imprisonment	126	8 (6)	1742	860 (49)	1955	908 (46)
Imprisonment	8	0 (0)	258	166 (64)	285	182 (64)
p value		1.000		<0.001		<0.001
<b>2018</b>						
No imprisonment	109	8 (7)	1979	889 (45)	2166	932 (43)
Imprisonment	16	1 (6)	300	172 (57)	338	186 (55)
p value		1.000		<0.001		<0.001
<b>2019</b>						
No imprisonment	129	7 (5)	1815	827 (46)	2041	878 (43)
Imprisonment	12	0 (0)	301	178 (59)	342	194 (57)
p value		1.000		<0.001		<0.001
<b>2020</b>						
No imprisonment	75	4 (5)	969	381 (39)	1068	395 (37)
Imprisonment	7	1 (14)	141	68 (48)	156	75 (48)
p value		0.367		0.044		0.008



**Table 1.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	1056	544 (52)	513	236 (46)	1580	786 (50)
Indigenous	218	122 (56)	141	68 (48)	365	193 (53)
p value		0.231		0.639		0.281
<b>2017</b>						
Non Indigenous	1290	603 (47)	611	288 (47)	1922	899 (47)
Indigenous	254	163 (64)	167	83 (50)	428	249 (58)
p value		<0.001		0.556		<0.001
<b>2018</b>						
Non Indigenous	1431	625 (44)	660	270 (41)	2101	899 (43)
Indigenous	305	175 (57)	208	99 (48)	516	276 (53)
p value		<0.001		0.089		<0.001
<b>2019</b>						
Non Indigenous	1309	584 (45)	610	253 (41)	1937	844 (44)
Indigenous	331	180 (54)	214	102 (48)	551	284 (52)
p value		0.001		0.116		0.001
<b>2020</b>						
Non Indigenous	676	234 (35)	277	101 (36)	958	337 (35)
Indigenous	167	91 (54)	115	54 (47)	284	145 (51)
p value		<0.001		0.053		<0.001

**Table 1.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	1201	626 (52)	638	294 (46)	1855	928 (50)
Non-English speaking	99	54 (55)	22	14 (64)	123	69 (56)
p value		0.643		0.105		0.192
<b>2017</b>						
English speaking	1476	729 (49)	769	366 (48)	2270	1106 (49)
Non-English speaking	91	51 (56)	27	14 (52)	121	65 (54)
p value		0.218		0.663		0.284
<b>2018</b>						
English speaking	1640	752 (46)	843	360 (43)	2492	1116 (45)
Non-English speaking	118	61 (52)	39	16 (41)	162	80 (49)
p value		0.219		0.836		0.254
<b>2019</b>						
English speaking	1561	726 (47)	811	347 (43)	2394	1081 (45)
Non-English speaking	100	53 (53)	22	12 (55)	125	67 (54)
p value		0.207		0.272		0.065
<b>2020</b>						
English speaking	824	319 (39)	391	157 (40)	1224	478 (39)
Non-English speaking	48	22 (46)	10	6 (60)	58	28 (48)
p value		0.326		0.328		0.160

**Table 1.3.11 HCV antibody prevalence by region/country of birth, gender and survey year**

National Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Australia	1141	596 (52)	588	271 (46)	1743	874 (50)
Other Oceania	45	27 (60)	23	12 (52)	69	40 (58)
Asia	19	11 (58)	2	0 (0)	22	11 (50)
UK & Ireland	44	22 (50)	25	12 (48)	70	35 (50)
Other	49	24 (49)	19	12 (63)	69	36 (52)
p value		0.806		0.422		0.788
<b>2017</b>						
Australia	1357	665 (49)	709	344 (49)	2086	1017 (49)
Other Oceania	41	21 (51)	30	11 (37)	74	34 (46)
Asia	17	9 (53)	9	6 (67)	26	15 (58)
UK & Ireland	71	40 (56)	33	13 (39)	105	54 (51)
Other	67	35 (52)	10	3 (30)	81	38 (47)
p value		0.775		0.287		0.832
<b>2018</b>						
Australia	1504	689 (46)	790	342 (43)	2303	1035 (45)
Other Oceania	57	23 (40)	23	6 (26)	82	29 (35)
Asia	26	17 (65)	4	4 (100)	30	21 (70)
UK & Ireland	82	39 (48)	38	14 (37)	120	53 (44)
Other	90	44 (49)	24	8 (33)	117	55 (47)
p value		0.282		0.052		0.028
<b>2019</b>						
Australia	1463	684 (47)	757	325 (43)	2238	1015 (45)
Other Oceania	38	19 (50)	23	11 (48)	66	32 (48)
Asia	23	7 (30)	3	1 (33)	26	8 (31)
UK & Ireland	55	31 (56)	28	14 (50)	83	45 (54)
Other	75	33 (44)	22	7 (32)	98	40 (41)
p value		0.299		0.741		0.204
<b>2020</b>						
Australia	740	292 (39)	365	149 (41)	1113	443 (40)
Other Oceania	33	10 (30)	9	2 (22)	42	12 (29)
Asia	16	5 (31)	2	1 (50)	18	6 (33)
UK & Ireland	34	10 (29)	16	5 (31)	50	15 (30)
Other	39	22 (56)	10	5 (50)	49	27 (55)
p value		0.102		0.679		0.054

## HCV RNA prevalence

**Table 1.4.1 HCV RNA prevalence by gender and survey year \***

National Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2016	504	188 (37)	257	68 (26)	767	256 (33)
2017	1073	305 (28)	529	110 (21)	1621	416 (26)
2018	932	195 (21)	458	89 (19)	1397	284 (20)
2019	1412	264 (19)	706	111 (16)	2140	378 (18)
2020	798	132 (17)	369	56 (15)	1168	187 (16)
X <sup>2</sup> p trend		<0.001		<0.001		<0.001

\* Weighted for gender and HCV antibody status

**Table 1.4.2 HCV RNA prevalence by sexual identity, gender and survey year \***

National Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Heterosexual	423	168 (40)	161	38 (24)	584	206 (35)
Bisexual	23	5 (22)	61	22 (36)	85	28 (33)
Homosexual	24	5 (21)	14	2 (14)	40	7 (18)
p value		0.065		0.039		0.032
<b>2017</b>						
Heterosexual	903	256 (28)	369	75 (20)	1275	331 (26)
Bisexual	58	22 (38)	84	18 (21)	147	40 (27)
Homosexual	31	3 (10)	31	7 (23)	68	11 (16)
p value		0.039		0.891		0.169
<b>2018</b>						
Heterosexual	764	166 (22)	309	65 (21)	1074	231 (22)
Bisexual	44	7 (16)	85	13 (15)	131	21 (16)
Homosexual	44	5 (11)	21	3 (14)	68	8 (12)
p value		0.155		0.439		0.062
<b>2019</b>						
Heterosexual	1148	215 (19)	460	69 (15)	1611	285 (18)
Bisexual	77	14 (18)	132	20 (15)	220	36 (16)
Homosexual	70	3 (4)	34	6 (18)	106	9 (8)
p value		0.008		0.921		0.043
<b>2020</b>						
Heterosexual	675	113 (17)	250	42 (17)	925	155 (17)
Bisexual	41	7 (17)	66	10 (15)	108	17 (16)
Homosexual	36	2 (6)	10	0 (0)	46	2 (4)
p value		0.311		0.422		0.147

**Table 1.4.3 HCV RNA prevalence by age group, gender and survey year \***

National Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	13	2 (15)	11	3 (27)	27	5 (19)
25-34 years	85	23 (27)	55	18 (33)	140	42 (30)
35-44 years	195	80 (41)	104	30 (29)	300	110 (37)
45+ years	209	82 (39)	86	17 (20)	298	99 (33)
p value		0.093		0.264		0.233
<b>2017</b>						
<25 years	52	5 (10)	27	5 (19)	81	10 (12)
25-34 years	191	57 (30)	105	23 (22)	304	80 (26)
35-44 years	398	118 (30)	189	42 (22)	590	160 (27)
45+ years	428	124 (29)	206	40 (19)	641	166 (26)
p value		0.060		0.908		0.092
<b>2018</b>						
<25 years	33	6 (18)	25	6 (24)	59	12 (20)
25-34 years	138	22 (16)	102	23 (23)	241	45 (19)
35-44 years	345	81 (23)	172	34 (20)	521	116 (22)
45+ years	410	84 (20)	157	26 (17)	570	110 (19)
p value		0.571		0.633		0.686
<b>2019</b>						
<25 years	44	5 (11)	39	7 (18)	84	12 (14)
25-34 years	220	27 (12)	146	24 (16)	372	52 (14)
35-44 years	503	102 (20)	277	46 (17)	785	148 (19)
45+ years	639	129 (20)	244	34 (14)	891	165 (19)
p value		0.028		0.773		0.143
<b>2020</b>						
<25 years	20	1 (5)	19	4 (21)	39	5 (13)
25-34 years	128	12 (9)	73	12 (16)	201	23 (11)
35-44 years	267	61 (23)	142	26 (18)	411	87 (21)
45+ years	381	58 (15)	135	14 (10)	516	72 (14)
p value		0.001		0.217		0.003

**Table 1.4.4 HCV RNA prevalence by years since first injection, gender and survey year \***

National Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	21	2 (10)	10	2 (20)	32	4 (13)
3 to 10 years	70	13 (19)	32	9 (28)	103	22 (21)
11+ years	388	162 (42)	209	57 (27)	602	219 (36)
p value		<0.001		0.648		<0.001
<b>2017</b>						
<3 years	66	2 (3)	27	1 (4)	94	3 (3)
3 to 10 years	138	28 (20)	76	18 (24)	216	46 (21)
11+ years	824	258 (31)	402	84 (21)	1243	344 (28)
p value		<0.001		0.081		<0.001
<b>2018</b>						
<3 years	37	3 (8)	23	3 (13)	60	6 (10)
3 to 10 years	118	20 (17)	66	15 (23)	184	35 (19)
11+ years	733	159 (22)	351	67 (19)	1090	227 (21)
p value		0.163		0.537		0.164
<b>2019</b>						
<3 years	87	7 (8)	43	1 (2)	130	8 (6)
3 to 10 years	174	22 (13)	126	28 (22)	305	51 (17)
11+ years	1073	220 (21)	509	76 (15)	1594	297 (19)
p value		0.001		0.007		0.001
<b>2020</b>						
<3 years	51	2 (4)	23	0 (0)	74	2 (3)
3 to 10 years	124	11 (9)	58	12 (21)	183	23 (13)
11+ years	601	113 (19)	279	43 (15)	881	156 (18)
p value		0.001		0.070		0.001

**Table 1.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year \***

National Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	364	132 (36)	181	44 (24)	551	177 (32)
Receptive sharing	74	37 (50)	47	17 (36)	121	54 (45)
p value		0.040		0.085		0.010
<b>2017</b>						
No receptive sharing	792	218 (28)	400	89 (22)	1207	307 (25)
Receptive sharing	167	62 (37)	68	10 (15)	235	72 (31)
p value		0.020		0.209		0.109
<b>2018</b>						
No receptive sharing	685	133 (19)	325	60 (18)	1012	193 (19)
Receptive sharing	143	48 (34)	69	18 (26)	214	66 (31)
p value		<0.001		0.164		<0.001
<b>2019</b>						
No receptive sharing	1055	205 (19)	527	81 (15)	1597	288 (18)
Receptive sharing	196	43 (22)	99	21 (21)	300	65 (22)
p value		0.456		0.169		0.152
<b>2020</b>						
No receptive sharing	602	94 (16)	252	38 (15)	856	132 (15)
Receptive sharing	92	32 (35)	73	14 (19)	165	46 (28)
p value		<0.001		0.457		<0.001

**Table 1.4.6 HCV RNA prevalence by last drug injected, gender and survey year \***

National Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	168	70 (42)	83	24 (29)	251	94 (37)
Methamphetamine	174	63 (36)	110	21 (19)	285	84 (29)
Other opioids	85	33 (39)	41	17 (41)	126	50 (40)
PIEDs	24	0 (0)	0	0 (0)	25	0 (0)
Other drugs	38	14 (37)	21	5 (24)	62	20 (32)
p value		0.005		0.018		0.001
<b>2017</b>						
Heroin	288	99 (34)	184	53 (29)	482	154 (32)
Methamphetamine	421	110 (26)	216	37 (17)	641	147 (23)
Other opioids	209	59 (28)	91	17 (19)	302	76 (25)
PIEDs	66	2 (3)	2	0 (0)	70	2 (3)
Other drugs	79	31 (39)	32	3 (9)	112	34 (30)
p value		<0.001		0.012		<0.001
<b>2018</b>						
Heroin	294	59 (20)	139	26 (19)	435	85 (20)
Methamphetamine	363	87 (24)	205	35 (17)	572	122 (21)
Other opioids	142	28 (20)	71	17 (24)	214	45 (21)
PIEDs	50	1 (2)	1	0 (0)	51	1 (2)
Other drugs	64	16 (25)	33	9 (27)	98	25 (26)
p value		0.038		0.531		0.026
<b>2019</b>						
Heroin	364	81 (22)	205	41 (20)	578	122 (21)
Methamphetamine	659	122 (19)	351	46 (13)	1019	171 (17)
Other opioids	202	39 (19)	87	9 (10)	291	49 (17)
PIEDs	73	1 (1)	5	0 (0)	78	1 (1)
Other drugs	90	18 (20)	48	13 (27)	139	30 (22)
p value		0.001		0.019		<0.001
<b>2020</b>						
Heroin	174	33 (19)	85	14 (16)	259	46 (18)
Methamphetamine	350	54 (15)	177	23 (13)	528	78 (15)
Other opioids	142	30 (21)	76	8 (11)	220	38 (17)
PIEDs	71	0 (0)	3	0 (0)	74	0 (0)
Other drugs	45	12 (27)	25	11 (44)	70	22 (31)
p value		<0.001		0.002		<0.001

**Table 1.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year \***

National Frequency of injection last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Less than daily	198	64 (32)	111	29 (26)	313	93 (30)
Daily or more	242	106 (44)	119	33 (28)	363	139 (38)
Not last month	48	10 (21)	25	6 (24)	73	16 (22)
p value		0.005		0.888		0.007
<b>2017</b>						
Less than daily	423	104 (25)	197	39 (20)	625	143 (23)
Daily or more	547	182 (33)	277	63 (23)	837	245 (29)
Not last month	93	16 (17)	51	8 (16)	145	26 (18)
p value		0.001		0.541		0.003
<b>2018</b>						
Less than daily	368	71 (19)	173	35 (20)	542	106 (20)
Daily or more	468	110 (24)	227	44 (19)	696	154 (22)
Not last month	81	12 (15)	52	8 (15)	134	20 (15)
p value		0.144		0.733		0.141
<b>2019</b>						
Less than daily	559	93 (17)	246	40 (16)	810	133 (16)
Daily or more	706	157 (22)	390	63 (16)	1108	223 (20)
Not last month	131	12 (9)	64	7 (11)	197	19 (10)
p value		<0.001		0.518		<0.001
<b>2020</b>						
Less than daily	322	47 (15)	145	21 (14)	469	69 (15)
Daily or more	377	78 (21)	183	30 (16)	560	109 (19)
Not last month	89	4 (4)	39	4 (10)	128	8 (6)
p value		<0.001		0.569		<0.001

**Table 1.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year \***

National Imprisonment last year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No imprisonment	413	142 (34)	230	59 (26)	647	201 (31)
Imprisonment	57	34 (60)	16	6 (38)	75	40 (53)
p value		<0.001		0.179		<0.001
<b>2017</b>						
No imprisonment	857	228 (27)	458	91 (20)	1329	320 (24)
Imprisonment	148	60 (41)	38	10 (26)	189	70 (37)
p value		0.002		0.283		<0.001
<b>2018</b>						
No imprisonment	732	147 (20)	388	76 (20)	1125	223 (20)
Imprisonment	134	32 (24)	41	9 (22)	176	41 (23)
p value		0.326		0.674		0.287
<b>2019</b>						
No imprisonment	1107	186 (17)	594	88 (15)	1718	276 (16)
Imprisonment	215	57 (27)	76	17 (22)	295	75 (25)
p value		<0.001		0.101		<0.001
<b>2020</b>						
No imprisonment	650	99 (15)	317	47 (15)	968	145 (15)
Imprisonment	105	25 (24)	35	7 (20)	141	32 (23)
p value		0.024		0.460		0.018

**Table 1.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year \***

National Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	413	147 (36)	215	54 (25)	633	201 (32)
Indigenous	76	35 (46)	37	12 (32)	114	47 (41)
p value		0.090		0.257		0.041
<b>2017</b>						
Non Indigenous	878	238 (27)	401	76 (19)	1293	315 (24)
Indigenous	171	57 (33)	116	32 (28)	292	90 (31)
p value		0.107		0.043		0.033
<b>2018</b>						
Non Indigenous	750	144 (19)	339	66 (19)	1094	210 (19)
Indigenous	163	47 (29)	107	20 (19)	272	67 (25)
p value		0.020		0.880		0.073
<b>2019</b>						
Non Indigenous	1117	185 (17)	514	71 (14)	1646	258 (16)
Indigenous	273	74 (27)	182	39 (21)	461	114 (25)
p value		<0.001		0.020		<0.001
<b>2020</b>						
Non Indigenous	610	87 (14)	247	34 (14)	857	121 (14)
Indigenous	155	37 (24)	110	20 (18)	265	56 (21)
p value		0.004		0.339		0.005

**Table 1.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year \***

National Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	459	163 (36)	245	66 (27)	710	229 (32)
Non-English speaking	37	21 (57)	9	2 (22)	47	23 (49)
p value		0.009		0.435		0.018
<b>2017</b>						
English speaking	1003	283 (28)	510	105 (21)	1530	389 (25)
Non-English speaking	62	19 (31)	18	5 (28)	82	24 (29)
p value		0.716		0.368		0.436
<b>2018</b>						
English speaking	859	178 (21)	432	85 (20)	1296	263 (20)
Non-English speaking	66	17 (26)	23	4 (17)	90	21 (23)
p value		0.364		0.956		0.484
<b>2019</b>						
English speaking	1322	248 (19)	685	105 (15)	2026	355 (18)
Non-English speaking	85	17 (20)	19	6 (32)	107	23 (21)
p value		0.858		0.056		0.242
<b>2020</b>						
English speaking	749	123 (16)	359	53 (15)	1110	176 (16)
Non-English speaking	44	9 (20)	9	3 (33)	53	12 (23)
p value		0.569		0.141		0.240



**Table 1.4.11 HCV RNA prevalence by region/country of birth, gender and survey year \***

National Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Australia	431	166 (39)	226	58 (26)	661	224 (34)
Other Oceania	12	3 (25)	6	5 (83)	20	8 (40)
Asia	11	5 (45)	2	0 (0)	13	5 (38)
UK & Ireland	17	3 (18)	13	2 (15)	30	5 (17)
Other	21	6 (29)	7	2 (29)	28	9 (32)
p value		0.322		0.055		0.318
<b>2017</b>						
Australia	931	259 (28)	471	97 (21)	1416	357 (25)
Other Oceania	27	8 (30)	22	5 (23)	51	14 (27)
Asia	10	5 (50)	4	1 (25)	14	6 (43)
UK & Ireland	49	15 (31)	21	3 (14)	70	18 (26)
Other	42	11 (26)	8	2 (25)	52	14 (27)
p value		0.800		0.930		0.765
<b>2018</b>						
Australia	806	166 (21)	400	80 (20)	1211	247 (20)
Other Oceania	26	3 (12)	12	2 (17)	39	5 (13)
Asia	9	5 (56)	1	0 (0)	10	5 (50)
UK & Ireland	35	5 (14)	20	5 (25)	55	10 (18)
Other	49	14 (29)	18	2 (11)	69	16 (23)
p value		0.014		0.650		0.060
<b>2019</b>						
Australia	1244	238 (19)	636	101 (16)	1895	340 (18)
Other Oceania	32	4 (13)	19	4 (21)	55	10 (18)
Asia	16	3 (19)	3	0 (0)	19	3 (16)
UK & Ireland	44	8 (18)	26	4 (15)	70	13 (19)
Other	63	10 (16)	21	1 (5)	85	11 (13)
p value		0.813		0.575		0.782
<b>2020</b>						
Australia	672	105 (16)	336	52 (15)	1009	157 (16)
Other Oceania	30	5 (17)	8	1 (13)	38	6 (16)
Asia	17	0 (0)	1	0 (0)	18	0 (0)
UK & Ireland	29	7 (24)	13	2 (15)	42	9 (21)
Other	36	13 (36)	10	1 (10)	46	14 (30)
p value		0.009		0.971		0.034

## Australian Capital Territory

Table 2.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Australian Capital Territory	2016	2017	2018	2019	2020*
<b>Number of sites</b>	1	1	1	1	1
<b>N° surveyed</b>	N=112	N=119	N=127	N=128	N=104
<b>Response rate (%)</b>	82%	89%	93%	71%	67%
<b>Gender (%)</b>					
Male	78 (70)	80 (67)	90 (71)	86 (67)	70 (67)
Female	32 (29)	38 (32)	35 (28)	42 (33)	33 (32)
Other	2 (2)	1 (1)	2 (2)	0 (0)	1 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Sexual identity (%)</b>					
Heterosexual	93 (83)	92 (77)	100 (79)	93 (73)	84 (81)
Bisexual	12 (11)	15 (13)	13 (10)	13 (10)	11 (11)
Gay/Lesbian	1 (1)	1 (1)	3 (2)	4 (3)	2 (2)
Other	-- --	-- --	-- --	-- --	3 (3)
Not reported	6 (5)	11 (9)	11 (9)	18 (14)	4 (4)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	84 (75)	90 (76)	98 (77)	106 (83)	82 (79)
Yes	23 (21)	28 (24)	27 (21)	21 (16)	19 (18)
Not reported	5 (4)	1 (1)	2 (2)	1 (1)	3 (3)
<b>Region/country of birth (%)</b>					
Australia	101 (90)	105 (88)	110 (87)	113 (88)	93 (89)
Other Oceania	1 (1)	3 (3)	1 (1)	6 (5)	3 (3)
Asia	1 (1)	2 (2)	1 (1)	0 (0)	1 (1)
UK & Ireland	6 (5)	2 (2)	6 (5)	4 (3)	3 (3)
Other	2 (2)	5 (4)	7 (6)	5 (4)	2 (2)
Not reported	1 (1)	2 (2)	2 (2)	0 (0)	2 (2)
<b>Main language spoken at home by parents (%)</b>					
English	104 (93)	114 (96)	114 (90)	119 (93)	99 (95)
Non-English	8 (7)	3 (3)	11 (9)	9 (7)	5 (5)
Not reported	0 (0)	2 (2)	2 (2)	0 (0)	0 (0)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	44	41.5	41	42	44
<i>Age range</i>	19-64	18-64	20-67	18-66	23-63
<i>Age group (%)</i>					
<25 years	4 (4)	3 (3)	4 (3)	5 (4)	1 (1)
25+ years	107 (96)	115 (97)	123 (97)	123 (96)	103 (99)
Not reported	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>					
<i>Age range</i>	12-55	10-49	10-50	11-43	11-53
N° not reported	4	0	5	3	3
<i>Median yrs since first injection</i>					
<i>Range</i>	<1-48	<1-46	<1-46	<1-46	<1-47
<i>Years since first injection</i>					
<3 years	2 (2)	3 (3)	3 (2)	8 (6)	4 (4)
3+ years	106 (95)	110 (92)	119 (94)	117 (91)	97 (93)
Not reported	4 (4)	6 (5)	5 (4)	3 (2)	3 (3)
<b>Imprisonment last year (%)</b>					
No	97 (87)	95 (80)	99 (78)	104 (81)	84 (81)
Yes	14 (13)	18 (15)	11 (9)	19 (15)	15 (14)
Not reported	1 (1)	6 (5)	17 (13)	5 (4)	5 (5)
<b>N° in prison</b>					
Injected in prison	4 (29)	6 (33)	5 (45)	5 (26)	3 (20)

\* Implementation of the 2020 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

**Table 2.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

Australian Capital Territory	2016	2017	2018	2019	2020
N° surveyed	N=112	N=119	N=127	N=128	N=104
<b>Drug last injected (%)</b>					
Cocaine	1 (1)	3 (3)	1 (1)	0 (0)	2 (2)
Methamphetamine	41 (37)	48 (40)	60 (47)	58 (45)	39 (38)
Heroin	45 (40)	58 (49)	51 (40)	59 (46)	50 (48)
Pharm. opioids	4 (4)	1 (1)	4 (3)	2 (2)	3 (3)
Methadone	8 (7)	3 (3)	3 (2)	5 (4)	4 (4)
Buprenorphine	5 (4)	1 (1)	0 (0)	0 (0)	1 (1)
Buprenorphine/naloxone	3 (3)	2 (2)	1 (1)	0 (0)	0 (0)
PIEDs	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
More than one	3 (3)	3 (3)	5 (4)	4 (3)	3 (3)
Other	2 (2)	0 (0)	1 (1)	0 (0)	1 (1)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
<b>Ever injected opioids</b>					
No	13 (12)	7 (6)	15 (12)	8 (6)	11 (11)
Yes	98 (88)	110 (92)	110 (87)	120 (94)	93 (89)
Not reported	1 (1)	2 (2)	2 (2)	0 (0)	0 (0)
<b>Frequency of injection last month (%)</b>					
Not last month	9 (8)	16 (13)	11 (9)	10 (8)	7 (7)
Less than weekly	14 (13)	16 (13)	17 (13)	18 (14)	14 (13)
Weekly not daily	29 (26)	27 (23)	30 (24)	32 (25)	24 (23)
Daily or more	58 (52)	57 (48)	66 (52)	66 (52)	59 (57)
Not reported	2 (2)	3 (3)	3 (2)	2 (2)	0 (0)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
No	96 (86)	100 (84)	103 (81)	111 (87)	89 (86)
Yes	15 (13)	15 (13)	20 (16)	15 (12)	11 (11)
Not reported	1 (1)	4 (3)	4 (3)	2 (2)	4 (4)
<b>Overdosed in last 12 months</b>					
No	87 (78)	90 (76)	93 (73)	101 (79)	77 (74)
Yes	24 (21)	24 (20)	30 (24)	26 (20)	23 (22)
Not reported	1 (1)	5 (4)	4 (3)	1 (1)	4 (4)

**Table 2.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

Australian Capital Territory	2016	2017	2018	2019	2020
N° injected last month	N=101	N=100	N=113	N=116	N=97
<b>Places injected last month (%)</b>					
All private	52 (51)	52 (52)	50 (44)	53 (46)	39 (40)
Any public	49 (49)	47 (47)	63 (56)	61 (53)	58 (60)
Not reported	0 (0)	1 (1)	0 (0)	2 (2)	0 (0)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	75 (74)	64 (64)	76 (67)	86 (74)	73 (75)
Most of the time	16 (16)	31 (31)	30 (27)	25 (22)	18 (19)
Half of the time	4 (4)	2 (2)	4 (4)	2 (2)	3 (3)
Some of the time	2 (2)	2 (2)	2 (2)	0 (0)	0 (0)
Not last month	2 (2)	0 (0)	0 (0)	1 (1)	1 (1)
Not reported	2 (2)	1 (1)	1 (1)	2 (2)	2 (2)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	81 (80)	71 (71)	83 (73)	99 (85)	79 (81)
Once	5 (5)	12 (12)	8 (7)	7 (6)	8 (8)
Twice	6 (6)	8 (8)	9 (8)	3 (3)	1 (1)
3-5 times	5 (5)	7 (7)	6 (5)	4 (3)	7 (7)
>5 times	3 (3)	2 (2)	6 (5)	2 (2)	1 (1)
Not reported	1 (1)	0 (0)	1 (1)	1 (1)	1 (1)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	81 (80)	71 (71)	83 (73)	99 (85)	79 (81)
One	8 (8)	10 (10)	11 (10)	4 (3)	8 (8)
Two	2 (2)	2 (2)	1 (1)	3 (3)	1 (1)
Three to five	3 (3)	0 (0)	2 (2)	1 (1)	0 (0)
More than five	1 (1)	1 (1)	2 (2)	0 (0)	0 (0)
Don't know	2 (2)	13 (13)	10 (9)	5 (4)	8 (8)
Not reported	4 (4)	3 (3)	4 (4)	4 (3)	1 (1)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	8 (8)	10 (10)	10 (9)	5 (4)	3 (3)
Casual sex partner	1 (1)	2 (2)	0 (0)	1 (1)	1 (1)
Close friend	5 (5)	7 (7)	5 (4)	4 (3)	9 (9)
Acquaintance	1 (1)	6 (6)	5 (4)	2 (2)	4 (4)
Other	1 (1)	2 (2)	1 (1)	3 (3)	0 (0)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	26 (26)	31 (31)	33 (29)	27 (23)	24 (25)
Water	18 (18)	21 (21)	21 (19)	14 (12)	12 (12)
Filter	10 (10)	16 (16)	11 (10)	7 (6)	9 (9)
Drug mix	12 (12)	10 (10)	14 (12)	9 (8)	8 (8)
None	63 (62)	65 (65)	74 (65)	79 (68)	65 (67)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	85 (84)	85 (85)	90 (80)	102 (88)	86 (89)
Yes	16 (16)	15 (15)	23 (20)	13 (11)	11 (11)
Not reported	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
<b>Source of needle acquisition</b>					
Needle Syringe Program	87 (86)	90 (90)	101 (89)	108 (93)	86 (89)
Chemist/Pharmacy	36 (36)	36 (36)	37 (33)	33 (28)	26 (27)
Personal sources	20 (20)	22 (22)	24 (21)	17 (15)	17 (18)
Dispensing/Vending Machine	23 (23)	28 (28)	29 (26)	32 (28)	17 (18)
Other sources	3 (3)	0 (0)	5 (4)	3 (3)	3 (3)

**Table 2.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

Australian Capital Territory	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=112	N=119	N=127	N=128	N=104
<b>Ever any treatment/therapy for drug use (%)</b>					
No	26 (23)	22 (18)	33 (26)	26 (20)	21 (20)
Yes	86 (77)	96 (81)	93 (73)	101 (80)	83 (80)
Not reported	0 (0)	1 (<1)	1 (<1)	1 (<1)	0 (0)
<b>History of methadone maintenance treatment (%)</b>					
Currently	41 (37)	44 (37)	33 (26)	49 (38)	33 (32)
Previously	23 (21)	20 (17)	29 (23)	32 (25)	23 (22)
Never	46 (41)	51 (43)	58 (46)	43 (34)	45 (43)
Not reported	2 (2)	4 (3)	7 (6)	4 (3)	3 (3)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	8 (7)	12 (10)	7 (6)	5 (4)	7 (7)
Previously	24 (21)	32 (27)	31 (24)	29 (23)	35 (34)
Never	76 (68)	74 (62)	86 (68)	91 (71)	60 (58)
Not reported	4 (4)	1 (1)	3 (2)	3 (2)	2 (2)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	9 (8)	11 (9)	8 (6)	9 (7)	3 (3)
Previously	23 (21)	29 (24)	33 (26)	28 (22)	29 (28)
Never	77 (69)	75 (63)	83 (65)	88 (69)	72 (69)
Not reported	3 (3)	4 (3)	3 (2)	3 (2)	0 (0)

**Table 2.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

Australian Capital Territory	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=112	N=119	N=127	N=128	N=104
<b>Previous HIV test (%)</b>					
Yes, ever	98 (88)	97 (82)	102 (80)	113 (88)	85 (82)
Yes, last year	49 (44)	59 (50)	62 (49)	70 (55)	49 (47)
>1 year ago	49 (44)	38 (32)	40 (32)	43 (34)	36 (35)
Never tested	11 (10)	19 (16)	15 (12)	12 (9)	14 (13)
Not reported	3 (3)	3 (3)	10 (8)	3 (2)	5 (5)
<b>Previous HCV test (%)</b>					
Yes, ever	94 (84)	92 (77)	104 (82)	116 (91)	87 (84)
Yes, last year	57 (51)	63 (53)	68 (54)	80 (63)	48 (46)
>1 year ago	37 (33)	29 (24)	36 (28)	36 (28)	39 (38)
Never tested	11 (10)	11 (9)	11 (9)	4 (3)	8 (8)
Not reported	7 (6)	16 (13)	12 (9)	8 (6)	9 (9)
<b>Lifetime treatment for HCV (%)#</b>					
<b>N° self-reported HCV diagnosis</b>	N=34	N=35	N=46	N=50	N=29
Antiviral treatment	8 (24)	16 (46)	21 (46)	33 (66)	16 (55)
No antiviral treatment	26 (76)	19 (54)	25 (54)	17 (34)	12 (41)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)
<b>Treatment for HCV in past 12 months (%)**</b>					
<b>N° self-reported HCV diagnosis</b>	N=33	N=28	N=40	N=37	N=18
Antiviral treatment	7 (21)	9 (32)	14 (35)	17 (46)	2 (11)
No antiviral treatment	26 (79)	19 (68)	26 (65)	20 (54)	15 (83)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (6)

# among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 2.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

Australian Capital Territory	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=112	N=119	N=127	N=128	N=104
<b>Sex with a regular partner last month (%)</b>					
No	73 (65)	75 (63)	75 (59)	78 (61)	69 (66)
Yes	38 (34)	39 (33)	43 (34)	46 (36)	31 (30)
Not reported	1 (1)	5 (4)	9 (7)	4 (3)	4 (4)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=38	N=39	N=43	N=46	N=31
Never	22 (58)	29 (74)	34 (79)	38 (83)	25 (81)
Sometimes	7 (18)	4 (10)	4 (9)	3 (7)	4 (13)
Every time	7 (18)	5 (13)	2 (5)	3 (7)	1 (3)
Not reported	2 (5)	1 (3)	3 (7)	2 (4)	1 (3)
<b>Sex with other partner(s) last month (%)</b>					
No	101 (90)	107 (90)	103 (81)	115 (90)	95 (91)
Yes	8 (7)	7 (6)	12 (9)	11 (9)	5 (5)
Not reported	3 (3)	5 (4)	12 (9)	2 (2)	4 (4)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=8	N=7	N=12	N=11	N=5
Never	2 (25)	3 (43)	7 (58)	7 (64)	2 (40)
Sometimes	5 (63)	1 (14)	0 (0)	1 (9)	3 (60)
Every time	1 (13)	1 (14)	4 (33)	2 (18)	0 (0)
Not reported	0 (0)	2 (29)	1 (8)	1 (9)	0 (0)
<b>Sex work last month (%)</b>					
No	105 (94)	111 (93)	108 (85)	117 (91)	97 (93)
Yes	3 (3)	3 (3)	8 (6)	5 (4)	4 (4)
Not reported	4 (4)	5 (4)	11 (9)	6 (5)	3 (3)
<b>Condom used at last sex work (%)</b>					
Yes	1 (33)	1 (33)	7 (88)	4 (80)	1 (25)

**Table 2.1.7 Number (percentage) of respondents by COVID-19 related behaviours in 2020**

<b>Australian Capital Territory</b>			
<b>N° surveyed</b>		<b>N=104</b>	
<b>More difficult to access sterile needles and syringes</b>		<b>Start or increase takeaway dose of methadone/bupe/suboxone</b>	
Yes	15 (14)	Yes	1 (4)
No	81 (78)	No	2 (74)
Not applicable	7 (7)	Not applicable	3 (24)
Not reported	1 (1)	Not reported	2 (2)
<b>Start depot buprenorphine</b>		<b>Inject own methadone/bupe/suboxone</b>	
Yes	9 (9)	Yes	11 (11)
No	70 (67)	No	74 (71)
Not applicable	24 (23)	Not applicable	17 (16)
Not reported	1 (1)	Not reported	2 (2)
<b>Access take home naloxone</b>		<b>COVID-19 test</b>	
Yes	27 (26)	Yes	27 (26)
No	58 (56)	No	71 (68)
Not applicable	15 (14)	Don't know	5 (5)
Not reported	4 (4)	Not reported	1 (1)
<b>Change illicit drug use</b>		<b>If YES, what was result (N=27)</b>	
Yes, increased	22 (21)	Positive	0 (0)
Yes, decreased	29 (28)	Negative	26 (96)
No change	51 (49)	Don't know	1 (4)
Not reported	2 (2)	Not reported	0 (0)

## HIV antibody prevalence

**Table 2.2.1 HIV antibody prevalence by gender and survey year**

Aust. Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2016	72	0 (0.0)	31	0 (0.0)	105	0 (0.0)
2017	80	0 (0.0)	38	0 (0.0)	119	0 (0.0)
2018	90	0 (0.0)	35	0 (0.0)	127	0 (0.0)
2019	84	0 (0.0)	42	0 (0.0)	126	0 (0.0)
2020	69	0 (0.0)	33	0 (0.0)	103	0 (0.0)
X <sup>2</sup> p trend		--		--		--

## HCV antibody prevalence

**Table 2.3.1 HCV antibody prevalence by gender and survey year**

Aust. Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2016	68	39 (57)	27	14 (52)	97	54 (56)
2017	77	46 (60)	38	23 (61)	116	70 (60)
2018	90	51 (57)	35	22 (63)	127	73 (57)
2019	84	38 (45)	42	23 (55)	126	61 (48)
2020	69	32 (46)	33	19 (58)	103	51 (50)
X <sup>2</sup> p trend		0.044		0.782		0.094

**Table 2.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

Aust. Capital Territory	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heterosexual	60	34 (57)	21	11 (52)	81	45 (56)
Bisexual	5	3 (60)	5	2 (40)	11	6 (55)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		1.000		1.000
<b>2017</b>						
Heterosexual	66	42 (64)	23	15 (65)	89	57 (64)
Bisexual	5	1 (20)	9	3 (33)	15	5 (33)
Homosexual	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.075		0.126		0.031
<b>2018</b>						
Heterosexual	77	43 (56)	22	14 (64)	100	57 (57)
Bisexual	6	2 (33)	7	4 (57)	13	6 (46)
Homosexual	2	1 (50)	0	0 (0)	3	1 (33)
p value		0.701		1.000		0.594
<b>2019</b>						
Heterosexual	64	28 (44)	27	15 (56)	91	43 (47)
Bisexual	5	3 (60)	8	5 (63)	13	8 (62)
Homosexual	3	3 (100)	1	0 (0)	4	3 (75)
p value		0.158		0.495		0.401
<b>2020</b>						
Heterosexual	63	28 (44)	21	12 (57)	84	40 (48)
Bisexual	5	3 (60)	5	3 (60)	10	6 (60)
Homosexual	0	0 (0)	2	1 (50)	2	1 (50)
p value		0.653		0.580		0.381



**Table 2.3.3 HCV antibody prevalence by age group, gender and survey year**

Aust. Capital Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	0	0 (0)	4	3 (75)	4	3 (75)
25-34 years	7	4 (57)	6	2 (33)	13	6 (46)
35-44 years	24	16 (67)	7	4 (57)	33	21 (64)
45+ years	36	19 (53)	10	5 (50)	46	24 (52)
p value		0.592		0.704		0.560
<b>2017</b>						
<25 years	0	0 (0)	3	1 (33)	3	1 (33)
25-34 years	15	7 (47)	10	5 (50)	26	13 (50)
35-44 years	27	19 (70)	12	7 (58)	39	26 (67)
45+ years	34	19 (56)	13	10 (77)	47	29 (62)
p value		0.287		0.393		0.417
<b>2018</b>						
<25 years	2	0 (0)	2	1 (50)	4	1 (25)
25-34 years	13	7 (54)	9	6 (67)	22	13 (59)
35-44 years	40	28 (70)	14	8 (57)	56	36 (64)
45+ years	35	16 (46)	10	7 (70)	45	23 (51)
p value		0.056		0.952		0.321
<b>2019</b>						
<25 years	1	0 (0)	4	2 (50)	5	2 (40)
25-34 years	9	1 (11)	10	6 (60)	19	7 (37)
35-44 years	33	16 (48)	14	6 (43)	47	22 (47)
45+ years	41	21 (51)	14	9 (64)	55	30 (55)
p value		0.097		0.777		0.602
<b>2020</b>						
<25 years	0	0 (0)	1	1 (100)	1	1 (100)
25-34 years	9	2 (22)	5	4 (80)	15	6 (40)
35-44 years	23	8 (35)	15	8 (53)	38	16 (42)
45+ years	37	22 (59)	12	6 (50)	49	28 (57)
p value		0.059		0.668		0.298

**Table 2.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

Aust. Capital Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	1	0 (0)	1	1 (100)	2	1 (50)
3 to 10 years	3	1 (33)	7	3 (43)	10	4 (40)
11+ years	60	36 (60)	19	10 (53)	81	47 (58)
p value		0.384		1.000		0.510
<b>2017</b>						
<3 years	1	0 (0)	2	1 (50)	3	1 (33)
3 to 10 years	10	5 (50)	6	2 (33)	16	7 (44)
11+ years	63	39 (62)	28	18 (64)	92	58 (63)
p value		0.383		0.391		0.213
<b>2018</b>						
<3 years	3	2 (67)	0	0 (0)	3	2 (67)
3 to 10 years	9	2 (22)	7	4 (57)	16	6 (38)
11+ years	74	43 (58)	27	17 (63)	103	60 (58)
p value		0.106		1.000		0.286
<b>2019</b>						
<3 years	3	0 (0)	5	0 (0)	8	0 (0)
3 to 10 years	6	1 (17)	6	5 (83)	12	6 (50)
11+ years	73	36 (49)	30	17 (57)	103	53 (51)
p value		0.108		0.016		0.014
<b>2020</b>						
<3 years	3	0 (0)	1	0 (0)	4	0 (0)
3 to 10 years	6	1 (17)	2	2 (100)	8	3 (38)
11+ years	59	31 (53)	28	15 (54)	88	46 (52)
p value		0.069		0.337		0.122

**Table 2.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

Aust. Capital Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	2	1 (50)	70	41 (59)	74	44 (59)
Receptive sharing	0	0 (0)	13	6 (46)	13	6 (46)
p value		--		0.407		0.371
<b>2017</b>						
No receptive sharing	3	1 (33)	65	37 (57)	71	41 (58)
Receptive sharing	0	0 (0)	26	16 (62)	27	17 (63)
p value		--		0.687		0.639
<b>2018</b>						
No receptive sharing	2	1 (50)	79	46 (58)	83	49 (59)
Receptive sharing	1	1 (100)	27	15 (56)	29	17 (59)
p value		1.000		0.808		0.969
<b>2019</b>						
No receptive sharing	8	0 (0)	87	45 (52)	97	46 (47)
Receptive sharing	0	0 (0)	15	8 (53)	16	9 (56)
p value		--		0.908		0.513
<b>2020</b>						
No receptive sharing	4	0 (0)	73	36 (49)	78	36 (46)
Receptive sharing	0	0 (0)	15	9 (60)	17	11 (65)
p value		--		0.451		0.166

**Table 2.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

Aust. Capital Territory Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	2	1 (50)	36	26 (72)	40	28 (70)
Methamphetamine	0	0 (0)	34	14 (41)	35	14 (40)
Other opioids	0	0 (0)	15	8 (53)	15	8 (53)
Other drugs	0	0 (0)	4	2 (50)	5	3 (60)
p value		--		0.072		0.076
<b>2017</b>						
Heroin	1	1 (100)	49	33 (67)	52	36 (69)
Methamphetamine	2	0 (0)	45	22 (49)	48	23 (48)
Other opioids	0	0 (0)	6	3 (50)	7	4 (57)
Other drugs	0	0 (0)	6	5 (83)	6	5 (83)
p value		0.083		0.172		0.104
<b>2018</b>						
Heroin	0	0 (0)	49	28 (57)	51	30 (59)
Methamphetamine	2	1 (50)	54	28 (52)	58	31 (53)
Other opioids	0	0 (0)	7	5 (71)	7	5 (71)
Other drugs	1	1 (100)	6	5 (83)	7	6 (86)
p value		0.386		0.411		0.358
<b>2019</b>						
Heroin	2	0 (0)	53	32 (60)	57	33 (58)
Methamphetamine	5	0 (0)	50	19 (38)	56	20 (36)
Other opioids	1	0 (0)	6	3 (50)	7	3 (43)
Other drugs	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.104		0.076
<b>2020</b>						
Heroin	1	0 (0)	46	28 (61)	50	30 (60)
Methamphetamine	3	0 (0)	35	16 (46)	38	16 (42)
Other opioids	0	0 (0)	8	3 (38)	8	3 (38)
Other drugs	0	0 (0)	7	2 (29)	7	2 (29)
p value		--		0.243		0.193

**Table 2.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

Aust. Capital Territory Frequency of injection last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	2	1 (50)	36	23 (64)	39	25 (64)
Daily or more	0	0 (0)	47	24 (51)	49	25 (51)
Not last month	0	0 (0)	6	3 (50)	7	3 (43)
p value		--		0.500		0.425
<b>2017</b>						
Less than daily	0	0 (0)	39	19 (49)	43	23 (53)
Daily or more	3	1 (33)	52	34 (65)	55	35 (64)
Not last month	0	0 (0)	15	10 (67)	15	10 (67)
p value		--		0.244		0.511
<b>2018</b>						
Less than daily	3	2 (67)	41	22 (54)	47	27 (57)
Daily or more	0	0 (0)	66	40 (61)	66	40 (61)
Not last month	0	0 (0)	9	4 (44)	11	6 (55)
p value		--		0.541		0.902
<b>2019</b>						
Less than daily	6	0 (0)	42	22 (52)	50	24 (48)
Daily or more	2	0 (0)	61	31 (51)	64	31 (48)
Not last month	0	0 (0)	10	4 (40)	10	4 (40)
p value		--		0.850		0.926
<b>2020</b>						
Less than daily	1	0 (0)	36	11 (31)	37	11 (30)
Daily or more	3	0 (0)	53	35 (66)	59	37 (63)
Not last month	0	0 (0)	7	3 (43)	7	3 (43)
p value		--		0.003		0.005

**Table 2.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

Aust. Capital Territory Imprisonment last year	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	2	1 (50)	78	43 (55)	84	46 (55)
Imprisonment	0	0 (0)	12	7 (58)	12	7 (58)
p value		--		0.835		0.816
<b>2017</b>						
No imprisonment	3	1 (33)	85	48 (56)	92	52 (57)
Imprisonment	0	0 (0)	17	11 (65)	18	12 (67)
p value		--		0.530		0.425
<b>2018</b>						
No imprisonment	2	1 (50)	95	50 (53)	99	53 (54)
Imprisonment	0	0 (0)	10	6 (60)	11	7 (64)
p value		--		0.748		0.751
<b>2019</b>						
No imprisonment	6	0 (0)	95	50 (53)	102	51 (50)
Imprisonment	2	0 (0)	15	6 (40)	19	7 (37)
p value		--		0.363		0.292
<b>2020</b>						
No imprisonment	3	0 (0)	80	38 (48)	83	38 (46)
Imprisonment	1	0 (0)	12	7 (58)	15	9 (60)
p value		--		0.310		0.310

**Table 2.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Aust. Capital Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	52	31 (60)	18	9 (50)	71	40 (56)
Indigenous	13	5 (38)	7	3 (43)	21	9 (43)
p value		0.170		1.000		0.277
<b>2017</b>						
Non Indigenous	62	38 (61)	25	15 (60)	88	54 (61)
Indigenous	14	7 (50)	13	8 (62)	27	15 (56)
p value		0.438		1.000		0.590
<b>2018</b>						
Non Indigenous	74	41 (55)	22	12 (55)	98	53 (54)
Indigenous	15	9 (60)	12	9 (75)	27	18 (67)
p value		0.744		0.292		0.242
<b>2019</b>						
Non Indigenous	73	34 (47)	31	16 (52)	104	50 (48)
Indigenous	10	4 (40)	11	7 (64)	21	11 (52)
p value		0.748		0.726		0.719
<b>2020</b>						
Non Indigenous	57	22 (39)	23	11 (48)	81	33 (41)
Indigenous	10	8 (80)	9	7 (78)	19	15 (79)
p value		0.034		0.235		0.004

**Table 2.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

Aust. Capital Territory Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	62	37 (60)	27	14 (52)	91	52 (57)
Non-English speaking	6	2 (33)	0	0 (0)	6	2 (33)
p value		0.390		--		0.401
<b>2017</b>						
English speaking	73	43 (59)	37	22 (59)	111	66 (59)
Non-English speaking	3	2 (67)	0	0 (0)	3	2 (67)
p value		1.000		--		1.000
<b>2018</b>						
English speaking	81	47 (58)	31	20 (65)	114	67 (59)
Non-English speaking	7	3 (43)	4	2 (50)	11	5 (45)
p value		0.459		0.618		0.393
<b>2019</b>						
English speaking	78	38 (49)	39	20 (51)	117	58 (50)
Non-English speaking	6	0 (0)	3	3 (100)	9	3 (33)
p value		0.030		0.102		0.494
<b>2020</b>						
English speaking	64	29 (45)	33	19 (58)	98	48 (49)
Non-English speaking	5	3 (60)	0	0 (0)	5	3 (60)
p value		0.657		--		0.678

**Table 2.3.11 HCV antibody prevalence by region/country of birth, gender and survey year**

Aust. Capital Territory Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Australia	64	37 (58)	25	13 (52)	91	51 (56)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	2	1 (50)	4	2 (50)
Other	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.837		1.000		0.884
<b>2017</b>						
Australia	64	38 (59)	37	22 (59)	102	61 (60)
Other Oceania	3	0 (0)	0	0 (0)	3	0 (0)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)
Other	4	3 (75)	1	1 (100)	5	4 (80)
p value		0.180		1.000		0.134
<b>2018</b>						
Australia	76	45 (59)	32	21 (66)	110	66 (60)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	5	2 (40)	1	0 (0)	6	2 (33)
Other	6	3 (50)	1	0 (0)	7	3 (43)
p value		0.472		0.139		0.212
<b>2019</b>						
Australia	72	33 (46)	39	21 (54)	111	54 (49)
Other Oceania	3	2 (67)	3	2 (67)	6	4 (67)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	4	2 (50)	0	0 (0)	4	2 (50)
Other	5	1 (20)	0	0 (0)	5	1 (20)
p value		0.618		1.000		0.520
<b>2020</b>						
Australia	60	27 (45)	31	18 (58)	92	45 (49)
Other Oceania	3	1 (33)	0	0 (0)	3	1 (33)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	1	1 (100)	2	1 (50)	3	2 (67)
Other	2	2 (100)	0	0 (0)	2	2 (100)
p value		0.315		1.000		0.636

## HCV RNA prevalence

**Table 2.4.1 HCV RNA prevalence by gender and survey year \***

Australian Capital Territory	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2016 <sup>#</sup>	6	2 (33)	1	0 (0)	7	2 (29)
2017	56	18 (32)	27	8 (30)	84	26 (31)
2018	67	17 (25)	26	9 (35)	95	26 (27)
2019	77	16 (21)	38	10 (26)	115	25 (22)
2020	61	14 (23)	29	5 (17)	90	19 (21)
X <sup>2</sup> p trend		0.172		0.286		0.087

\* Weighted for gender and HCV antibody status

# A number of ACT samples were subject to a failed run due to incompatibility with the HCV RNA testing platform in 2016

Totals include respondents where gender was reported as other or not reported

**Table 2.4.2 HCV RNA prevalence by sexual identity, gender and survey year \***

Australian Capital Territory	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heterosexual	6	2 (33)	1	0 (0)	7	2 (29)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2017</b>						
Heterosexual	45	13 (29)	14	4 (29)	59	17 (29)
Bisexual	5	2 (40)	7	1 (14)	13	3 (23)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
p value		0.860		0.243		0.270
<b>2018</b>						
Heterosexual	62	14 (23)	17	5 (29)	80	20 (25)
Bisexual	2	1 (50)	6	3 (50)	8	4 (50)
Homosexual	1	0 (0)	0	0 (0)	2	0 (0)
p value		0.608		0.598		0.315
<b>2019</b>						
Heterosexual	61	12 (20)	25	6 (24)	85	17 (20)
Bisexual	4	1 (25)	8	2 (25)	12	3 (25)
Homosexual	3	1 (33)	1	0 (0)	4	1 (25)
p value		0.823		0.856		0.924
<b>2020</b>						
Heterosexual	56	13 (23)	18	2 (11)	74	15 (20)
Bisexual	4	1 (25)	4	2 (50)	8	3 (38)
Homosexual	0	0 (0)	2	0 (0)	2	0 (0)
p value		0.886		0.193		0.466

**Table 2.4.3 HCV RNA prevalence by age group, gender and survey year \***

Australian Capital Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	1	0 (0)	1	0 (0)
35-44 years	3	2 (67)	0	0 (0)	3	2 (67)
45+ years	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.153		--		0.243
<b>2017</b>						
<25 years	0	0 (0)	2	1 (50)	2	1 (50)
25-34 years	12	4 (33)	6	1 (17)	18	5 (28)
35-44 years	24	7 (29)	7	2 (29)	31	9 (29)
45+ years	20	7 (35)	12	4 (33)	32	11 (34)
p value		0.830		0.882		0.845
<b>2018</b>						
<25 years	2	0 (0)	1	1 (100)	3	1 (33)
25-34 years	9	3 (33)	6	4 (67)	16	8 (50)
35-44 years	29	7 (24)	12	3 (25)	42	10 (24)
45+ years	26	6 (23)	7	1 (14)	34	7 (21)
p value		0.803		0.045		0.212
<b>2019</b>						
<25 years	1	0 (0)	4	1 (25)	5	1 (20)
25-34 years	8	1 (13)	9	5 (56)	17	6 (35)
35-44 years	32	7 (22)	12	2 (17)	44	9 (20)
45+ years	35	8 (23)	13	2 (15)	49	10 (20)
p value		0.858		0.128		0.650
<b>2020</b>						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	9	0 (0)	5	2 (40)	14	2 (14)
35-44 years	19	3 (16)	12	3 (25)	31	6 (19)
45+ years	33	10 (30)	12	0 (0)	44	10 (23)
p value		0.100		0.169		0.837



**Table 2.4.4 HCV RNA prevalence by years since first injection, gender and survey year \***

Australian Capital Territory	Male		Female		Total	
Years of injection	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	2	0 (0)	1	0 (0)	3	0 (0)
11+ years	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.414		--		0.361
<b>2017</b>						
<3 years	1	1 (100)	1	0 (0)	2	1 (50)
3 to 10 years	8	3 (38)	5	3 (60)	13	6 (46)
11+ years	45	14 (31)	19	3 (16)	65	18 (28)
p value		0.482		0.110		0.384
<b>2018</b>						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	8	2 (25)	4	3 (75)	12	5 (42)
11+ years	56	13 (23)	22	6 (27)	79	20 (25)
p value		0.233		0.091		0.161
<b>2019</b>						
<3 years	3	0 (0)	5	0 (0)	8	0 (0)
3 to 10 years	6	0 (0)	6	4 (67)	12	4 (33)
11+ years	65	15 (23)	28	6 (21)	93	20 (22)
p value		0.278		0.027		0.222
<b>2020</b>						
<3 years	3	0 (0)	1	0 (0)	4	0 (0)
3 to 10 years	6	0 (0)	2	1 (50)	8	1 (13)
11+ years	51	14 (27)	24	4 (17)	75	18 (24)
p value		0.210		0.449		0.439

**Table 2.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year \***

Australian Capital Territory	Male		Female		Total	
Receptively shared syringe last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	3	2 (67)	1	0 (0)	4	2 (50)
Receptive sharing	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.277		--		0.225
<b>2017</b>						
No receptive sharing	34	12 (35)	16	4 (25)	51	16 (31)
Receptive sharing	16	6 (38)	5	3 (60)	21	9 (43)
p value		0.862		0.169		0.392
<b>2018</b>						
No receptive sharing	40	10 (25)	20	8 (40)	61	19 (31)
Receptive sharing	19	5 (26)	4	1 (25)	23	6 (26)
p value		0.917		0.554		0.680
<b>2019</b>						
No receptive sharing	55	12 (22)	33	9 (27)	88	20 (23)
Receptive sharing	14	3 (21)	1	0 (0)	15	3 (20)
p value		0.951		0.557		0.732
<b>2020</b>						
No receptive sharing	46	12 (26)	21	3 (14)	67	14 (21)
Receptive sharing	10	1 (10)	6	2 (33)	16	3 (19)
p value		0.321		0.294		0.803

**Table 2.4.6 HCV RNA prevalence by last drug injected, gender and survey year \***

Australian Capital Territory Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	2	1 (50)	1	0 (0)	3	1 (33)
Methamphetamine	3	1 (33)	0	0 (0)	3	1 (33)
Other opioids	1	0 (0)	0	0 (0)	1	0 (0)
Other drugs	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.755		--		0.863
<b>2017</b>						
Heroin	18	7 (39)	15	3 (20)	33	11 (33)
Methamphetamine	31	7 (23)	10	4 (40)	41	11 (27)
Other opioids	3	1 (33)	1	0 (0)	4	1 (25)
Other drugs	4	3 (75)	1	0 (0)	5	3 (60)
p value		0.203		0.648		0.439
<b>2018</b>						
Heroin	29	7 (24)	10	4 (40)	41	12 (29)
Methamphetamine	32	9 (28)	11	2 (18)	43	11 (26)
Other opioids	4	0 (0)	2	1 (50)	6	1 (17)
Other drugs	0	0 (0)	3	2 (67)	3	2 (67)
p value		0.441		0.333		0.419
<b>2019</b>						
Heroin	30	6 (20)	23	7 (30)	53	12 (23)
Methamphetamine	37	8 (22)	12	2 (17)	50	10 (20)
Other opioids	5	0 (0)	2	0 (0)	7	0 (0)
Other drugs	3	1 (33)	1	1 (100)	4	2 (50)
p value		0.655		0.215		0.266
<b>2020</b>						
Heroin	32	6 (19)	12	2 (17)	43	8 (19)
Methamphetamine	21	5 (24)	12	2 (17)	33	7 (21)
Other opioids	2	0 (0)	5	1 (20)	7	1 (14)
Other drugs	6	2 (33)	1	0 (0)	7	2 (29)
p value		0.744		0.971		0.893

**Table 2.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year \***

Australian Capital Territory	Male		Female		Total	
Frequency of injection last month	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	4	0 (0)	0	0 (0)	4	0 (0)
Daily or more	2	2 (100)	1	0 (0)	3	2 (67)
Not last month	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.009		--		0.072
<b>2017</b>						
Less than daily	24	8 (33)	9	3 (33)	33	11 (33)
Daily or more	27	9 (33)	11	4 (36)	39	14 (36)
Not last month	5	0 (0)	5	1 (20)	11	1 (9)
p value		0.308		0.829		0.288
<b>2018</b>						
Less than daily	25	5 (20)	10	4 (40)	35	9 (26)
Daily or more	35	10 (29)	13	5 (38)	50	16 (32)
Not last month	5	1 (20)	3	0 (0)	8	1 (13)
p value		0.701		0.406		0.504
<b>2019</b>						
Less than daily	29	10 (34)	17	3 (18)	47	13 (28)
Daily or more	40	5 (13)	17	6 (35)	57	11 (19)
Not last month	5	0 (0)	4	1 (25)	9	1 (11)
p value		0.049		0.524		0.391
<b>2020</b>						
Less than daily	21	2 (10)	8	0 (0)	29	2 (7)
Daily or more	36	10 (28)	20	5 (25)	55	15 (27)
Not last month	4	1 (25)	2	0 (0)	6	1 (17)
p value		0.260		0.227		0.098

**Table 2.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year \***

Australian Capital Territory	Male		Female		Total	
Imprisonment last year	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	6	2 (33)	1	0 (0)	7	2 (29)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2017</b>						
No imprisonment	48	15 (31)	24	7 (29)	72	22 (31)
Imprisonment	5	2 (40)	3	1 (33)	8	3 (38)
p value		0.901		0.890		0.980
<b>2018</b>						
No imprisonment	50	12 (24)	20	7 (35)	71	20 (28)
Imprisonment	6	1 (17)	2	1 (50)	8	2 (25)
p value		0.636		0.706		0.812
<b>2019</b>						
No imprisonment	56	13 (23)	35	7 (20)	91	20 (22)
Imprisonment	17	2 (12)	2	2 (100)	19	4 (21)
p value		0.305		0.011		0.928
<b>2020</b>						
No imprisonment	50	9 (18)	23	2 (9)	73	11 (15)
Imprisonment	8	3 (38)	5	2 (40)	13	5 (38)
p value		0.219		0.081		0.052

**Table 2.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year \***

Australian Capital Territory	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Non Indigenous	5	1 (20)	1	0 (0)	6	1 (17)
Indigenous	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.192		--		0.284
<b>2017</b>						
Non Indigenous	48	18 (38)	17	4 (24)	66	22 (33)
Indigenous	8	0 (0)	10	4 (40)	18	4 (22)
p value		0.042		0.401		0.322
<b>2018</b>						
Non Indigenous	55	11 (20)	17	5 (24)	73	16 (22)
Indigenous	12	5 (42)	8	5 (63)	20	10 (50)
p value		0.099		0.156		0.017
<b>2019</b>						
Non Indigenous	67	14 (21)	29	5 (17)	96	18 (19)
Indigenous	9	2 (22)	10	5 (50)	19	7 (37)
p value		0.961		0.044		0.113
<b>2020</b>						
Non Indigenous	50	10 (20)	19	1 (5)	69	11 (16)
Indigenous	9	2 (22)	9	4 (44)	18	6 (33)
p value		0.928		0.017		0.123

**Table 2.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year \***

Australian Capital Territory	Male		Female		Total	
Main language spoken at home by parents	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
English speaking	6	2 (33)	1	0 (0)	7	2 (29)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2017</b>						
English speaking	53	17 (32)	27	8 (30)	80	25 (31)
Non-English speaking	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.790		--		0.750
<b>2018</b>						
English speaking	61	16 (26)	22	8 (36)	85	24 (28)
Non-English speaking	4	1 (25)	4	1 (25)	8	2 (25)
p value		0.964		0.678		0.856
<b>2019</b>						
English speaking	70	16 (23)	35	9 (26)	106	24 (23)
Non-English speaking	6	0 (0)	3	1 (33)	9	1 (11)
p value		0.186		0.730		0.368
<b>2020</b>						
English speaking	56	12 (21)	29	5 (17)	85	16 (19)
Non-English speaking	5	2 (40)	0	0 (0)	5	2 (40)
p value		0.308		--		0.255

**Table 2.4.11 HCV RNA prevalence by region/country of birth, gender and survey year \***

Australian Capital Territory		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
<b>2016</b>							
Australia	6	2 (33)	1	0 (0)	7	2 (29)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	
<b>2017</b>							
Australia	49	15 (31)	26	7 (27)	75	22 (29)	
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)	
Asia	1	1 (100)	0	0 (0)	1	1 (100)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	4	2 (50)	1	1 (100)	5	3 (60)	
p value		0.326		0.121		0.207	
<b>2018</b>							
Australia	58	16 (28)	24	9 (38)	83	25 (30)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	6	1 (17)	1	0 (0)	7	1 (14)	
p value		0.799		0.551		0.588	
<b>2019</b>							
Australia	66	15 (23)	35	9 (26)	102	23 (23)	
Other Oceania	3	0 (0)	3	1 (33)	6	1 (17)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)	
Other	5	0 (0)	0	0 (0)	5	0 (0)	
p value		0.352		0.733		0.465	
<b>2020</b>							
Australia	52	12 (23)	28	5 (18)	80	16 (20)	
Other Oceania	3	0 (0)	0	0 (0)	3	0 (0)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	1	1 (100)	1	0 (0)	2	1 (50)	
Other	2	1 (50)	0	0 (0)	2	1 (50)	
p value		0.253		0.652		0.518	

## New South Wales

Table 3.1.1 Number (percentage) of respondents by demographic characteristics and survey year

New South Wales	2016	2017	2018	2019	2020*
<b>Number of sites</b>	17	17	19	18	12
<b>N° surveyed</b>	N=532	N=575	N=574	N=553	N=338
<b>Response rate (%)</b>	36%	31%	37%	41%	25%
<b>Gender (%)</b>					
Male	372 (70)	402 (70)	420 (73)	397 (72)	242 (72)
Female	153 (29)	159 (28)	147 (26)	146 (26)	91 (27)
Other	6 (1)	11 (2)	5 (1)	9 (2)	5 (1)
Not reported	1 (<1)	3 (1)	2 (<1)	1 (<1)	0 (0)
<b>Sexual identity (%)</b>					
Heterosexual	417 (78)	443 (77)	417 (73)	397 (72)	257 (76)
Bisexual	52 (10)	45 (8)	65 (11)	69 (12)	36 (11)
Gay/Lesbian	32 (6)	43 (7)	36 (6)	38 (7)	21 (6)
Other	-- --	-- --	-- --	-- --	9 (3)
Not reported	31 (6)	44 (8)	56 (10)	49 (9)	15 (4)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	418 (79)	466 (81)	446 (78)	424 (77)	252 (75)
Yes	99 (19)	97 (17)	94 (16)	118 (21)	67 (20)
Not reported	15 (3)	12 (2)	34 (6)	11 (2)	19 (6)
<b>Region/country of birth (%)</b>					
Australia	455 (86)	492 (86)	470 (82)	471 (85)	276 (82)
Other Oceania	25 (5)	23 (4)	22 (4)	22 (4)	9 (3)
Asia	10 (2)	11 (2)	6 (1)	9 (2)	12 (4)
UK & Ireland	11 (2)	18 (3)	16 (3)	12 (2)	9 (3)
Other	22 (4)	21 (4)	38 (7)	29 (5)	25 (7)
Not reported	9 (2)	10 (2)	22 (4)	10 (2)	7 (2)
<b>Main language spoken at home by parents (%)</b>					
English	495 (93)	546 (95)	512 (89)	510 (92)	303 (90)
Non-English	31 (6)	26 (5)	43 (7)	37 (7)	28 (8)
Not reported	6 (1)	3 (1)	19 (3)	6 (1)	7 (2)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	42	43	44	44	42.5
<i>Age range</i>	18-75	17-76	18-69	18-73	18-67
<i>Age group (%)</i>					
<25 years	20 (4)	28 (5)	24 (4)	23 (4)	10 (3)
25+ years	512 (96)	545 (95)	550 (96)	530 (96)	328 (97)
Not reported	0 (0)	2 (<1)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>					
<i>Age range</i>	10-76	10-76	10-54	10-63	10-60
N° not reported	16	36	41	22	15
<i>Median yrs since first injection</i>					
<i>Range</i>	<1-49	<1-50	<1-53	<1-59	<1-52
<i>Years since first injection</i>					
<3 years	30 (6)	46 (8)	28 (5)	40 (7)	27 (8)
3+ years	485 (91)	493 (86)	505 (88)	491 (89)	296 (88)
Not reported	17 (3)	36 (6)	41 (7)	22 (4)	15 (4)
<b>Imprisonment last year (%)</b>					
No	430 (81)	455 (79)	459 (80)	454 (82)	265 (78)
Yes	71 (13)	69 (12)	68 (12)	67 (12)	41 (12)
Not reported	31 (6)	51 (9)	47 (8)	32 (6)	32 (9)
<b>N° in prison</b>					
Injected in prison	34 (48)	26 (38)	26 (38)	26 (39)	15 (37)

\* Implementation of the 2020 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

**Table 3.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

<b>New South Wales</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° surveyed</b>	N=532	N=575	N=574	N=553	N=338
<b>Drug last injected (%)</b>					
Cocaine	12 (2)	13 (2)	11 (2)	11 (2)	2 (1)
Methamphetamine	189 (36)	205 (36)	203 (35)	213 (39)	118 (35)
Heroin	170 (32)	190 (33)	175 (30)	172 (31)	94 (28)
Pharm. opioids	16 (3)	20 (3)	26 (5)	15 (3)	8 (2)
Methadone	49 (9)	39 (7)	41 (7)	30 (5)	32 (9)
Buprenorphine	5 (1)	5 (1)	5 (1)	8 (1)	2 (1)
Buprenorphine/naloxone	1 (<1)	2 (<1)	3 (1)	3 (1)	4 (1)
PIEDs	52 (10)	57 (10)	64 (11)	56 (10)	47 (14)
More than one	33 (6)	29 (5)	37 (6)	24 (4)	22 (7)
Other	5 (1)	9 (2)	4 (1)	13 (2)	2 (1)
Not reported	0 (0)	6 (1)	5 (1)	8 (1)	7 (2)
<b>Ever injected opioids</b>					
No	103 (19)	144 (25)	135 (24)	133 (24)	109 (32)
Yes	428 (80)	429 (75)	419 (73)	418 (76)	229 (68)
Not reported	1 (<1)	2 (<1)	20 (3)	2 (<1)	0 (0)
<b>Frequency of injection last month (%)</b>					
Not last month	46 (9)	73 (13)	94 (16)	80 (14)	42 (12)
Less than weekly	95 (18)	99 (17)	90 (16)	85 (15)	51 (15)
Weekly not daily	140 (26)	131 (23)	136 (24)	123 (22)	84 (25)
Daily or more	240 (45)	263 (46)	232 (40)	254 (46)	155 (46)
Not reported	11 (2)	9 (2)	22 (4)	11 (2)	6 (2)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
No	420 (79)	463 (81)	464 (81)	432 (78)	276 (82)
Yes	99 (19)	82 (14)	77 (13)	96 (17)	47 (14)
Not reported	13 (2)	30 (5)	33 (6)	25 (5)	15 (4)
<b>Overdosed in last 12 months</b>					
No	431 (81)	453 (79)	436 (76)	432 (78)	287 (85)
Yes	86 (16)	88 (15)	103 (18)	92 (17)	35 (10)
Not reported	15 (3)	34 (6)	35 (6)	29 (5)	16 (5)

**Table 3.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>New South Wales</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° injected last month</b>	<b>N=475</b>	<b>N=493</b>	<b>N=458</b>	<b>N=462</b>	<b>N=290</b>
<b>Places injected last month (%)</b>					
All private	284 (60)	321 (65)	298 (65)	261 (56)	184 (63)
Any public	186 (39)	169 (34)	158 (35)	200 (43)	104 (36)
Not reported	5 (1)	3 (1)	2 (<1)	1 (<1)	2 (1)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	362 (76)	406 (82)	363 (79)	355 (77)	230 (79)
Most of the time	83 (17)	67 (14)	71 (16)	83 (18)	44 (15)
Half of the time	8 (2)	6 (1)	7 (2)	8 (2)	3 (1)
Some of the time	13 (3)	4 (1)	6 (1)	9 (2)	3 (1)
Not last month	2 (0)	3 (1)	6 (1)	3 (1)	1 (<1)
Not reported	7 (1)	7 (1)	5 (1)	4 (1)	9 (3)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	415 (87)	428 (87)	384 (84)	388 (84)	257 (89)
Once	19 (4)	19 (4)	25 (5)	24 (5)	11 (4)
Twice	16 (3)	21 (4)	13 (3)	17 (4)	6 (2)
3-5 times	9 (2)	9 (2)	20 (4)	16 (3)	3 (1)
>5 times	13 (3)	8 (2)	7 (2)	10 (2)	8 (3)
Not reported	3 (1)	8 (2)	9 (2)	7 (2)	5 (2)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	415 (87)	428 (87)	384 (84)	388 (84)	257 (89)
One	22 (5)	19 (4)	31 (7)	26 (6)	8 (3)
Two	5 (1)	5 (1)	5 (1)	7 (2)	3 (1)
Three to five	5 (1)	3 (1)	5 (1)	5 (1)	5 (2)
More than five	6 (1)	5 (1)	3 (1)	2 (<1)	3 (1)
Don't know	11 (2)	14 (3)	12 (3)	15 (3)	6 (2)
Not reported	11 (2)	19 (4)	18 (4)	19 (4)	8 (3)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	23 (5)	23 (5)	25 (5)	19 (4)	13 (4)
Casual sex partner	5 (1)	1 (<1)	0 (0)	2 (<1)	3 (1)
Close friend	12 (3)	16 (3)	15 (3)	16 (3)	6 (2)
Acquaintance	8 (2)	5 (1)	8 (2)	12 (3)	6 (2)
Other	3 (1)	3 (1)	8 (2)	8 (2)	4 (1)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	81 (17)	95 (19)	87 (19)	100 (22)	55 (19)
Water	64 (13)	59 (12)	72 (16)	78 (17)	39 (13)
Filter	36 (8)	30 (6)	35 (8)	37 (8)	21 (7)
Drug mix	35 (7)	31 (6)	33 (7)	51 (11)	23 (8)
None	356 (75)	367 (74)	330 (72)	317 (69)	209 (72)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	419 (88)	432 (88)	394 (86)	396 (86)	238 (82)
Yes	48 (10)	57 (12)	56 (12)	64 (14)	45 (16)
Not reported	8 (2)	4 (1)	8 (2)	2 (<1)	7 (2)
<b>Source of needle acquisition</b>					
Needle Syringe Program	426 (90)	428 (87)	393 (86)	398 (86)	240 (83)
Chemist/Pharmacy	93 (20)	80 (16)	83 (18)	79 (17)	55 (19)
Personal sources	59 (12)	39 (8)	56 (12)	76 (16)	35 (12)
Dispensing/Vending Machine	143 (30)	111 (23)	124 (27)	159 (34)	92 (32)
Other sources	19 (4)	16 (3)	26 (6)	14 (3)	14 (5)



**Table 3.1.4** Number (percentage) of respondents by treatment for drug use and survey year

New South Wales	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=532	N=575	N=574	N=553	N=338
<b>Ever any treatment/therapy for drug use (%)</b>					
No	129 (24)	161 (28)	153 (27)	168 (30)	103 (30)
Yes	396 (75)	408 (71)	402 (70)	381 (69)	234 (69)
Not reported	6 (1)	6 (1)	19 (3)	4 (1)	1 (<1)
<b>History of methadone maintenance treatment (%)</b>					
Currently	196 (37)	192 (33)	183 (32)	187 (34)	90 (27)
Previously	105 (20)	104 (18)	132 (23)	103 (19)	67 (20)
Never	216 (41)	262 (46)	225 (39)	252 (46)	158 (47)
Not reported	15 (3)	17 (3)	34 (6)	11 (2)	23 (7)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	21 (4)	39 (7)	47 (8)	33 (6)	24 (7)
Previously	155 (29)	122 (21)	147 (26)	148 (27)	74 (22)
Never	338 (64)	396 (69)	348 (61)	363 (66)	218 (65)
Not reported	18 (3)	18 (3)	32 (6)	9 (2)	22 (7)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	21 (4)	41 (7)	35 (6)	26 (5)	17 (5)
Previously	112 (21)	98 (17)	130 (23)	126 (23)	67 (20)
Never	379 (71)	420 (73)	374 (65)	389 (70)	251 (74)
Not reported	20 (4)	16 (3)	35 (6)	12 (2)	3 (1)

**Table 3.1.5** Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

New South Wales	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=532	N=575	N=574	N=553	N=338
<b>Previous HIV test (%)</b>					
Yes, ever	471 (89)	461 (80)	463 (81)	463 (84)	255 (75)
Yes, last year	283 (53)	283 (49)	307 (53)	274 (50)	156 (46)
>1 year ago	188 (35)	178 (31)	156 (27)	189 (34)	99 (29)
Never tested	48 (9)	69 (12)	70 (12)	63 (11)	60 (18)
Not reported	13 (2)	45 (8)	41 (7)	27 (5)	23 (7)
<b>Previous HCV test (%)</b>					
Yes, ever	448 (84)	456 (79)	452 (79)	455 (82)	271 (80)
Yes, last year	282 (53)	316 (55)	315 (55)	309 (56)	167 (49)
>1 year ago	166 (31)	140 (24)	137 (24)	146 (26)	104 (31)
Never tested	36 (7)	56 (10)	53 (9)	54 (10)	31 (9)
Not reported	48 (9)	63 (11)	69 (12)	44 (8)	36 (11)
<b>Lifetime treatment for HCV (%)<sup>#</sup></b>					
<b>N° self-reported HCV diagnosis</b>	N=169	N=157	N=163	N=147	N=64
Antiviral treatment	53 (31)	77 (49)	97 (60)	93 (63)	46 (72)
No antiviral treatment	116 (69)	78 (50)	65 (40)	53 (36)	18 (28)
Not reported	0 (0)	2 (1)	1 (1)	1 (1)	0 (0)
<b>Treatment for HCV in past 12 months (%)<sup>**</sup></b>					
<b>N° self-reported HCV diagnosis</b>	N=163	N=142	N=131	N=114	N=47
Antiviral treatment	44 (27)	57 (40)	57 (44)	53 (46)	22 (47)
No antiviral treatment	119 (73)	83 (58)	73 (56)	60 (53)	25 (53)
Not reported	0 (0)	2 (1)	1 (1)	1 (1)	0 (0)

<sup>#</sup> among people who tested HCV antibody positive and did not report spontaneous clearance

<sup>\*\*</sup> excludes people who reported treatment induced clearance more than 12 months previously

**Table 3.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

<b>New South Wales</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° surveyed</b>	N=532	N=575	N=574	N=553	N=338
<b>Sex with a regular partner last month (%)</b>					
No	257 (48)	286 (50)	279 (49)	279 (50)	143 (42)
Yes	257 (48)	247 (43)	255 (44)	245 (44)	174 (51)
Not reported	18 (3)	42 (7)	40 (7)	29 (5)	21 (6)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=257	N=247	N=255	N=245	N=174
Never	186 (72)	187 (76)	182 (71)	171 (70)	127 (73)
Sometimes	28 (11)	24 (10)	26 (10)	35 (14)	21 (12)
Every time	29 (11)	27 (11)	32 (13)	26 (11)	20 (11)
Not reported	14 (5)	9 (4)	15 (6)	13 (5)	6 (3)
<b>Sex with other partner(s) last month (%)</b>					
No	416 (78)	441 (77)	437 (76)	421 (76)	252 (75)
Yes	92 (17)	78 (14)	82 (14)	91 (16)	61 (18)
Not reported	24 (5)	56 (10)	55 (10)	41 (7)	25 (7)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=92	N=78	N=82	N=91	N=61
Never	29 (32)	31 (40)	33 (40)	35 (38)	25 (41)
Sometimes	28 (30)	23 (29)	21 (26)	20 (22)	19 (31)
Every time	35 (38)	22 (28)	25 (30)	28 (31)	15 (25)
Not reported	0 (0)	2 (3)	3 (4)	8 (9)	2 (3)
<b>Sex work last month (%)</b>					
No	479 (90)	482 (84)	487 (85)	474 (86)	293 (87)
Yes	29 (5)	35 (6)	30 (5)	28 (5)	20 (6)
Not reported	24 (5)	58 (10)	57 (10)	51 (9)	25 (7)
<b>Condom used at last sex work (%)</b>					
Yes	17 (59)	24 (69)	19 (63)	19 (68)	10 (50)

**Table 3.1.7 Number (percentage) of respondents by COVID-19 related behaviours in 2020**

<b>New South Wales</b>			
<b>N° surveyed</b>		<b>N=338</b>	
<b>More difficult to access sterile needles and syringes</b>		<b>Start or increase takeaway dose of methadone/bupe/suboxone</b>	
Yes	45 (13)	Yes	48 (14)
No	226 (67)	No	151 (45)
Not applicable	39 (12)	Not applicable	95 (28)
Not reported	28 (8)	Not reported	44 (13)
<b>Start depot buprenorphine</b>		<b>Inject own methadone/bupe/suboxone</b>	
Yes	20 (6)	Yes	43 (13)
No	189 (56)	No	168 (50)
Not applicable	92 (27)	Not applicable	92 (27)
Not reported	37 (11)	Not reported	35 (10)
<b>Access take home naloxone</b>		<b>COVID-19 test</b>	
Yes	56 (17)	Yes	138 (41)
No	155 (46)	No	155 (46)
Not applicable	85 (25)	Don't know	9 (3)
Not reported	42 (12)	Not reported	36 (11)
<b>Change illicit drug use</b>		<b>If YES, what was result (N=138)</b>	
Yes, increased	35 (10)	Positive	2 (1)
Yes, decreased	89 (26)	Negative	129 (93)
No change	172 (51)	Don't know	4 (3)
Not reported	42 (12)	Not reported	3 (2)

## HIV antibody prevalence

Table 3.2.1 HIV antibody prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
2016	354	11 (3.1)	148	1 (0.7)	509	13 (2.6)
2017	369	17 (4.6)	150	3 (2.0)	533	21 (3.9)
2018	395	15 (3.8)	144	1 (0.7)	546	17 (3.1)
2019	387	22 (5.7)	143	1 (0.7)	540	24 (4.4)
2020	232	11 (4.7)	88	0 (0.0)	325	13 (4.0)
X <sup>2</sup> p trend		0.189		0.381		0.194

Table 3.2.2 HIV antibody prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
Heterosexual	293	0 (0.0)	106	0 (0.0)	401	0 (0.0)
Bisexual	16	1 (6.3)	32	1 (3.1)	48	2 (4.2)
Homosexual	25	9 (36.0)	0	0 (0.0)	29	10 (34.5)
p value		<0.001		0.232		<0.001
<b>2017</b>						
Heterosexual	293	3 (1.0)	119	1 (0.8)	415	5 (1.2)
Bisexual	24	2 (4.2)	15	2 (13.3)	41	3 (7.3)
Homosexual	25	12 (48.0)	5	0 (0.0)	36	12 (33.3)
p value		<0.001		0.054		<0.001
<b>2018</b>						
Heterosexual	301	0 (0.0)	90	1 (1.1)	392	1 (0.3)
Bisexual	26	2 (7.7)	36	0 (0.0)	64	2 (3.1)
Homosexual	26	10 (38.5)	7	0 (0.0)	34	11 (32.4)
p value		<0.001		1.000		<0.001
<b>2019</b>						
Heterosexual	299	1 (0.3)	88	1 (1.1)	388	2 (0.5)
Bisexual	26	4 (15.3)	36	0 (0.0)	67	5 (7.5)
Homosexual	31	17 (54.8)	6	0 (0.0)	38	17 (44.7)
p value		<0.001		1.000		<0.001
<b>2020</b>						
Heterosexual	194	2 (1.0)	53	0 (0.0)	248	2 (0.8)
Bisexual	8	0 (0.0)	24	0 (0.0)	34	1 (2.9)
Homosexual	18	9 (50.0)	1	0 (0.0)	20	10 (50.0)
p value		<0.001		--		<0.001

**Table 3.2.3 HIV antibody prevalence by age group, gender and survey year**

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
<25 years	18	0 (0.0)	2	0 (0.0)	20	0 (0.0)
25-34 years	59	4 (6.8)	32	0 (0.0)	93	4 (4.3)
35-44 years	131	2 (1.5)	54	1 (1.9)	186	3 (1.6)
45+ years	146	5 (3.4)	60	0 (0.0)	210	6 (2.9)
p value		0.249		0.595		0.498
<b>2017</b>						
<25 years	19	0 (0.0)	5	0 (0.0)	24	0 (0.0)
25-34 years	55	0 (0.0)	21	0 (0.0)	80	1 (1.3)
35-44 years	114	6 (5.3)	61	2 (3.3)	177	8 (4.5)
45+ years	180	11 (6.1)	62	1 (1.6)	250	12 (4.8)
p value		0.230		0.786		0.462
<b>2018</b>						
<25 years	14	1 (7.1)	7	0 (0.0)	22	1 (4.6)
25-34 years	54	5 (9.3)	24	0 (0.0)	79	5 (6.3)
35-44 years	127	3 (2.4)	55	1 (1.8)	184	4 (2.2)
45+ years	200	6 (3.0)	58	0 (0.0)	261	7 (2.7)
p value		0.094		0.597		0.229
<b>2019</b>						
<25 years	15	0 (0.0)	6	0 (0.0)	21	0 (0.0)
25-34 years	66	3 (4.6)	25	0 (0.0)	93	3 (3.2)
35-44 years	118	3 (2.5)	51	0 (0.0)	171	3 (1.8)
45+ years	188	16 (8.5)	61	1 (1.6)	255	18 (7.1)
p value		0.150		1.000		0.051
<b>2020</b>						
<25 years	8	0 (0.0)	1	0 (0.0)	10	0 (0.0)
25-34 years	49	1 (2.0)	16	0 (0.0)	65	1 (1.5)
35-44 years	70	1 (1.4)	37	0 (0.0)	107	1 (0.9)
45+ years	105	9 (8.6)	34	0 (0.0)	143	11 (7.7)
p value		0.154		--		0.039

**Table 3.2.4 HIV antibody prevalence by last drug injected, gender and survey year**

New South Wales Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Heroin	106	1 (0.9)	57	1 (1.8)	165	2 (1.2)
Methamphetamine	121	9 (7.4)	56	0 (0.0)	180	10 (5.6)
Other opioids	47	0 (0.0)	21	0 (0.0)	68	0 (0.0)
PIEDs	48	0 (0.0)	0	0 (0.0)	49	0 (0.0)
Other drugs	32	1 (3.1)	14	0 (0.0)	47	1 (2.1)
p value		0.024		1.000		0.046
<b>2017</b>						
Heroin	110	3 (2.7)	61	1 (1.6)	177	4 (2.3)
Methamphetamine	134	11 (8.2)	51	2 (3.9)	188	14 (7.5)
Other opioids	43	1 (2.3)	21	0 (0.0)	65	1 (1.5)
PIEDs	43	0 (0.0)	3	0 (0.0)	47	0 (0.0)
Other drugs	39	2 (5.1)	14	0 (0.0)	56	2 (3.6)
p value		0.134		0.831		0.051
<b>2018</b>						
Heroin	107	3 (2.8)	56	0 (0.0)	165	3 (1.8)
Methamphetamine	140	9 (6.4)	47	1 (2.1)	191	11 (5.8)
Other opioids	47	1 (2.1)	27	0 (0.0)	74	1 (1.4)
PIEDs	56	0 (0.0)	3	0 (0.0)	60	0 (0.0)
Other drugs	42	2 (4.8)	10	0 (0.0)	52	2 (3.9)
p value		0.247		0.608		0.106
<b>2019</b>						
Heroin	110	1 (0.9)	51	0 (0.0)	168	2 (1.2)
Methamphetamine	153	19 (12.4)	51	1 (2.0)	207	20 (9.7)
Other opioids	36	2 (5.6)	19	0 (0.0)	55	2 (3.6)
PIEDs	54	0 (0.0)	2	0 (0.0)	56	0 (0.0)
Other drugs	29	0 (0.0)	17	0 (0.0)	46	0 (0.0)
p value		<0.001		1.000		<0.001
<b>2020</b>						
Heroin	62	1 (1.6)	28	0 (0.0)	91	1 (1.1)
Methamphetamine	80	9 (11.3)	30	0 (0.0)	113	10 (8.9)
Other opioids	27	0 (0.0)	19	0 (0.0)	46	0 (0.0)
PIEDs	43	0 (0.0)	2	0 (0.0)	45	0 (0.0)
Other drugs	16	0 (0.0)	7	0 (0.0)	24	1 (4.2)
p value		0.019		--		0.012

**Table 3.2.5 HIV antibody prevalence by years of injection, gender and survey year**

New South Wales Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
<3 years	21	0 (0.0)	7	0 (0.0)	29	0 (0.0)
3 to 10 years	59	4 (6.8)	21	0 (0.0)	81	4 (4.9)
11+ years	263	6 (2.3)	116	1 (0.9)	384	8 (2.1)
p value		0.189		1.000		0.349
<b>2017</b>						
<3 years	34	0 (0.0)	8	0 (0.0)	42	0 (0.0)
3 to 10 years	50	4 (8.0)	11	0 (0.0)	63	5 (7.9)
11+ years	285	13 (4.6)	131	3 (2.3)	428	16 (3.7)
p value		0.236		1.000		0.114
<b>2018</b>						
<3 years	19	1 (5.3)	5	0 (0.0)	24	1 (4.2)
3 to 10 years	60	5 (8.3)	13	0 (0.0)	73	5 (6.9)
11+ years	316	9 (2.9)	126	1 (0.8)	449	11 (2.5)
p value		0.090		1.000		0.098
<b>2019</b>						
<3 years	31	1 (3.2)	8	0 (0.0)	39	1 (2.6)
3 to 10 years	63	7 (11.1)	11	0 (0.0)	75	7 (9.3)
11+ years	275	14 (5.1)	122	1 (0.8)	405	16 (4.0)
p value		0.144		1.000		0.121
<b>2020</b>						
<3 years	19	1 (5.3)	8	0 (0.0)	27	1 (3.7)
3 to 10 years	42	3 (7.1)	7	0 (0.0)	50	3 (6.0)
11+ years	161	7 (4.4)	70	0 (0.0)	235	9 (3.8)
p value		0.582		--		0.698

**Table 3.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year**

New South Wales Receptively shared syringe last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
No receptive sharing	279	9 (3.2)	114	1 (0.9)	398	10 (2.5)
Receptive sharing	37	0 (0.0)	18	0 (0.0)	55	0 (0.0)
p value		0.606		1.000		0.618
<b>2017</b>						
No receptive sharing	277	13 (4.7)	112	2 (1.8)	398	15 (3.8)
Receptive sharing	38	1 (2.6)	15	1 (6.7)	54	3 (5.6)
p value		1.000		0.316		0.463
<b>2018</b>						
No receptive sharing	284	12 (4.2)	87	0 (0.0)	374	12 (3.2)
Receptive sharing	48	2 (4.2)	17	0 (0.0)	65	2 (3.1)
p value		1.000		--		1.000
<b>2019</b>						
No receptive sharing	277	18 (6.5)	98	0 (0.0)	381	19 (5.0)
Receptive sharing	47	3 (6.4)	17	1 (5.9)	65	4 (6.2)
p value		1.000		0.148		0.760
<b>2020</b>						
No receptive sharing	174	7 (4.0)	69	0 (0.0)	247	9 (3.6)
Receptive sharing	16	0 (0.0)	11	0 (0.0)	27	0 (0.0)
p value		1.000		--		0.606

**Table 3.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year**

New South Wales		Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
Less than daily	165	5 (3.0)	60	0 (0.0)	229	5 (2.2)	
Daily or more	153	4 (2.6)	73	1 (1.4)	227	5 (2.2)	
Not last month	30	1 (3.3)	12	0 (0.0)	43	1 (2.3)	
p value		1.000		1.000		1.000	
<b>2017</b>							
Less than daily	169	7 (4.1)	45	2 (4.4)	215	9 (4.2)	
Daily or more	150	7 (4.7)	85	1 (1.2)	245	9 (3.7)	
Not last month	44	2 (4.6)	19	0 (0.0)	65	2 (3.1)	
p value		1.000		0.520		0.949	
<b>2018</b>							
Less than daily	166	6 (3.6)	52	0 (0.0)	220	6 (2.7)	
Daily or more	169	8 (4.7)	57	0 (0.0)	227	8 (3.5)	
Not last month	56	1 (1.8)	33	1 (3.0)	92	3 (3.3)	
p value		0.725		0.232		0.898	
<b>2019</b>							
Less than daily	155	13 (8.4)	49	0 (0.0)	205	13 (6.3)	
Daily or more	171	8 (4.7)	69	1 (1.5)	246	10 (4.1)	
Not last month	51	1 (2.0)	24	0 (0.0)	78	1 (1.3)	
p value		0.209		1.000		0.195	
<b>2020</b>							
Less than daily	95	3 (3.2)	33	0 (0.0)	129	3 (2.3)	
Daily or more	98	4 (4.1)	48	0 (0.0)	149	6 (4.0)	
Not last month	34	4 (11.8)	7	0 (0.0)	42	4 (9.5)	
p value		0.137		--		0.119	

**Table 3.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year**

New South Wales		Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
No imprisonment	278	6 (2.2)	131	0 (0.0)	412	6 (1.5)	
Imprisonment	58	3 (5.2)	10	1 (10.0)	68	4 (5.9)	
p value		0.190		0.071		0.040	
<b>2017</b>							
No imprisonment	283	16 (5.7)	128	1 (0.8)	421	18 (4.3)	
Imprisonment	51	0 (0.0)	10	1 (10.0)	63	1 (1.6)	
p value		0.145		0.140		0.491	
<b>2018</b>							
No imprisonment	320	14 (4.4)	123	1 (0.8)	448	16 (3.6)	
Imprisonment	52	1 (1.9)	15	0 (0.0)	68	1 (1.5)	
p value		0.705		1.000		0.712	
<b>2019</b>							
No imprisonment	315	21 (6.7)	123	1 (0.8)	445	23 (5.2)	
Imprisonment	48	0 (0.0)	14	0 (0.0)	64	0 (0.0)	
p value		0.091		1.000		0.098	
<b>2020</b>							
No imprisonment	180	11 (6.1)	72	0 (0.0)	257	13 (5.1)	
Imprisonment	28	0 (0.0)	12	0 (0.0)	40	0 (0.0)	
p value		0.367		--		0.228	



**Table 3.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year**

New South Wales		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
No condom use	116	5 (4.3)	60	0 (0.0)	176	5 (2.8)	
Condom use	35	0 (0.0)	17	1 (5.9)	54	2 (3.7)	
p value		0.590		0.221		0.668	
<b>2017</b>							
No condom use	107	11 (10.3)	63	1 (1.6)	171	12 (7.0)	
Condom use	37	0 (0.0)	11	0 (0.0)	49	0 (0.0)	
p value		0.066		1.000		0.073	
<b>2018</b>							
No condom use	128	3 (2.3)	49	0 (0.0)	178	3 (1.7)	
Condom use	37	5 (13.5)	16	0 (0.0)	56	5 (8.9)	
p value		0.015		--		0.021	
<b>2019</b>							
No condom use	120	8 (6.7)	49	0 (0.0)	169	8 (4.7)	
Condom use	44	1 (2.3)	13	1 (7.7)	59	2 (3.4)	
p value		0.447		0.210		1.000	
<b>2020</b>							
No condom use	83	6 (7.2)	37	0 (0.0)	122	7 (5.7)	
Condom use	28	1 (3.6)	13	0 (0.0)	41	1 (2.4)	
p value		0.677		--		0.681	

**Table 3.2.10 HIV antibody prevalence by sex work last month, gender and survey year**

New South Wales		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
No sex work	324	6 (1.9)	129	1 (0.8)	457	8 (1.8)	
Sex work	15	3 (20.0)	11	0 (0.0)	29	3 (10.3)	
p value		0.005		1.000		0.023	
<b>2017</b>							
No sex work	316	14 (4.4)	124	2 (1.6)	447	16 (3.6)	
Sex work	15	2 (13.3)	12	0 (0.0)	33	3 (9.1)	
p value		0.159		1.000		0.135	
<b>2018</b>							
No sex work	354	10 (2.8)	117	1 (0.9)	476	12 (2.5)	
Sex work	13	2 (15.4)	15	0 (0.0)	30	2 (6.7)	
p value		0.063		1.000		0.199	
<b>2019</b>							
No sex work	338	18 (5.3)	121	1 (0.8)	465	20 (4.3)	
Sex work	12	2 (16.7)	12	0 (0.0)	27	2 (7.4)	
p value		0.145		1.000		0.343	
<b>2020</b>							
No sex work	210	10 (4.8)	72	0 (0.0)	285	11 (3.9)	
Sex work	7	1 (14.3)	10	0 (0.0)	19	2 (10.5)	
p value		0.309		--		0.191	

**Table 3.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

New South Wales Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Non Indigenous	283	7 (2.5)	109	0 (0.0)	399	8 (2.0)
Indigenous	59	3 (5.1)	37	1 (2.7)	96	4 (4.2)
p value		0.386		0.253		0.260
<b>2017</b>						
Non Indigenous	306	14 (4.6)	110	1 (0.9)	428	16 (3.7)
Indigenous	56	3 (5.4)	37	2 (5.4)	95	5 (5.3)
p value		0.734		0.156		0.561
<b>2018</b>						
Non Indigenous	321	9 (2.8)	110	0 (0.0)	437	9 (2.1)
Indigenous	62	5 (8.1)	30	0 (0.0)	93	6 (6.5)
p value		0.043		--		0.020
<b>2019</b>						
Non Indigenous	315	17 (5.4)	94	0 (0.0)	417	17 (4.1)
Indigenous	65	5 (7.7)	47	1 (2.1)	113	7 (6.2)
p value		0.557		0.333		0.337
<b>2020</b>						
Non Indigenous	184	10 (5.4)	56	0 (0.0)	243	11 (4.5)
Indigenous	35	1 (2.9)	29	0 (0.0)	66	2 (3.0)
p value		1.000		--		0.742

**Table 3.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year**

New South Wales Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
English speaking	324	10 (3.1)	142	1 (0.7)	472	12 (2.5)
Non-English speaking	25	0 (0.0)	5	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		1.000
<b>2017</b>						
English speaking	350	17 (4.9)	143	3 (2.1)	507	21 (4.1)
Non-English speaking	17	0 (0.0)	7	0 (0.0)	24	0 (0.0)
p value		1.000		1.000		0.616
<b>2018</b>						
English speaking	361	15 (4.2)	135	0 (0.0)	501	16 (3.2)
Non-English speaking	33	0 (0.0)	8	0 (0.0)	43	0 (0.0)
p value		0.625		--		0.628
<b>2019</b>						
English speaking	354	21 (5.9)	136	0 (0.0)	498	22 (4.4)
Non-English speaking	29	1 (3.5)	7	1 (14.3)	37	2 (5.4)
p value		1.000		0.049		0.678
<b>2020</b>						
English speaking	206	10 (4.9)	81	0 (0.0)	292	12 (4.1)
Non-English speaking	24	1 (4.2)	4	0 (0.0)	28	1 (3.6)
p value		1.000		--		1.000

**Table 3.2.13 HIV antibody prevalence by region/country of birth, gender and survey year**

New South Wales		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
Australia	304	10 (3.3)	125	1 (0.8)	434	11 (2.5)	
Other Oceania	14	0 (0.0)	10	0 (0.0)	25	1 (4.0)	
Asia	8	0 (0.0)	1	0 (0.0)	10	0 (0.0)	
UK & Ireland	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
Other	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)	
p value		1.000		1.000		0.825	
<b>2017</b>							
Australia	317	14 (4.4)	131	2 (1.5)	459	17 (3.7)	
Other Oceania	14	1 (7.1)	6	0 (0.0)	21	1 (4.8)	
Asia	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
UK & Ireland	11	0 (0.0)	5	0 (0.0)	17	0 (0.0)	
Other	14	1 (7.1)	4	0 (0.0)	19	1 (5.3)	
p value		0.651		1.000		0.743	
<b>2018</b>							
Australia	330	12 (3.6)	125	0 (0.0)	460	12 (2.6)	
Other Oceania	14	1 (7.1)	7	0 (0.0)	22	2 (9.1)	
Asia	5	0 (0.0)	0	0 (0.0)	5	0 (0.0)	
UK & Ireland	13	1 (7.7)	3	0 (0.0)	16	1 (6.3)	
Other	31	1 (3.2)	6	0 (0.0)	38	1 (2.6)	
p value		0.478		--		0.240	
<b>2019</b>							
Australia	329	18 (5.5)	127	1 (0.8)	461	20 (4.3)	
Other Oceania	14	1 (7.1)	5	0 (0.0)	22	1 (4.6)	
Asia	9	3 (33.3)	0	0 (0.0)	9	3 (33.3)	
UK & Ireland	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
Other	20	0 (0.0)	7	0 (0.0)	28	0 (0.0)	
p value		0.044		1.000		0.024	
<b>2020</b>							
Australia	189	7 (3.7)	72	0 (0.0)	265	8 (3.0)	
Other Oceania	8	1 (12.5)	1	0 (0.0)	9	1 (11.1)	
Asia	10	1 (10.0)	2	0 (0.0)	12	1 (8.3)	
UK & Ireland	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)	
Other	18	1 (5.6)	7	0 (0.0)	25	1 (4.0)	
p value		0.277		--		0.296	

## HCV antibody prevalence

Table 3.3.1 HCV antibody prevalence by gender and survey year

New South Wales Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2016	331	174 (53)	137	75 (55)	473	252 (53)
2017	357	172 (48)	146	73 (50)	515	252 (49)
2018	395	183 (46)	144	60 (42)	546	247 (45)
2019	384	154 (40)	141	72 (51)	535	231 (43)
2020	233	79 (34)	88	34 (39)	326	115 (35)
X <sup>2</sup> p trend		<0.001		0.049		<0.001

Table 3.3.2 HCV antibody prevalence by sexual identity, gender and survey year

New South Wales Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Heterosexual	271	147 (54)	96	51 (53)	368	199 (54)
Bisexual	16	6 (38)	32	20 (63)	48	26 (54)
Homosexual	25	9 (36)	0	0 (0)	28	11 (39)
p value		0.108		0.355		0.315
<b>2017</b>						
Heterosexual	281	149 (53)	115	62 (54)	398	212 (53)
Bisexual	24	8 (33)	15	6 (40)	40	15 (38)
Homosexual	25	3 (12)	5	3 (60)	36	10 (28)
p value		<0.001		0.628		0.004
<b>2018</b>						
Heterosexual	301	143 (48)	90	34 (38)	392	178 (45)
Bisexual	26	12 (46)	36	17 (47)	64	31 (48)
Homosexual	26	8 (31)	7	3 (43)	34	11 (32)
p value		0.259		0.616		0.282
<b>2019</b>						
Heterosexual	297	126 (42)	85	46 (54)	383	173 (45)
Bisexual	25	8 (32)	37	18 (49)	67	29 (43)
Homosexual	31	4 (13)	6	2 (33)	38	6 (16)
p value		0.003		0.575		0.002
<b>2020</b>						
Heterosexual	194	69 (36)	53	18 (34)	248	88 (35)
Bisexual	8	3 (38)	24	15 (63)	34	18 (53)
Homosexual	19	2 (11)	1	0 (0)	21	2 (10)
p value		0.107		0.030		0.007

**Table 3.3.3 HCV antibody prevalence by age group, gender and survey year**

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	17	4 (24)	2	1 (50)	19	5 (26)
25-34 years	56	14 (25)	31	18 (58)	88	33 (38)
35-44 years	125	74 (59)	49	23 (47)	175	97 (55)
45+ years	133	82 (62)	55	33 (60)	191	117 (61)
p value		<0.001		0.566		<0.001
<b>2017</b>						
<25 years	17	0 (0)	5	1 (20)	22	1 (5)
25-34 years	52	17 (33)	20	9 (45)	75	27 (36)
35-44 years	110	48 (44)	60	33 (55)	172	82 (48)
45+ years	177	107 (60)	60	30 (50)	244	142 (58)
p value		<0.001		0.489		<0.001
<b>2018</b>						
<25 years	14	2 (14)	7	0 (0)	22	2 (9)
25-34 years	54	12 (22)	24	11 (46)	79	24 (30)
35-44 years	126	66 (52)	55	24 (44)	183	91 (50)
45+ years	201	103 (51)	58	25 (43)	262	130 (50)
p value		<0.001		0.151		<0.001
<b>2019</b>						
<25 years	15	3 (20)	7	1 (14)	22	4 (18)
25-34 years	66	13 (20)	25	16 (64)	93	29 (31)
35-44 years	116	52 (45)	51	26 (51)	169	80 (47)
45+ years	187	86 (46)	58	29 (50)	251	118 (47)
p value		<0.001		0.144		0.003
<b>2020</b>						
<25 years	8	0 (0)	1	0 (0)	10	0 (0)
25-34 years	49	10 (20)	16	3 (19)	65	13 (20)
35-44 years	70	22 (31)	37	15 (41)	107	37 (35)
45+ years	106	47 (44)	34	16 (47)	144	65 (45)
p value		0.003		0.202		<0.001

**Table 3.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

New South Wales Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
<3 years	21	2 (10)	7	1 (14)	29	4 (14)
3 to 10 years	55	15 (27)	18	8 (44)	74	23 (31)
11+ years	245	152 (62)	109	65 (60)	357	219 (61)
p value		<0.001		0.048		<0.001
<b>2017</b>						
<3 years	34	2 (6)	8	0 (0)	42	2 (5)
3 to 10 years	48	17 (35)	11	4 (36)	60	21 (35)
11+ years	252	142 (56)	118	67 (57)	380	216 (57)
p value		<0.001		0.002		<0.001
<b>2018</b>						
<3 years	19	1 (5)	5	0 (0)	24	1 (4)
3 to 10 years	60	6 (10)	13	3 (23)	73	9 (12)
11+ years	288	164 (57)	119	55 (46)	413	223 (54)
p value		<0.001		0.040		<0.001
<b>2019</b>						
<3 years	30	2 (7)	9	0 (0)	39	2 (5)
3 to 10 years	63	11 (17)	11	3 (27)	75	15 (20)
11+ years	273	134 (49)	119	69 (58)	400	206 (52)
p value		<0.001		<0.001		<0.001
<b>2020</b>						
<3 years	19	2 (11)	8	0 (0)	27	2 (7)
3 to 10 years	42	7 (17)	7	3 (43)	50	10 (20)
11+ years	161	68 (42)	70	31 (44)	235	101 (43)
p value		<0.001		0.042		<0.001

**Table 3.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

New South Wales Receptively shared syringe last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No receptive sharing	23	4 (17)	337	190 (56)	369	197 (53)
Receptive sharing	3	0 (0)	47	28 (60)	52	30 (58)
p value		1.000		0.679		0.560
<b>2017</b>						
No receptive sharing	28	2 (7)	337	178 (53)	383	188 (49)
Receptive sharing	3	0 (0)	43	25 (58)	52	27 (52)
p value		1.000		0.510		0.701
<b>2018</b>						
No receptive sharing	16	0 (0)	338	160 (47)	374	168 (45)
Receptive sharing	0	0 (0)	59	36 (61)	65	40 (62)
p value		--		0.052		0.013
<b>2019</b>						
No receptive sharing	28	1 (4)	340	156 (46)	378	163 (43)
Receptive sharing	4	1 (25)	56	34 (61)	63	37 (59)
p value		0.238		0.040		0.021
<b>2020</b>						
No receptive sharing	22	2 (9)	220	83 (38)	248	87 (35)
Receptive sharing	1	0 (0)	25	13 (52)	27	13 (48)
p value		1.000		0.166		0.180

**Table 3.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

New South Wales Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	1	0 (0)	151	94 (62)	156	95 (61)
Methamphetamine	10	3 (30)	148	81 (55)	162	86 (53)
Other opioids	1	1 (100)	60	45 (75)	62	47 (76)
PIEDs	15	0 (0)	28	0 (0)	45	0 (0)
Other drugs	1	0 (0)	37	19 (51)	40	21 (53)
p value		0.028		<0.001		<0.001
<b>2017</b>						
Heroin	4	0 (0)	152	100 (66)	170	110 (65)
Methamphetamine	15	2 (13)	156	67 (43)	179	70 (39)
Other opioids	0	0 (0)	59	39 (66)	62	40 (65)
PIEDs	20	0 (0)	24	0 (0)	46	0 (0)
Other drugs	3	0 (0)	45	28 (62)	50	28 (56)
p value		0.286		<0.001		<0.001
<b>2018</b>						
Heroin	2	0 (0)	156	94 (60)	162	96 (59)
Methamphetamine	10	1 (10)	167	71 (43)	190	77 (41)
Other opioids	1	0 (0)	65	40 (62)	73	44 (60)
PIEDs	11	0 (0)	43	1 (2)	60	1 (2)
Other drugs	0	0 (0)	46	21 (46)	50	23 (46)
p value		0.691		<0.001		<0.001
<b>2019</b>						
Heroin	6	0 (0)	150	91 (61)	163	95 (58)
Methamphetamine	15	2 (13)	185	75 (41)	204	79 (39)
Other opioids	1	0 (0)	52	25 (48)	53	25 (47)
PIEDs	13	0 (0)	37	0 (0)	54	0 (0)
Other drugs	1	0 (0)	41	27 (66)	44	29 (66)
p value		0.564		<0.001		<0.001
<b>2020</b>						
Heroin	4	1 (25)	85	42 (49)	90	43 (48)
Methamphetamine	7	1 (14)	105	35 (33)	114	37 (32)
Other opioids	2	0 (0)	42	21 (50)	45	22 (49)
PIEDs	12	0 (0)	26	0 (0)	44	0 (0)
Other drugs	1	0 (0)	21	12 (57)	23	12 (52)
p value		0.499		<0.001		<0.001

**Table 3.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

New South Wales Frequency of injection last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	15	2 (13)	195	101 (52)	212	104 (49)
Daily or more	11	2 (18)	192	120 (63)	212	126 (59)
Not last month	2	0 (0)	37	18 (49)	41	19 (46)
p value		1.000		0.064		0.063
<b>2017</b>						
Less than daily	20	2 (10)	182	89 (49)	209	91 (44)
Daily or more	11	0 (0)	205	119 (58)	234	129 (55)
Not last month	11	0 (0)	49	26 (53)	64	28 (44)
p value		0.489		0.197		0.035
<b>2018</b>						
Less than daily	10	0 (0)	202	93 (46)	221	95 (43)
Daily or more	6	0 (0)	203	105 (52)	226	115 (51)
Not last month	8	1 (13)	75	30 (40)	92	33 (36)
p value		0.583		0.190		0.037
<b>2019</b>						
Less than daily	15	1 (7)	181	70 (39)	201	75 (37)
Daily or more	17	1 (6)	220	123 (56)	245	128 (52)
Not last month	7	0 (0)	66	26 (39)	78	26 (33)
p value		1.000		0.001		0.001
<b>2020</b>						
Less than daily	11	2 (18)	116	38 (33)	130	40 (31)
Daily or more	12	0 (0)	133	60 (45)	149	62 (42)
Not last month	4	0 (0)	32	12 (38)	42	12 (29)
p value		0.436		0.135		0.101

**Table 3.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

New South Wales Imprisonment last year	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	24	2 (8)	349	193 (55)	382	200 (52)
Imprisonment	3	1 (33)	58	36 (62)	64	37 (58)
p value		0.308		0.336		0.418
<b>2017</b>						
No imprisonment	40	2 (5)	343	174 (51)	406	183 (45)
Imprisonment	0	0 (0)	52	43 (83)	61	49 (80)
p value		--		<0.001		<0.001
<b>2018</b>						
No imprisonment	18	0 (0)	401	185 (46)	448	194 (43)
Imprisonment	6	1 (17)	57	32 (56)	68	36 (53)
p value		0.250		0.157		0.136
<b>2019</b>						
No imprisonment	36	2 (6)	389	175 (45)	440	181 (41)
Imprisonment	2	0 (0)	58	29 (50)	64	31 (48)
p value		1.000		0.475		0.269
<b>2020</b>						
No imprisonment	24	2 (8)	223	80 (36)	258	83 (32)
Imprisonment	3	0 (0)	34	17 (50)	40	18 (45)
p value		1.000		0.113		0.111



**Table 3.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

New South Wales Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	263	130 (49)	101	55 (54)	369	188 (51)
Indigenous	56	37 (66)	34	19 (56)	90	56 (62)
p value		0.024		0.885		0.055
<b>2017</b>						
Non Indigenous	297	128 (43)	107	50 (47)	414	184 (44)
Indigenous	53	38 (72)	36	21 (58)	91	60 (66)
p value		<0.001		0.228		<0.001
<b>2018</b>						
Non Indigenous	321	144 (45)	110	41 (37)	437	189 (43)
Indigenous	62	34 (55)	30	16 (53)	93	50 (54)
p value		0.149		0.112		0.064
<b>2019</b>						
Non Indigenous	311	116 (37)	92	44 (48)	411	165 (40)
Indigenous	66	34 (52)	47	26 (55)	114	60 (53)
p value		0.032		0.403		0.017
<b>2020</b>						
Non Indigenous	185	60 (32)	56	20 (36)	244	82 (34)
Indigenous	35	15 (43)	29	12 (41)	66	27 (41)
p value		0.233		0.609		0.270

**Table 3.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

New South Wales Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	303	164 (54)	132	71 (54)	439	238 (54)
Non-English speaking	23	8 (35)	4	3 (75)	28	11 (39)
p value		0.073		0.625		0.125
<b>2017</b>						
English speaking	340	166 (49)	139	69 (50)	491	242 (49)
Non-English speaking	15	5 (33)	7	4 (57)	22	9 (41)
p value		0.296		1.000		0.442
<b>2018</b>						
English speaking	361	169 (47)	135	58 (43)	501	230 (46)
Non-English speaking	33	14 (42)	8	2 (25)	43	17 (40)
p value		0.628		0.468		0.421
<b>2019</b>						
English speaking	352	140 (40)	134	69 (51)	494	213 (43)
Non-English speaking	28	13 (46)	7	3 (43)	36	17 (47)
p value		0.489		0.715		0.631
<b>2020</b>						
English speaking	207	69 (33)	81	32 (40)	293	103 (35)
Non-English speaking	24	10 (42)	4	2 (50)	28	12 (43)
p value		0.415		1.000		0.417

**Table 3.3.11 HCV antibody prevalence by region/country of birth, gender and survey year**

<b>New South Wales</b>		<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Region/Country of birth</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	
<b>2016</b>							
Australia	285	150 (53)	116	62 (53)	405	215 (53)	
Other Oceania	14	7 (50)	10	5 (50)	24	12 (50)	
Asia	6	2 (33)	1	0 (0)	8	2 (25)	
UK & Ireland	7	4 (57)	3	3 (100)	10	7 (70)	
Other	13	8 (62)	6	4 (67)	19	12 (63)	
p value		0.851		0.440		0.356	
<b>2017</b>							
Australia	306	144 (47)	127	64 (50)	442	213 (48)	
Other Oceania	13	9 (69)	6	3 (50)	20	13 (65)	
Asia	5	2 (40)	3	1 (33)	8	3 (38)	
UK & Ireland	11	6 (55)	5	3 (60)	17	10 (59)	
Other	14	6 (43)	4	2 (50)	19	8 (42)	
p value		0.576		1.000		0.466	
<b>2018</b>							
Australia	330	154 (47)	125	52 (42)	460	209 (45)	
Other Oceania	14	7 (50)	7	3 (43)	22	10 (45)	
Asia	5	4 (80)	0	0 (0)	5	4 (80)	
UK & Ireland	13	6 (46)	3	2 (67)	16	8 (50)	
Other	31	11 (35)	6	2 (33)	38	14 (37)	
p value		0.445		0.860		0.474	
<b>2019</b>							
Australia	327	132 (40)	125	64 (51)	457	199 (44)	
Other Oceania	14	7 (50)	5	3 (60)	22	11 (50)	
Asia	9	3 (33)	0	0 (0)	9	3 (33)	
UK & Ireland	7	3 (43)	4	3 (75)	11	6 (55)	
Other	19	6 (32)	7	2 (29)	27	8 (30)	
p value		0.857		0.517		0.493	
<b>2020</b>							
Australia	190	65 (34)	72	26 (36)	266	93 (35)	
Other Oceania	8	1 (13)	1	0 (0)	9	1 (11)	
Asia	10	3 (30)	2	1 (50)	12	4 (33)	
UK & Ireland	4	0 (0)	4	2 (50)	8	2 (25)	
Other	18	10 (56)	7	4 (57)	25	14 (56)	
p value		0.136		0.709		0.130	

## HCV RNA prevalence

Table 3.4.1 HCV RNA prevalence by gender and survey year \*

New South Wales Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2016 <sup>#</sup>	89	32 (36)	32	7 (22)	122	39 (32)
2017	186	52 (28)	74	13 (18)	265	65 (25)
2018	270	50 (19)	98	20 (20)	373	71 (19)
2019	320	46 (14)	118	26 (22)	446	72 (16)
2020	214	19 (9)	81	9 (11)	295	29 (10)
X <sup>2</sup> p trend		<0.001		0.320		<0.001

\* Weighted for gender and HCV antibody status

# A number of NSW samples were subject to a failed run due to incompatibility with the HCV RNA testing platform in 2016

Totals include respondents where gender was reported as other or not reported

Table 3.4.2 HCV RNA prevalence by sexual identity, gender and survey year \*

New South Wales Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heterosexual	74	30 (41)	20	2 (10)	95	32 (34)
Bisexual	2	0 (0)	11	4 (36)	13	4 (31)
Homosexual	8	2 (25)	0	0 (0)	8	2 (25)
p value		0.330		0.067		0.814
<b>2017</b>						
Heterosexual	165	49 (30)	63	11 (17)	229	60 (26)
Bisexual	8	1 (13)	5	1 (20)	13	2 (15)
Homosexual	6	0 (0)	2	1 (50)	11	1 (9)
p value		0.186		0.487		0.350
<b>2018</b>						
Heterosexual	202	37 (18)	59	12 (20)	262	49 (19)
Bisexual	17	5 (29)	22	4 (18)	41	9 (22)
Homosexual	20	3 (15)	6	3 (50)	27	6 (22)
p value		0.501		0.266		0.842
<b>2019</b>						
Heterosexual	254	36 (14)	69	14 (20)	323	50 (15)
Bisexual	20	2 (10)	32	8 (25)	57	10 (18)
Homosexual	26	0 (0)	6	0 (0)	33	0 (0)
p value		0.112		0.416		0.036
<b>2020</b>						
Heterosexual	179	18 (10)	49	6 (12)	228	24 (11)
Bisexual	8	0 (0)	21	3 (14)	29	3 (10)
Homosexual	17	0 (0)	1	0 (0)	18	0 (0)
p value		0.319		0.915		0.381

**Table 3.4.3 HCV RNA prevalence by age group, gender and survey year \***

New South Wales Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	6	3 (50)	0	0 (0)	6	3 (50)
25-34 years	15	1 (7)	5	4 (80)	20	5 (25)
35-44 years	24	9 (38)	14	2 (14)	38	11 (29)
45+ years	44	18 (41)	13	1 (8)	58	20 (34)
p value		0.228		0.005		0.648
<b>2017</b>						
<25 years	8	0 (0)	3	0 (0)	11	0 (0)
25-34 years	31	11 (35)	8	1 (13)	40	12 (30)
35-44 years	47	7 (15)	26	8 (31)	75	15 (20)
45+ years	99	33 (33)	35	4 (11)	137	38 (28)
p value		0.082		0.227		0.249
<b>2018</b>						
<25 years	12	1 (8)	5	0 (0)	18	1 (6)
25-34 years	31	5 (16)	13	2 (15)	44	7 (16)
35-44 years	81	21 (26)	35	7 (20)	117	30 (26)
45+ years	146	23 (16)	45	10 (22)	193	33 (17)
p value		0.132		0.588		0.109
<b>2019</b>						
<25 years	12	2 (17)	6	1 (17)	18	3 (17)
25-34 years	56	5 (9)	22	5 (23)	80	10 (13)
35-44 years	96	22 (23)	41	10 (24)	138	32 (23)
45+ years	156	17 (11)	49	10 (20)	210	27 (13)
p value		0.035		0.899		0.049
<b>2020</b>						
<25 years	7	0 (0)	1	0 (0)	8	0 (0)
25-34 years	45	3 (7)	17	1 (6)	62	5 (8)
35-44 years	67	8 (12)	32	5 (16)	99	13 (13)
45+ years	96	8 (8)	31	3 (10)	127	11 (9)
p value		0.714		0.723		0.458

**Table 3.4.4 HCV RNA prevalence by years since first injection, gender and survey year \***

New South Wales Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	5	1 (20)	1	0 (0)	6	1 (17)
3 to 10 years	17	4 (24)	5	1 (20)	22	5 (23)
11+ years	59	24 (41)	26	5 (19)	87	29 (33)
p value		0.403		0.706		0.647
<b>2017</b>						
<3 years	19	0 (0)	4	0 (0)	24	0 (0)
3 to 10 years	19	6 (32)	5	1 (20)	24	7 (29)
11+ years	136	43 (32)	60	12 (20)	202	56 (28)
p value		0.024		0.588		0.018
<b>2018</b>						
<3 years	15	1 (7)	5	0 (0)	20	1 (5)
3 to 10 years	37	2 (5)	5	2 (40)	42	4 (10)
11+ years	197	44 (22)	83	16 (19)	284	60 (21)
p value		0.030		0.304		0.045
<b>2019</b>						
<3 years	25	2 (8)	7	0 (0)	32	2 (6)
3 to 10 years	49	3 (6)	11	2 (18)	60	6 (10)
11+ years	232	37 (16)	98	23 (23)	337	59 (18)
p value		0.139		0.331		0.085
<b>2020</b>						
<3 years	18	2 (11)	8	0 (0)	25	2 (8)
3 to 10 years	39	3 (8)	6	1 (17)	45	4 (9)
11+ years	147	13 (9)	65	8 (12)	212	22 (10)
p value		0.898		0.564		0.877

**Table 3.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year \***

New South Wales Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	64	22 (34)	23	4 (17)	87	26 (30)
Receptive sharing	11	7 (64)	5	1 (20)	16	8 (50)
p value		0.091		0.939		0.163
<b>2017</b>						
No receptive sharing	142	38 (27)	50	11 (22)	196	49 (25)
Receptive sharing	16	6 (38)	5	0 (0)	21	6 (29)
p value		0.395		0.207		0.762
<b>2018</b>						
No receptive sharing	193	32 (17)	57	10 (18)	252	42 (17)
Receptive sharing	34	14 (41)	13	3 (23)	47	17 (36)
p value		0.002		0.767		0.004
<b>2019</b>						
No receptive sharing	232	32 (14)	81	20 (25)	318	53 (17)
Receptive sharing	36	10 (28)	12	4 (33)	50	14 (28)
p value		0.037		0.643		0.056
<b>2020</b>						
No receptive sharing	161	15 (9)	64	9 (14)	225	25 (11)
Receptive sharing	15	4 (27)	11	0 (0)	25	4 (16)
p value		0.045		0.187		0.515

**Table 3.4.6 HCV RNA prevalence by last drug injected, gender and survey year \***

New South Wales Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	27	12 (44)	15	2 (13)	45	14 (31)
Methamphetamine	19	8 (42)	7	2 (29)	26	10 (38)
Other opioids	12	6 (50)	6	2 (33)	18	9 (50)
PIEDs	10	0 (0)	0	0 (0)	10	0 (0)
Other drugs	15	4 (27)	3	1 (33)	19	5 (26)
p value		0.186		0.681		0.194
<b>2017</b>						
Heroin	50	16 (32)	29	8 (28)	83	25 (30)
Methamphetamine	75	16 (21)	19	2 (11)	95	18 (19)
Other opioids	23	11 (48)	16	2 (13)	39	13 (33)
PIEDs	24	0 (0)	2	0 (0)	26	0 (0)
Other drugs	14	8 (57)	7	1 (14)	22	9 (41)
p value		0.001		0.494		0.013
<b>2018</b>						
Heroin	79	16 (20)	38	8 (21)	119	24 (20)
Methamphetamine	91	22 (24)	31	5 (16)	125	27 (22)
Other opioids	27	6 (22)	18	4 (22)	45	10 (22)
PIEDs	34	1 (3)	0	0 (0)	36	1 (3)
Other drugs	31	4 (13)	2	2 (100)	40	6 (15)
p value		0.080		0.972		0.095
<b>2019</b>						
Heroin	95	20 (21)	37	9 (24)	138	28 (20)
Methamphetamine	123	16 (13)	44	9 (20)	169	25 (15)
Other opioids	30	5 (17)	17	3 (18)	47	8 (17)
PIEDs	43	0 (0)	2	0 (0)	45	0 (0)
Other drugs	22	4 (18)	13	6 (46)	36	10 (28)
p value		0.024		0.350		0.007
<b>2020</b>						
Heroin	56	8 (14)	29	1 (3)	85	9 (11)
Methamphetamine	74	7 (9)	24	4 (17)	97	11 (11)
Other opioids	24	3 (13)	20	2 (10)	44	5 (11)
PIEDs	38	0 (0)	2	0 (0)	40	0 (0)
Other drugs	15	2 (13)	6	2 (33)	21	4 (19)
p value		0.206		0.245		0.145

**Table 3.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year \***

New South Wales Frequency of injection last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	33	7 (21)	13	2 (15)	46	10 (22)
Daily or more	44	22 (50)	14	2 (14)	59	25 (42)
Not last month	10	1 (10)	5	2 (40)	15	4 (27)
p value		0.027		0.218		0.068
<b>2017</b>						
Less than daily	96	19 (20)	22	3 (14)	118	22 (19)
Daily or more	64	26 (41)	37	9 (24)	106	35 (33)
Not last month	25	6 (24)	15	1 (7)	41	8 (20)
p value		0.043		0.287		0.070
<b>2018</b>						
Less than daily	119	20 (17)	33	7 (21)	154	27 (18)
Daily or more	111	27 (24)	39	5 (13)	151	32 (21)
Not last month	36	3 (8)	25	6 (24)	62	9 (15)
p value		0.086		0.419		0.508
<b>2019</b>						
Less than daily	133	15 (11)	40	10 (25)	174	24 (14)
Daily or more	136	27 (20)	55	14 (25)	197	42 (21)
Not last month	46	3 (7)	21	2 (10)	69	5 (7)
p value		0.036		0.263		0.013
<b>2020</b>						
Less than daily	89	9 (10)	31	5 (16)	120	14 (12)
Daily or more	89	11 (12)	45	4 (9)	134	15 (11)
Not last month	31	0 (0)	5	0 (0)	36	0 (0)
p value		0.125		0.433		0.096

**Table 3.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year \***

New South Wales Imprisonment last year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	69	24 (35)	29	7 (24)	98	31 (32)
Imprisonment	15	7 (47)	2	0 (0)	17	7 (41)
p value		0.471		0.327		0.569
<b>2017</b>						
No imprisonment	138	32 (23)	63	10 (16)	203	43 (21)
Imprisonment	34	17 (50)	5	2 (40)	40	19 (48)
p value		0.087		0.170		0.011
<b>2018</b>						
No imprisonment	213	37 (17)	84	19 (23)	301	56 (19)
Imprisonment	40	9 (23)	10	1 (10)	51	10 (20)
p value		0.465		0.300		0.943
<b>2019</b>						
No imprisonment	264	33 (13)	104	21 (20)	374	55 (15)
Imprisonment	37	9 (24)	10	4 (40)	49	13 (27)
p value		0.061		0.151		0.039
<b>2020</b>						
No imprisonment	167	14 (8)	66	9 (14)	233	24 (10)
Imprisonment	25	3 (12)	12	0 (0)	37	3 (8)
p value		0.640		0.174		0.642

**Table 3.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year \***

New South Wales		Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	
<b>2016</b>							
Non Indigenous	67	23 (34)	27	6 (22)	95	29 (31)	
Indigenous	18	7 (39)	5	1 (20)	23	8 (35)	
p value		0.769		0.692		0.816	
<b>2017</b>							
Non Indigenous	156	37 (24)	52	8 (15)	213	45 (21)	
Indigenous	28	12 (43)	21	5 (24)	50	17 (34)	
p value		0.095		0.412		0.126	
<b>2018</b>							
Non Indigenous	222	38 (17)	72	15 (21)	299	53 (18)	
Indigenous	39	12 (31)	23	3 (13)	63	15 (24)	
p value		0.048		0.317		0.318	
<b>2019</b>							
Non Indigenous	263	31 (12)	78	13 (17)	348	45 (13)	
Indigenous	53	13 (25)	37	11 (30)	91	24 (26)	
p value		0.014		0.090		0.001	
<b>2020</b>							
Non Indigenous	169	13 (8)	50	6 (12)	219	20 (9)	
Indigenous	33	3 (9)	29	3 (10)	62	6 (10)	
p value		0.880		0.840		0.858	

**Table 3.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year \***

New South Wales		Male		Female		Total	
Main language spoken at home by parents	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	
<b>2016</b>							
English speaking	85	30 (35)	30	6 (20)	117	36 (31)	
Non-English speaking	2	1 (50)	2	1 (50)	4	2 (50)	
p value		0.673		0.357		0.443	
<b>2017</b>							
English speaking	179	51 (28)	68	12 (18)	253	63 (25)	
Non-English speaking	7	1 (14)	5	1 (20)	12	2 (17)	
p value		0.257		0.973		0.344	
<b>2018</b>							
English speaking	252	48 (19)	92	19 (21)	347	68 (20)	
Non-English speaking	18	2 (11)	6	1 (17)	26	3 (12)	
p value		0.364		0.695		0.273	
<b>2019</b>							
English speaking	298	42 (14)	112	25 (22)	417	67 (16)	
Non-English speaking	21	4 (19)	6	1 (17)	28	5 (18)	
p value		0.558		0.750		0.835	
<b>2020</b>							
English speaking	190	16 (8)	76	8 (11)	266	25 (9)	
Non-English speaking	22	3 (14)	4	1 (25)	27	4 (15)	
p value		0.493		0.416		0.361	



Table 3.4.11 HCV RNA prevalence by region/country of birth, gender and survey year \*

New South Wales		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
<b>2016</b>							
Australia	73	27 (37)	27	5 (19)	101	32 (32)	
Other Oceania	2	1 (50)	1	1 (100)	4	3 (75)	
Asia	2	0 (0)	1	0 (0)	3	0 (0)	
UK & Ireland	1	0 (0)	2	0 (0)	3	0 (0)	
Other	5	2 (40)	1	1 (100)	7	3 (43)	
p value		0.636		0.066		0.125	
<b>2017</b>							
Australia	165	48 (29)	62	11 (18)	232	59 (25)	
Other Oceania	10	1 (10)	3	1 (33)	13	3 (23)	
Asia	1	0 (0)	2	0 (0)	3	0 (0)	
UK & Ireland	6	2 (33)	3	0 (0)	9	2 (22)	
Other	3	0 (0)	4	1 (25)	8	1 (13)	
p value		0.536		0.765		0.836	
<b>2018</b>							
Australia	225	43 (19)	84	18 (21)	312	62 (20)	
Other Oceania	9	1 (11)	5	1 (20)	15	2 (13)	
Asia	4	2 (50)	0	0 (0)	4	2 (50)	
UK & Ireland	11	2 (18)	2	1 (50)	13	3 (23)	
Other	20	2 (10)	6	0 (0)	26	2 (8)	
p value		0.440		0.430		0.268	
<b>2019</b>							
Australia	277	41 (15)	104	25 (24)	386	65 (17)	
Other Oceania	11	0 (0)	4	1 (25)	17	2 (12)	
Asia	6	2 (33)	0	0 (0)	6	2 (33)	
UK & Ireland	3	0 (0)	4	0 (0)	7	0 (0)	
Other	17	2 (12)	6	0 (0)	24	2 (8)	
p value		0.385		0.380		0.367	
<b>2020</b>							
Australia	176	15 (9)	66	7 (11)	242	23 (10)	
Other Oceania	7	0 (0)	0	0 (0)	7	0 (0)	
Asia	11	0 (0)	1	0 (0)	12	0 (0)	
UK & Ireland	3	0 (0)	4	1 (25)	7	1 (14)	
Other	15	4 (27)	8	1 (13)	24	5 (21)	
p value		0.139		0.845		0.255	

## Northern Territory

Table 4.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Northern Territory	2016	2017	2018	2019	2020*
<b>Number of sites</b>	3	3	3	3	3
<b>N° surveyed</b>	N=87	N=66	N=67	N=85	N=37
<b>Response rate (%)</b>	49%	39%	37%	42%	23%
<b>Gender (%)</b>					
Male	59 (68)	34 (52)	41 (61)	53 (62)	25 (68)
Female	26 (30)	30 (45)	26 (39)	31 (36)	12 (32)
Other	2 (2)	2 (3)	0 (0)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Sexual identity (%)</b>					
Heterosexual	67 (77)	46 (70)	60 (90)	68 (80)	30 (81)
Bisexual	9 (10)	8 (12)	3 (4)	8 (9)	4 (11)
Gay/Lesbian	4 (5)	2 (3)	4 (6)	2 (2)	0 (0)
Other	-- --	-- --	-- --	-- --	1 (3)
Not reported	7 (8)	10 (15)	0 (0)	7 (8)	2 (5)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	52 (60)	42 (64)	41 (61)	55 (65)	25 (68)
Yes	31 (36)	18 (27)	25 (37)	30 (35)	10 (27)
Not reported	4 (5)	6 (9)	1 (1)	0 (0)	2 (5)
<b>Region/country of birth (%)</b>					
Australia	75 (86)	59 (89)	62 (93)	79 (93)	35 (95)
Other Oceania	1 (1)	2 (3)	2 (3)	1 (1)	1 (3)
Asia	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)
UK & Ireland	0 (0)	1 (2)	0 (0)	1 (1)	0 (0)
Other	5 (6)	1 (2)	1 (1)	3 (4)	0 (0)
Not reported	5 (6)	3 (5)	1 (1)	1 (1)	1 (3)
<b>Main language spoken at home by parents (%)</b>					
English	79 (91)	63 (95)	64 (96)	80 (94)	33 (89)
Non-English	4 (5)	0 (0)	1 (1)	4 (5)	2 (5)
Not reported	4 (5)	3 (5)	2 (3)	1 (1)	2 (5)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	43	43	43	43.5	45
<i>Age range</i>	21-65	19-62	24-61	30-70	21-64
<i>Age group (%)</i>					
<25 years	2 (2)	5 (8)	1 (1)	0 (0)	1 (3)
25+ years	85 (98)	61 (92)	65 (97)	84 (99)	36 (97)
Not reported	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
<i>Median age first injection</i>					
<i>Age range</i>	11-45	14-40	10-43	11-65	10-42
N° not reported	2	4	5	3	0
<i>Median yrs since first injection</i>					
<i>Range</i>	2-46	0-44	1-47	2-50	4-51
<i>Years since first injection</i>					
<3 years	4 (5)	3 (5)	2 (3)	1 (1)	0 (0)
3+ years	81 (93)	59 (89)	60 (90)	81 (95)	37 (100)
Not reported	2 (2)	4 (6)	5 (7)	3 (4)	0 (0)
<b>Imprisonment last year (%)</b>					
No	72 (83)	57 (86)	59 (88)	68 (80)	32 (86)
Yes	8 (9)	3 (5)	4 (6)	10 (12)	3 (8)
Not reported	7 (8)	6 (9)	4 (6)	7 (8)	2 (5)
<b>N° in prison</b>					
Injected in prison	1 (13)	0 (0)	1 (25)	1 (10)	0 (0)

\* Implementation of the 2020 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

**Table 4.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

<b>Northern Territory</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° surveyed</b>	<b>N=87</b>	<b>N=66</b>	<b>N=67</b>	<b>N=85</b>	<b>N=37</b>
<b>Drug last injected (%)</b>					
Cocaine	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)
Methamphetamine	37 (43)	31 (47)	27 (40)	46 (54)	25 (68)
Heroin	4 (5)	3 (5)	1 (1)	0 (0)	0 (0)
Pharm. opioids	30 (34)	22 (33)	24 (36)	23 (27)	7 (19)
Methadone	2 (2)	3 (5)	1 (1)	6 (7)	0 (0)
Buprenorphine	2 (2)	0 (0)	5 (7)	4 (5)	3 (8)
Buprenorphine/naloxone	4 (5)	3 (5)	2 (3)	0 (0)	1 (3)
PIEDs	1 (1)	1 (2)	2 (3)	0 (0)	0 (0)
More than one	7 (8)	1 (2)	5 (7)	2 (2)	1 (3)
Other	0 (0)	1 (2)	0 (0)	1 (1)	0 (0)
Not reported	0 (0)	1 (2)	0 (0)	1 (1)	0 (0)
<b>Ever injected opioids</b>					
No	13 (15)	10 (15)	12 (18)	19 (22)	10 (27)
Yes	73 (84)	56 (85)	53 (79)	65 (76)	27 (73)
Not reported	1 (1)	0 (0)	2 (3)	1 (1)	0 (0)
<b>Frequency of injection last month (%)</b>					
Not last month	8 (9)	8 (12)	1 (1)	6 (7)	5 (14)
Less than weekly	10 (11)	5 (8)	6 (9)	8 (9)	8 (22)
Weekly not daily	15 (17)	11 (17)	14 (21)	12 (14)	7 (19)
Daily or more	54 (62)	42 (64)	44 (66)	59 (69)	17 (46)
Not reported	0 (0)	0 (0)	2 (3)	0 (0)	0 (0)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
No	69 (79)	54 (82)	54 (81)	63 (74)	33 (89)
Yes	13 (15)	8 (12)	8 (12)	17 (20)	2 (5)
Not reported	5 (6)	4 (6)	5 (7)	5 (6)	2 (5)
<b>Overdosed in last 12 months</b>					
No	68 (78)	56 (85)	56 (84)	72 (85)	33 (89)
Yes	13 (15)	6 (9)	6 (9)	8 (9)	1 (3)
Not reported	6 (7)	4 (6)	5 (7)	5 (6)	3 (8)

**Table 4.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>Northern Territory</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° injected last month</b>	<b>N=79</b>	<b>N=58</b>	<b>N=64</b>	<b>N=79</b>	<b>N=32</b>
<b>Places injected last month (%)</b>					
All private	52 (66)	31 (53)	40 (63)	51 (65)	19 (59)
Any public	27 (34)	27 (47)	24 (38)	28 (35)	12 (38)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	67 (85)	50 (86)	53 (83)	67 (85)	26 (81)
Most of the time	9 (11)	3 (5)	11 (17)	8 (10)	2 (6)
Half of the time	0 (0)	1 (2)	0 (0)	2 (3)	2 (6)
Some of the time	0 (0)	0 (0)	0 (0)	1 (1)	1 (3)
Not last month	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	2 (3)	4 (7)	0 (0)	1 (1)	1 (3)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	70 (89)	52 (90)	55 (86)	70 (89)	27 (84)
Once	3 (4)	2 (3)	6 (9)	3 (4)	1 (3)
Twice	3 (4)	0 (0)	1 (2)	0 (0)	1 (3)
3-5 times	0 (0)	3 (5)	1 (2)	4 (5)	1 (3)
>5 times	1 (1)	1 (2)	1 (2)	1 (1)	1 (3)
Not reported	2 (3)	0 (0)	0 (0)	1 (1)	1 (3)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	70 (89)	52 (90)	55 (86)	70 (89)	27 (84)
One	2 (3)	0 (0)	5 (8)	2 (3)	0 (0)
Two	0 (0)	2 (3)	1 (2)	1 (1)	1 (3)
Three to five	0 (0)	1 (2)	0 (0)	1 (1)	0 (0)
More than five	1 (1)	0 (0)	1 (2)	0 (0)	1 (3)
Don't know	2 (3)	1 (2)	1 (2)	2 (3)	2 (6)
Not reported	4 (5)	2 (3)	1 (2)	3 (4)	1 (3)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	2 (3)	2 (3)	6 (9)	3 (4)	2 (6)
Casual sex partner	1 (1)	1 (2)	1 (2)	1 (1)	0 (0)
Close friend	1 (1)	2 (3)	2 (3)	0 (0)	2 (6)
Acquaintance	1 (1)	1 (2)	0 (0)	3 (4)	0 (0)
Other	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	21 (27)	9 (16)	8 (13)	15 (19)	3 (9)
Water	18 (23)	13 (22)	10 (16)	10 (13)	5 (16)
Filter	7 (9)	5 (9)	8 (13)	7 (9)	3 (9)
Drug mix	9 (11)	5 (9)	8 (13)	4 (5)	0 (0)
None	50 (63)	40 (69)	50 (78)	55 (70)	25 (78)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	67 (85)	46 (79)	54 (84)	63 (80)	26 (81)
Yes	10 (13)	9 (16)	10 (16)	16 (20)	5 (16)
Not reported	2 (3)	3 (5)	0 (0)	0 (0)	1 (3)
<b>Source of needle acquisition</b>					
Needle Syringe Program	75 (95)	46 (79)	58 (91)	67 (85)	28 (88)
Chemist/Pharmacy	9 (11)	10 (17)	11 (17)	9 (11)	0 (0)
Personal sources	12 (15)	10 (17)	5 (8)	7 (9)	1 (3)
Dispensing/Vending Machine	0 (0)	12 (21)	15 (23)	17 (22)	5 (16)
Other sources	1 (1)	0 (0)	0 (0)	1 (1)	1 (3)

**Table 4.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

Northern Territory	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=87	N=66	N=67	N=85	N=37
<b>Ever any treatment/therapy for drug use (%)</b>					
No	39 (45)	28 (42)	31 (46)	39 (46)	16 (43)
Yes	45 (52)	35 (53)	35 (52)	46 (54)	21 (57)
Not reported	3 (3)	3 (5)	1 (1)	0 (0)	0 (0)
<b>History of methadone maintenance treatment (%)</b>					
Currently	1 (1)	1 (2)	1 (1)	10 (12)	1 (3)
Previously	19 (22)	10 (15)	11 (16)	17 (20)	7 (19)
Never	60 (69)	51 (77)	50 (75)	57 (67)	28 (76)
Not reported	7 (8)	4 (6)	5 (7)	1 (1)	1 (3)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	9 (10)	2 (3)	6 (9)	5 (6)	6 (16)
Previously	15 (17)	13 (20)	15 (22)	17 (20)	4 (11)
Never	58 (67)	48 (73)	44 (66)	62 (73)	26 (70)
Not reported	5 (6)	3 (5)	2 (3)	1 (1)	1 (3)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	12 (14)	7 (11)	2 (3)	3 (4)	4 (11)
Previously	13 (15)	10 (15)	16 (24)	18 (21)	6 (16)
Never	56 (64)	46 (70)	46 (69)	64 (75)	27 (73)
Not reported	6 (7)	3 (5)	3 (4)	0 (0)	0 (0)

**Table 4.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

Northern Territory	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=87	N=66	N=67	N=85	N=37
<b>Previous HIV test (%)</b>					
Yes, ever	72 (83)	50 (76)	54 (81)	69 (81)	26 (70)
Yes, last year	48 (55)	34 (52)	34 (51)	43 (51)	14 (38)
>1 year ago	24 (28)	16 (24)	20 (30)	26 (31)	12 (32)
Never tested	10 (11)	10 (15)	10 (15)	11 (13)	9 (24)
Not reported	5 (6)	6 (9)	3 (4)	5 (6)	2 (5)
<b>Previous HCV test (%)</b>					
Yes, ever	74 (85)	49 (74)	51 (76)	66 (78)	27 (73)
Yes, last year	49 (56)	32 (48)	34 (51)	44 (52)	10 (27)
>1 year ago	25 (29)	17 (26)	17 (25)	22 (26)	17 (46)
Never tested	5 (6)	8 (12)	6 (9)	8 (9)	3 (8)
Not reported	8 (9)	9 (14)	10 (15)	11 (13)	7 (19)
<b>Lifetime treatment for HCV (%)<sup>#</sup></b>					
<b>N° self-reported HCV diagnosis</b>	N=21	N=15	N=19	N=23	N=2
Antiviral treatment	4 (19)	3 (20)	3 (16)	16 (70)	2 (100)
No antiviral treatment	17 (81)	9 (60)	16 (84)	7 (30)	0 (0)
Not reported	0 (0)	3 (20)	0 (0)	0 (0)	0 (0)
<b>Treatment for HCV in past 12 months (%)<sup>**</sup></b>					
<b>N° self-reported HCV diagnosis</b>	N=21	N=14	N=19	N=16	N=1
Antiviral treatment	4 (19)	1 (7)	3 (16)	8 (50)	1 (100)
No antiviral treatment	17 (81)	10 (71)	16 (84)	8 (50)	0 (0)
Not reported	0 (0)	3 (21)	0 (0)	0 (0)	0 (0)

<sup>#</sup> among people who tested HCV antibody positive and did not report spontaneous clearance

<sup>\*</sup> excludes people who reported treatment induced clearance more than 12 months previously

**Table 4.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

<b>Northern Territory</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° surveyed</b>	N=87	N=66	N=67	N=85	N=37
<b>Sex with a regular partner last month (%)</b>					
No	52 (60)	36 (55)	29 (43)	43 (51)	22 (59)
Yes	28 (32)	25 (38)	33 (49)	36 (42)	13 (35)
Not reported	7 (8)	5 (8)	5 (7)	6 (7)	2 (5)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=28	N=25	N=33	N=36	N=13
Never	16 (57)	16 (64)	22 (67)	28 (78)	11 (85)
Sometimes	6 (21)	5 (20)	4 (12)	5 (14)	1 (8)
Every time	5 (18)	2 (8)	4 (12)	3 (8)	1 (8)
Not reported	1 (4)	2 (8)	3 (9)	0 (0)	0 (0)
<b>Sex with other partner(s) last month (%)</b>					
No	69 (79)	49 (74)	44 (66)	58 (68)	31 (84)
Yes	15 (17)	12 (18)	17 (25)	20 (24)	4 (11)
Not reported	3 (3)	5 (8)	6 (9)	7 (8)	2 (5)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=15	N=12	N=17	N=20	N=4
Never	3 (20)	2 (17)	7 (41)	7 (35)	0 (0)
Sometimes	6 (40)	4 (33)	1 (6)	6 (30)	0 (0)
Every time	5 (33)	6 (50)	7 (41)	6 (30)	4 (100)
Not reported	1 (7)	0 (0)	2 (12)	1 (5)	0 (0)
<b>Sex work last month (%)</b>					
No	70 (80)	52 (79)	53 (79)	67 (79)	31 (84)
Yes	9 (10)	7 (11)	6 (9)	11 (13)	3 (8)
Not reported	8 (9)	7 (11)	8 (12)	7 (8)	3 (8)
<b>Condom used at last sex work (%)</b>					
Yes	8 (90)	6 (86)	3 (50)	7 (64)	3 (100)

**Table 4.1.7 Number (percentage) of respondents by COVID-19 related behaviours in 2020**

<b>Northern Territory</b>			
<b>N° surveyed</b>		<b>N=37</b>	
<b>More difficult to access sterile needles and syringes</b>		<b>Start or increase takeaway dose of methadone/bupe/suboxone</b>	
Yes	1 (3)	Yes	2 (5)
No	29 (78)	No	24 (65)
Not applicable	5 (14)	Not applicable	9 (24)
Not reported	2 (5)	Not reported	2 (5)
<b>Start depot buprenorphine</b>		<b>Inject own methadone/bupe/suboxone</b>	
Yes	0 (0)	Yes	1 (3)
No	27 (73)	No	24 (65)
Not applicable	8 (22)	Not applicable	10 (27)
Not reported	2 (5)	Not reported	2 (5)
<b>Access take home naloxone</b>		<b>COVID-19 test</b>	
Yes	5 (14)	Yes	8 (22)
No	20 (54)	No	25 (68)
Not applicable	10 (27)	Don't know	1 (3)
Not reported	2 (5)	Not reported	3 (8)
<b>Change illicit drug use</b>		<b>If YES, what was result (N=8)</b>	
Yes, increased	2 (5)	Positive	0 (0)
Yes, decreased	10 (27)	Negative	8 (100)
No change	23 (62)	Don't know	0 (0)
Not reported	2 (5)	Not reported	0 (0)

## HIV antibody prevalence

**Table 4.2.1 HIV antibody prevalence by gender and survey year**

Northern Territory Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2016	59	0 (0.0)	26	0 (0.0)	87	0 (0.0)
2017	34	0 (0.0)	29	0 (0.0)	65	0 (0.0)
2018	41	0 (0.0)	25	0 (0.0)	66	0 (0.0)
2019	52	1 (1.9)	29	1 (3.5)	82	2 (2.4)
2020	20	0 (0.0)	10	0 (0.0)	30	0 (0.0)
X <sup>2</sup> p trend		0.343		0.318		0.169

## HCV antibody prevalence

**Table 4.3.1 HCV antibody prevalence by gender and survey year**

Northern Territory Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2016	59	23 (39)	26	12 (46)	87	35 (40)
2017	32	15 (47)	29	8 (28)	63	23 (37)
2018	41	15 (37)	25	11 (44)	66	26 (39)
2019	51	23 (45)	29	7 (24)	81	30 (37)
2020	20	5 (25)	10	0 (0)	30	5 (17)
X <sup>2</sup> p trend		0.641		0.023		0.120

**Table 4.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

Northern Territory Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heterosexual	49	19 (39)	17	9 (53)	67	28 (42)
Bisexual	2	0 (0)	6	1 (17)	9	1 (11)
Homosexual	3	2 (67)	1	1 (100)	4	3 (75)
p value		0.486		0.166		0.071
<b>2017</b>						
Heterosexual	28	12 (43)	15	2 (13)	43	14 (33)
Bisexual	0	0 (0)	7	1 (14)	8	1 (13)
Homosexual	0	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.051		0.079
<b>2018</b>						
Heterosexual	40	15 (38)	20	9 (45)	60	24 (40)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	1	0 (0)	3	2 (67)	4	2 (50)
p value		1.000		0.480		0.656
<b>2019</b>						
Heterosexual	43	20 (47)	21	4 (19)	65	24 (37)
Bisexual	4	2 (50)	3	1 (33)	7	3 (43)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
p value		1.000		0.234		1.000
<b>2020</b>						
Heterosexual	19	5 (26)	5	0 (0)	24	5 (21)
Bisexual	1	0 (0)	2	0 (0)	3	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		--		1.000



**Table 4.3.3 HCV antibody prevalence by age group, gender and survey year**

Northern Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	1	0 (0)	0	0 (0)	2	0 (0)
25-34 years	7	4 (57)	2	0 (0)	9	4 (44)
35-44 years	23	3 (13)	10	6 (60)	33	9 (27)
45+ years	28	16 (57)	14	6 (43)	43	22 (51)
p value		0.003		0.443		0.111
<b>2017</b>						
<25 years	2	1 (50)	3	0 (0)	5	1 (20)
25-34 years	5	0 (0)	2	1 (50)	8	1 (13)
35-44 years	13	4 (31)	10	3 (30)	23	7 (30)
45+ years	12	10 (83)	14	4 (29)	27	14 (52)
p value		0.003		0.729		0.152
<b>2018</b>						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	5	1 (20)	4	1 (25)	9	2 (22)
35-44 years	18	5 (28)	7	4 (57)	25	9 (36)
45+ years	16	8 (50)	14	6 (43)	30	14 (47)
p value		0.417		0.654		0.501
<b>2019</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	9	3 (33)	5	0 (0)	14	3 (21)
35-44 years	14	7 (50)	15	5 (33)	29	12 (41)
45+ years	27	13 (48)	9	2 (22)	37	15 (41)
p value		0.799		0.376		0.459
<b>2020</b>						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	3	0 (0)	0	0 (0)	3	0 (0)
35-44 years	4	1 (25)	3	0 (0)	7	1 (14)
45+ years	12	4 (33)	7	0 (0)	19	4 (21)
p value		0.830		--		1.000

**Table 4.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

Northern Territory Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	1	0 (0)	2	1 (50)	4	1 (25)
3 to 10 years	4	0 (0)	2	1 (50)	6	1 (17)
11+ years	54	23 (43)	21	9 (43)	75	32 (43)
p value		0.200		1.000		0.507
<b>2017</b>						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	4	2 (50)	5	0 (0)	9	2 (22)
11+ years	25	11 (44)	20	8 (40)	47	19 (40)
p value		1.000		0.197		0.282
<b>2018</b>						
<3 years	2	0 (0)	0	0 (0)	2	0 (0)
3 to 10 years	6	3 (50)	2	1 (50)	8	4 (50)
11+ years	31	10 (32)	21	8 (38)	52	18 (35)
p value		0.555		1.000		0.419
<b>2019</b>						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	5	2 (40)	5	0 (0)	10	2 (20)
11+ years	43	20 (47)	23	7 (30)	67	27 (40)
p value		1.000		0.461		0.370
<b>2020</b>						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	3	0 (0)	0	0 (0)	3	0 (0)
11+ years	17	5 (29)	10	0 (0)	27	5 (19)
p value		0.539		--		1.000

**Table 4.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

Northern Territory Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	4	1 (25)	65	29 (45)	70	31 (44)
Receptive sharing	0	0 (0)	6	3 (50)	7	3 (43)
p value		--		1.000		1.000
<b>2017</b>						
No receptive sharing	3	3 (100)	42	17 (40)	49	19 (39)
Receptive sharing	0	0 (0)	6	1 (17)	6	1 (17)
p value		--		0.388		0.399
<b>2018</b>						
No receptive sharing	2	2 (100)	49	20 (41)	55	24 (44)
Receptive sharing	0	0 (0)	9	2 (22)	9	2 (22)
p value		--		0.459		0.291
<b>2019</b>						
No receptive sharing	1	0 (0)	62	22 (35)	66	23 (35)
Receptive sharing	0	0 (0)	8	4 (50)	8	4 (50)
p value		--		0.458		0.452
<b>2020</b>						
No receptive sharing	0	0 (0)	22	3 (14)	22	3 (14)
Receptive sharing	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		1.000		1.000

**Table 4.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

Northern Territory Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Methamphetamine	2	1 (50)	35	10 (29)	37	11 (30)
Pharm. Opioids	0	0 (0)	29	14 (48)	30	15 (50)
OST*	1	0 (0)	7	4 (57)	8	4 (50)
Other drugs	1	0 (0)	10	5 (50)	12	5 (42)
p value		0.513		0.265		0.360
<b>2017</b>						
Methamphetamine	1	1 (100)	28	7 (25)	30	7 (23)
Pharm. Opioids	0	0 (0)	19	10 (53)	22	12 (55)
OST*	1	1 (100)	4	2 (50)	5	2 (40)
Other drugs	1	1 (100)	5	2 (40)	6	2 (33)
p value		--		0.261		0.146
<b>2018</b>						
Methamphetamine	1	1 (100)	24	11 (46)	26	12 (46)
Pharm. Opioids	0	0 (0)	21	6 (29)	23	8 (35)
OST*	0	0 (0)	7	4 (57)	8	5 (63)
Other drugs	1	1 (100)	7	1 (14)	8	1 (13)
p value		--		0.241		0.181
<b>2019</b>						
Methamphetamine	1	0 (0)	39	12 (31)	42	13 (31)
Pharm. Opioids	0	0 (0)	23	11 (48)	23	11 (48)
OST*	0	0 (0)	10	3 (30)	10	3 (30)
Other drugs	0	0 (0)	4	2 (50)	5	2 (40)
p value		--		0.511		0.563
<b>2020</b>						
Methamphetamine	0	0 (0)	19	2 (11)	19	2 (11)
Pharm. Opioids	0	0 (0)	6	2 (33)	6	2 (33)
OST*	0	0 (0)	4	0 (0)	4	0 (0)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.057		0.057

\*OST = methadone, buprenorphine & burpenorphine/naloxone

**Table 4.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

Northern Territory Frequency of injection last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	2	0 (0)	22	9 (41)	25	10 (40)
Daily or more	2	1 (50)	51	23 (45)	54	24 (44)
Not last month	0	0 (0)	8	1 (13)	8	1 (13)
p value		1.000		0.229		0.248
<b>2017</b>						
Less than daily	2	2 (100)	12	5 (42)	15	5 (33)
Daily or more	1	1 (100)	36	13 (36)	40	15 (38)
Not last month	0	0 (0)	8	3 (38)	8	3 (38)
p value		--		0.922		1.000
<b>2018</b>						
Less than daily	1	1 (100)	18	9 (50)	20	10 (50)
Daily or more	1	1 (100)	40	13 (33)	44	16 (36)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.363		0.481
<b>2019</b>						
Less than daily	0	0 (0)	19	9 (47)	20	9 (45)
Daily or more	1	0 (0)	52	17 (33)	55	18 (33)
Not last month	0	0 (0)	6	3 (50)	6	3 (50)
p value		--		0.378		0.483
<b>2020</b>						
Less than daily	0	0 (0)	12	2 (17)	12	2 (17)
Daily or more	0	0 (0)	14	1 (7)	14	1 (7)
Not last month	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		0.134		0.134

**Table 4.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

Northern Territory Imprisonment last year	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	4	1 (25)	67	29 (43)	72	31 (43)
Imprisonment	0	0 (0)	7	2 (29)	8	2 (25)
p value		--		0.692		0.459
<b>2017</b>						
No imprisonment	3	3 (100)	50	19 (38)	56	21 (38)
Imprisonment	0	0 (0)	2	0 (0)	2	0 (0)
p value		--		0.527		0.530
<b>2018</b>						
No imprisonment	2	2 (100)	54	20 (37)	59	23 (39)
Imprisonment	0	0 (0)	3	2 (67)	4	3 (75)
p value		--		0.553		0.297
<b>2019</b>						
No imprisonment	1	0 (0)	65	27 (42)	66	27 (41)
Imprisonment	0	0 (0)	7	2 (29)	8	2 (25)
p value		--		0.694		0.469
<b>2020</b>						
No imprisonment	0	0 (0)	25	5 (20)	25	5 (20)
Imprisonment	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		1.000		1.000

**Table 4.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Northern Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	35	19 (54)	17	8 (47)	52	27 (52)
Indigenous	21	4 (19)	8	4 (50)	31	8 (26)
p value		0.012		1.000		0.020
<b>2017</b>						
Non Indigenous	24	12 (50)	15	5 (33)	40	17 (43)
Indigenous	5	1 (20)	11	2 (18)	17	3 (18)
p value		0.343		0.658		0.128
<b>2018</b>						
Non Indigenous	27	9 (33)	14	7 (50)	41	16 (39)
Indigenous	14	6 (43)	11	4 (36)	25	10 (40)
p value		0.548		0.689		0.937
<b>2019</b>						
Non Indigenous	39	16 (41)	13	1 (8)	53	17 (32)
Indigenous	12	7 (58)	16	6 (38)	28	13 (46)
p value		0.292		0.093		0.203
<b>2020</b>						
Non Indigenous	12	3 (25)	9	0 (0)	21	3 (14)
Indigenous	6	1 (17)	1	0 (0)	7	1 (14)
p value		1.000		--		1.000

**Table 4.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

Northern Territory Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	52	22 (42)	25	12 (48)	79	34 (43)
Non-English speaking	4	1 (25)	0	0 (0)	4	1 (25)
p value		0.636		--		0.635
<b>2017</b>						
English speaking	30	14 (47)	28	8 (29)	60	22 (37)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2018</b>						
English speaking	39	14 (36)	25	11 (44)	64	25 (39)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000
<b>2019</b>						
English speaking	48	22 (46)	28	7 (25)	77	29 (38)
Non-English speaking	3	1 (33)	1	0 (0)	4	1 (25)
p value		1.000		1.000		1.000
<b>2020</b>						
English speaking	18	4 (22)	9	0 (0)	27	4 (15)
Non-English speaking	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		--		1.000

**Table 4.3.11 HCV antibody prevalence by region/country of birth, gender and survey year**

Northern Territory Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Australia	51	20 (39)	23	11 (48)	75	31 (41)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	3	1 (33)	1	1 (100)	5	2 (40)
p value		0.527		1.000		0.552
<b>2017</b>						
Australia	26	11 (42)	28	8 (29)	56	19 (34)
Other Oceania	2	2 (100)	0	0 (0)	2	2 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.143		--		0.075
<b>2018</b>						
Australia	38	14 (37)	24	11 (46)	62	25 (40)
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	1	0 (0)	1	0 (0)
p value		1.000		1.000		1.000
<b>2019</b>						
Australia	47	21 (45)	28	7 (25)	76	28 (37)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.849		1.000		0.824
<b>2020</b>						
Australia	18	5 (28)	10	0 (0)	28	5 (18)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		--		1.000

## HCV RNA prevalence

**Table 4.4.1 HCV RNA prevalence by gender and survey year \***

Northern Territory Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2016	19	3 (16)	8	4 (50)	28	7 (25)
2017	26	5 (19)	22	4 (18)	50	9 (18)
2018	27	6 (22)	16	4 (25)	43	10 (23)
2019	36	4 (11)	18	2 (11)	56	6 (11)
2019	12	0 (0)	6	0 (0)	18	0 (0)
X <sup>2</sup> p trend		0.189		0.031		0.020

\* Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

**Table 4.4.2 HCV RNA prevalence by sexual identity, gender and survey year \***

Northern Territory Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heterosexual	16	2 (13)	4	3 (75)	20	5 (25)
Bisexual	1	0 (0)	3	0 (0)	5	0 (0)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.834		0.227		0.241
<b>2017</b>						
Heterosexual	23	4 (17)	10	2 (20)	34	6 (18)
Bisexual	0	0 (0)	7	1 (14)	8	1 (13)
Homosexual	0	0 (0)	1	1 (100)	1	1 (100)
p value		--		0.141		0.109
<b>2018</b>						
Heterosexual	27	6 (22)	12	3 (25)	39	9 (23)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.566		0.549
<b>2019</b>						
Heterosexual	28	4 (14)	15	1 (7)	43	5 (12)
Bisexual	3	0 (0)	1	0 (0)	4	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.731		0.935		0.698
<b>2020</b>						
Heterosexual	12	0 (0)	4	0 (0)	16	0 (0)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

**Table 4.4.3 HCV RNA prevalence by age group, gender and survey year \***

Northern Territory Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	0	0 (0)	0	0 (0)	1	0 (0)
25-34 years	1	0 (0)	0	0 (0)	1	0 (0)
35-44 years	9	0 (0)	2	2 (100)	11	2 (18)
45+ years	9	3 (33)	6	1 (17)	15	5 (33)
p value		0.109		0.141		0.704
<b>2017</b>						
<25 years	2	0 (0)	4	0 (0)	6	0 (0)
25-34 years	5	0 (0)	1	0 (0)	7	0 (0)
35-44 years	11	3 (27)	6	3 (50)	17	6 (35)
45+ years	8	2 (25)	11	1 (9)	20	3 (15)
p value		0.477		0.227		0.126
<b>2018</b>						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	2	0 (0)	3	1 (33)	5	1 (20)
35-44 years	11	2 (18)	4	2 (50)	16	4 (25)
45+ years	11	4 (36)	9	1 (11)	20	5 (25)
p value		0.575		0.200		0.889
<b>2019</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	4	0 (0)	3	0 (0)	7	0 (0)
35-44 years	7	0 (0)	12	2 (17)	19	2 (11)
45+ years	24	4 (17)	6	0 (0)	30	4 (13)
p value		0.405		0.464		0.617
<b>2020</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	0 (0)	0	0 (0)	2	0 (0)
35-44 years	1	0 (0)	2	0 (0)	3	0 (0)
45+ years	9	0 (0)	4	0 (0)	13	0 (0)
p value		--		--		--



**Table 4.4.4 HCV RNA prevalence by years since first injection, gender and survey year \***

Northern Territory Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
<3 years	0	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	1	0 (0)	0	0 (0)	1	0 (0)
11+ years	18	3 (17)	8	4 (50)	26	7 (27)
p value		0.640		--		0.704
<b>2017</b>						
<3 years	1	0 (0)	1	0 (0)	2	0 (0)
3 to 10 years	4	1 (25)	4	0 (0)	8	1 (13)
11+ years	21	4 (19)	15	4 (27)	38	8 (21)
p value		0.836		0.548		0.727
<b>2018</b>						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	2	1 (50)	1	0 (0)	3	1 (33)
11+ years	22	4 (18)	13	4 (31)	35	8 (23)
p value		0.539		0.562		0.790
<b>2019</b>						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 10 years	2	0 (0)	4	0 (0)	6	0 (0)
11+ years	32	4 (13)	16	2 (13)	47	6 (13)
p value		0.566		0.720		0.606
<b>2020</b>						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	1	0 (0)	0	0 (0)	1	0 (0)
11+ years	11	0 (0)	6	0 (0)	17	0 (0)
p value		--		--		--

**Table 4.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year \***

Northern Territory Receptively shared syringe last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No receptive sharing	15	3 (20)	7	4 (57)	26	7 (27)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2017</b>						
No receptive sharing	22	5 (23)	17	4 (24)	41	9 (22)
Receptive sharing	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.454		0.493		0.311
<b>2018</b>						
No receptive sharing	20	5 (25)	12	3 (25)	33	8 (24)
Receptive sharing	5	1 (20)	3	1 (33)	8	2 (25)
p value		0.808		0.956		0.869
<b>2019</b>						
No receptive sharing	29	4 (14)	17	1 (6)	46	5 (11)
Receptive sharing	4	0 (0)	3	1 (33)	7	1 (14)
p value		0.496		0.153		0.805
<b>2020</b>						
No receptive sharing	8	0 (0)	6	0 (0)	14	0 (0)
Receptive sharing	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		--

**Table 4.4.6 HCV RNA prevalence by last drug injected, gender and survey year \***

Northern Territory Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Methamphetamine	9	0 (0)	3	0 (0)	12	0 (0)
Pharm. Opioids	9	3 (33)	3	3 (100)	13	7 (54)
OAT	0	0 (0)	0	0 (0)	0	0 (0)
Other drugs	1	0 (0)	2	0 (0)	3	0 (0)
p value		0.097		0.084		0.007
<b>2017</b>						
Methamphetamine	10	2 (20)	10	1 (10)	21	3 (14)
Pharm. Opioids	9	2 (22)	8	1 (13)	17	3 (18)
OAT	3	1 (33)	2	1 (50)	6	2 (33)
Other drugs	4	0 (0)	2	1 (50)	6	1 (17)
p value		0.659		0.469		0.696
<b>2018</b>						
Methamphetamine	13	4 (31)	5	1 (20)	18	5 (28)
Pharm. Opioids	8	2 (25)	7	2 (29)	16	4 (25)
OAT	4	0 (0)	2	1 (50)	6	1 (17)
Other drugs	0	0 (0)	2	0 (0)	2	0 (0)
p value		0.467		0.651		0.755
<b>2019</b>						
Methamphetamine	15	2 (13)	11	1 (9)	26	3 (12)
Pharm. Opioids	12	2 (17)	6	0 (0)	18	2 (11)
OAT	6	0 (0)	1	0 (0)	7	0 (0)
Other drugs	3	0 (0)	2	0 (0)	5	0 (0)
p value		0.746		0.849		0.707
<b>2020</b>						
Methamphetamine	5	0 (0)	5	0 (0)	9	0 (0)
Pharm. Opioids	4	0 (0)	1	0 (0)	5	0 (0)
OAT	3	0 (0)	0	0 (0)	3	0 (0)
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		--

OAT: methadone, buprenorphine or buprenorphine-naloxone

**Table 4.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year \***

Northern Territory Frequency of injection last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	3	0 (0)	1	1 (100)	5	1 (20)
Daily or more	15	3 (20)	6	3 (50)	21	6 (29)
Not last month	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.526		0.399		0.660
<b>2017</b>						
Less than daily	7	1 (14)	7	1 (14)	15	2 (13)
Daily or more	17	4 (24)	12	3 (25)	30	7 (23)
Not last month	2	0 (0)	3	0 (0)	5	0 (0)
p value		0.645		0.630		0.386
<b>2018</b>						
Less than daily	8	3 (38)	6	1 (17)	14	4 (29)
Daily or more	18	3 (17)	9	3 (33)	27	6 (22)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		0.289		0.533		0.816
<b>2019</b>						
Less than daily	11	2 (18)	5	1 (20)	15	3 (20)
Daily or more	23	2 (9)	15	1 (7)	37	3 (8)
Not last month	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.820		0.630		0.607
<b>2020</b>						
Less than daily	5	0 (0)	2	0 (0)	7	0 (0)
Daily or more	5	0 (0)	4	0 (0)	9	0 (0)
Not last month	2	0 (0)	0	0 (0)	2	0 (0)
p value		--		--		--

**Table 4.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year \***

Northern Territory Imprisonment last year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	16	3 (19)	8	4 (50)	25	7 (28)
Imprisonment	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.620		--		0.544
<b>2017</b>						
No imprisonment	23	5 (22)	16	4 (25)	43	9 (21)
Imprisonment	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.463		--		0.492
<b>2018</b>						
No imprisonment	24	4 (17)	14	3 (21)	38	8 (21)
Imprisonment	2	1 (50)	1	1 (100)	3	2 (67)
p value		0.395		0.134		0.129
<b>2019</b>						
No imprisonment	31	4 (13)	18	1 (6)	48	5 (10)
Imprisonment	2	0 (0)	2	1 (50)	4	1 (25)
p value		0.561		0.059		0.452
<b>2020</b>						
No imprisonment	10	0 (0)	5	0 (0)	15	0 (0)
Imprisonment	1	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		--

**Table 4.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year \***

Northern Territory Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	13	3 (23)	7	3 (43)	20	6 (30)
Indigenous	5	0 (0)	1	1 (100)	7	1 (14)
p value		0.213		0.315		0.675
<b>2017</b>						
Non Indigenous	19	4 (21)	10	2 (20)	29	6 (21)
Indigenous	4	0 (0)	10	2 (20)	16	2 (13)
p value		0.261		0.941		0.432
<b>2018</b>						
Non Indigenous	20	4 (20)	7	2 (29)	27	6 (22)
Indigenous	7	2 (29)	9	2 (22)	16	4 (25)
p value		0.681		0.733		0.525
<b>2019</b>						
Non Indigenous	32	2 (6)	9	0 (0)	41	2 (5)
Indigenous	4	2 (50)	11	2 (18)	15	4 (27)
p value		0.108		0.183		0.102
<b>2020</b>						
Non Indigenous	8	0 (0)	6	0 (0)	14	0 (0)
Indigenous	3	0 (0)	0	0 (0)	3	0 (0)
p value		--		--		--

**Table 4.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year \***

Northern Territory Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	15	3 (20)	8	4 (50)	27	7 (26)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2017</b>						
English speaking	24	4 (17)	22	4 (18)	48	8 (17)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2018</b>						
English speaking	26	6 (23)	16	4 (25)	42	10 (24)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2019</b>						
English speaking	34	4 (12)	19	2 (11)	53	6 (11)
Non-English speaking	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.644		0.746		0.569
<b>2020</b>						
English speaking	11	0 (0)	6	0 (0)	17	0 (0)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

**Table 4.4.11 HCV RNA prevalence by region/country of birth, gender and survey year \***

Northern Territory		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
<b>2016</b>							
Australia	17	2 (12)	8	4 (50)	26	6 (23)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	1	1 (100)	0	0 (0)	1	1 (100)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.045		--		0.114	
<b>2017</b>							
Australia	21	2 (10)	22	4 (18)	45	6 (13)	
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)	
Other	1	1 (100)	0	0 (0)	1	1 (100)	
p value		0.016		--		0.010	
<b>2018</b>							
Australia	26	6 (23)	15	4 (27)	41	10 (24)	
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	1	0 (0)	1	0 (0)	
p value		0.597		0.533		0.719	
<b>2019</b>							
Australia	32	4 (13)	19	2 (11)	51	6 (12)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	2	0 (0)	0	0 (0)	2	0 (0)	
Other	2	0 (0)	1	0 (0)	3	0 (0)	
p value		0.859		0.746		0.823	
<b>2020</b>							
Australia	11	0 (0)	6	0 (0)	17	0 (0)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		--		--		--	

## Queensland

**Table 5.1.1 Number (percentage) of respondents by demographic characteristics and survey year**

Queensland	2016	2017	2018	2019	2020*
<b>Number of sites</b>	8	9	9	9	7
<b>N° surveyed</b>	N=349	N=619	N=633	N=574	N=391
<b>Response rate (%)</b>	30%	33%	41%	34%	33%
<b>Gender (%)</b>					
Male	230 (66)	447 (72)	441 (70)	407 (71)	285 (73)
Female	117 (34)	171 (28)	191 (30)	160 (28)	104 (27)
Other	1 (<1)	1 (<1)	1 (<1)	3 (1)	1 (<1)
Not reported	1 (<1)	0 (0)	0 (0)	1 (1)	1 (<1)
<b>Sexual identity (%)</b>					
Heterosexual	258 (74)	483 (78)	506 (80)	427 (74)	315 (81)
Bisexual	47 (13)	55 (9)	62 (10)	63 (11)	38 (10)
Gay/Lesbian	18 (5)	33 (5)	25 (4)	27 (5)	12 (3)
Other	-- --	-- --	-- --	-- --	8 (2)
Not reported	26 (7)	48 (8)	40 (6)	57 (10)	18 (5)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	294 (84)	501 (81)	511 (81)	452 (79)	317 (81)
Yes	44 (13)	100 (16)	115 (18)	116 (20)	64 (16)
Not reported	11 (3)	18 (3)	7 (1)	6 (1)	10 (3)
<b>Region/country of birth (%)</b>					
Australia	304 (87)	548 (89)	570 (90)	525 (91)	352 (90)
Other Oceania	13 (4)	32 (5)	20 (3)	12 (2)	15 (4)
Asia	2 (1)	2 (<1)	0 (0)	4 (1)	1 (<1)
UK & Ireland	16 (5)	19 (3)	24 (4)	11 (2)	11 (3)
Other	5 (1)	11 (2)	15 (2)	17 (3)	8 (2)
Not reported	9 (3)	7 (1)	4 (1)	5 (1)	4 (1)
<b>Main language spoken at home by parents (%)</b>					
English	329 (94)	594 (96)	612 (97)	550 (96)	382 (98)
Non-English	12 (3)	22 (4)	18 (3)	22 (4)	9 (2)
Not reported	8 (2)	3 (<1)	3 (<1)	2 (<1)	0 (0)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	40	41	41	42	42
<i>Age range</i>	17-76	16-75	14-78	16-70	19-69
<i>Age group (%)</i>					
<25 years	21 (6)	37 (6)	37 (6)	30 (5)	19 (5)
25+ years	328 (94)	581 (94)	595 (94)	543 (95)	372 (95)
Not reported	0 (0)	1 (<1)	1 (<1)	1 (<1)	0 (0)
<i>Median age first injection</i>					
<i>Age range</i>	11-55	10-65	10-64	10-60	11-59
N° not reported	16	16	22	26	4
<i>Median yrs since first injection</i>					
<i>Range</i>	<1-53	<1-59	<1-52	<1-51	<1-53
<i>Years since first injection</i>					
<3 years	22 (6)	47 (8)	42 (7)	51 (9)	32 (8)
3+ years	311 (89)	556 (90)	569 (90)	497 (87)	354 (91)
Not reported	16 (5)	16 (3)	22 (3)	26 (5)	5 (1)
<b>Imprisonment last year (%)</b>					
No	299 (86)	528 (85)	535 (85)	480 (84)	336 (86)
Yes	39 (11)	69 (11)	72 (11)	66 (12)	39 (10)
Not reported	11 (3)	22 (4)	26 (4)	28 (5)	16 (4)
<b>N° in prison</b>					
Injected in prison	16 (41)	27 (39)	29 (40)	30 (45)	18 (46)

\* Implementation of the 2020 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

**Table 5.1.2** Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Queensland N° surveyed	2016 N=349	2017 N=619	2018 N=633	2019 N=574	2020 N=391
<b>Drug last injected (%)</b>					
Cocaine	1 (<1)	5 (1)	10 (2)	3 (1)	2 (1)
Methamphetamine	136 (39)	265 (43)	304 (48)	281 (49)	156 (40)
Heroin	56 (16)	89 (14)	84 (13)	93 (16)	63 (16)
Pharm. opioids	53 (15)	117 (19)	104 (16)	75 (13)	69 (18)
Methadone	28 (8)	27 (4)	28 (4)	29 (5)	22 (6)
Buprenorphine	11 (3)	23 (4)	33 (5)	22 (4)	23 (6)
Buprenorphine/naloxone	13 (4)	11 (2)	17 (3)	9 (2)	4 (1)
PIEDs	21 (6)	49 (8)	28 (4)	27 (5)	31 (8)
More than one	22 (6)	22 (4)	21 (3)	26 (5)	16 (4)
Other	8 (2)	6 (1)	3 (<1)	8 (1)	2 (1)
Not reported	0 (0)	5 (1)	1 (<1)	1 (<1)	3 (1)
<b>Ever injected opioids</b>					
No	74 (21)	173 (28)	151 (24)	143 (25)	101 (26)
Yes	274 (79)	446 (72)	480 (76)	428 (75)	290 (74)
Not reported	1 (<1)	0 (0)	2 (<1)	3 (1)	0 (0)
<b>Frequency of injection last month (%)</b>					
Not last month	31 (9)	54 (9)	41 (6)	47 (8)	46 (12)
Less than weekly	49 (14)	94 (15)	90 (14)	86 (15)	59 (15)
Weekly not daily	80 (23)	150 (24)	160 (25)	133 (23)	78 (20)
Daily or more	177 (51)	316 (51)	332 (52)	305 (53)	204 (52)
Not reported	12 (3)	5 (1)	10 (2)	3 (1)	4 (1)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
No	287 (82)	496 (80)	499 (79)	457 (80)	320 (82)
Yes	57 (16)	106 (17)	117 (18)	96 (17)	67 (17)
Not reported	5 (1)	17 (3)	17 (3)	21 (4)	4 (1)
<b>Overdosed in last 12 months</b>					
No	285 (82)	512 (83)	521 (82)	478 (83)	329 (84)
Yes	57 (16)	93 (15)	96 (15)	78 (14)	58 (15)
Not reported	7 (2)	14 (2)	16 (3)	18 (3)	4 (1)

**Table 5.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>Queensland</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° injected last month</b>	<b>N=306</b>	<b>N=560</b>	<b>N=582</b>	<b>N=524</b>	<b>N=341</b>
<b>Places injected last month (%)</b>					
All private	208 (68)	375 (67)	378 (65)	327 (62)	225 (66)
Any public	96 (31)	182 (33)	198 (34)	194 (37)	116 (34)
Not reported	2 (1)	3 (1)	6 (1)	3 (1)	0 (0)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	240 (78)	434 (78)	445 (76)	416 (79)	274 (80)
Most of the time	52 (17)	98 (18)	107 (18)	87 (17)	55 (16)
Half of the time	5 (2)	8 (1)	8 (1)	8 (2)	6 (2)
Some of the time	3 (1)	12 (2)	14 (2)	8 (2)	5 (1)
Not last month	2 (1)	4 (1)	2 (<1)	2 (<1)	0 (0)
Not reported	4 (1)	4 (1)	6 (1)	3 (1)	1 (<1)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	245 (80)	471 (84)	490 (84)	464 (89)	292 (86)
Once	14 (5)	27 (5)	29 (5)	13 (2)	16 (5)
Twice	18 (6)	22 (4)	17 (3)	17 (3)	10 (3)
3-5 times	11 (4)	19 (3)	23 (4)	15 (3)	13 (4)
>5 times	15 (5)	16 (3)	18 (3)	12 (2)	9 (3)
Not reported	3 (1)	5 (1)	5 (1)	3 (1)	1 (<1)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	245 (80)	471 (84)	490 (84)	464 (89)	292 (86)
One	24 (8)	32 (6)	37 (6)	19 (4)	18 (5)
Two	7 (2)	7 (1)	7 (1)	4 (1)	7 (2)
Three to five	1 (<1)	5 (1)	5 (1)	6 (1)	3 (1)
More than five	3 (1)	3 (1)	10 (2)	4 (1)	2 (1)
Don't know	13 (4)	27 (5)	20 (3)	14 (3)	9 (3)
Not reported	13 (4)	15 (3)	13 (2)	13 (2)	10 (3)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	20 (7)	24 (4)	29 (5)	19 (4)	16 (5)
Casual sex partner	3 (1)	4 (1)	5 (1)	3 (1)	4 (1)
Close friend	14 (5)	25 (4)	33 (6)	19 (4)	15 (4)
Acquaintance	12 (4)	12 (2)	17 (3)	9 (2)	5 (1)
Other	4 (1)	9 (2)	7 (1)	6 (1)	4 (1)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	59 (19)	102 (18)	116 (20)	102 (19)	43 (13)
Water	45 (15)	106 (19)	105 (18)	102 (19)	47 (14)
Filter	33 (11)	69 (12)	63 (11)	59 (11)	17 (5)
Drug mix	37 (12)	52 (9)	51 (9)	63 (12)	21 (6)
None	223 (73)	381 (68)	413 (71)	368 (70)	263 (77)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	249 (81)	474 (85)	475 (82)	442 (84)	305 (89)
Yes	51 (17)	81 (14)	97 (17)	78 (15)	35 (10)
Not reported	6 (2)	5 (1)	10 (2)	4 (1)	1 (<1)
<b>Source of needle acquisition</b>					
Needle Syringe Program	274 (90)	502 (90)	533 (92)	473 (90)	309 (91)
Chemist/Pharmacy	88 (29)	138 (25)	143 (25)	161 (31)	89 (26)
Personal sources	27 (9)	53 (9)	44 (8)	55 (11)	24 (7)
Dispensing/Vending Machine	50 (16)	76 (14)	66 (11)	87 (17)	45 (13)
Other sources	6 (2)	16 (3)	21 (4)	12 (2)	9 (3)



**Table 5.1.4** Number (percentage) of respondents by treatment for drug use and survey year

Queensland	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=349	N=619	N=633	N=574	N=391
<b>Ever any treatment/therapy for drug use (%)</b>					
No	102 (29)	204 (33)	187 (30)	179 (31)	126 (32)
Yes	241 (69)	412 (67)	443 (70)	394 (69)	264 (68)
Not reported	6 (2)	3 (<1)	3 (<1)	1 (<1)	1 (<1)
<b>History of methadone maintenance treatment (%)</b>					
Currently	63 (18)	89 (14)	87 (14)	81 (14)	58 (15)
Previously	83 (24)	125 (20)	141 (22)	113 (20)	77 (20)
Never	193 (55)	394 (64)	391 (62)	369 (64)	247 (63)
Not reported	10 (3)	11 (2)	14 (2)	11 (2)	9 (2)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	30 (9)	41 (7)	56 (9)	52 (9)	45 (12)
Previously	93 (27)	138 (22)	147 (23)	131 (23)	99 (25)
Never	214 (61)	429 (69)	415 (66)	381 (66)	240 (61)
Not reported	12 (3)	11 (2)	15 (2)	10 (2)	7 (2)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	23 (7)	37 (6)	54 (9)	44 (8)	26 (7)
Previously	89 (26)	128 (21)	139 (22)	125 (22)	90 (23)
Never	229 (66)	442 (71)	428 (68)	395 (69)	273 (70)
Not reported	8 (2)	12 (2)	12 (2)	10 (2)	2 (1)

**Table 5.1.5** Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Queensland	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=349	N=619	N=619	N=574	N=391
<b>Previous HIV test (%)</b>					
Yes, ever	292 (84)	510 (82)	534 (84)	489 (85)	328 (84)
Yes, last year	186 (53)	302 (49)	312 (49)	287 (50)	180 (46)
>1 year ago	106 (30)	208 (34)	222 (35)	202 (35)	148 (38)
Never tested	45 (13)	90 (15)	78 (12)	69 (12)	56 (14)
Not reported	12 (3)	19 (3)	21 (3)	16 (3)	7 (2)
<b>Previous HCV test (%)</b>					
Yes, ever	294 (84)	516 (83)	540 (85)	482 (84)	341 (87)
Yes, last year	211 (60)	343 (55)	342 (54)	322 (56)	192 (49)
>1 year ago	83 (24)	173 (28)	198 (31)	160 (28)	149 (38)
Never tested	28 (8)	63 (10)	37 (6)	46 (8)	29 (7)
Not reported	27 (8)	40 (6)	56 (9)	46 (8)	21 (5)
<b>Lifetime treatment for HCV (%)<sup>#</sup></b>					
<b>N° self-reported HCV diagnosis</b>	N=104	N=156	N=172	N=146	N=100
Antiviral treatment	34 (33)	69 (44)	101 (59)	92 (63)	65 (65)
No antiviral treatment	69 (66)	87 (56)	69 (40)	54 (37)	35 (35)
Not reported	1 (1)	0 (0)	2 (1)	0 (0)	0 (0)
<b>Treatment for HCV in past 12 months (%)<sup>**</sup></b>					
<b>N° self-reported HCV diagnosis</b>	N=102	N=143	N=129	N=113	N=62
Antiviral treatment	28 (27)	52 (36)	50 (39)	48 (42)	23 (37)
No antiviral treatment	57 (71)	91 (64)	77 (60)	65 (58)	39 (63)
Not reported	1 (1)	0 (0)	2 (2)	0 (0)	0 (0)

<sup>#</sup> among people who tested HCV antibody positive and did not report spontaneous clearance

<sup>\*\*</sup> excludes people who reported treatment induced clearance more than 12 months previously

**Table 5.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

Queensland	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=349	N=619	N=633	N=574	N=391
<b>Sex with a regular partner last month (%)</b>					
No	165 (47)	316 (51)	319 (50)	301 (52)	217 (56)
Yes	175 (50)	279 (45)	297 (47)	256 (45)	168 (43)
Not reported	9 (3)	24 (4)	17 (3)	17 (3)	6 (2)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=175	N=279	N=297	N=256	N=168
Never	130 (74)	198 (71)	230 (77)	197 (77)	133 (79)
Sometimes	24 (14)	37 (13)	32 (11)	26 (10)	12 (7)
Every time	15 (9)	33 (12)	16 (5)	22 (9)	15 (9)
Not reported	6 (3)	11 (4)	19 (6)	11 (4)	8 (5)
<b>Sex with other partner(s) last month (%)</b>					
No	294 (84)	497 (80)	500 (79)	457 (80)	317 (81)
Yes	44 (13)	92 (15)	108 (17)	96 (17)	58 (15)
Not reported	11 (3)	30 (5)	25 (4)	21 (4)	16 (4)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=44	N=92	N=108	N=96	N=58
Never	21 (48)	31 (34)	49 (45)	43 (45)	28 (48)
Sometimes	11 (25)	33 (36)	36 (33)	25 (26)	15 (26)
Every time	11 (25)	23 (25)	17 (16)	21 (22)	14 (24)
Not reported	1 (2)	5 (5)	6 (6)	7 (7)	1 (2)
<b>Sex work last month (%)</b>					
No	314 (90)	568 (92)	581 (92)	528 (92)	363 (93)
Yes	18 (5)	22 (4)	30 (5)	21 (4)	14 (4)
Not reported	17 (5)	29 (5)	22 (3)	25 (4)	14 (4)
<b>Condom used at last sex work (%)</b>					
Yes	12 (67)	17 (77)	16 (53)	13 (62)	8 (57)

**Table 5.1.7 Number (percentage) of respondents by COVID-19 related behaviours in 2020**

Queensland			
N° surveyed		N=391	
<b>More difficult to access sterile needles and syringes</b>		<b>Start or increase takeaway dose of methadone/bupe/suboxone</b>	
Yes	29 (7)	Yes	37 (9)
No	287 (73)	No	205 (52)
Not applicable	29 (7)	Not applicable	99 (25)
Not reported	46 (12)	Not reported	50 (13)
<b>Start depot buprenorphine</b>		<b>Inject own methadone/bupe/suboxone</b>	
Yes	9 (2)	Yes	47 (12)
No	248 (63)	No	203 (52)
Not applicable	82 (21)	Not applicable	91 (23)
Not reported	52 (13)	Not reported	50 (13)
<b>Access take home naloxone</b>		<b>COVID-19 test</b>	
Yes	41 (10)	Yes	78 (20)
No	212 (54)	No	246 (63)
Not applicable	86 (22)	Don't know	16 (4)
Not reported	52 (13)	Not reported	51 (13)
<b>Change illicit drug use</b>		<b>If YES, what was result (N=78)</b>	
Yes, increased	39 (10)	Positive	0 (0)
Yes, decreased	94 (24)	Negative	77 (99)
No change	203 (52)	Don't know	0 (0)
Not reported	55 (14)	Not reported	1 (1)

## HIV antibody prevalence

**Table 5.2.1 HIV antibody prevalence by gender and survey year**

Queensland Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2016	224	4 (1.8)	115	0 (0.0)	341	4 (1.2)
2017	441	14 (3.2)	167	1 (0.6)	609	15 (2.5)
2018	437	6 (1.4)	189	2 (1.1)	627	8 (1.3)
2019	401	11 (2.7)	157	0 (0.0)	565	12 (2.1)
2020	284	13 (4.6)	102	1 (1.0)	388	14 (3.6)
X <sup>2</sup> p trend		0.138		0.638		0.082

**Table 5.2.2 HIV antibody prevalence by sexual identity, gender and survey year**

Queensland Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Heterosexual	184	0 (0.0)	67	0 (0.0)	253	0 (0.0)
Bisexual	13	1 (7.7)	33	0 (0.0)	46	1 (2.2)
Homosexual	10	3 (30.0)	8	0 (0.0)	18	3 (16.7)
p value		<0.001		--		<0.001
<b>2017</b>						
Heterosexual	358	3 (0.8)	118	0 (0.0)	476	3 (0.6)
Bisexual	27	3 (11.1)	28	1 (3.6)	55	4 (7.3)
Homosexual	22	7 (31.8)	7	0 (0.0)	30	7 (23.3)
p value		<0.001		0.229		<0.001
<b>2018</b>						
Heterosexual	365	1 (0.3)	136	2 (1.5)	501	3 (0.6)
Bisexual	25	2 (8.0)	36	0 (0.0)	61	2 (3.3)
Homosexual	21	3 (14.3)	3	0 (0.0)	25	3 (12.0)
p value		<0.001		1.000		0.001
<b>2019</b>						
Heterosexual	322	1 (0.3)	95	0 (0.0)	419	1 (0.2)
Bisexual	24	4 (16.7)	36	0 (0.0)	62	4 (6.5)
Homosexual	21	6 (28.6)	5	0 (0.0)	27	7 (25.9)
p value		<0.001		--		<0.001
<b>2020</b>						
Heterosexual	245	2 (0.8)	69	1 (1.5)	314	3 (1.0)
Bisexual	13	3 (23.1)	21	0 (0.0)	36	3 (8.3)
Homosexual	9	7 (77.8)	3	0 (0.0)	12	7 (58.3)
p value		<0.001		1.000		<0.001

**Table 5.2.3 HIV antibody prevalence by age group, gender and survey year**

Queensland Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
<25 years	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)
25-34 years	56	0 (0.0)	29	0 (0.0)	85	0 (0.0)
35-44 years	79	0 (0.0)	41	0 (0.0)	121	0 (0.0)
45+ years	75	4 (5.3)	38	0 (0.0)	114	4 (3.5)
p value		0.060		--		0.060
<b>2017</b>						
<25 years	25	0 (0.0)	11	0 (0.0)	37	0 (0.0)
25-34 years	86	3 (3.5)	41	0 (0.0)	127	3 (2.4)
35-44 years	157	5 (3.2)	53	0 (0.0)	210	5 (2.4)
45+ years	172	6 (3.5)	62	1 (1.6)	234	7 (3.0)
p value		1.000		1.000		0.935
<b>2018</b>						
<25 years	21	0 (0.0)	15	0 (0.0)	36	0 (0.0)
25-34 years	75	1 (1.3)	46	2 (4.4)	122	3 (2.5)
35-44 years	158	2 (1.3)	67	0 (0.0)	225	2 (0.9)
45+ years	182	3 (1.7)	61	0 (0.0)	243	3 (1.2)
p value		1.000		0.211		0.671
<b>2019</b>						
<25 years	18	0 (0.0)	12	0 (0.0)	30	0 (0.0)
25-34 years	62	1 (1.6)	34	0 (0.0)	99	2 (2.0)
35-44 years	147	2 (1.4)	67	0 (0.0)	217	2 (0.9)
45+ years	173	8 (4.6)	44	0 (0.0)	218	8 (3.7)
p value		0.330		--		0.244
<b>2020</b>						
<25 years	11	0 (0.0)	7	1 (14.3)	18	1 (5.6)
25-34 years	42	3 (7.1)	20	0 (0.0)	62	3 (4.8)
35-44 years	103	4 (3.9)	40	0 (0.0)	144	4 (2.8)
45+ years	128	6 (4.7)	35	0 (0.0)	164	6 (3.7)
p value		0.814		0.069		0.621

**Table 5.2.4 HIV antibody prevalence by last drug injected, gender and survey year**

Queensland Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Heroin	32	0 (0.0)	22	0 (0.0)	54	0 (0.0)
Methamphetamine	88	3 (3.4)	44	0 (0.0)	133	3 (2.3)
Other opioids	65	0 (0.0)	37	0 (0.0)	103	0 (0.0)
PIEDs	20	1 (5.0)	0	0 (0.0)	20	1 (5.0)
Other drugs	19	0 (0.0)	12	0 (0.0)	31	0 (0.0)
p value		0.313		--		0.199
<b>2017</b>						
Heroin	57	0 (0.0)	31	1 (3.2)	88	1 (1.1)
Methamphetamine	176	11 (6.3)	84	0 (0.0)	261	11 (4.2)
Other opioids	132	1 (0.8)	45	0 (0.0)	177	1 (0.6)
PIEDs	48	0 (0.0)	0	0 (0.0)	48	0 (0.0)
Other drugs	28	2 (7.1)	7	0 (0.0)	35	2 (5.7)
p value		0.011		0.228		0.045
<b>2018</b>						
Heroin	56	0 (0.0)	27	0 (0.0)	83	0 (0.0)
Methamphetamine	200	6 (3.0)	100	2 (2.0)	301	8 (2.7)
Other opioids	130	0 (0.0)	50	0 (0.0)	180	0 (0.0)
PIEDs	27	0 (0.0)	1	0 (0.0)	28	0 (0.0)
Other drugs	23	0 (0.0)	11	0 (0.0)	34	0 (0.0)
p value		0.218		0.719		0.119
<b>2019</b>						
Heroin	58	2 (3.5)	31	0 (0.0)	90	2 (2.2)
Methamphetamine	189	9 (4.8)	85	0 (0.0)	277	10 (3.6)
Other opioids	101	0 (0.0)	31	0 (0.0)	134	0 (0.0)
PIEDs	24	0 (0.0)	3	0 (0.0)	27	0 (0.0)
Other drugs	29	0 (0.0)	7	0 (0.0)	36	0 (0.0)
p value		0.131		--		0.138
<b>2020</b>						
Heroin	45	0 (0.0)	17	0 (0.0)	62	0 (0.0)
Methamphetamine	110	11 (10.0)	44	1 (2.3)	155	12 (7.7)
Other opioids	85	2 (2.4)	32	0 (0.0)	118	2 (1.7)
PIEDs	29	0 (0.0)	1	0 (0.0)	30	0 (0.0)
Other drugs	14	0 (0.0)	8	0 (0.0)	22	0 (0.0)
p value		0.030		1.000		0.025

**Table 5.2.5 HIV antibody prevalence by years of injection, gender and survey year**

Queensland Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
<3 years	16	0 (0.0)	5	0 (0.0)	21	0 (0.0)
3 to 10 years	46	3 (6.5)	12	0 (0.0)	58	3 (5.2)
11+ years	151	1 (0.7)	94	0 (0.0)	247	1 (0.4)
p value		0.061		--		0.041
<b>2017</b>						
<3 years	31	0 (0.0)	15	0 (0.0)	46	0 (0.0)
3 to 10 years	63	4 (6.4)	35	0 (0.0)	98	4 (4.1)
11+ years	347	10 (2.9)	117	1 (0.9)	465	11 (2.4)
p value		0.280		1.000		0.302
<b>2018</b>						
<3 years	28	1 (3.6)	13	0 (0.0)	41	1 (2.4)
3 to 10 years	61	2 (3.3)	34	0 (0.0)	95	2 (2.1)
11+ years	348	3 (0.9)	142	2 (1.4)	491	5 (1.0)
p value		0.126		1.000		0.268
<b>2019</b>						
<3 years	36	2 (5.6)	14	0 (0.0)	50	2 (4.0)
3 to 10 years	59	2 (3.4)	29	0 (0.0)	90	3 (3.3)
11+ years	285	7 (2.5)	110	0 (0.0)	399	7 (1.8)
p value		0.369		--		0.302
<b>2020</b>						
<3 years	24	0 (0.0)	8	0 (0.0)	32	0 (0.0)
3 to 10 years	42	5 (11.9)	18	1 (5.6)	60	6 (10.0)
11+ years	213	8 (3.8)	76	0 (0.0)	291	8 (2.8)
p value		0.053		0.255		0.025

**Table 5.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year**

Queensland Receptively shared syringe last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
No receptive sharing	153	3 (2.0)	86	0 (0.0)	239	3 (1.3)
Receptive sharing	41	1 (2.4)	15	0 (0.0)	57	1 (1.8)
p value		1.000		--		0.577
<b>2017</b>						
No receptive sharing	337	11 (3.3)	129	1 (0.8)	467	12 (2.6)
Receptive sharing	55	1 (1.8)	28	0 (0.0)	83	1 (1.2)
p value		1.000		1.000		0.703
<b>2018</b>						
No receptive sharing	337	4 (1.2)	147	2 (1.4)	485	6 (1.2)
Receptive sharing	62	2 (3.2)	25	0 (0.0)	87	2 (2.3)
p value		0.236		1.000		0.350
<b>2019</b>						
No receptive sharing	321	9 (2.8)	130	0 (0.0)	456	10 (2.2)
Receptive sharing	40	1 (2.5)	15	0 (0.0)	56	1 (1.8)
p value		1.000		--		1.000
<b>2020</b>						
No receptive sharing	217	11 (5.1)	71	1 (1.4)	290	12 (4.1)
Receptive sharing	32	1 (3.1)	15	0 (0.0)	47	1 (2.1)
p value		1.000		1.000		1.000

**Table 5.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year**

Queensland Frequency of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
Less than daily	82	4 (4.9)	44	0 (0.0)	126	4 (3.2)
Daily or more	113	0 (0.0)	59	0 (0.0)	173	0 (0.0)
Not last month	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
p value		0.046		--		0.045
<b>2017</b>						
Less than daily	179	11 (6.2)	60	0 (0.0)	240	11 (4.6)
Daily or more	217	1 (0.5)	97	1 (1.0)	314	2 (0.6)
Not last month	40	2 (5.0)	10	0 (0.0)	50	2 (4.0)
p value		0.002		1.000		0.004
<b>2018</b>						
Less than daily	176	2 (1.1)	72	2 (2.8)	248	4 (1.6)
Daily or more	226	4 (1.8)	102	0 (0.0)	329	4 (1.2)
Not last month	27	0 (0.0)	13	0 (0.0)	40	0 (0.0)
p value		0.797		0.282		0.843
<b>2019</b>						
Less than daily	163	7 (4.3)	53	0 (0.0)	218	7 (3.2)
Daily or more	200	3 (1.5)	93	0 (0.0)	297	4 (1.4)
Not last month	37	1 (2.7)	10	0 (0.0)	47	1 (2.1)
p value		0.221		--		0.267
<b>2020</b>						
Less than daily	93	7 (7.5)	41	1 (2.4)	136	8 (5.9)
Daily or more	156	5 (3.2)	46	0 (0.0)	202	5 (2.5)
Not last month	32	1 (3.1)	14	0 (0.0)	46	1 (2.2)
p value		0.238		0.545		0.235

**Table 5.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year**

Queensland Imprisonment last year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
No imprisonment	192	3 (1.6)	98	0 (0.0)	292	3 (1.0)
Imprisonment	27	1 (3.7)	11	0 (0.0)	38	1 (2.6)
p value		0.412		--		0.388
<b>2017</b>						
No imprisonment	367	13 (3.5)	152	1 (0.7)	520	14 (2.7)
Imprisonment	57	1 (1.8)	10	0 (0.0)	67	1 (1.5)
p value		0.704		1.000		1.000
<b>2018</b>						
No imprisonment	365	5 (1.4)	165	2 (1.2)	531	7 (1.3)
Imprisonment	55	1 (1.8)	16	0 (0.0)	71	1 (1.4)
p value		0.572		1.000		1.000
<b>2019</b>						
No imprisonment	334	11 (3.3)	133	0 (0.0)	472	12 (2.5)
Imprisonment	48	0 (0.0)	15	0 (0.0)	65	0 (0.0)
p value		0.372		--		0.377
<b>2020</b>						
No imprisonment	240	10 (4.2)	91	1 (1.1)	333	11 (3.3)
Imprisonment	33	3 (9.1)	6	0 (0.0)	39	3 (7.7)
p value		0.198		1.000		0.172



**Table 5.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year**

Queensland	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
No condom use	77	2 (2.6)	46	0 (0.0)	125	2 (1.6)
Condom use	28	1 (3.6)	11	0 (0.0)	39	1 (2.6)
p value		1.000		--		0.560
<b>2017</b>						
No condom use	134	3 (2.2)	63	1 (1.6)	197	4 (2.0)
Condom use	49	4 (8.2)	18	0 (0.0)	68	4 (5.9)
p value		0.840		1.000		0.210
<b>2018</b>						
No condom use	145	3 (2.1)	84	0 (0.0)	229	3 (1.3)
Condom use	35	1 (2.9)	11	0 (0.0)	47	1 (2.1)
p value		0.582		--		0.528
<b>2019</b>						
No condom use	128	6 (4.7)	65	0 (0.0)	196	6 (3.1)
Condom use	32	0 (0.0)	14	0 (0.0)	47	0 (0.0)
p value		0.601		--		0.600
<b>2020</b>						
No condom use	88	6 (6.8)	43	0 (0.0)	131	6 (4.6)
Condom use	21	1 (4.8)	5	0 (0.0)	26	1 (3.9)
p value		1.000		--		1.000

**Table 5.2.10 HIV antibody prevalence by sex work last month, gender and survey year**

Queensland	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
No sex work	208	4 (1.9)	97	0 (0.0)	307	4 (1.3)
Sex work	9	0 (0.0)	9	0 (0.0)	18	0 (0.0)
p value		1.000		--		1.000
<b>2017</b>						
No sex work	413	13 (3.2)	146	1 (0.7)	559	14 (2.5)
Sex work	10	1 (10.0)	11	0 (0.0)	22	1 (4.6)
p value		0.288		1.000		0.444
<b>2018</b>						
No sex work	409	6 (1.5)	168	2 (1.2)	577	8 (1.4)
Sex work	14	0 (0.0)	14	0 (0.0)	29	0 (0.0)
p value		1.000		1.000		1.000
<b>2019</b>						
No sex work	373	9 (2.4)	140	0 (0.0)	519	10 (1.9)
Sex work	13	2 (15.4)	7	0 (0.0)	21	2 (9.5)
p value		0.049		--		0.075
<b>2020</b>						
No sex work	268	10 (3.7)	91	1 (1.1)	361	11 (3.1)
Sex work	9	3 (33.3)	4	0 (0.0)	13	3 (23.1)
p value		0.006		1.000		0.010

**Table 5.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Queensland Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Non Indigenous	193	4 (2.1)	94	0 (0.0)	289	4 (1.4)
Indigenous	25	0 (0.0)	19	0 (0.0)	44	0 (0.0)
p value		1.000		--		1.000
<b>2017</b>						
Non Indigenous	358	11 (3.1)	135	1 (0.7)	493	12 (2.4)
Indigenous	69	3 (4.4)	30	0 (0.0)	100	3 (3.0)
p value		0.482		1.000		0.727
<b>2018</b>						
Non Indigenous	362	3 (0.8)	143	2 (1.4)	506	5 (1.0)
Indigenous	71	3 (4.2)	44	0 (0.0)	115	3 (2.6)
p value		0.058		1.000		0.170
<b>2019</b>						
Non Indigenous	314	8 (2.6)	129	0 (0.0)	448	9 (2.0)
Indigenous	83	3 (3.6)	27	0 (0.0)	112	3 (2.7)
p value		0.705		--		0.714
<b>2020</b>						
Non Indigenous	231	9 (3.9)	82	1 (1.2)	314	10 (3.2)
Indigenous	45	3 (6.7)	19	0 (0.0)	64	3 (4.7)
p value		0.421		1.000		0.468

**Table 5.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year**

Queensland Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
English speaking	210	3 (1.4)	111	0 (0.0)	323	3 (0.9)
Non-English speaking	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)
p value		0.156		--		0.126
<b>2017</b>						
English speaking	425	14 (3.3)	159	1 (0.6)	584	15 (2.6)
Non-English speaking	13	0 (0.0)	8	0 (0.0)	22	0 (0.0)
p value		1.000		1.000		1.000
<b>2018</b>						
English speaking	425	6 (1.4)	183	0 (0.0)	608	6 (1.0)
Non-English speaking	11	0 (0.0)	6	2 (33.3)	18	2 (11.1)
p value		1.000		0.001		0.020
<b>2019</b>						
English speaking	383	11 (2.9)	153	0 (0.0)	542	12 (2.2)
Non-English speaking	17	0 (0.0)	4	0 (0.0)	22	0 (0.0)
p value		1.000		--		1.000
<b>2020</b>						
English speaking	276	13 (4.7)	101	1 (1.0)	379	14 (3.7)
Non-English speaking	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)
p value		1.000		1.000		1.000

Table 5.2.13 HIV antibody prevalence by region/country of birth, gender and survey year

Queensland	Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Australia	196	3 (1.5)	101	0 (0.0)	298	3 (1.0)
Other Oceania	8	0 (0.0)	4	0 (0.0)	12	0 (0.0)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	7	0 (0.0)	8	0 (0.0)	16	0 (0.0)
Other	5	1 (20.0)	0	0 (0.0)	5	1 (20.0)
p value		0.146		--		0.117
<b>2017</b>						
Australia	398	14 (3.5)	141	1 (0.7)	539	15 (2.8)
Other Oceania	13	0 (0.0)	17	0 (0.0)	31	0 (0.0)
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
UK & Ireland	14	0 (0.0)	5	0 (0.0)	19	0 (0.0)
Other	9	0 (0.0)	2	0 (0.0)	11	0 (0.0)
p value		1.000		1.000		1.000
<b>2018</b>						
Australia	391	5 (1.3)	175	2 (1.1)	566	7 (1.2)
Other Oceania	16	0 (0.0)	3	0 (0.0)	20	0 (0.0)
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
UK & Ireland	17	1 (5.9)	7	0 (0.0)	24	1 (4.2)
Other	11	0 (0.0)	4	0 (0.0)	15	0 (15.0)
p value		0.475		1.000		0.550
<b>2019</b>						
Australia	366	11 (3.0)	145	0 (0.0)	517	12 (2.3)
Other Oceania	9	0 (0.0)	2	0 (0.0)	12	0 (0.0)
Asia	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
UK & Ireland	8	0 (0.0)	3	0 (0.0)	11	0 (0.0)
Other	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)
p value		1.000		--		1.000
<b>2020</b>						
Australia	252	12 (4.8)	95	1 (1.1)	349	13 (3.7)
Other Oceania	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
UK & Ireland	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)
Other	7	0 (0.0)	1	0 (0.0)	8	0 (0.0)
p value		0.607		1.000		0.584

## HCV antibody prevalence

Table 5.3.1 HCV antibody prevalence by gender and survey year

Queensland Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2016	204	98 (48)	101	54 (53)	306	153 (50)
2017	425	179 (42)	161	66 (41)	587	245 (42)
2018	436	182 (42)	188	84 (45)	625	266 (43)
2019	401	175 (44)	156	57 (37)	564	234 (41)
2020	283	104 (37)	102	42 (41)	387	146 (38)
X <sup>2</sup> p trend		0.062		0.056		0.007

Table 5.3.2 HCV antibody prevalence by sexual identity, gender and survey year

Queensland Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Heterosexual	165	80 (48)	58	31 (53)	224	112 (50)
Bisexual	12	3 (25)	32	19 (59)	44	22 (50)
Homosexual	10	6 (60)	4	1 (25)	14	7 (50)
p value		0.205		0.408		1.000
<b>2017</b>						
Heterosexual	343	142 (41)	113	46 (41)	456	188 (41)
Bisexual	26	17 (65)	27	12 (44)	53	29 (55)
Homosexual	24	7 (29)	8	2 (25)	33	9 (27)
p value		0.024		0.642		0.038
<b>2018</b>						
Heterosexual	364	160 (44)	136	61 (45)	500	221 (44)
Bisexual	25	8 (32)	36	17 (47)	61	25 (41)
Homosexual	21	7 (33)	3	1 (33)	25	8 (32)
p value		0.340		0.939		0.450
<b>2019</b>						
Heterosexual	322	142 (44)	94	34 (36)	418	178 (43)
Bisexual	24	11 (46)	36	14 (39)	62	25 (40)
Homosexual	21	6 (29)	5	3 (60)	27	9 (33)
p value		0.414		0.531		0.620
<b>2020</b>						
Heterosexual	244	92 (38)	69	30 (43)	313	122 (39)
Bisexual	13	2 (15)	21	10 (48)	36	12 (33)
Homosexual	9	1 (11)	3	0 (0)	12	1 (8)
p value		0.027		0.559		0.064

Table 5.3.3 HCV antibody prevalence by age group, gender and survey year

Queensland Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	14	3 (21)	5	2 (40)	19	5 (26)
25-34 years	52	19 (37)	28	14 (50)	80	33 (41)
35-44 years	76	41 (54)	36	21 (58)	112	62 (55)
45+ years	62	35 (56)	32	17 (53)	95	53 (56)
p value		0.023		0.848		0.026
<b>2017</b>						
<25 years	24	2 (8)	11	2 (18)	36	4 (11)
25-34 years	84	30 (36)	42	22 (52)	126	52 (41)
35-44 years	148	65 (44)	53	17 (32)	201	82 (41)
45+ years	168	82 (49)	55	25 (45)	223	107 (48)
p value		0.001		0.081		<0.001
<b>2018</b>						
<25 years	20	2 (10)	15	3 (20)	35	5 (14)
25-34 years	76	23 (30)	45	18 (40)	122	41 (34)
35-44 years	158	59 (37)	67	34 (51)	225	93 (41)
45+ years	181	97 (54)	61	29 (48)	242	126 (52)
p value		<0.001		0.153		<0.001
<b>2019</b>						
<25 years	18	5 (28)	12	2 (17)	30	7 (23)
25-34 years	62	16 (26)	34	11 (32)	99	28 (28)
35-44 years	147	66 (45)	67	26 (39)	217	93 (43)
45+ years	173	88 (51)	43	18 (42)	217	106 (49)
p value		0.003		0.412		0.001
<b>2020</b>						
<25 years	11	3 (27)	7	2 (29)	18	5 (28)
25-34 years	42	3 (7)	20	9 (45)	62	12 (19)
35-44 years	103	42 (41)	40	17 (43)	144	59 (41)
45+ years	127	56 (44)	35	14 (40)	163	70 (43)
p value		<0.001		0.921		0.005

**Table 5.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

Queensland Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
<3 years	16	0 (0)	4	1 (25)	20	1 (5)
3 to 10 years	45	13 (29)	11	3 (27)	56	16 (29)
11+ years	132	77 (58)	82	50 (61)	215	128 (60)
p value		<0.001		0.045		<0.001
<b>2017</b>						
<3 years	31	1 (3)	15	2 (13)	46	3 (7)
3 to 10 years	62	10 (16)	35	7 (20)	97	17 (18)
11+ years	318	161 (51)	111	57 (51)	430	218 (51)
p value		<0.001		<0.001		<0.001
<b>2018</b>						
<3 years	28	1 (4)	13	1 (8)	41	2 (5)
3 to 10 years	60	11 (18)	33	8 (24)	93	19 (20)
11+ years	333	164 (49)	137	73 (53)	470	237 (50)
p value		<0.001		<0.001		<0.001
<b>2019</b>						
<3 years	36	3 (8)	14	0 (0)	50	3 (6)
3 to 10 years	59	12 (20)	29	7 (24)	90	19 (21)
11+ years	285	151 (53)	109	50 (46)	398	203 (51)
p value		<0.001		<0.001		<0.001
<b>2020</b>						
<3 years	24	3 (13)	8	0 (0)	32	3 (9)
3 to 10 years	42	2 (5)	18	5 (28)	60	7 (12)
11+ years	212	96 (45)	76	37 (49)	290	133 (46)
p value		<0.001		0.008		<0.001

**Table 5.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

Queensland Receptively shared syringe last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No receptive sharing	10	0 (0)	198	102 (52)	217	107 (49)
Receptive sharing	4	0 (0)	47	27 (57)	52	28 (54)
p value		--		0.464		0.557
<b>2017</b>						
No receptive sharing	34	1 (3)	407	182 (45)	449	186 (41)
Receptive sharing	8	2 (25)	68	36 (53)	80	41 (51)
p value		0.088		0.208		0.102
<b>2018</b>						
No receptive sharing	30	1 (3)	441	189 (43)	483	194 (40)
Receptive sharing	7	1 (14)	75	45 (60)	87	50 (57)
p value		0.347		0.006		0.003
<b>2019</b>						
No receptive sharing	41	2 (5)	401	175 (44)	455	183 (40)
Receptive sharing	3	0 (0)	48	31 (65)	56	33 (59)
p value		1.000		0.006		0.007
<b>2020</b>						
No receptive sharing	22	2 (9)	265	104 (39)	289	107 (37)
Receptive sharing	3	0 (0)	43	23 (53)	47	24 (51)
p value		0.770		0.078		0.067

**Table 5.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

Queensland Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	1	0 (0)	41	27 (66)	43	27 (63)
Methamphetamine	10	0 (0)	105	51 (49)	120	55 (46)
Other opioids	1	0 (0)	81	49 (60)	85	51 (60)
PIEDs	3	0 (0)	15	0 (0)	19	0 (0)
Other drugs	4	1 (25)	21	11 (52)	30	14 (47)
p value		0.412		<0.001		<0.001
<b>2017</b>						
Heroin	4	1 (25)	77	44 (57)	82	46 (56)
Methamphetamine	20	1 (5)	230	87 (38)	255	91 (36)
Other opioids	6	1 (17)	160	93 (58)	170	96 (56)
PIEDs	12	0 (0)	34	2 (6)	47	2 (4)
Other drugs	4	0 (0)	23	7 (30)	30	8 (27)
p value		0.349		<0.001		<0.001
<b>2018</b>						
Heroin	3	1 (33)	74	36 (49)	80	40 (50)
Methamphetamine	25	1 (4)	262	99 (38)	297	102 (34)
Other opioids	1	0 (0)	172	99 (58)	177	101 (57)
PIEDs	7	0 (0)	19	0 (0)	27	0 (0)
Other drugs	4	0 (0)	27	16 (59)	33	17 (52)
p value		0.218		<0.001		<0.001
<b>2019</b>						
Heroin	1	0 (0)	87	55 (63)	90	57 (63)
Methamphetamine	31	1 (3)	230	71 (31)	275	75 (27)
Other opioids	4	1 (25)	125	78 (62)	133	82 (62)
PIEDs	11	0 (0)	15	0 (0)	27	0 (0)
Other drugs	3	1 (33)	29	16 (55)	36	18 (50)
p value		0.102		<0.001		<0.001
<b>2020</b>						
Heroin	0	0 (0)	61	37 (61)	61	37 (61)
Methamphetamine	14	3 (21)	138	29 (21)	155	34 (22)
Other opioids	3	0 (0)	112	57 (51)	116	58 (50)
PIEDs	11	0 (0)	18	1 (6)	30	1 (3)
Other drugs	3	0 (0)	17	13 (76)	20	13 (65)
p value		0.258		<0.001		<0.001

**Table 5.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

Queensland	<3 years		3+ years		Total	
Frequency of injection last month	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	10	0 (0)	101	54 (53)	116	57 (49)
Daily or more	4	0 (0)	146	77 (53)	155	80 (52)
Not last month	5	1 (20)	16	7 (44)	26	10 (38)
p value		0.474		0.766		0.461
<b>2017</b>						
Less than daily	23	1 (4)	201	81 (40)	229	84 (37)
Daily or more	19	2 (11)	278	138 (50)	304	144 (47)
Not last month	4	0 (0)	45	14 (31)	51	15 (29)
p value		0.683		0.022		0.008
<b>2018</b>						
Less than daily	22	2 (9)	217	91 (42)	246	96 (39)
Daily or more	15	0 (0)	304	146 (48)	329	151 (46)
Not last month	3	0 (0)	34	13 (38)	40	13 (33)
p value		0.577		0.276		0.111
<b>2019</b>						
Less than daily	25	1 (4)	185	74 (40)	217	77 (35)
Daily or more	19	1 (5)	267	133 (50)	297	140 (47)
Not last month	6	1 (17)	34	13 (38)	47	15 (32)
p value		0.491		0.083		0.012
<b>2020</b>						
Less than daily	16	0 (0)	119	41 (34)	136	41 (30)
Daily or more	9	2 (22)	190	86 (45)	201	90 (45)
Not last month	7	1 (14)	37	10 (27)	46	12 (26)
p value		0.113		0.043		0.006

**Table 5.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

Queensland	<3 years		3+ years		Total	
Imprisonment last year	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	16	0 (0)	233	115 (49)	263	122 (46)
Imprisonment	1	0 (0)	33	26 (79)	35	27 (77)
p value		--		0.002		0.001
<b>2017</b>						
No imprisonment	40	2 (5)	450	190 (42)	501	196 (39)
Imprisonment	3	0 (0)	58	34 (59)	64	37 (58)
p value		1.000		0.018		0.004
<b>2018</b>						
No imprisonment	39	2 (5)	472	210 (44)	529	218 (41)
Imprisonment	2	0 (0)	65	35 (54)	70	37 (53)
p value		1.000		0.156		0.064
<b>2019</b>						
No imprisonment	46	3 (7)	402	170 (42)	471	181 (38)
Imprisonment	3	0 (0)	60	41 (68)	65	41 (63)
p value		1.000		<0.001		<0.001
<b>2020</b>						
No imprisonment	31	2 (6)	297	112 (38)	333	117 (35)
Imprisonment	1	1 (100)	37	17 (46)	38	18 (47)
p value		0.094		0.372		0.138



**Table 5.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Queensland	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	176	80 (45)	82	39 (48)	259	120 (46)
Indigenous	22	14 (64)	18	14 (78)	40	28 (70)
p value		0.107		0.035		0.005
<b>2017</b>						
Non Indigenous	346	134 (39)	130	51 (39)	476	185 (39)
Indigenous	66	41 (62)	29	15 (52)	96	56 (58)
p value		<0.001		0.217		<0.001
<b>2018</b>						
Non Indigenous	362	145 (40)	142	63 (44)	505	208 (41)
Indigenous	69	35 (51)	44	21 (48)	113	56 (50)
p value		0.100		0.695		0.104
<b>2019</b>						
Non Indigenous	314	128 (41)	128	42 (33)	447	170 (38)
Indigenous	83	45 (54)	27	15 (56)	112	62 (55)
p value		0.028		0.026		0.001
<b>2020</b>						
Non Indigenous	231	76 (33)	82	33 (40)	314	109 (35)
Indigenous	44	26 (59)	19	9 (47)	63	35 (56)
p value		0.001		0.570		0.002

**Table 5.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

Queensland	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	191	90 (47)	98	51 (52)	290	142 (49)
Non-English speaking	9	5 (56)	2	2 (100)	11	7 (64)
p value		0.738		0.497		0.375
<b>2017</b>						
English speaking	410	175 (43)	153	61 (40)	563	236 (42)
Non-English speaking	13	3 (23)	8	5 (63)	22	8 (36)
p value		0.253		0.274		0.604
<b>2018</b>						
English speaking	423	176 (42)	182	82 (45)	605	258 (43)
Non-English speaking	11	5 (45)	6	2 (33)	18	7 (39)
p value		0.798		0.693		0.751
<b>2019</b>						
English speaking	383	166 (43)	152	55 (36)	541	223 (41)
Non-English speaking	17	8 (47)	4	2 (50)	22	10 (45)
p value		0.762		0.623		0.693
<b>2020</b>						
English speaking	275	99 (36)	101	41 (41)	378	140 (37)
Non-English speaking	8	5 (63)	1	1 (100)	9	6 (67)
p value		0.148		0.412		0.087

**Table 5.3.11 HCV antibody prevalence by region/country of birth, gender and survey year**

Queensland		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
<b>2016</b>							
Australia	178	87 (49)	90	47 (52)	268	134 (50)	
Other Oceania	7	3 (43)	3	2 (67)	10	5 (50)	
Asia	2	1 (50)	0	0 (0)	2	1 (50)	
UK & Ireland	7	4 (57)	7	4 (57)	15	9 (60)	
Other	5	1 (20)	0	0 (0)	5	1 (20)	
p value		0.812		1.000		0.682	
<b>2017</b>							
Australia	383	162 (42)	136	61 (45)	519	223 (43)	
Other Oceania	13	6 (46)	16	3 (19)	30	9 (30)	
Asia	1	0 (0)	1	1 (100)	2	1 (50)	
UK & Ireland	14	8 (57)	5	1 (20)	19	9 (47)	
Other	9	1 (11)	2	0 (0)	11	1 (9)	
p value		0.194		0.069		0.087	
<b>2018</b>							
Australia	389	164 (42)	174	80 (46)	563	244 (43)	
Other Oceania	16	6 (38)	3	1 (33)	20	7 (35)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	17	9 (53)	7	2 (29)	24	11 (46)	
Other	11	2 (18)	4	1 (25)	15	3 (20)	
p value		0.319		0.694		0.285	
<b>2019</b>							
Australia	366	163 (45)	144	52 (36)	516	217 (42)	
Other Oceania	9	5 (56)	2	1 (50)	12	6 (50)	
Asia	2	0 (0)	2	0 (0)	4	0 (0)	
UK & Ireland	8	3 (38)	3	2 (67)	11	5 (45)	
Other	12	2 (17)	5	2 (40)	17	4 (24)	
p value		0.213		0.728		0.246	
<b>2020</b>							
Australia	251	94 (37)	95	41 (43)	348	135 (39)	
Other Oceania	11	4 (36)	4	1 (25)	15	5 (33)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	9	1 (11)	2	0 (0)	11	1 (9)	
Other	7	4 (57)	1	0 (0)	8	4 (50)	
p value		0.347		0.586		0.230	

## HCV RNA prevalence

Table 5.4.1 HCV RNA prevalence by gender and survey year \*

Queensland Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2016	90	25 (28)	46	14 (30)	136	39 (29)
2017	368	83 (23)	141	20 (14)	509	103 (20)
2018	196	43 (22)	84	16 (19)	280	59 (21)
2019	371	62 (17)	144	16 (11)	522	79 (15)
2020	270	40 (15)	98	10 (10)	369	50 (14)
X <sup>2</sup> p trend		<0.001		0.007		<0.001

\* Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 5.4.2 HCV RNA prevalence by sexual identity, gender and survey year \*

Queensland Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Heterosexual	76	22 (29)	26	8 (31)	102	30 (29)
Bisexual	3	1 (33)	13	5 (38)	17	6 (35)
Homosexual	5	2 (40)	4	0 (0)	9	2 (22)
p value		0.924		0.292		0.659
<b>2017</b>						
Heterosexual	303	68 (22)	101	10 (10)	404	78 (19)
Bisexual	24	9 (38)	20	5 (25)	44	14 (32)
Homosexual	14	1 (7)	7	2 (29)	21	3 (14)
p value		0.135		0.085		0.150
<b>2018</b>						
Heterosexual	172	39 (23)	62	12 (19)	234	51 (22)
Bisexual	8	1 (13)	14	3 (21)	22	4 (18)
Homosexual	6	0 (0)	3	0 (0)	9	0 (0)
p value		0.332		0.680		0.228
<b>2019</b>						
Heterosexual	300	50 (17)	86	9 (10)	388	61 (16)
Bisexual	23	6 (26)	34	4 (12)	58	10 (17)
Homosexual	19	1 (5)	5	1 (20)	25	2 (8)
p value		0.203		0.801		0.554
<b>2020</b>						
Heterosexual	232	33 (14)	65	6 (9)	298	39 (13)
Bisexual	13	1 (8)	21	4 (19)	36	5 (14)
Homosexual	9	0 (0)	3	0 (0)	12	0 (0)
p value		0.016		0.521		0.118

**Table 5.4.3 HCV RNA prevalence by age group, gender and survey year \***

Queensland Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	2	0 (0)	4	1 (25)	6	1 (17)
25-34 years	19	5 (26)	9	4 (44)	29	9 (31)
35-44 years	29	8 (28)	16	4 (25)	45	12 (27)
45+ years	39	12 (31)	16	4 (25)	56	17 (30)
p value		0.752		0.549		0.782
<b>2017</b>						
<25 years	22	1 (5)	10	2 (20)	33	3 (9)
25-34 years	71	22 (31)	35	8 (23)	106	30 (28)
35-44 years	138	33 (24)	45	3 (7)	183	36 (20)
45+ years	135	27 (20)	50	7 (14)	185	34 (18)
p value		0.098		0.232		0.101
<b>2018</b>						
<25 years	10	2 (20)	6	1 (17)	16	3 (19)
25-34 years	43	5 (12)	23	3 (13)	66	8 (12)
35-44 years	74	18 (24)	26	5 (19)	100	23 (23)
45+ years	69	18 (26)	28	7 (25)	97	25 (26)
p value		0.407		0.612		0.222
<b>2019</b>						
<25 years	17	2 (12)	11	3 (27)	28	5 (18)
25-34 years	55	5 (9)	29	2 (7)	87	8 (9)
35-44 years	136	28 (21)	65	11 (17)	204	38 (19)
45+ years	162	28 (17)	39	0 (0)	202	28 (14)
p value		0.288		0.019		0.178
<b>2020</b>						
<25 years	10	1 (10)	8	1 (13)	18	2 (11)
25-34 years	37	1 (3)	19	5 (26)	57	6 (11)
35-44 years	101	23 (23)	38	4 (11)	140	27 (19)
45+ years	122	15 (12)	33	0 (0)	155	15 (10)
p value		0.011		0.030		0.063

**Table 5.4.4 HCV RNA prevalence by years since first injection, gender and survey year \***

Queensland Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	5	0 (0)	3	0 (0)	8	0 (0)
3 to 10 years	19	4 (21)	3	1 (33)	22	5 (23)
11+ years	59	17 (29)	38	12 (32)	97	29 (30)
p value		0.293		0.440		0.149
<b>2017</b>						
<3 years	28	1 (4)	12	1 (8)	40	2 (5)
3 to 10 years	51	6 (12)	31	4 (13)	82	10 (12)
11+ years	278	72 (26)	98	15 (15)	376	87 (23)
p value		0.003		0.773		0.003
<b>2018</b>						
<3 years	11	0 (0)	7	0 (0)	18	0 (0)
3 to 10 years	33	7 (21)	15	1 (7)	48	8 (17)
11+ years	149	36 (24)	59	14 (24)	208	50 (24)
p value		0.225		0.086		0.052
<b>2019</b>						
<3 years	33	2 (6)	13	1 (8)	46	3 (7)
3 to 10 years	55	6 (11)	25	4 (16)	82	10 (12)
11+ years	264	52 (20)	102	11 (11)	370	64 (17)
p value		0.055		0.631		0.113
<b>2020</b>						
<3 years	23	0 (0)	8	0 (0)	30	0 (0)
3 to 10 years	41	1 (2)	18	4 (22)	60	5 (8)
11+ years	201	38 (19)	72	6 (8)	274	44 (16)
p value		0.003		0.150		0.019

**Table 5.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year \***

Queensland Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	60	16 (27)	33	10 (30)	94	26 (28)
Receptive sharing	13	4 (31)	6	2 (33)	19	6 (32)
p value		0.886		0.752		0.777
<b>2017</b>						
No receptive sharing	281	64 (23)	109	17 (16)	390	81 (21)
Receptive sharing	47	12 (26)	23	3 (13)	70	15 (21)
p value		0.708		0.741		0.915
<b>2018</b>						
No receptive sharing	150	29 (19)	60	12 (20)	210	42 (20)
Receptive sharing	29	11 (38)	15	3 (20)	45	14 (31)
p value		0.039		0.750		0.122
<b>2019</b>						
No receptive sharing	296	50 (17)	118	13 (11)	418	64 (15)
Receptive sharing	37	8 (22)	14	2 (14)	52	10 (19)
p value		0.501		0.649		0.457
<b>2020</b>						
No receptive sharing	205	26 (13)	67	6 (9)	273	32 (12)
Receptive sharing	29	12 (41)	16	3 (19)	45	15 (33)
p value		<0.001		0.246		<0.001

**Table 5.4.6 HCV RNA prevalence by last drug injected, gender and survey year \***

Queensland Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	9	1 (11)	8	2 (25)	17	3 (18)
Methamphetamine	26	8 (31)	17	5 (29)	43	13 (30)
Other opioids	34	13 (38)	14	4 (29)	48	18 (38)
PIEDs	9	0 (0)	0	0 (0)	9	0 (0)
Other drugs	8	2 (25)	7	2 (29)	15	4 (27)
p value		0.145		0.993		0.173
<b>2017</b>						
Heroin	39	13 (33)	25	7 (28)	65	20 (31)
Methamphetamine	147	37 (25)	71	10 (14)	219	47 (21)
Other opioids	114	24 (21)	38	3 (8)	152	27 (18)
PIEDs	41	2 (5)	0	0 (0)	41	2 (5)
Other drugs	23	6 (26)	7	0 (0)	30	6 (20)
p value		0.045		0.112		0.033
<b>2018</b>						
Heroin	22	6 (27)	9	2 (22)	31	8 (26)
Methamphetamine	87	21 (24)	47	9 (19)	134	30 (22)
Other opioids	58	10 (17)	21	4 (19)	79	15 (19)
PIEDs	13	0 (0)	0	0 (0)	13	0 (0)
Other drugs	13	4 (31)	5	0 (0)	18	4 (22)
p value		0.271		0.677		0.420
<b>2019</b>						
Heroin	55	10 (18)	28	2 (7)	83	12 (14)
Methamphetamine	175	28 (16)	76	7 (9)	254	35 (14)
Other opioids	92	19 (21)	30	3 (10)	124	23 (19)
PIEDs	21	0 (0)	3	0 (0)	24	0 (0)
Other drugs	27	6 (22)	7	2 (29)	34	8 (24)
p value		0.208		0.525		0.105
<b>2020</b>						
Heroin	44	7 (16)	18	1 (6)	61	8 (13)
Methamphetamine	105	15 (14)	42	3 (7)	147	18 (12)
Other opioids	78	15 (19)	29	1 (3)	109	16 (15)
PIEDs	28	0 (0)	1	0 (0)	29	0 (0)
Other drugs	11	3 (27)	8	5 (63)	19	8 (42)
p value		0.124		<0.001		0.001

**Table 5.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year \***

Queensland Frequency of injection last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	31	8 (26)	17	6 (35)	48	14 (29)
Daily or more	42	12 (29)	23	6 (26)	65	18 (28)
Not last month	14	4 (29)	5	1 (20)	19	6 (32)
p value		0.955		0.856		0.977
<b>2017</b>						
Less than daily	149	34 (23)	52	8 (15)	201	42 (21)
Daily or more	183	44 (24)	80	12 (15)	263	56 (21)
Not last month	33	4 (12)	9	0 (0)	42	4 (10)
p value		0.441		0.420		0.281
<b>2018</b>						
Less than daily	84	19 (23)	30	8 (27)	114	27 (24)
Daily or more	95	21 (22)	45	7 (16)	140	29 (21)
Not last month	14	2 (14)	6	0 (0)	20	2 (10)
p value		0.753		0.181		0.354
<b>2019</b>						
Less than daily	152	21 (14)	46	4 (9)	200	26 (13)
Daily or more	182	38 (21)	88	11 (13)	273	48 (18)
Not last month	36	4 (11)	10	0 (0)	46	4 (9)
p value		0.142		0.469		0.162
<b>2020</b>						
Less than daily	90	12 (13)	39	2 (5)	129	14 (11)
Daily or more	145	26 (18)	45	7 (16)	189	33 (17)
Not last month	33	1 (3)	14	1 (7)	46	2 (4)
p value		0.073		0.275		0.029

**Table 5.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year \***

Queensland Imprisonment last year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	83	20 (24)	43	13 (30)	126	33 (26)
Imprisonment	6	4 (67)	1	1 (100)	7	5 (71)
p value		0.015		0.144		0.008
<b>2017</b>						
No imprisonment	305	65 (21)	128	16 (13)	434	81 (19)
Imprisonment	47	14 (30)	7	3 (43)	54	17 (31)
p value		0.163		0.044		0.026
<b>2018</b>						
No imprisonment	162	35 (22)	74	14 (19)	236	50 (21)
Imprisonment	27	7 (26)	7	1 (14)	35	8 (23)
p value		0.759		0.621		0.911
<b>2019</b>						
No imprisonment	310	43 (14)	121	11 (9)	435	55 (13)
Imprisonment	45	14 (31)	14	3 (21)	61	18 (30)
p value		0.004		0.164		<0.001
<b>2020</b>						
No imprisonment	231	29 (13)	88	8 (9)	319	38 (12)
Imprisonment	30	9 (30)	6	1 (17)	36	10 (28)
p value		0.017		0.613		0.012

**Table 5.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year \***

Queensland	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	83	22 (27)	38	10 (26)	121	32 (26)
Indigenous	4	2 (50)	8	4 (50)	12	6 (50)
p value		0.110		0.237		0.051
<b>2017</b>						
Non Indigenous	298	61 (20)	113	13 (12)	411	74 (18)
Indigenous	59	22 (37)	26	7 (27)	85	29 (34)
p value		0.009		0.046		0.002
<b>2018</b>						
Non Indigenous	159	34 (21)	65	11 (17)	224	45 (20)
Indigenous	33	9 (27)	18	4 (22)	52	14 (27)
p value		0.497		0.496		0.367
<b>2019</b>						
Non Indigenous	290	39 (13)	118	9 (8)	412	48 (12)
Indigenous	78	23 (29)	26	6 (23)	105	30 (29)
p value		<0.001		0.018		<0.001
<b>2020</b>						
Non Indigenous	218	27 (12)	79	8 (10)	297	35 (12)
Indigenous	44	13 (30)	18	2 (11)	62	15 (24)
p value		0.006		0.932		0.016

**Table 5.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year \***

Queensland	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	84	22 (26)	45	13 (29)	129	35 (27)
Non-English speaking	4	3 (75)	1	1 (100)	5	4 (80)
p value		0.065		0.133		0.030
<b>2017</b>						
English speaking	354	82 (23)	134	17 (13)	488	99 (20)
Non-English speaking	12	1 (8)	7	3 (43)	19	4 (21)
p value		0.283		0.021		0.922
<b>2018</b>						
English speaking	188	42 (22)	80	16 (20)	268	58 (22)
Non-English speaking	6	1 (17)	4	0 (0)	10	1 (10)
p value		0.661		0.999		0.349
<b>2019</b>						
English speaking	354	59 (17)	141	15 (11)	501	75 (15)
Non-English speaking	16	3 (19)	3	1 (33)	20	4 (20)
p value		0.843		0.190		0.521
<b>2020</b>						
English speaking	263	38 (14)	97	10 (10)	361	48 (13)
Non-English speaking	7	2 (29)	1	0 (0)	8	2 (25)
p value		0.324		0.739		0.357



Table 5.4.11 HCV RNA prevalence by region/country of birth, gender and survey year \*

Queensland	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Australia	80	22 (28)	39	11 (28)	119	33 (28)
Other Oceania	3	1 (33)	3	1 (33)	6	2 (33)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	2	0 (0)	4	1 (25)	6	1 (17)
Other	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.414		0.546		0.406
<b>2017</b>						
Australia	326	74 (23)	120	17 (14)	447	91 (20)
Other Oceania	12	3 (25)	14	2 (14)	27	5 (19)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	13	4 (31)	4	1 (25)	17	5 (29)
Other	8	0 (0)	2	0 (0)	10	0 (0)
p value		0.454		0.849		0.370
<b>2018</b>						
Australia	180	40 (22)	75	15 (20)	255	55 (22)
Other Oceania	6	1 (17)	1	0 (0)	7	1 (14)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	5	1 (20)	4	1 (25)	9	2 (22)
Other	3	1 (33)	4	0 (0)	7	1 (14)
p value		0.952		0.727		0.908
<b>2019</b>						
Australia	338	61 (18)	132	15 (11)	476	77 (16)
Other Oceania	9	1 (11)	2	0 (0)	12	1 (8)
Asia	2	0 (0)	2	0 (0)	4	0 (0)
UK & Ireland	8	0 (0)	3	0 (0)	11	0 (0)
Other	10	0 (0)	5	1 (20)	15	1 (7)
p value		0.323		0.853		0.377
<b>2020</b>						
Australia	239	34 (14)	91	10 (11)	332	44 (13)
Other Oceania	10	3 (30)	4	0 (0)	14	3 (21)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	8	0 (0)	2	0 (0)	10	0 (0)
Other	7	3 (43)	1	0 (0)	8	3 (38)
p value		0.125		0.842		0.194

## South Australia

**Table 6.1.1 Number (percentage) of respondents by demographic characteristics and survey year**

South Australia	2016	2017	2018	2019	2020*
<b>Number of sites</b>	7	7	7	7	6
<b>N° surveyed</b>	N=247	N=270	N=321	N=326	N=20
<b>Response rate (%)</b>	52%	54%	53%	57%	--
<b>Gender (%)</b>					
Male	151 (61)	138 (51)	197 (61)	191 (59)	13 (65)
Female	95 (38)	127 (47)	123 (38)	134 (41)	7 (35)
Other	0 (0)	5 (2)	1 (<1)	1 (<1)	0 (0)
Not reported	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Sexual identity (%)</b>					
Heterosexual	196 (79)	190 (70)	248 (77)	257 (79)	16 (80)
Bisexual	20 (8)	37 (14)	30 (9)	27 (8)	1 (5)
Gay/Lesbian	10 (4)	25 (9)	20 (6)	19 (6)	0 (0)
Other	-- --	-- --	-- --	-- --	1 (5)
Not reported	21 (9)	18 (7)	23 (7)	23 (7)	2 (10)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	192 (78)	210 (78)	264 (82)	251 (77)	17 (85)
Yes	49 (20)	49 (18)	51 (16)	67 (21)	3 (15)
Not reported	6 (2)	11 (4)	6 (2)	8 (2)	0 (0)
<b>Region/country of birth (%)</b>					
Australia	215 (87)	238 (88)	277 (86)	285 (87)	17 (85)
Other Oceania	9 (4)	3 (1)	4 (1)	5 (2)	0 (0)
Asia	0 (0)	2 (1)	6 (2)	6 (2)	0 (0)
UK & Ireland	12 (5)	12 (4)	21 (7)	20 (6)	3 (15)
Other	9 (4)	12 (4)	11 (3)	7 (2)	0 (0)
Not reported	2 (1)	3 (1)	2 (1)	3 (1)	0 (0)
<b>Main language spoken at home by parents (%)</b>					
English	228 (92)	255 (94)	293 (91)	312 (96)	20 (100)
Non-English	17 (7)	14 (5)	25 (8)	12 (4)	0 (0)
Not reported	2 (1)	1 (<1)	3 (1)	2 (1)	0 (0)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	43	43	43	44	48
<i>Age range</i>	17-67	18-69	18-71	19-72	32-62
<i>Age group (%)</i>					
<25 years	12 (5)	21 (8)	10 (3)	8 (2)	0 (0)
25+ years	235 (95)	249 (92)	310 (97)	315 (97)	20 (100)
Not reported	0 (0)	0 (0)	1 (<1)	3 (1)	0 (0)
<i>Median age first injection</i>	19	18	18	18	21
<i>Age range</i>	10-55	10-60	10-64	12-67	12-42
<i>N° not reported</i>	5	17	11	23	0
<i>Median yrs since first injection</i>	21	22	23	24	27
<i>Range</i>	<1-47	1-47	1-49	<1-52	<1-45
<i>Years since first injection</i>					
<3 years	15 (6)	10 (4)	8 (2)	8 (2)	2 (10)
3+ years	227 (92)	243 (90)	302 (94)	295 (90)	18 (90)
Not reported	5 (2)	17 (6)	11 (3)	23 (7)	0 (0)
<b>Imprisonment last year (%)</b>					
No	211 (85)	224 (83)	261 (81)	267 (82)	19 (95)
Yes	24 (10)	32 (12)	33 (10)	32 (10)	1 (5)
Not reported	12 (5)	14 (5)	27 (8)	27 (8)	0 (0)
<b>N° in prison</b>	N=24	N=32	N=33	N=32	N=1
Injected in prison	4 (17)	6 (19)	9 (27)	6 (19)	0 (0)

\* Implementation of the 2020 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

**Table 6.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

South Australia	2016	2017	2018	2019	2020
N° surveyed	N=247	N=270	N=321	N=326	N=20
<b>Drug last injected (%)</b>					
Cocaine	1 (<1)	4 (1)	2 (1)	0 (0)	0 (0)
Methamphetamine	147 (60)	133 (49)	183 (57)	175 (54)	12 (60)
Heroin	45 (18)	89 (33)	98 (31)	79 (24)	5 (25)
Pharm. opioids	24 (10)	17 (6)	5 (2)	10 (3)	1 (5)
Methadone	11 (4)	11 (4)	16 (5)	33 (10)	1 (5)
Buprenorphine	3 (1)	2 (1)	2 (1)	1 (<1)	0 (0)
Buprenorphine/naloxone	1 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)
PIEDs	2 (1)	2 (1)	0 (0)	2 (1)	0 (0)
More than one	13 (5)	8 (3)	13 (4)	17 (5)	1 (5)
Other	0 (0)	2 (1)	0 (0)	2 (1)	0 (0)
Not reported	0 (0)	1 (<1)	2 (1)	7 (2)	0 (0)
<b>Ever injected opioids</b>					
No	67 (27)	68 (25)	84 (26)	85 (26)	7 (35)
Yes	178 (72)	199 (74)	234 (73)	237 (73)	13 (65)
Not reported	2 (1)	3 (1)	3 (1)	4 (1)	0 (0)
<b>Frequency of injection last month (%)</b>					
Not last month	11 (4)	28 (10)	15 (5)	40 (12)	1 (5)
Less than weekly	40 (16)	37 (14)	56 (17)	49 (15)	5 (25)
Weekly not daily	79 (32)	69 (26)	94 (29)	83 (25)	4 (20)
Daily or more	114 (46)	130 (48)	151 (47)	143 (44)	10 (50)
Not reported	3 (1)	6 (2)	5 (2)	11 (3)	0 (0)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
No	202 (82)	208 (77)	252 (79)	255 (78)	19 (95)
Yes	43 (17)	59 (22)	57 (18)	53 (16)	1 (5)
Not reported	2 (1)	3 (1)	12 (4)	18 (6)	0 (0)
<b>Overdosed in last 12 months</b>					
No	194 (79)	220 (81)	258 (80)	282 (87)	18 (90)
Yes	48 (19)	44 (16)	49 (15)	26 (8)	2 (10)
Not reported	5 (2)	6 (2)	14 (4)	18 (6)	0 (0)

**Table 6.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

South Australia	2016	2017	2018	2019	2020
N° injected last month	N=233	N=236	N=301	N=275	N=19
<b>Places injected last month (%)</b>					
All private	125 (54)	130 (55)	161 (53)	156 (57)	13 (68)
Any public	106 (45)	104 (44)	136 (45)	114 (41)	6 (32)
Not reported	2 (1)	2 (1)	4 (1)	5 (2)	0 (0)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	180 (77)	188 (80)	232 (77)	218 (79)	18 (95)
Most of the time	40 (17)	40 (17)	59 (20)	41 (15)	1 (5)
Half of the time	6 (3)	4 (2)	3 (1)	5 (2)	0 (0)
Some of the time	2 (1)	1 (<1)	1 (<1)	2 (1)	0 (0)
Not last month	1 (<1)	1 (<1)	6 (2)	2 (1)	0 (0)
Not reported	4 (2)	2 (1)	0 (0)	7 (3)	0 (0)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	180 (77)	194 (82)	258 (86)	224 (81)	19 (100)
Once	21 (9)	14 (6)	18 (6)	19 (7)	0 (0)
Twice	14 (6)	17 (7)	10 (3)	15 (5)	0 (0)
3-5 times	11 (5)	5 (2)	5 (2)	5 (2)	0 (0)
>5 times	5 (2)	2 (1)	6 (2)	5 (2)	0 (0)
Not reported	2 (1)	4 (2)	4 (1)	7 (3)	0 (0)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	180 (77)	194 (82)	258 (86)	224 (81)	19 (100)
One	18 (8)	22 (9)	21 (7)	18 (7)	0 (0)
Two	5 (2)	2 (1)	3 (1)	5 (2)	0 (0)
Three to five	5 (2)	4 (2)	0 (0)	4 (1)	0 (0)
More than five	2 (1)	3 (1)	0 (0)	3 (1)	0 (0)
Don't know	9 (4)	5 (2)	7 (2)	8 (3)	0 (0)
Not reported	14 (6)	6 (3)	12 (4)	13 (5)	0 (0)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	24 (10)	18 (8)	17 (6)	24 (9)	0 (0)
Casual sex partner	1 (<1)	3 (1)	1 (<1)	1 (<1)	0 (0)
Close friend	13 (6)	11 (5)	9 (3)	8 (3)	0 (0)
Acquaintance	6 (3)	4 (2)	4 (1)	6 (2)	0 (0)
Other	1 (<1)	3 (1)	1 (<1)	4 (1)	0 (0)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	30 (13)	50 (21)	41 (14)	45 (16)	1 (5)
Water	50 (21)	48 (20)	62 (21)	56 (20)	1 (5)
Filter	17 (7)	23 (10)	23 (8)	24 (9)	0 (0)
Drug mix	20 (9)	22 (9)	32 (11)	22 (8)	1 (5)
None	161 (69)	155 (66)	208 (69)	184 (67)	16 (84)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	187 (80)	183 (78)	250 (83)	231 (84)	18 (95)
Yes	43 (18)	50 (21)	44 (15)	38 (14)	1 (5)
Not reported	3 (1)	3 (1)	7 (2)	6 (2)	0 (0)
<b>Source of needle acquisition</b>					
Needle Syringe Program	203 (87)	210 (89)	266 (88)	238 (87)	16 (84)
Chemist/Pharmacy	41 (18)	45 (19)	60 (20)	44 (16)	3 (16)
Personal sources	37 (16)	32 (14)	53 (18)	43 (16)	4 (21)
Dispensing/Vending Machine	47 (20)	43 (18)	56 (19)	55 (20)	3 (16)
Other sources	3 (1)	4 (2)	4 (1)	3 (1)	0 (0)

**Table 6.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

South Australia	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=247	N=270	N=321	N=326	N=20
<b>Ever any treatment/therapy for drug use (%)</b>					
No	92 (37)	81 (30)	104 (32)	109 (33)	6 (30)
Yes	153 (62)	188 (70)	216 (67)	214 (66)	14 (70)
Not reported	2 (1)	1 (<1)	1 (<1)	3 (1)	0 (0)
<b>History of methadone maintenance treatment (%)</b>					
Currently	44 (18)	73 (27)	68 (21)	86 (26)	4 (20)
Previously	47 (19)	48 (18)	81 (25)	49 (15)	2 (10)
Never	144 (58)	142 (53)	160 (50)	181 (56)	13 (65)
Not reported	12 (5)	7 (3)	12 (4)	10 (3)	1 (5)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	13 (5)	17 (6)	13 (4)	10 (3)	2 (10)
Previously	54 (22)	78 (29)	86 (27)	70 (21)	6 (30)
Never	170 (69)	164 (61)	214 (67)	240 (74)	12 (60)
Not reported	10 (4)	11 (4)	8 (2)	6 (2)	0 (0)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	23 (9)	23 (9)	22 (7)	21 (6)	2 (10)
Previously	36 (15)	71 (26)	69 (22)	57 (17)	5 (25)
Never	180 (73)	171 (63)	222 (69)	240 (74)	13 (65)
Not reported	8 (3)	5 (2)	8 (2)	8 (2)	0 (0)

**Table 6.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

South Australia	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=247	N=270	N=321	N=326	N=20
<b>Previous HIV test (%)</b>					
Yes, ever	198 (80)	210 (78)	256 (80)	241 (74)	16 (80)
Yes, last year	112 (45)	122 (45)	149 (46)	124 (38)	8 (40)
>1 year ago	86 (35)	88 (33)	107 (33)	117 (36)	8 (40)
Never tested	45 (18)	55 (20)	52 (16)	60 (18)	4 (20)
Not reported	4 (2)	5 (2)	13 (4)	25 (8)	0 (0)
<b>Previous HCV test (%)</b>					
Yes, ever	201 (81)	220 (81)	241 (75)	241 (74)	17 (85)
Yes, last year	121 (49)	149 (55)	145 (45)	150 (46)	8 (40)
>1 year ago	80 (32)	71 (26)	96 (30)	91 (28)	9 (45)
Never tested	31 (13)	37 (14)	45 (14)	48 (15)	2 (10)
Not reported	15 (6)	13 (5)	35 (11)	37 (11)	1 (5)
<b>Lifetime treatment for HCV (%)#</b>					
<b>N° self-reported HCV diagnosis</b>	N=48	N=68	N=68	N=56	N=3
Antiviral treatment	22 (46)	34 (50)	44 (65)	41 (73)	3 (100)
No antiviral treatment	26 (54)	34 (50)	23 (34)	15 (27)	0 (0)
Not reported	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
<b>Treatment for HCV in past 12 months (%)**</b>					
<b>N° self-reported HCV diagnosis</b>	N=42	N=64	N=53	N=38	N=1
Antiviral treatment	13 (31)	25 (39)	22 (42)	21 (55)	1 (100)
No antiviral treatment	29 (69)	39 (61)	30 (57)	17 (45)	0 (0)
Not reported	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)

# among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 6.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

South Australia	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=247	N=270	N=321	N=326	N=20
<b>Sex with a regular partner last month (%)</b>					
No	94 (38)	130 (48)	152 (47)	165 (51)	14 (70)
Yes	146 (59)	131 (49)	145 (45)	134 (41)	6 (30)
Not reported	7 (3)	9 (3)	24 (7)	27 (8)	0 (0)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=146	N=131	N=145	N=134	N=6
Never	112 (77)	95 (73)	114 (79)	89 (66)	4 (67)
Sometimes	12 (8)	14 (11)	7 (5)	18 (13)	0 (0)
Every time	13 (9)	16 (12)	16 (11)	19 (14)	0 (0)
Not reported	9 (6)	6 (5)	8 (6)	8 (6)	2 (33)
<b>Sex with other partner(s) last month (%)</b>					
No	202 (82)	232 (86)	257 (80)	254 (78)	18 (90)
Yes	39 (16)	29 (11)	38 (12)	43 (13)	2 (10)
Not reported	6 (2)	9 (3)	26 (8)	29 (9)	0 (0)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=39	N=29	N=38	N=43	N=2
Never	17 (44)	7 (24)	7 (18)	21 (49)	1 (50)
Sometimes	12 (31)	11 (38)	14 (37)	10 (23)	1 (50)
Every time	9 (23)	9 (31)	17 (45)	12 (28)	0 (0)
Not reported	1 (3)	2 (7)	0 (0)	0 (0)	0 (0)
<b>Sex work last month (%)</b>					
No	228 (92)	232 (86)	286 (89)	279 (86)	20 (100)
Yes	11 (4)	22 (8)	15 (5)	12 (4)	0 (0)
Not reported	8 (3)	16 (6)	20 (6)	35 (11)	0 (0)
<b>Condom used at last sex work (%)</b>					
Yes	9 (82)	16 (73)	10 (67)	7 (58)	0 (0)

**Table 6.1.7 Number (percentage) of respondents by COVID-19 related behaviours in 2020**

South Australia			
N° surveyed		N=20	
<b>More difficult to access sterile needles and syringes</b>		<b>Start or increase takeaway dose of methadone/bupe/suboxone</b>	
Yes	1 (5)	Yes	3 (15)
No	16 (80)	No	8 (40)
Not applicable	3 (15)	Not applicable	8 (40)
Not reported	0 (0)	Not reported	1 (5)
<b>Start depot buprenorphine</b>		<b>Inject own methadone/bupe/suboxone</b>	
Yes	0 (0)	Yes	0 (0)
No	14 (70)	No	10 (50)
Not applicable	5 (25)	Not applicable	8 (40)
Not reported	1 (5)	Not reported	2 (10)
<b>Access take home naloxone</b>		<b>COVID-19 test</b>	
Yes	4 (20)	Yes	4 (20)
No	8 (40)	No	15 (75)
Not applicable	7 (35)	Don't know	1 (5)
Not reported	1 (5)	Not reported	0 (0)
<b>Change illicit drug use</b>		<b>If YES, what was result (N=4)</b>	
Yes, increased	2 (10)	Positive	0 (0)
Yes, decreased	4 (20)	Negative	4 (100)
No change	14 (70)	Don't know	0 (0)
Not reported	0 (0)	Not reported	0 (0)

## HIV antibody prevalence

**Table 6.2.1 HIV antibody prevalence by gender and survey year**

South Australia Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2016	150	1 (0.7)	94	0 (0.0)	245	1 (0.4)
2017	132	5 (3.8)	125	0 (0.0)	262	5 (1.9)
2018	193	2 (1.0)	122	0 (0.0)	315	2 (0.6)
2019	177	4 (2.3)	126	0 (0.0)	304	4 (1.3)
2020	13	0 (0.0)	7	0 (0.0)	20	0 (0.0)
X <sup>2</sup> p trend		0.775		--		0.745

**Table 6.2.2 HIV antibody prevalence by sexual identity, gender and survey year**

South Australia Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Heterosexual	129	1 (0.8)	66	0 (0.0)	195	1 (0.5)
Bisexual	7	0 (0.0)	12	0 (0.0)	19	0 (0.0)
Homosexual	3	0 (0.0)	7	0 (0.0)	10	0 (0.0)
p value		1.000		--		1.000
<b>2017</b>						
Heterosexual	103	1 (1.0)	79	0 (0.0)	183	1 (0.6)
Bisexual	7	1 (14.3)	26	0 (0.0)	37	1 (2.7)
Homosexual	9	3 (33.3)	16	0 (0.0)	25	3 (12.0)
p value		0.001		--		0.005
<b>2018</b>						
Heterosexual	167	2 (1.2)	76	0 (0.0)	243	2 (0.8)
Bisexual	4	0 (0.0)	26	0 (0.0)	30	0 (0.0)
Homosexual	9	0 (0.0)	11	0 (0.0)	20	0 (0.0)
p value		1.000		--		1.000
<b>2019</b>						
Heterosexual	149	2 (1.3)	92	0 (0.0)	241	2 (0.8)
Bisexual	6	1 (16.7)	17	0 (0.0)	24	1 (4.2)
Homosexual	8	1 (12.5)	10	0 (0.0)	18	1 (5.6)
p value		0.037		--		0.106
<b>2020</b>						
Heterosexual	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)
Bisexual	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
Homosexual	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
p value		--		--		--



**Table 6.2.3 HIV antibody prevalence by age group, gender and survey year**

South Australia	Male		Female		Total	
Age group	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
<25 years	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)
25-34 years	24	0 (0.0)	20	0 (0.0)	44	0 (0.0)
35-44 years	44	0 (0.0)	36	0 (0.0)	81	0 (0.0)
45+ years	73	1 (1.4)	35	0 (0.0)	108	1 (0.9)
p value		1.000		--		1.000
<b>2017</b>						
<25 years	11	1 (9.1)	9	0 (0.0)	21	1 (4.8)
25-34 years	17	0 (0.0)	26	0 (0.0)	45	0 (0.0)
35-44 years	41	1 (2.4)	43	0 (0.0)	86	1 (1.2)
45+ years	63	3 (4.8)	47	0 (0.0)	110	3 (2.7)
p value		0.571		--		0.386
<b>2018</b>						
<25 years	4	0 (0.0)	6	0 (0.0)	10	0 (0.0)
25-34 years	34	1 (2.9)	20	0 (0.0)	54	1 (1.9)
35-44 years	65	0 (0.0)	48	0 (0.0)	113	0 (0.0)
45+ years	90	1 (1.1)	47	0 (0.0)	137	1 (0.7)
p value		0.468		--		0.495
<b>2019</b>						
<25 years	4	0 (0.0)	3	0 (0.0)	7	0 (0.0)
25-34 years	21	0 (0.0)	23	0 (0.0)	44	0 (0.0)
35-44 years	58	1 (1.7)	45	0 (0.0)	103	1 (1.0)
45+ years	92	3 (3.3)	55	0 (0.0)	148	3 (2.0)
p value		1.000		--		0.832
<b>2020</b>						
<25 years	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
25-34 years	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
35-44 years	4	0 (0.0)	2	0 (0.0)	6	0 (0.0)
45+ years	8	0 (0.0)	5	0 (0.0)	13	0 (0.0)
p value		--		--		--

**Table 6.2.4 HIV antibody prevalence by last drug injected, gender and survey year**

South Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Heroin	25	0 (0.0)	18	0 (0.0)	43	0 (0.0)
Methamphetamine	85	1 (1.2)	61	0 (0.0)	147	1 (0.7)
Other opioids	28	0 (0.0)	11	0 (0.0)	39	0 (0.0)
Other drugs	12	0 (0.0)	4	0 (0.0)	16	0 (0.0)
p value		1.000		--		1.000
<b>2017</b>						
Heroin	40	1 (2.5)	46	0 (0.0)	86	1 (1.2)
Methamphetamine	61	4 (6.6)	65	0 (0.0)	128	4 (3.1)
Other opioids	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
Other drugs	10	0 (0.0)	4	0 (0.0)	17	0 (0.0)
p value		0.715		--		0.781
<b>2018</b>						
Heroin	66	0 (0.0)	32	0 (0.0)	98	0 (0.0)
Methamphetamine	102	2 (2.0)	79	0 (0.0)	181	2 (1.1)
Other opioids	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)
Other drugs	11	0 (0.0)	3	0 (0.0)	14	0 (0.0)
p value		0.633		--		0.639
<b>2019</b>						
Heroin	41	0 (0.0)	32	0 (0.0)	74	0 (0.0)
Methamphetamine	94	3 (3.2)	67	0 (0.0)	161	3 (1.9)
Other opioids	29	1 (3.5)	14	0 (0.0)	43	1 (2.3)
Other drugs	12	0 (0.0)	8	0 (0.0)	20	0 (0.0)
p value		0.723		--		0.608
<b>2020</b>						
Heroin	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
Methamphetamine	7	0 (0.0)	5	0 (0.0)	12	0 (0.0)
Other opioids	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
Other drugs	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
p value		--		--		--

**Table 6.2.5 HIV antibody prevalence by years of injection, gender and survey year**

South Australia	Male		Female		Total	
Years of injection	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
<3 years	9	0 (0.0)	6	0 (0.0)	15	0 (0.0)
3 to 10 years	17	0 (0.0)	8	0 (0.0)	25	0 (0.0)
11+ years	120	1 (0.8)	79	0 (0.0)	200	1 (0.5)
p value		1.000		--		1.000
<b>2017</b>						
<3 years	6	1 (16.7)	4	0 (0.0)	10	1 (10.0)
3 to 10 years	21	1 (4.8)	23	0 (0.0)	47	1 (2.1)
11+ years	105	3 (2.9)	98	0 (0.0)	205	3 (1.5)
p value		0.143		--		0.144
<b>2018</b>						
<3 years	3	0 (0.0)	5	0 (0.0)	8	0 (0.0)
3 to 10 years	24	0 (0.0)	19	0 (0.0)	43	0 (0.0)
11+ years	166	2 (1.2)	98	0 (0.0)	264	2 (0.8)
p value		1.000		--		1.000
<b>2019</b>						
<3 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
3 to 10 years	16	0 (0.0)	20	0 (0.0)	36	0 (0.0)
11+ years	147	4 (2.7)	92	0 (0.0)	240	4 (1.7)
p value		1.000		--		1.000
<b>2020</b>						
<3 years	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
3 to 10 years	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
11+ years	10	0 (0.0)	7	0 (0.0)	17	0 (0.0)
p value		--		--		--

**Table 6.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year**

South Australia	Male		Female		Total	
Receptively shared syringe last month	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
No receptive sharing	106	1 (0.9)	71	0 (0.0)	178	1 (0.6)
Receptive sharing	30	0 (0.0)	21	0 (0.0)	51	0 (0.0)
p value		1.000		--		1.000
<b>2017</b>						
No receptive sharing	94	2 (2.1)	91	0 (0.0)	188	2 (1.1)
Receptive sharing	19	2 (10.5)	16	0 (0.0)	37	2 (5.4)
p value		0.131		--		0.127
<b>2018</b>						
No receptive sharing	159	2 (1.3)	96	0 (0.0)	255	2 (0.8)
Receptive sharing	18	0 (0.0)	19	0 (0.0)	37	0 (0.0)
p value		1.000		--		1.000
<b>2019</b>						
No receptive sharing	125	3 (2.4)	84	0 (0.0)	210	3 (1.4)
Receptive sharing	24	0 (0.0)	15	0 (0.0)	39	0 (0.0)
p value		1.000		--		1.000
<b>2020</b>						
No receptive sharing	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)
Receptive sharing	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)
p value		--		--		--

**Table 6.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year**

South Australia		Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
Less than daily	64	1 (1.6)	53	0 (0.0)	118	1 (0.9)	
Daily or more	73	0 (0.0)	40	0 (0.0)	113	0 (0.0)	
Not last month	11	0 (0.0)	0	0 (0.0)	11	0 (0.0)	
p value		0.507		--		1.000	
<b>2017</b>							
Less than daily	47	1 (2.1)	55	0 (0.0)	105	1 (1.0)	
Daily or more	68	3 (4.4)	53	0 (0.0)	123	3 (2.4)	
Not last month	13	1 (7.7)	15	0 (0.0)	28	1 (3.6)	
p value		0.390		--		0.414	
<b>2018</b>							
Less than daily	91	0 (0.0)	58	0 (0.0)	149	0 (0.0)	
Daily or more	89	2 (2.3)	58	0 (0.0)	147	2 (1.4)	
Not last month	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)	
p value		0.321		--		0.312	
<b>2019</b>							
Less than daily	67	1 (1.5)	57	0 (0.0)	125	1 (0.8)	
Daily or more	87	2 (2.3)	87	0 (0.0)	131	2 (1.5)	
Not last month	18	0 (0.0)	18	0 (0.0)	38	0 (0.0)	
p value		1.000		--		1.000	
<b>2020</b>							
Less than daily	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
Daily or more	6	0 (0.0)	4	0 (0.0)	10	0 (0.0)	
Not last month	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
p value		--		--		--	

**Table 6.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year**

South Australia		Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
No imprisonment	122	0 (0.0)	87	0 (0.0)	210	0 (0.0)	
Imprisonment	18	1 (5.6)	5	0 (0.0)	23	1 (4.4)	
p value		0.129		--		0.099	
<b>2017</b>							
No imprisonment	105	4 (3.8)	109	0 (0.0)	219	4 (1.8)	
Imprisonment	19	1 (5.3)	10	0 (0.0)	29	1 (3.5)	
p value		0.571		--		0.466	
<b>2018</b>							
No imprisonment	150	1 (0.7)	106	0 (0.0)	256	1 (0.4)	
Imprisonment	25	1 (4.0)	7	0 (0.0)	32	1 (3.1)	
p value		0.266		--		0.210	
<b>2019</b>							
No imprisonment	138	3 (2.2)	109	0 (0.0)	248	3 (1.2)	
Imprisonment	23	0 (0.0)	9	0 (0.0)	32	0 (0.0)	
p value		1.000		--		1.000	
<b>2020</b>							
No imprisonment	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)	
Imprisonment	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)	
p value		--		--		--	

**Table 6.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year**

South Australia		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
No condom use	56	0 (0.0)	54	0 (0.0)	111	0 (0.0)	
Condom use	17	1 (5.9)	8	0 (0.0)	25	1 (4.0)	
p value		0.233		--		0.184	
<b>2017</b>							
No condom use	36	2 (5.6)	54	0 (0.0)	91	2 (2.2)	
Condom use	18	2 (11.1)	12	0 (0.0)	30	2 (6.7)	
p value		0.594		--		0.256	
<b>2018</b>							
No condom use	56	1 (1.8)	57	0 (0.0)	113	1 (0.9)	
Condom use	17	0 (0.0)	6	0 (0.0)	23	0 (0.0)	
p value		1.000		--		1.000	
<b>2019</b>							
No condom use	38	1 (2.6)	43	0 (0.0)	81	1 (1.2)	
Condom use	20	0 (0.0)	16	0 (0.0)	36	0 (0.0)	
p value		1.000		--		1.000	
<b>2020</b>							
No condom use	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)	
Condom use	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
p value		--		--		--	

**Table 6.2.10 HIV antibody prevalence by sex work last month, gender and survey year**

South Australia		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
No sex work	139	1 (0.7)	86	0 (0.0)	226	1 (0.4)	
Sex work	5	0 (0.0)	6	0 (0.0)	11	0 (0.0)	
p value		1.000		--		1.000	
<b>2017</b>							
No sex work	114	4 (3.5)	107	0 (0.0)	225	4 (1.8)	
Sex work	10	1 (10.0)	10	0 (0.0)	21	1 (4.8)	
p value		0.348		--		0.362	
<b>2018</b>							
No sex work	180	2 (1.1)	101	0 (0.0)	281	2 (0.7)	
Sex work	3	0 (0.0)	11	0 (0.0)	14	0 (0.0)	
p value		1.000		--		1.000	
<b>2019</b>							
No sex work	154	3 (2.0)	107	0 (0.0)	262	3 (1.2)	
Sex work	4	0 (0.0)	7	0 (0.0)	11	0 (0.0)	
p value		1.000		--		1.000	
<b>2020</b>							
No sex work	13	0 (0.0)	7	0 (0.0)	20	0 (0.0)	
Sex work	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
p value		--		--		--	

**Table 6.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

South Australia		Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
Non Indigenous	116	0 (0.0)	74	0 (0.0)	191	0 (0.0)	
Indigenous	29	1 (3.5)	19	0 (0.0)	48	1 (2.1)	
p value		0.200		--		0.201	
<b>2017</b>							
Non Indigenous	105	4 (3.8)	96	0 (0.0)	205	4 (2.0)	
Indigenous	23	1 (4.4)	22	0 (0.0)	46	1 (2.2)	
p value		1.000		--		1.000	
<b>2018</b>							
Non Indigenous	158	1 (0.6)	102	0 (0.0)	260	1 (0.4)	
Indigenous	32	1 (3.1)	17	0 (0.0)	49	1 (2.0)	
p value		0.309		--		0.292	
<b>2019</b>							
Non Indigenous	135	4 (3.0)	98	0 (0.0)	233	4 (1.7)	
Indigenous	39	0 (0.0)	24	0 (0.0)	64	0 (0.0)	
p value		0.576		--		0.581	
<b>2020</b>							
Non Indigenous	10	0 (0.0)	7	0 (0.0)	17	0 (0.0)	
Indigenous	3	0 (0.0)	0	0 (0.0)	3	0 (0.0)	
p value		--		--		--	

**Table 6.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year**

South Australia		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
English speaking	136	1 (0.7)	90	0 (0.0)	227	1 (0.4)	
Non-English speaking	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)	
p value		1.000		--		1.000	
<b>2017</b>							
English speaking	122	4 (3.3)	122	0 (0.0)	247	4 (1.6)	
Non-English speaking	9	1 (11.1)	3	0 (0.0)	14	1 (7.1)	
p value		0.303		--		0.243	
<b>2018</b>							
English speaking	171	1 (0.6)	119	0 (0.0)	290	1 (0.3)	
Non-English speaking	19	1 (5.3)	3	0 (0.0)	22	1 (4.6)	
p value		0.190		--		0.136	
<b>2019</b>							
English speaking	167	3 (1.8)	124	0 (0.0)	292	3 (1.0)	
Non-English speaking	9	1 (11.1)	2	0 (0.0)	11	1 (9.1)	
p value		0.191		--		0.138	
<b>2020</b>							
English speaking	13	0 (0.0)	7	0 (0.0)	20	0 (0.0)	
Non-English speaking	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
p value		--		--		--	

**Table 6.2.13 HIV antibody prevalence by region/country of birth, gender and survey year**

South Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
Australia	126	1 (0.8)	86	0 (0.0)	213	1 (0.5)	
Other Oceania	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)	
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
UK & Ireland	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)	
Other	8	0 (0.0)	1	0 (0.0)	9	0 (0.0)	
p value		1.000		--			1.000
<b>2017</b>							
Australia	116	3 (2.6)	112	0 (0.0)	231	3 (1.3)	
Other Oceania	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)	
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)	
UK & Ireland	3	1 (33.3)	8	0 (0.0)	11	1 (9.1)	
Other	9	0 (0.0)	1	0 (0.0)	12	0 (0.0)	
p value		0.169		--			0.236
<b>2018</b>							
Australia	164	2 (1.2)	110	0 (0.0)	274	2 (0.7)	
Other Oceania	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)	
Asia	6	0 (0.0)	0	0 (0.0)	6	0 (0.0)	
UK & Ireland	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)	
Other	7	0 (0.0)	2	0 (0.0)	9	0 (0.0)	
p value		1.000		--			1.000
<b>2019</b>							
Australia	153	4 (2.6)	113	0 (0.0)	267	4 (1.5)	
Other Oceania	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)	
Asia	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)	
UK & Ireland	10	0 (0.0)	8	0 (0.0)	18	0 (0.0)	
Other	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)	
p value		1.000		--			1.000
<b>2020</b>							
Australia	12	0 (0.0)	5	0 (0.0)	17	0 (0.0)	
Other Oceania	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
Asia	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
UK & Ireland	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)	
Other	0	0 (0.0)	0	0 (0.0)	0	0 (0.0)	
p value		--		--			--

## HCV antibody prevalence

**Table 6.3.1 HCV antibody prevalence by gender and survey year**

South Australia Survey year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2016	141	62 (44)	90	27 (30)	232	89 (38)
2017	128	60 (47)	125	54 (43)	258	115 (45)
2018	187	89 (48)	122	34 (28)	309	123 (40)
2019	175	82 (47)	126	43 (34)	302	125 (41)
2020	13	2 (15)	7	2 (29)	20	4 (20)
X <sup>2</sup> p trend		0.876		0.672		0.771

**Table 6.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

South Australia Sexual identity	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Heterosexual	120	52 (43)	62	22 (35)	182	74 (41)
Bisexual	7	3 (43)	12	1 (8)	19	4 (21)
Homosexual	3	1 (33)	7	0 (0)	10	1 (10)
p value		1.000		0.041		0.048
<b>2017</b>						
Heterosexual	101	47 (47)	79	36 (46)	181	83 (46)
Bisexual	6	2 (33)	26	14 (54)	36	17 (47)
Homosexual	9	4 (44)	16	2 (13)	25	6 (24)
p value		0.915		0.019		0.107
<b>2018</b>						
Heterosexual	161	81 (50)	76	22 (29)	237	103 (43)
Bisexual	4	0 (0)	26	7 (27)	30	7 (23)
Homosexual	9	2 (22)	11	2 (18)	20	4 (20)
p value		0.045		0.847		0.019
<b>2019</b>						
Heterosexual	147	73 (50)	92	33 (36)	239	106 (44)
Bisexual	6	2 (33)	17	5 (29)	24	7 (29)
Homosexual	8	0 (0)	10	1 (10)	18	1 (6)
p value		0.009		0.256		0.001
<b>2020</b>						
Heterosexual	11	2 (18)	5	1 (20)	16	3 (19)
Bisexual	0	0 (0)	1	1 (100)	1	1 (100)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.333		0.405



**Table 6.3.3 HCV antibody prevalence by age group, gender and survey year**

South Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	9	2 (22)	3	0 (0)	12	2 (17)
25-34 years	23	9 (39)	20	5 (25)	43	14 (33)
35-44 years	41	15 (37)	35	11 (31)	77	26 (34)
45+ years	68	36 (53)	32	11 (34)	100	47 (47)
p value		0.178		0.764		0.085
<b>2017</b>						
<25 years	11	0 (0)	9	2 (22)	21	2 (10)
25-34 years	17	4 (24)	26	8 (31)	45	13 (29)
35-44 years	38	20 (53)	43	22 (51)	83	42 (51)
45+ years	62	36 (58)	47	22 (47)	109	58 (53)
p value		<0.001		0.220		<0.001
<b>2018</b>						
<25 years	4	0 (0)	6	0 (0)	10	0 (0)
25-34 years	33	9 (27)	20	4 (20)	53	13 (25)
35-44 years	63	31 (49)	48	15 (31)	111	46 (41)
45+ years	87	49 (56)	47	15 (32)	134	64 (48)
p value		0.006		0.368		0.001
<b>2019</b>						
<25 years	4	1 (25)	3	1 (33)	7	2 (29)
25-34 years	21	7 (33)	23	4 (17)	44	11 (25)
35-44 years	57	20 (35)	45	15 (33)	102	35 (34)
45+ years	91	54 (59)	55	23 (42)	147	77 (52)
p value		0.008		0.195		0.002
<b>2020</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	1	0 (0)	0	0 (0)	1	0 (0)
35-44 years	4	0 (0)	2	0 (0)	6	0 (0)
45+ years	8	2 (25)	5	2 (40)	13	4 (31)
p value		0.590		1.000		0.404

**Table 6.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

South Australia Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
<3 years	9	0 (0)	6	1 (17)	15	1 (7)
3 to 10 years	17	3 (18)	8	1 (13)	25	4 (16)
11+ years	112	57 (51)	75	25 (33)	188	82 (44)
p value		<0.001		0.509		0.001
<b>2017</b>						
<3 years	6	1 (17)	4	1 (25)	10	2 (20)
3 to 10 years	21	1 (5)	23	6 (26)	47	8 (17)
11+ years	90	51 (57)	93	46 (49)	185	97 (52)
p value		<0.001		0.101		<0.001
<b>2018</b>						
<3 years	3	0 (0)	5	0 (0)	8	0 (0)
3 to 10 years	24	3 (13)	19	2 (11)	43	5 (12)
11+ years	154	82 (53)	96	32 (33)	250	114 (46)
p value		<0.001		0.053		<0.001
<b>2019</b>						
<3 years	3	0 (0)	4	0 (0)	7	0 (0)
3 to 10 years	16	2 (13)	20	7 (35)	36	9 (25)
11+ years	145	74 (51)	92	33 (36)	238	107 (45)
p value		0.002		0.466		0.005
<b>2020</b>						
<3 years	2	0 (0)	0	0 (0)	2	0 (0)
3 to 10 years	1	0 (0)	0	0 (0)	1	0 (0)
11+ years	10	2 (20)	7	2 (29)	17	4 (24)
p value		1.000		--		1.000

**Table 6.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

South Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No receptive sharing	11	1 (9)	155	63 (41)	168	64 (38)
Receptive sharing	3	0 (0)	45	17 (38)	49	18 (37)
p value		1.000		0.730		0.863
<b>2017</b>						
No receptive sharing	6	2 (33)	173	75 (43)	185	79 (43)
Receptive sharing	4	0 (0)	29	15 (52)	36	17 (47)
p value		0.467		0.401		0.617
<b>2018</b>						
No receptive sharing	4	0 (0)	240	94 (39)	249	97 (39)
Receptive sharing	3	0 (0)	32	18 (56)	37	19 (51)
p value		--		0.065		0.152
<b>2019</b>						
No receptive sharing	5	0 (0)	193	83 (43)	209	90 (43)
Receptive sharing	0	0 (0)	35	12 (34)	38	13 (34)
p value		--		0.336		0.309
<b>2020</b>						
No receptive sharing	2	0 (0)	17	4 (24)	19	4 (21)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

**Table 6.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

South Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	0	0 (0)	39	22 (56)	40	22 (55)
Methamphetamine	13	1 (8)	125	40 (32)	140	42 (30)
Other opioids	0	0 (0)	35	18 (51)	35	18 (51)
Other drugs	2	0 (0)	12	5 (42)	14	5 (36)
p value		0.685		0.022		0.010
<b>2017</b>						
Heroin	1	1 (100)	80	49 (61)	83	51 (61)
Methamphetamine	7	1 (14)	113	36 (32)	126	40 (32)
Other opioids	0	0 (0)	26	15 (58)	30	17 (57)
Other drugs	2	0 (0)	10	4 (40)	13	4 (31)
p value		0.098		<0.001		<0.001
<b>2018</b>						
Heroin	1	0 (0)	92	48 (52)	95	50 (53)
Methamphetamine	7	0 (0)	163	53 (33)	174	54 (31)
Other opioids	0	0 (0)	21	11 (52)	21	11 (52)
Other drugs	0	0 (0)	12	4 (33)	13	5 (38)
p value		--		0.012		0.004
<b>2019</b>						
Heroin	0	0 (0)	69	43 (62)	72	46 (64)
Methamphetamine	6	0 (0)	141	40 (28)	157	44 (28)
Other opioids	0	0 (0)	40	19 (48)	41	20 (49)
Other drugs	1	0 (0)	17	10 (59)	20	10 (50)
p value		--		<0.001		<0.001
<b>2020</b>						
Heroin	0	0 (0)	5	2 (40)	5	2 (40)
Methamphetamine	2	0 (0)	10	2 (20)	12	2 (17)
Other opioids	0	0 (0)	2	0 (0)	2	0 (0)
Other drugs	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		0.615		0.555

**Table 6.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

South Australia	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Less than daily	8	1 (13)	101	44 (44)	110	45 (41)
Daily or more	6	0 (0)	100	37 (37)	108	38 (35)
Not last month	1	0 (0)	10	4 (40)	11	4 (36)
p value		1.000		0.621		0.659
<b>2017</b>						
Less than daily	6	1 (17)	94	42 (45)	105	44 (42)
Daily or more	4	1 (25)	110	49 (45)	119	54 (45)
Not last month	0	0 (0)	25	13 (52)	28	14 (50)
p value		1.000		0.782		0.717
<b>2018</b>						
Less than daily	2	0 (0)	141	56 (40)	147	58 (39)
Daily or more	5	0 (0)	135	58 (43)	143	60 (42)
Not last month	1	0 (0)	13	3 (23)	14	3 (21)
p value		--		0.392		0.335
<b>2019</b>						
Less than daily	3	0 (0)	116	44 (38)	124	47 (38)
Daily or more	3	0 (0)	118	52 (44)	130	57 (44)
Not last month	1	0 (0)	33	16 (48)	38	16 (42)
p value		--		0.457		0.624
<b>2020</b>						
Less than daily	2	0 (0)	7	2 (29)	9	2 (22)
Daily or more	0	0 (0)	10	2 (20)	10	2 (20)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000

**Table 6.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

South Australia	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No imprisonment	11	1 (9)	183	72 (39)	198	75 (38)
Imprisonment	3	0 (0)	19	10 (53)	22	10 (45)
p value		1.000		0.262		0.489
<b>2017</b>						
No imprisonment	8	2 (25)	197	90 (46)	217	98 (45)
Imprisonment	2	0 (0)	25	9 (36)	28	10 (36)
p value		1.000		0.359		0.343
<b>2018</b>						
No imprisonment	6	0 (0)	241	93 (39)	251	96 (38)
Imprisonment	2	0 (0)	29	16 (55)	31	16 (52)
p value		--		0.086		0.151
<b>2019</b>						
No imprisonment	5	0 (0)	222	92 (41)	246	101 (41)
Imprisonment	1	0 (0)	30	15 (50)	32	15 (47)
p value		--		0.373		0.530
<b>2020</b>						
No imprisonment	2	0 (0)	17	4 (24)	19	4 (21)
Imprisonment	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000

**Table 6.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

South Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	108	40 (37)	71	22 (31)	180	62 (34)
Indigenous	28	19 (68)	18	5 (28)	46	24 (52)
p value		0.003		0.791		0.027
<b>2017</b>						
Non Indigenous	103	48 (47)	96	43 (45)	203	91 (45)
Indigenous	21	10 (48)	22	9 (41)	44	20 (45)
p value		0.932		0.741		0.940
<b>2018</b>						
Non Indigenous	154	65 (42)	102	31 (30)	256	96 (38)
Indigenous	30	22 (73)	17	3 (18)	47	25 (53)
p value		0.002		0.389		0.043
<b>2019</b>						
Non Indigenous	133	65 (49)	98	33 (34)	231	98 (42)
Indigenous	39	14 (36)	24	9 (38)	64	23 (36)
p value		0.153		0.724		0.351
<b>2020</b>						
Non Indigenous	10	2 (20)	7	2 (29)	17	4 (24)
Indigenous	3	0 (0)	0	0 (0)	3	0 (0)
p value		1.000		--		1.000

**Table 6.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

South Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	127	53 (42)	87	26 (30)	215	79 (37)
Non-English speaking	13	8 (62)	2	1 (50)	15	9 (60)
p value		0.170		0.517		0.073
<b>2017</b>						
English speaking	118	55 (47)	122	54 (44)	243	110 (45)
Non-English speaking	9	4 (44)	3	0 (0)	14	4 (29)
p value		0.900		0.258		0.276
<b>2018</b>						
English speaking	167	81 (49)	119	34 (29)	286	115 (40)
Non-English speaking	17	8 (47)	3	0 (0)	20	8 (40)
p value		0.910		0.559		0.985
<b>2019</b>						
English speaking	165	79 (48)	124	42 (34)	290	121 (42)
Non-English speaking	9	3 (33)	2	1 (50)	11	4 (36)
p value		0.503		1.000		1.000
<b>2020</b>						
English speaking	13	2 (15)	7	2 (29)	20	4 (20)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

**Table 6.3.11 HCV antibody prevalence by region/country of birth, gender and survey year**

South Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
<b>2016</b>							
Australia	119	51 (43)	83	24 (29)	203	75 (37)	
Other Oceania	6	3 (50)	3	2 (67)	9	5 (56)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	7	3 (43)	2	1 (50)	9	4 (44)	
Other	8	4 (50)	1	0 (0)	9	4 (44)	
p value		0.975		0.374		0.633	
<b>2017</b>							
Australia	113	54 (48)	112	47 (42)	228	102 (45)	
Other Oceania	1	1 (100)	2	1 (50)	3	2 (67)	
Asia	1	0 (0)	1	1 (100)	2	1 (50)	
UK & Ireland	2	1 (50)	8	4 (50)	10	5 (50)	
Other	9	2 (22)	1	0 (0)	12	2 (17)	
p value		0.312		0.846		0.273	
<b>2018</b>							
Australia	159	75 (47)	110	30 (27)	269	105 (39)	
Other Oceania	2	0 (0)	2	1 (50)	4	1 (25)	
Asia	6	4 (67)	0	0 (0)	6	4 (67)	
UK & Ireland	12	7 (58)	8	3 (38)	20	10 (50)	
Other	7	3 (43)	2	0 (0)	9	3 (33)	
p value		0.592		0.660		0.547	
<b>2019</b>							
Australia	152	69 (45)	113	38 (34)	266	107 (40)	
Other Oceania	2	1 (50)	2	0 (0)	4	1 (25)	
Asia	5	1 (20)	1	1 (100)	6	2 (33)	
UK & Ireland	10	7 (70)	8	3 (38)	18	10 (56)	
Other	4	2 (50)	2	1 (50)	6	3 (50)	
p value		0.426		0.600		0.656	
<b>2020</b>							
Australia	12	2 (17)	5	1 (20)	17	3 (18)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	2	1 (50)	3	1 (33)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		1.000		1.000		0.509	

## HCV RNA prevalence

Table 6.4.1 HCV RNA prevalence by gender and survey year \*

South Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2016	75	27 (36)	47	10 (21)	123	37 (30)
2017	104	30 (29)	94	21 (22)	201	51 (26)
2018	87	21 (24)	56	8 (14)	143	29 (20)
2019	117	18 (15)	85	5 (6)	203	23 (11)
2020	9	1 (11)	5	0 (0)	14	1 (7)
X <sup>2</sup> p trend		<0.001		0.001		<0.001

\* Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 6.4.2 HCV RNA prevalence by sexual identity, gender and survey year \*

South Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heterosexual	65	24 (37)	30	7 (23)	95	31 (33)
Bisexual	6	2 (33)	7	2 (29)	13	4 (31)
Homosexual	1	0 (0)	5	0 (0)	6	0 (0)
p value		0.768		0.453		0.251
<b>2017</b>						
Heterosexual	84	26 (31)	59	14 (24)	143	40 (28)
Bisexual	7	1 (14)	19	4 (21)	29	5 (17)
Homosexual	5	1 (20)	14	3 (21)	19	4 (21)
p value		0.778		0.918		0.521
<b>2018</b>						
Heterosexual	66	17 (26)	35	6 (17)	100	23 (23)
Bisexual	4	0 (0)	12	1 (8)	16	1 (6)
Homosexual	8	0 (0)	5	0 (0)	14	0 (0)
p value		0.178		0.369		0.037
<b>2019</b>						
Heterosexual	96	15 (16)	58	4 (7)	155	19 (12)
Bisexual	5	1 (20)	12	0 (0)	18	1 (6)
Homosexual	8	0 (0)	9	0 (0)	17	0 (0)
p value		0.492		0.444		0.221
<b>2020</b>						
Heterosexual	7	1 (14)	4	0 (0)	11	1 (9)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		0.933

**Table 6.4.3 HCV RNA prevalence by age group, gender and survey year \***

South Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	4	0 (0)	1	0 (0)	5	0 (0)
25-34 years	9	2 (22)	11	2 (18)	20	4 (20)
35-44 years	25	8 (32)	20	4 (20)	45	13 (29)
45+ years	37	16 (43)	15	4 (27)	53	20 (38)
p value		0.378		0.820		0.201
<b>2017</b>						
<25 years	6	1 (17)	5	1 (20)	13	2 (15)
25-34 years	12	1 (8)	20	2 (10)	32	3 (9)
35-44 years	40	15 (38)	28	10 (36)	70	25 (36)
45+ years	45	13 (29)	41	8 (20)	86	21 (24)
p value		0.273		0.247		0.560
<b>2018</b>						
<25 years	1	0 (0)	4	0 (0)	6	0 (0)
25-34 years	23	5 (22)	14	3 (21)	37	8 (22)
35-44 years	30	7 (23)	23	5 (22)	53	12 (23)
45+ years	33	9 (27)	14	0 (0)	47	9 (19)
p value		0.903		0.155		0.630
<b>2019</b>						
<25 years	2	0 (0)	3	0 (0)	5	0 (0)
25-34 years	17	2 (12)	16	2 (13)	33	4 (12)
35-44 years	37	3 (8)	27	1 (4)	63	4 (6)
45+ years	60	13 (22)	39	2 (5)	100	15 (15)
p value		0.307		0.680		0.322
<b>2020</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	0	0 (0)	0	0 (0)
35-44 years	3	0 (0)	1	0 (0)	4	0 (0)
45+ years	6	1 (17)	4	0 (0)	10	1 (10)
p value		0.501		--		0.525



**Table 6.4.4 HCV RNA prevalence by years since first injection, gender and survey year \***

South Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	5	0 (0)	2	0 (0)	7	0 (0)
3 to 10 years	12	1 (8)	4	0 (0)	16	1 (6)
11+ years	58	26 (45)	41	10 (24)	99	36 (36)
p value		0.015		0.382		0.010
<b>2017</b>						
<3 years	4	0 (0)	2	0 (0)	7	0 (0)
3 to 10 years	16	2 (13)	13	2 (15)	30	4 (13)
11+ years	74	23 (31)	74	18 (24)	150	41 (27)
p value		0.162		0.547		0.092
<b>2018</b>						
<3 years	1	0 (0)	2	0 (0)	3	0 (0)
3 to 10 years	10	0 (0)	12	1 (8)	22	1 (5)
11+ years	72	19 (26)	42	7 (17)	114	26 (23)
p value		0.196		0.565		0.074
<b>2019</b>						
<3 years	2	0 (0)	3	0 (0)	5	0 (0)
3 to 10 years	10	0 (0)	15	3 (20)	25	3 (12)
11+ years	97	18 (19)	62	1 (2)	160	19 (12)
p value		0.291		0.016		0.719
<b>2020</b>						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	0	0 (0)	0	0 (0)	0	0 (0)
11+ years	8	1 (13)	5	0 (0)	13	1 (8)
p value		0.749		--		0.797

**Table 6.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year \***

South Australia Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	52	19 (37)	35	7 (20)	88	26 (30)
Receptive sharing	16	6 (38)	12	3 (25)	28	10 (36)
p value		0.912		0.475		0.634
<b>2017</b>						
No receptive sharing	75	23 (31)	68	13 (19)	146	36 (25)
Receptive sharing	16	4 (25)	13	1 (8)	30	5 (17)
p value		0.619		0.443		0.394
<b>2018</b>						
No receptive sharing	70	16 (23)	42	6 (14)	112	22 (20)
Receptive sharing	8	4 (50)	11	1 (9)	20	5 (25)
p value		0.127		0.519		0.611
<b>2019</b>						
No receptive sharing	88	15 (17)	58	4 (7)	147	19 (13)
Receptive sharing	12	2 (17)	12	0 (0)	23	2 (9)
p value		0.983		0.347		0.552
<b>2020</b>						
No receptive sharing	7	1 (14)	5	0 (0)	12	1 (8)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

**Table 6.4.6 HCV RNA prevalence by last drug injected, gender and survey year \***

South Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	13	6 (46)	8	3 (38)	21	10 (48)
Methamphetamine	44	13 (30)	31	4 (13)	76	17 (22)
Other opioids	12	4 (33)	5	3 (60)	18	7 (39)
Other drugs	5	3 (60)	3	0 (0)	8	3 (38)
p value		0.583		0.090		0.163
<b>2017</b>						
Heroin	33	11 (33)	38	13 (34)	72	24 (33)
Methamphetamine	41	11 (27)	44	6 (14)	87	17 (20)
Other opioids	18	5 (28)	8	1 (13)	26	6 (23)
Other drugs	8	3 (38)	2	0 (0)	12	3 (25)
p value		0.946		0.155		0.308
<b>2018</b>						
Heroin	28	5 (18)	16	2 (13)	44	7 (16)
Methamphetamine	44	11 (25)	35	4 (11)	79	15 (19)
Other opioids	8	3 (38)	3	2 (67)	11	5 (45)
Other drugs	4	1 (25)	2	0 (0)	6	1 (17)
p value		0.810		0.065		0.254
<b>2019</b>						
Heroin	24	5 (21)	23	2 (9)	48	7 (15)
Methamphetamine	65	8 (12)	43	2 (5)	109	10 (9)
Other opioids	18	3 (17)	10	1 (10)	29	4 (14)
Other drugs	6	2 (33)	5	0 (0)	11	2 (18)
p value		0.529		0.826		0.671
<b>2020</b>						
Heroin	3	0 (0)	1	0 (0)	4	0 (0)
Methamphetamine	4	1 (25)	3	0 (0)	7	1 (14)
Other opioids	1	0 (0)	1	0 (0)	2	0 (0)
Other drugs	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.827		--		0.868

**Table 6.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year \***

South Australia Frequency of injection last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	42	13 (31)	26	5 (19)	69	18 (26)
Daily or more	26	13 (50)	21	5 (24)	47	18 (38)
Not last month	6	1 (17)	0	0 (0)	6	1 (17)
p value		0.166		0.716		0.277
<b>2017</b>						
Less than daily	33	8 (24)	43	8 (19)	78	16 (21)
Daily or more	60	19 (32)	38	7 (18)	99	26 (26)
Not last month	8	1 (13)	11	6 (55)	19	8 (42)
p value		0.599		0.025		0.267
<b>2018</b>						
Less than daily	40	6 (15)	30	3 (10)	70	9 (13)
Daily or more	42	14 (33)	23	4 (17)	66	19 (29)
Not last month	3	1 (33)	2	0 (0)	5	1 (20)
p value		0.165		0.618		0.104
<b>2019</b>						
Less than daily	51	5 (10)	43	1 (2)	95	6 (6)
Daily or more	51	12 (24)	29	3 (10)	80	15 (19)
Not last month	12	1 (8)	10	1 (10)	23	2 (9)
p value		0.128		0.330		0.033
<b>2020</b>						
Less than daily	3	0 (0)	2	0 (0)	5	0 (0)
Daily or more	5	1 (20)	3	0 (0)	8	1 (13)
Not last month	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.588		--		0.759

**Table 6.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year \***

South Australia Imprisonment last year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	66	25 (38)	46	9 (20)	112	34 (30)
Imprisonment	6	2 (33)	1	0 (0)	7	3 (43)
p value		0.825		0.620		0.709
<b>2017</b>						
No imprisonment	82	21 (26)	84	20 (24)	169	41 (24)
Imprisonment	12	5 (42)	6	0 (0)	18	5 (28)
p value		0.258		0.135		0.792
<b>2018</b>						
No imprisonment	70	14 (20)	49	7 (14)	119	21 (18)
Imprisonment	8	5 (63)	3	0 (0)	12	5 (42)
p value		0.010		0.413		0.035
<b>2019</b>						
No imprisonment	86	13 (15)	71	5 (7)	158	18 (11)
Imprisonment	17	2 (12)	8	0 (0)	24	2 (8)
p value		0.750		0.440		0.639
<b>2020</b>						
No imprisonment	8	1 (13)	5	0 (0)	13	1 (8)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

**Table 6.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year \***

South Australia	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	61	20 (33)	41	9 (22)	102	29 (28)
Indigenous	12	7 (58)	6	1 (17)	19	8 (42)
p value		0.151		0.560		0.286
<b>2017</b>						
Non Indigenous	80	24 (30)	75	20 (27)	159	44 (28)
Indigenous	21	5 (24)	13	1 (8)	34	6 (18)
p value		0.682		0.238		0.336
<b>2018</b>						
Non Indigenous	72	15 (21)	47	8 (17)	119	23 (19)
Indigenous	14	5 (36)	7	0 (0)	21	5 (24)
p value		0.204		0.205		0.554
<b>2019</b>						
Non Indigenous	89	14 (16)	67	4 (6)	157	18 (11)
Indigenous	26	4 (15)	15	1 (7)	42	5 (12)
p value		0.956		0.981		0.962
<b>2020</b>						
Non Indigenous	7	1 (14)	5	0 (0)	12	1 (8)
Indigenous	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.617		--		0.695

**Table 6.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year \***

South Australia	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	68	24 (35)	45	10 (22)	114	34 (30)
Non-English speaking	7	3 (43)	2	0 (0)	9	3 (33)
p value		0.465		0.456		0.561
<b>2017</b>						
English speaking	96	26 (27)	92	21 (23)	189	47 (25)
Non-English speaking	7	3 (43)	2	0 (0)	11	3 (27)
p value		0.202		0.355		0.635
<b>2018</b>						
English speaking	74	18 (24)	54	8 (15)	129	26 (20)
Non-English speaking	11	3 (27)	2	0 (0)	13	3 (23)
p value		0.903		0.564		0.824
<b>2019</b>						
English speaking	112	18 (16)	84	5 (6)	197	23 (12)
Non-English speaking	4	0 (0)	1	0 (0)	5	0 (0)
p value		0.383		0.803		0.416
<b>2020</b>						
English speaking	8	1 (13)	5	0 (0)	13	1 (8)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

**Table 6.4.11 HCV RNA prevalence by region/country of birth, gender and survey year \***

South Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
<b>2016</b>							
Australia	62	25 (40)	43	7 (16)	108	32 (30)	
Other Oceania	2	0 (0)	2	2 (100)	4	2 (50)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	4	1 (25)	2	1 (50)	6	2 (33)	
Other	5	1 (20)	0	0 (0)	5	1 (20)	
p value		0.543		0.014		0.978	
<b>2017</b>							
Australia	90	26 (29)	84	20 (24)	176	46 (26)	
Other Oceania	1	1 (100)	1	0 (0)	2	1 (50)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	3	0 (0)	7	0 (0)	10	0 (0)	
Other	7	1 (14)	1	0 (0)	9	1 (11)	
p value		0.393		0.404		0.231	
<b>2018</b>							
Australia	73	18 (25)	52	8 (15)	125	26 (21)	
Other Oceania	1	0 (0)	1	0 (0)	2	0 (0)	
Asia	3	1 (33)	0	0 (0)	3	1 (33)	
UK & Ireland	5	0 (0)	2	0 (0)	7	0 (0)	
Other	3	2 (67)	1	0 (0)	4	2 (50)	
p value		0.415		0.831		0.332	
<b>2019</b>							
Australia	104	16 (15)	74	4 (5)	179	20 (11)	
Other Oceania	1	0 (0)	1	0 (0)	2	0 (0)	
Asia	1	0 (0)	1	0 (0)	2	0 (0)	
UK & Ireland	8	2 (25)	7	1 (14)	15	3 (20)	
Other	2	0 (0)	2	0 (0)	4	0 (0)	
p value		0.868		0.846		0.688	
<b>2020</b>							
Australia	8	1 (13)	4	0 (0)	12	1 (8)	
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)	
Asia	0	0 (0)	0	0 (0)	0	0 (0)	
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.749		--		0.724	

## Tasmania

Table 7.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Tasmania	2016	2017	2018	2019	2020*
<b>Number of sites</b>	4	4	4	4	4
<b>N° surveyed</b>	N=35	N=63	N=62	N=40	N=35
<b>Response rate (%)</b>	25%	30%	23%	17%	17%
<b>Gender (%)</b>					
Male	17 (49)	33 (52)	40 (65)	21 (53)	21 (60)
Female	18 (51)	30 (48)	21 (34)	19 (48)	14 (40)
Other	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Sexual identity (%)</b>					
Heterosexual	31 (89)	51 (81)	52 (84)	35 (88)	32 (91)
Bisexual	2 (6)	6 (10)	5 (8)	4 (10)	1 (3)
Gay/Lesbian	1 (3)	3 (5)	0 (0)	0 (0)	2 (6)
Other	-- --	-- --	-- --	-- --	0 (0)
Not reported	1 (3)	3 (5)	5 (8)	1 (3)	0 (0)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	31 (89)	55 (87)	49 (79)	36 (90)	31 (89)
Yes	3 (9)	7 (11)	11 (18)	4 (10)	4 (11)
Not reported	1 (3)	1 (2)	2 (3)	0 (0)	0 (0)
<b>Region/country of birth (%)</b>					
Australia	33 (94)	59 (94)	58 (94)	39 (98)	33 (94)
Other Oceania	0 (0)	0 (0)	1 (2)	1 (3)	0 (0)
Asia	0 (0)	2 (3)	0 (0)	0 (0)	0 (0)
UK & Ireland	1 (3)	1 (2)	2 (3)	0 (0)	2 (6)
Other	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Main language spoken at home by parents (%)</b>					
English	33 (94)	63 (100)	61 (98)	40 (100)	35 (100)
Non-English	1 (3)	0 (0)	1 (2)	0 (0)	0 (0)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	42	42	41.5	42	43
<i>Age range</i>	29-59	21-60	21-59	24-59	28-66
<i>Age group (%)</i>					
<25 years	0 (0)	2 (3)	2 (3)	1 (3)	0 (0)
25+ years	35 (100)	61 (97)	60 (97)	39 (98)	35 (100)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age first injection</i>	21	20.5	19	20	20
<i>Age range</i>	14-45	14-57	13-48	13-38	13-36
N° not reported	1	3	3	0	0
<i>Median yrs since first injection</i>	19	19	20	22	23
<i>Range</i>	7-29	2-46	1-40	5-45	1-46
<i>Years since first injection</i>					
<3 years	0 (0)	1 (2)	1 (2)	0 (0)	1 (3)
3+ years	34 (97)	59 (94)	59 (95)	40 (100)	34 (97)
Not reported	1 (3)	3 (5)	2 (3)	0 (0)	0 (0)
<b>Imprisonment last year (%)</b>					
No	33 (94)	57 (90)	56 (90)	36 (90)	30 (86)
Yes	1 (3)	4 (6)	3 (5)	4 (10)	5 (14)
Not reported	1 (3)	2 (3)	3 (5)	0 (0)	0 (0)
<b>N° in prison</b>	N=1	N=4	N=3	N=4	N=5
Injected in prison	0 (0)	0 (0)	2 (67)	0 (0)	0 (0)

\* Implementation of the 2020 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

**Table 7.1.2** Number (percentage) of respondents by last drug injected, frequency of injecting and survey year

Tasmania	2016	2017	2018	2019	2020
N° surveyed	N=35	N=63	N=62	N=40	N=35
<b>Drug last injected (%)</b>					
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	13 (37)	21 (33)	22 (35)	18 (45)	15 (43)
Heroin	1 (3)	2 (3)	2 (3)	2 (5)	1 (3)
Pharm. opioids	7 (20)	15 (24)	19 (31)	3 (8)	9 (26)
Methadone	10 (29)	15 (24)	12 (19)	11 (28)	7 (20)
Buprenorphine	1 (3)	2 (3)	2 (3)	2 (5)	0 (0)
Buprenorphine/naloxone	1 (3)	1 (2)	2 (3)	1 (3)	0 (0)
PIEDs	0 (0)	1 (2)	0 (0)	1 (3)	1 (3)
More than one	0 (0)	3 (5)	1 (2)	0 (0)	1 (3)
Other	2 (6)	0 (0)	2 (3)	2 (5)	0 (0)
Not reported	0 (0)	3 (5)	0 (0)	0 (0)	1 (3)
<b>Ever injected opioids</b>					
No	4 (11)	5 (8)	3 (5)	3 (8)	2 (6)
Yes	30 (86)	57 (90)	59 (95)	37 (93)	33 (94)
Not reported	1 (3)	1 (2)	0 (0)	0 (0)	0 (0)
<b>Frequency of injection last month (%)</b>					
Not last month	7 (20)	5 (8)	2 (3)	3 (8)	5 (14)
Less than weekly	7 (20)	9 (14)	7 (11)	8 (20)	7 (20)
Weekly not daily	14 (40)	17 (27)	27 (44)	17 (43)	12 (34)
Daily or more	7 (20)	32 (51)	26 (42)	11 (28)	11 (31)
Not reported	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
No	32 (91)	55 (87)	57 (92)	38 (95)	34 (97)
Yes	2 (6)	8 (13)	4 (6)	2 (5)	1 (3)
Not reported	1 (3)	0 (0)	1 (2)	0 (0)	0 (0)
<b>Overdosed in last 12 months</b>					
No	32 (91)	58 (92)	55 (89)	31 (78)	30 (86)
Yes	2 (6)	5 (8)	4 (6)	9 (23)	5 (14)
Not reported	1 (3)	0 (0)	3 (5)	0 (0)	0 (0)

**Table 7.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>Tasmania</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° injected last month</b>	<b>N=28</b>	<b>N=58</b>	<b>N=60</b>	<b>N=36</b>	<b>N=30</b>
<b>Places injected last month (%)</b>					
All private	19 (68)	36 (62)	35 (58)	24 (67)	24 (80)
Any public	9 (32)	22 (38)	25 (42)	12 (33)	6 (20)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	13 (46)	50 (86)	47 (78)	30 (83)	26 (87)
Most of the time	10 (36)	8 (14)	9 (15)	3 (8)	4 (13)
Half of the time	1 (4)	0 (0)	1 (2)	1 (3)	0 (0)
Some of the time	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
Not last month	4 (14)	0 (0)	2 (3)	2 (6)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	24 (86)	55 (95)	56 (93)	34 (94)	30 (100)
Once	2 (7)	1 (2)	0 (0)	1 (3)	0 (0)
Twice	1 (4)	1 (2)	1 (2)	0 (0)	0 (0)
3-5 times	0 (0)	0 (0)	1 (2)	1 (3)	0 (0)
>5 times	1 (4)	1 (2)	2 (3)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	24 (86)	55 (95)	56 (93)	34 (94)	30 (100)
One	2 (7)	2 (3)	1 (2)	0 (0)	0 (0)
Two	1 (4)	0 (0)	1 (2)	0 (0)	0 (0)
Three to five	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)
More than five	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
Don't know	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	1 (2)	2 (6)	0 (0)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	1 (4)	2 (3)	1 (2)	0 (0)	0 (0)
Casual sex partner	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
Close friend	3 (11)	0 (0)	2 (3)	0 (0)	0 (0)
Acquaintance	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	4 (14)	8 (14)	5 (8)	3 (8)	0 (0)
Water	4 (14)	6 (10)	5 (8)	3 (8)	1 (3)
Filter	1 (4)	9 (16)	2 (3)	4 (11)	0 (0)
Drug mix	3 (11)	4 (7)	4 (7)	1 (3)	0 (0)
None	21 (75)	40 (69)	52 (87)	26 (72)	28 (93)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	25 (89)	48 (83)	53 (88)	35 (97)	28 (93)
Yes	3 (11)	7 (12)	7 (12)	1 (3)	2 (7)
Not reported	0 (0)	3 (5)	0 (0)	0 (0)	0 (0)
<b>Source of needle acquisition</b>					
Needle Syringe Program	26 (93)	57 (98)	57 (95)	36 (100)	29 (97)
Chemist/Pharmacy	4 (14)	10 (17)	8 (13)	6 (17)	8 (27)
Personal sources	2 (7)	5 (9)	2 (3)	2 (6)	0 (0)
Dispensing/Vending Machine	5 (18)	16 (28)	9 (15)	8 (22)	7 (23)
Other sources	0 (0)	0 (0)	2 (3)	0 (0)	0 (0)



**Table 7.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

Tasmania	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=35	N=47	N=62	N=40	N=35
<b>Ever any treatment/therapy for drug use (%)</b>					
No	6 (17)	16 (25)	12 (19)	10 (25)	11 (31)
Yes	28 (80)	47 (75)	50 (81)	30 (75)	24 (69)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)
<b>History of methadone maintenance treatment (%)</b>					
Currently	17 (49)	24 (38)	16 (26)	10 (25)	7 (20)
Previously	4 (11)	16 (25)	24 (39)	11 (28)	5 (14)
Never	12 (34)	22 (35)	20 (32)	19 (48)	23 (66)
Not reported	2 (6)	1 (2)	2 (3)	0 (0)	0 (0)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	3 (9)	7 (11)	6 (10)	5 (13)	2 (6)
Previously	5 (14)	11 (17)	19 (31)	6 (15)	9 (26)
Never	26 (74)	44 (70)	35 (56)	29 (73)	24 (69)
Not reported	1 (3)	1 (2)	2 (3)	0 (0)	0 (0)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	1 (3)	2 (3)	4 (6)	2 (5)	1 (3)
Previously	4 (11)	11 (17)	19 (31)	6 (15)	9 (26)
Never	29 (83)	49 (78)	37 (60)	32 (80)	24 (69)
Not reported	1 (3)	1 (2)	2 (3)	0 (0)	1 (3)

**Table 7.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

Tasmania	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=35	N=63	N=62	N=40	N=35
<b>Previous HIV test (%)</b>					
Yes, ever	26 (74)	54 (86)	49 (79)	33 (83)	29 (83)
Yes, last year	17 (49)	24 (38)	21 (34)	14 (35)	15 (43)
>1 year ago	9 (26)	30 (48)	28 (45)	19 (48)	14 (40)
Never tested	8 (23)	9 (14)	9 (15)	6 (15)	6 (17)
Not reported	1 (3)	0 (0)	4 (6)	1 (3)	0 (0)
<b>Previous HCV test (%)</b>					
Yes, ever	30 (86)	52 (83)	53 (85)	36 (90)	29 (83)
Yes, last year	21 (60)	31 (49)	35 (56)	22 (55)	18 (51)
>1 year ago	9 (26)	21 (33)	18 (29)	14 (35)	11 (31)
Never tested	3 (9)	8 (13)	5 (8)	1 (3)	3 (9)
Not reported	2 (6)	3 (5)	4 (6)	3 (8)	3 (9)
<b>Lifetime treatment for HCV (%)#</b>					
<b>N° self-reported HCV diagnosis</b>	N=9	N=20	N=21	N=11	N=4
Antiviral treatment	2 (22)	11 (55)	15 (71)	6 (55)	3 (75)
No antiviral treatment	5 (56)	9 (45)	6 (29)	5 (45)	1 (25)
Not reported	2 (22)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Treatment for HCV in past 12 months (%)**</b>					
<b>N° self-reported HCV diagnosis</b>	N=9	N=18	N=17	N=8	N=3
Antiviral treatment	2 (22)	7 (39)	9 (53)	2 (25)	1 (33)
No antiviral treatment	5 (56)	11 (61)	8 (47)	6 (75)	2 (67)
Not reported	2 (22)	0 (0)	0 (0)	0 (0)	0 (0)

# among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 7.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

Tasmania	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=35	N=63	N=62	N=40	N=35
<b>Sex with a regular partner last month (%)</b>					
No	17 (49)	29 (46)	32 (52)	15 (38)	10 (29)
Yes	16 (46)	34 (54)	26 (42)	11 (28)	11 (31)
Not reported	2 (6)	0 (0)	4 (6)	14 (35)	14 (40)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=16	N=34	N=26	N=11	N=11
Never	12 (75)	31 (91)	21 (81)	9 (82)	9 (82)
Sometimes	3 (19)	0 (0)	4 (15)	1 (9)	1 (9)
Every time	1 (6)	3 (9)	0 (0)	1 (9)	1 (9)
Not reported	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
<b>Sex with other partner(s) last month (%)</b>					
No	30 (86)	62 (98)	51 (82)	24 (60)	21 (60)
Yes	1 (3)	1 (2)	6 (10)	2 (5)	1 (3)
Not reported	4 (11)	0 (0)	5 (8)	14 (35)	13 (37)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=1	N=1	N=6	N=2	N=1
Never	0 (0)	0 (0)	4 (67)	2 (100)	1 (100)
Sometimes	0 (0)	1 (100)	2 (33)	0 (0)	0 (0)
Every time	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<b>Sex work last month (%)</b>					
No	31 (89)	59 (94)	55 (89)	26 (65)	22 (63)
Yes	1 (3)	2 (3)	1 (2)	0 (0)	0 (0)
Not reported	3 (9)	2 (3)	6 (10)	14 (35)	13 (37)
<b>Condom used at last sex work (%)</b>					
Yes	1 (100)	1 (50)	0 (0)	0 (0)	0 (0)

**Table 7.1.7 Number (percentage) of respondents by COVID-19 related behaviours in 2020**

<b>Tasmania</b>			
<b>N° surveyed</b>	<b>N=35</b>		
<b>More difficult to access sterile needles and syringes</b>		<b>Start or increase takeaway dose of methadone/bupe/suboxone</b>	
Yes	1 (3)	Yes	0 (0)
No	32 (91)	No	17 (49)
Not applicable	0 (0)	Not applicable	15 (43)
Not reported	2 (6)	Not reported	3 (9)
<b>Start depot buprenorphine</b>		<b>Inject own methadone/bupe/suboxone</b>	
Yes	1 (3)	Yes	3 (9)
No	17 (49)	No	14 (40)
Not applicable	14 (40)	Not applicable	16 (46)
Not reported	3 (9)	Not reported	2 (6)
<b>Access take home naloxone</b>		<b>COVID-19 test</b>	
Yes	13 (37)	Yes	5 (14)
No	12 (34)	No	25 (71)
Not applicable	6 (17)	Don't know	2 (6)
Not reported	4 (11)	Not reported	3 (9)
<b>Change illicit drug use</b>		<b>If YES, what was result (N=5)</b>	
Yes, increased	4 (11)	Positive	0 (0)
Yes, decreased	9 (26)	Negative	5 (100)
No change	19 (54)	Don't know	0 (0)
Not reported	3 (9)	Not reported	0 (0)

## HIV antibody prevalence

**Table 7.2.1 HIV antibody prevalence by gender and survey year**

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2016	17	0 (0.0)	18	0 (0.0)	35	0 (0.0)
2017	32	0 (0.0)	30	0 (0.0)	62	0 (0.0)
2018	40	0 (0.0)	21	0 (0.0)	62	0 (0.0)
2019	20	1 (5.0)	18	0 (0.0)	38	1 (2.6)
2020	20	0 (0.0)	14	0 (0.0)	34	0 (0.0)
X <sup>2</sup> p trend		0.399		--		0.380

## HCV antibody prevalence

**Table 7.3.1 HCV antibody prevalence by gender and survey year**

Tasmania Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2016	17	7 (41)	18	6 (33)	35	13 (37)
2017	32	14 (44)	29	15 (52)	61	29 (48)
2018	40	21 (53)	21	12 (57)	62	34 (55)
2019	19	7 (37)	18	6 (33)	37	13 (35)
2020	20	6 (30)	14	3 (21)	34	9 (26)
X <sup>2</sup> p trend		0.390		0.277		0.177

**Table 7.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

Tasmania Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heterosexual	15	7 (47)	16	6 (38)	31	13 (42)
Bisexual	0	0 (0)	2	0 (0)	2	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		0.529		0.696
<b>2017</b>						
Heterosexual	28	13 (46)	23	11 (48)	51	24 (47)
Bisexual	0	0 (0)	4	2 (50)	4	2 (50)
Homosexual	2	0 (0)	1	1 (100)	3	1 (33)
p value		0.492		1.000		1.000
<b>2018</b>						
Heterosexual	34	18 (53)	18	9 (50)	52	27 (52)
Bisexual	2	0 (0)	2	2 (100)	5	3 (60)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.486		0.479		1.000
<b>2019</b>						
Heterosexual	18	7 (39)	14	6 (43)	32	13 (41)
Bisexual	1	0 (0)	3	0 (0)	4	0 (0)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		0.515		0.274
<b>2020</b>						
Heterosexual	19	6 (32)	12	3 (25)	31	9 (29)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		1.000		1.000		1.000

**Table 7.3.3 HCV antibody prevalence by age group, gender and survey year**

Tasmania Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	3	1 (33)	3	1 (33)
35-44 years	11	6 (55)	11	5 (45)	22	11 (50)
45+ years	6	1 (17)	4	0 (0)	10	1 (10)
p value		0.304		0.314		0.106
<b>2017</b>						
<25 years	2	0 (0)	0	0 (0)	2	0 (0)
25-34 years	3	1 (33)	6	5 (83)	9	6 (67)
35-44 years	12	6 (50)	12	6 (50)	24	12 (50)
45+ years	15	7 (47)	11	4 (36)	26	11 (42)
p value		0.745		0.223		0.385
<b>2018</b>						
<25 years	1	1 (100)	0	0 (0)	2	2 (100)
25-34 years	6	3 (50)	3	2 (67)	9	5 (56)
35-44 years	19	8 (42)	12	8 (67)	31	16 (52)
45+ years	14	9 (64)	6	2 (33)	20	11 (55)
p value		0.490		0.475		0.798
<b>2019</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	1	0 (0)	4	2 (50)	5	2 (40)
35-44 years	12	3 (25)	7	1 (14)	19	4 (21)
45+ years	6	4 (67)	7	3 (43)	13	7 (54)
p value		0.129		0.541		0.178
<b>2020</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	4	0 (0)	5	1 (20)	9	1 (11)
35-44 years	5	2 (40)	3	1 (33)	8	3 (38)
45+ years	11	4 (36)	6	1 (17)	17	5 (29)
p value		0.532		1.000		0.475

**Table 7.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

Tasmania Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	1	0 (0)	1	0 (0)	2	0 (0)
11+ years	16	7 (44)	16	6 (38)	32	13 (41)
p value		1.000		1.000		0.513
<b>2017</b>						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	4	0 (0)	1	1 (100)	5	1 (20)
11+ years	25	14 (56)	27	14 (52)	52	28 (54)
p value		0.067		1.000		0.194
<b>2018</b>						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	5	2 (40)	3	1 (33)	9	4 (44)
11+ years	33	17 (52)	17	11 (65)	50	28 (56)
p value		1.000		0.537		0.845
<b>2019</b>						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	2	0 (0)	4	1 (25)	6	1 (17)
11+ years	17	7 (41)	14	5 (36)	31	12 (39)
p value		0.509		1.000		0.394
<b>2020</b>						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	2	0 (0)	4	1 (25)	6	1 (17)
11+ years	17	6 (35)	10	2 (20)	27	8 (30)
p value		1.000		1.000		1.000

**Table 7.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

Tasmania Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	0	0 (0)	24	9 (38)	24	9 (38)
Receptive sharing	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.285		0.285
<b>2017</b>						
No receptive sharing	1	1 (100)	49	25 (51)	53	25 (47)
Receptive sharing	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		1.000		0.605
<b>2018</b>						
No receptive sharing	1	1 (100)	53	30 (57)	56	32 (57)
Receptive sharing	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		0.322		0.318
<b>2019</b>						
No receptive sharing	0	0 (0)	32	13 (41)	32	13 (41)
Receptive sharing	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
<b>2020</b>						
No receptive sharing	1	0 (0)	28	9 (32)	29	9 (31)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

**Table 7.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

Tasmania Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Methamphetamine	0	0 (0)	13	2 (15)	13	2 (15)
Pharmaceutical opioids	0	0 (0)	7	3 (43)	7	3 (43)
OST	0	0 (0)	12	7 (58)	12	7 (58)
Other drugs	0	0 (0)	2	1 (50)	3	1 (33)
p value		--		0.164		0.167
<b>2017</b>						
Methamphetamine	1	1 (100)	19	6 (32)	20	6 (30)
Pharmaceutical opioids	0	0 (0)	12	7 (58)	15	7 (47)
OST	0	0 (0)	18	12 (67)	18	12 (67)
Other drugs	0	0 (0)	8	4 (50)	8	4 (50)
p value		--		0.180		0.162
<b>2018</b>						
Methamphetamine	0	0 (0)	21	10 (48)	22	10 (45)
Pharmaceutical opioids	1	1 (100)	17	10 (59)	19	12 (63)
OST	0	0 (0)	16	9 (56)	16	9 (56)
Other drugs	0	0 (0)	5	3 (60)	5	3 (60)
p value		--		0.895		0.710
<b>2019</b>						
Methamphetamine	0	0 (0)	16	6 (38)	16	6 (38)
Pharmaceutical opioids	0	0 (0)	3	0 (0)	3	0 (0)
OST	0	0 (0)	14	6 (43)	14	6 (43)
Other drugs	0	0 (0)	3	1 (33)	3	1 (33)
p value		--		0.573		0.573
<b>2020</b>						
Methamphetamine	1	0 (0)	13	2 (15)	14	2 (14)
Pharmaceutical opioids	0	0 (0)	9	3 (33)	9	3 (33)
OST	0	0 (0)	7	3 (43)	7	3 (43)
Other drugs	0	0 (0)	4	1 (25)	4	1 (25)
p value		--		0.581		0.521

**Table 7.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

Tasmania Frequency of injection last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	0	0 (0)	21	10 (48)	21	10 (48)
Daily or more	0	0 (0)	7	2 (29)	7	2 (29)
Not last month	0	0 (0)	6	1 (17)	7	1 (14)
p value		--		0.473		0.310
<b>2017</b>						
Less than daily	0	0 (0)	25	11 (44)	25	11 (44)
Daily or more	1	1 (100)	27	16 (59)	31	16 (52)
Not last month	0	0 (0)	5	2 (40)	5	2 (40)
p value		--		0.569		0.802
<b>2018</b>						
Less than daily	0	0 (0)	33	19 (58)	34	19 (56)
Daily or more	1	1 (100)	24	12 (50)	26	14 (54)
Not last month	0	0 (0)	2	1 (50)	2	1 (50)
p value		--		0.798		1.000
<b>2019</b>						
Less than daily	0	0 (0)	24	7 (29)	24	7 (29)
Daily or more	0	0 (0)	9	6 (67)	9	6 (67)
Not last month	0	0 (0)	3	0 (0)	3	0 (0)
p value		--		0.081		0.081
<b>2020</b>						
Less than daily	1	0 (0)	18	6 (33)	19	6 (32)
Daily or more	0	0 (0)	10	3 (30)	10	3 (30)
Not last month	0	0 (0)	5	0 (0)	5	0 (0)
p value		--		0.480		0.485

**Table 7.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

Tasmania Imprisonment last year	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	0	0 (0)	32	13 (41)	33	13 (39)
Imprisonment	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		1.000		1.000
<b>2017</b>						
No imprisonment	1	1 (100)	51	27 (53)	55	27 (49)
Imprisonment	0	0 (0)	4	2 (50)	4	2 (50)
p value		--		1.000		1.000
<b>2018</b>						
No imprisonment	0	0 (0)	55	29 (53)	56	29 (52)
Imprisonment	0	0 (0)	3	3 (100)	3	3 (100)
p value		--		0.245		0.243
<b>2019</b>						
No imprisonment	0	0 (0)	33	10 (30)	33	10 (30)
Imprisonment	0	0 (0)	4	3 (75)	4	3 (75)
p value		--		0.115		0.115
<b>2020</b>						
No imprisonment	1	0 (0)	28	8 (29)	29	8 (28)
Imprisonment	0	0 (0)	5	1 (20)	5	1 (20)
p value		--		0.582		1.000



**Table 7.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Tasmania Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	16	7 (44)	15	4 (27)	31	11 (35)
Indigenous	0	0 (0)	3	2 (67)	3	2 (67)
p value		--		0.245		0.544
<b>2017</b>						
Non Indigenous	28	11 (39)	26	13 (50)	54	24 (44)
Indigenous	4	3 (75)	2	1 (50)	6	4 (67)
p value		0.295		1.000		0.404
<b>2018</b>						
Non Indigenous	32	14 (44)	17	10 (59)	49	24 (49)
Indigenous	7	6 (86)	3	1 (33)	11	8 (73)
p value		0.091		0.566		0.193
<b>2019</b>						
Non Indigenous	16	5 (31)	17	6 (35)	33	11 (33)
Indigenous	3	2 (67)	1	0 (0)	4	2 (50)
p value		0.523		1.000		0.602
<b>2020</b>						
Non Indigenous	16	5 (31)	14	3 (21)	30	8 (27)
Indigenous	4	1 (25)	0	0 (0)	4	1 (25)
p value		1.000		--		1.000

**Table 7.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

Tasmania Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	15	7 (47)	18	6 (33)	33	13 (39)
Non-English speaking	1	0 (0)	0	0 (0)	1	0 (0)
p value		1.000		--		1.000
<b>2017</b>						
English speaking	32	14 (44)	29	15 (52)	61	29 (48)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2018</b>						
English speaking	40	21 (53)	21	12 (57)	61	33 (54)
Non-English speaking	0	0 (0)	0	0 (0)	1	1 (100)
p value		--		--		1.000
<b>2019</b>						
English speaking	19	7 (37)	18	6 (33)	37	13 (35)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2020</b>						
English speaking	20	6 (30)	14	3 (21)	34	9 (26)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

Table 7.3.11 HCV antibody prevalence by region/country of birth, gender and survey year

Tasmania Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Australia	16	7 (44)	17	6 (35)	33	13 (39)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		1.000		1.000
<b>2017</b>						
Australia	29	13 (45)	28	14 (50)	57	27 (47)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	0 (0)	1	1 (100)	2	1 (50)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.835		1.000		0.862
<b>2018</b>						
Australia	38	21 (55)	20	12 (60)	58	33 (57)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)
Other	0	0 (0)	0	0 (0)	1	1 (100)
p value		0.219		0.429		0.137
<b>2019</b>						
Australia	19	7 (37)	17	6 (35)	36	13 (36)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		1.000		1.000
<b>2020</b>						
Australia	19	6 (32)	13	3 (23)	32	9 (28)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		1.000		1.000

## HCV RNA prevalence

Table 7.4.1 HCV RNA prevalence by gender and survey year \*

Tasmania	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2016	4	2 (50)	2	0 (0)	6	2 (33)
2017	27	8 (30)	26	9 (35)	53	17 (32)
2018	32	6 (19)	17	5 (29)	49	11 (22)
2019	16	3 (19)	16	3 (19)	32	5 (16)
2020	18	2 (11)	13	3 (23)	31	5 (16)
X <sup>2</sup> p trend		0.063		0.465		0.046

\* Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 7.4.2 HCV RNA prevalence by sexual identity, gender and survey year \*

Tasmania	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heterosexual	2	2 (100)	1	0 (0)	4	2 (50)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.072		--		0.428
<b>2017</b>						
Heterosexual	25	8 (32)	20	9 (45)	45	17 (38)
Bisexual	0	0 (0)	5	0 (0)	5	0 (0)
Homosexual	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.346		0.150		0.111
<b>2018</b>						
Heterosexual	28	4 (14)	13	4 (31)	41	8 (20)
Bisexual	0	0 (0)	2	1 (50)	3	1 (33)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.544		0.445
<b>2019</b>						
Heterosexual	15	3 (20)	12	2 (17)	27	4 (15)
Bisexual	1	0 (0)	3	1 (33)	4	1 (25)
Homosexual	0	3 (0)	0	0 (0)	0	0 (0)
p value		0.637		0.457		0.789
<b>2020</b>						
Heterosexual	17	2 (12)	11	3 (27)	28	5 (18)
Bisexual	0	0 (0)	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.719		0.747		0.743

**Table 7.4.3 HCV RNA prevalence by age group, gender and survey year \***

Tasmania Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	0	0 (0)	1	0 (0)
35-44 years	1	1 (100)	1	0 (0)	2	1 (50)
45+ years	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.488		--		0.622
<b>2017</b>						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	3	0 (0)	5	3 (60)	8	3 (38)
35-44 years	11	4 (36)	12	2 (17)	23	6 (26)
45+ years	12	4 (33)	9	4 (44)	21	8 (38)
p value		0.567		0.175		0.821
<b>2018</b>						
<25 years	0	0 (0)	0	0 (0)	1	0 (0)
25-34 years	5	1 (20)	2	1 (50)	7	2 (29)
35-44 years	15	1 (7)	10	2 (20)	25	3 (12)
45+ years	12	4 (33)	4	1 (25)	16	5 (31)
p value		0.227		0.634		0.430
<b>2019</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	0	0 (0)	3	1 (33)	3	1 (33)
35-44 years	10	1 (10)	6	1 (17)	16	2 (13)
45+ years	6	2 (33)	6	1 (17)	12	3 (25)
p value		0.340		0.886		0.669
<b>2020</b>						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	4	0 (0)	5	1 (20)	9	1 (11)
35-44 years	5	1 (20)	2	0 (0)	7	1 (14)
45+ years	10	1 (10)	5	1 (20)	15	2 (13)
p value		0.631		0.770		0.997

**Table 7.4.4 HCV RNA prevalence by years since first injection, gender and survey year \***

Tasmania Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	0	0 (0)	1	0 (0)	1	0 (0)
11+ years	4	2 (50)	1	0 (0)	5	2 (40)
p value		--		--		0.445
<b>2017</b>						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	3	0 (0)	1	1 (100)	4	1 (25)
11+ years	22	8 (36)	24	8 (33)	46	16 (35)
p value		0.357		0.179		0.734
<b>2018</b>						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 10 years	4	1 (25)	3	1 (33)	8	2 (25)
11+ years	26	3 (12)	13	4 (31)	39	7 (18)
p value		0.064		0.710		0.127
<b>2019</b>						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	0	0 (0)	3	2 (67)	3	2 (67)
11+ years	16	3 (19)	12	1 (8)	29	3 (10)
p value		--		0.065		0.066
<b>2020</b>						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 10 years	2	0 (0)	4	1 (25)	6	1 (17)
11+ years	16	2 (13)	8	1 (13)	24	4 (17)
p value		0.800		0.611		0.846

**Table 7.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year \***

Tasmania Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	3	1 (33)	1	0 (0)	4	2 (50)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2017</b>						
No receptive sharing	24	6 (25)	23	8 (35)	47	14 (30)
Receptive sharing	1	1 (100)	2	1 (50)	3	2 (67)
p value		0.123		0.585		0.094
<b>2018</b>						
No receptive sharing	28	5 (18)	16	5 (31)	44	10 (23)
Receptive sharing	2	0 (0)	0	0 (0)	3	0 (0)
p value		0.525		--		0.375
<b>2019</b>						
No receptive sharing	16	3 (19)	13	3 (23)	29	5 (17)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2020</b>						
No receptive sharing	17	2 (12)	9	3 (33)	26	5 (19)
Receptive sharing	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--

**Table 7.4.6 HCV RNA prevalence by last drug injected, gender and survey year \***

Tasmania Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Methamphetamine	0	0 (0)	1	0 (0)	1	0 (0)
Pharm. Opioids	1	0 (0)	0	0 (0)	1	0 (0)
OAT	2	2 (100)	1	0 (0)	3	2 (67)
Other drugs	0	0 (0)	0	0 (0)	1	0 (0)
p value		0.072		--		0.375
<b>2017</b>						
Methamphetamine	6	0 (0)	10	2 (20)	16	2 (13)
Pharm. Opioids	11	4 (36)	4	2 (50)	15	6 (40)
OAT	7	2 (29)	7	5 (71)	15	7 (47)
Other drugs	2	1 (50)	5	0 (0)	7	1 (14)
p value		0.308		0.070		0.172
<b>2018</b>						
Methamphetamine	7	0 (0)	7	2 (29)	14	2 (14)
Pharm. Opioids	14	3 (21)	3	1 (33)	17	4 (24)
OAT	9	3 (33)	5	1 (20)	14	4 (29)
Other drugs	2	0 (0)	1	0 (0)	4	0 (0)
p value		0.344		0.902		0.650
<b>2019</b>						
Methamphetamine	8	2 (25)	6	2 (33)	14	3 (21)
Pharm. Opioids	1	0 (0)	2	0 (0)	3	0 (0)
OAT	6	0 (0)	8	1 (13)	14	1 (7)
Other drugs	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.161		0.534		0.067
<b>2020</b>						
Methamphetamine	7	1 (14)	6	1 (17)	14	2 (14)
Pharm. Opioids	6	1 (17)	1	0 (0)	7	1 (14)
OAT	3	0 (0)	3	1 (33)	6	1 (17)
Other drugs	2	0 (0)	2	0 (0)	4	0 (0)
p value		0.821		0.726		0.841

OAT: methadone, buprenorphine or buprenorphine-naloxone

**Table 7.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year \***

Tasmania Frequency of injection last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	4	2 (50)	1	0 (0)	5	2 (40)
Daily or more	0	0 (0)	0	0 (0)	0	0 (0)
Not last month	0	0 (0)	1	0 (0)	1	0 (0)
p value		--		--		0.263
<b>2017</b>						
Less than daily	7	0 (0)	13	3 (23)	20	3 (15)
Daily or more	18	7 (39)	12	6 (50)	30	13 (43)
Not last month	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.139		0.270		0.093
<b>2018</b>						
Less than daily	16	1 (6)	12	4 (33)	28	5 (18)
Daily or more	15	4 (27)	4	1 (25)	19	5 (26)
Not last month	1	1 (100)	1	0 (0)	2	1 (50)
p value		0.045		0.837		0.433
<b>2019</b>						
Less than daily	12	2 (17)	9	2 (22)	21	3 (14)
Daily or more	4	1 (25)	4	1 (25)	8	2 (25)
Not last month	0	0 (0)	3	0 (0)	3	0 (0)
p value		0.735		0.705		0.714
<b>2020</b>						
Less than daily	12	1 (8)	7	3 (43)	18	4 (22)
Daily or more	6	1 (17)	2	0 (0)	8	1 (13)
Not last month	1	0 (0)	4	0 (0)	5	0 (0)
p value		0.792		0.264		0.558

**Table 7.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year \***

Tasmania Imprisonment last year	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	4	2 (50)	2	0 (0)	6	2 (33)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2017</b>						
No imprisonment	26	8 (31)	22	8 (36)	48	16 (33)
Imprisonment	1	0 (0)	3	1 (33)	4	1 (25)
p value		0.508		0.988		0.767
<b>2018</b>						
No imprisonment	28	4 (14)	17	5 (29)	45	9 (20)
Imprisonment	1	0 (0)	0	0 (0)	2	0 (0)
p value		0.691		--		0.500
<b>2019</b>						
No imprisonment	14	1 (7)	15	3 (20)	29	3 (10)
Imprisonment	3	2 (67)	1	0 (0)	3	2 (67)
p value		0.026		0.654		0.066
<b>2020</b>						
No imprisonment	14	1 (7)	12	3 (25)	26	4 (15)
Imprisonment	4	1 (25)	1	0 (0)	5	1 (20)
p value		0.303		0.613		0.681

**Table 7.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year \***

Tasmania Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	4	2 (50)	2	0 (0)	6	2 (33)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2017</b>						
Non Indigenous	25	8 (32)	22	8 (36)	47	16 (34)
Indigenous	2	0 (0)	3	0 (0)	5	0 (0)
p value		0.333		0.219		0.118
<b>2018</b>						
Non Indigenous	25	4 (16)	12	5 (42)	37	9 (24)
Indigenous	6	1 (17)	3	0 (0)	10	1 (10)
p value		0.962		0.221		0.376
<b>2019</b>						
Non Indigenous	15	2 (13)	15	3 (20)	29	4 (14)
Indigenous	2	1 (50)	1	0 (0)	3	1 (33)
p value		0.203		0.654		0.417
<b>2020</b>						
Non Indigenous	14	2 (14)	13	3 (23)	27	5 (19)
Indigenous	4	0 (0)	0	0 (0)	4	0 (0)
p value		0.427		--		0.375

**Table 7.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year \***

Tasmania Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	4	2 (50)	2	0 (0)	6	2 (33)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2017</b>						
English speaking	27	8 (30)	26	9 (35)	53	17 (32)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2018</b>						
English speaking	31	6 (19)	17	5 (29)	48	11 (23)
Non-English speaking	0	0 (0)	0	0 (0)	1	0 (0)
p value		--		--		0.605
<b>2019</b>						
English speaking	16	3 (19)	16	3 (19)	32	5 (16)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2020</b>						
English speaking	18	2 (11)	12	3 (25)	31	5 (16)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--



Table 7.4.11 HCV RNA prevalence by region/country of birth, gender and survey year \*

Tasmania Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Australia	4	2 (50)	2	0 (0)	6	2 (33)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		--		--
<b>2017</b>						
Australia	24	7 (29)	25	8 (32)	49	15 (31)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	0 (0)	1	1 (100)	2	1 (50)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.294		0.168		0.308
<b>2018</b>						
Australia	29	6 (21)	16	5 (31)	45	11 (24)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)
Other	0	0 (0)	0	0 (0)	1	0 (0)
p value		0.786		0.540		0.756
<b>2019</b>						
Australia	14	3 (21)	15	3 (20)	31	5 (16)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		--		0.654		0.664
<b>2020</b>						
Australia	17	2 (12)	12	3 (25)	29	5 (17)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	1	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.719		0.613		0.541

## Victoria

Table 8.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Victoria	2016	2017	2018	2019	2020*
<b>Number of sites</b>	6	6	6	6	--
<b>N° surveyed</b>	N=423	N=380	N=437	N=375	--
<b>Response rate (%)</b>	70%	56%	51%	52%	--
<b>Gender (%)</b>					
Male	268 (63)	247 (65)	290 (66)	240 (64)	-- --
Female	151 (36)	127 (33)	145 (33)	130 (35)	-- --
Other	2 (<1)	3 (1)	2 (<1)	3 (1)	-- --
Not reported	2 (<1)	3 (1)	0 (0)	2 (1)	-- --
<b>Sexual identity (%)</b>					
Heterosexual	329 (78)	293 (77)	342 (78)	277 (74)	-- --
Bisexual	45 (11)	35 (9)	33 (8)	39 (10)	-- --
Gay/Lesbian	13 (3)	16 (4)	18 (4)	17 (5)	-- --
Other	-- --	-- --	-- --	-- --	-- --
Not reported	36 (9)	36 (9)	44 (10)	42 (11)	-- --
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	341 (81)	320 (84)	359 (82)	296 (79)	-- --
Yes	70 (17)	55 (14)	71 (16)	66 (18)	-- --
Not reported	12 (3)	5 (1)	7 (2)	13 (3)	-- --
<b>Region/country of birth (%)</b>					
Australia	363 (86)	333 (88)	373 (85)	333 (89)	-- --
Other Oceania	8 (2)	9 (2)	12 (3)	7 (2)	-- --
Asia	7 (2)	5 (1)	6 (1)	3 (1)	-- --
UK & Ireland	16 (4)	13 (3)	20 (5)	7 (2)	-- --
Other	20 (5)	19 (5)	24 (5)	20 (5)	-- --
Not reported	9 (2)	1 (<1)	2 (<1)	5 (1)	-- --
<b>Main language spoken at home by parents (%)</b>					
English	380 (90)	336 (88)	393 (90)	345 (92)	-- --
Non-English	38 (9)	44 (12)	43 (10)	27 (7)	-- --
Not reported	5 (1)	0 (0)	1 (<1)	3 (1)	-- --
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	41	42	42	42	-- --
<i>Age range</i>	17-69	19-67	17-69	20-70	-- --
<b>Age group (%)</b>					
<25 years	13 (3)	7 (2)	8 (2)	6 (2)	-- --
25+ years	409 (97)	370 (97)	424 (97)	363 (97)	-- --
Not reported	1 (<1)	3 (1)	5 (1)	6 (2)	-- --
<b>Median age first injection</b>					
<i>Median age first injection</i>	18	18	18	18	-- --
<i>Age range</i>	10-48	10-58	11-52	10-51	--
<i>N° not reported</i>	18	12	23	27	--
<b>Median yrs since first injection</b>					
<i>Median yrs since first injection</i>	21	23	22	22	--
<i>Range</i>	<1-49	<1-47	<1-46	<1-52	--
<b>Years since first injection</b>					
<3 years	12 (3)	8 (2)	18 (4)	13 (3)	-- --
3+ years	393 (93)	360 (95)	396 (91)	333 (89)	-- --
Not reported	18 (4)	12 (3)	23 (5)	29 (8)	-- --
<b>Imprisonment last year (%)</b>					
No	331 (78)	303 (80)	335 (77)	268 (71)	-- --
Yes	60 (14)	50 (13)	75 (17)	83 (22)	-- --
Not reported	32 (8)	27 (7)	27 (6)	24 (6)	-- --
<b>N° in prison</b>					
<i>N° in prison</i>	N=60	N=50	N=75	N=83	-- --
<i>Injected in prison</i>	17 (28)	15 (30)	19 (25)	20 (24)	-- --

\* Implementation of the 2020 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

**Table 8.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

Victoria	2016	2017	2018	2019	2020
N° surveyed	N=423	N=380	N=437	N=375	--
<b>Drug last injected (%)</b>					
Cocaine	2 (<1)	2 (1)	3 (1)	4 (1)	-- --
Methamphetamine	134 (32)	92 (24)	158 (36)	126 (34)	-- --
Heroin	222 (52)	234 (62)	223 (51)	198 (53)	-- --
Pharm. opioids	12 (3)	11 (3)	4 (1)	8 (2)	-- --
Methadone	5 (1)	4 (1)	3 (1)	3 (1)	-- --
Buprenorphine	11 (3)	7 (2)	7 (2)	1 (<1)	-- --
Buprenorphine/naloxone	7 (2)	4 (1)	8 (2)	2 (1)	-- --
PIEDs	1 (<1)	1 (<1)	2 (<1)	0 (0)	-- --
More than one	24 (6)	19 (5)	22 (5)	25 (7)	-- --
Other	5 (1)	1 (<1)	5 (1)	5 (1)	-- --
Not reported	0 (0)	5 (1)	2 (<1)	3 (1)	-- --
<b>Ever injected opioids</b>					
No	43 (10)	24 (6)	40 (9)	31 (8)	-- --
Yes	379 (90)	353 (93)	393 (90)	343 (91)	-- --
Not reported	1 (<1)	3 (1)	4 (1)	1 (<1)	-- --
<b>Frequency of injection last month (%)</b>					
Not last month	31 (7)	25 (7)	36 (8)	23 (6)	-- --
Less than weekly	58 (14)	70 (18)	66 (15)	47 (13)	-- --
Weekly not daily	99 (23)	79 (21)	104 (24)	62 (17)	-- --
Daily or more	226 (53)	202 (53)	224 (51)	240 (64)	-- --
Not reported	9 (2)	4 (1)	7 (2)	3 (1)	-- --
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
No	339 (80)	309 (81)	356 (81)	299 (80)	-- --
Yes	71 (17)	56 (15)	67 (15)	65 (17)	-- --
Not reported	13 (3)	15 (4)	14 (3)	11 (3)	-- --
<b>Overdosed in last 12 months</b>					
No	298 (70)	272 (72)	297 (68)	255 (68)	-- --
Yes	112 (27)	91 (24)	125 (29)	103 (27)	-- --
Not reported	13 (3)	17 (4)	15 (3)	17 (5)	-- --

**Table 8.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

Victoria	2016	2017	2018	2019	2020
<b>N° injected last month</b>	N=383	N=351	N=394	N=349	--
<b>Places injected last month (%)</b>					
All private	148 (39)	128 (36)	152 (39)	125 (36)	--
Any public	233 (61)	219 (62)	239 (61)	222 (64)	--
Not reported	2 (1)	4 (1)	3 (1)	2 (1)	--
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	259 (68)	267 (76)	301 (76)	252 (72)	--
Most of the time	102 (27)	70 (20)	69 (18)	78 (22)	--
Half of the time	9 (2)	3 (1)	6 (2)	3 (1)	--
Some of the time	7 (2)	1 (<1)	6 (2)	3 (1)	--
Not last month	3 (1)	0 (0)	5 (1)	2 (1)	--
Not reported	3 (1)	10 (3)	7 (2)	11 (3)	--
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	302 (79)	288 (82)	321 (81)	291 (83)	--
Once	27 (7)	18 (5)	22 (6)	20 (6)	--
Twice	20 (5)	18 (5)	14 (4)	13 (4)	--
3-5 times	17 (4)	11 (3)	16 (4)	15 (4)	--
>5 times	15 (4)	8 (2)	18 (5)	6 (2)	--
Not reported	2 (1)	8 (2)	3 (1)	4 (1)	--
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	302 (79)	288 (82)	321 (81)	291 (83)	--
One	35 (9)	22 (6)	26 (7)	27 (8)	--
Two	7 (2)	7 (2)	5 (1)	4 (1)	--
Three to five	6 (2)	1 (<1)	6 (2)	3 (1)	--
More than five	2 (1)	2 (1)	6 (2)	0 (0)	--
Don't know	17 (4)	15 (4)	17 (4)	15 (4)	--
Not reported	14 (4)	16 (5)	13 (3)	9 (3)	--
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	36 (9)	11 (3)	26 (7)	21 (6)	--
Casual sex partner	2 (1)	6 (2)	6 (2)	3 (1)	--
Close friend	20 (5)	14 (4)	18 (5)	10 (3)	--
Acquaintance	7 (2)	10 (3)	4 (1)	11 (3)	--
Other	6 (2)	11 (3)	6 (2)	11 (3)	--
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	133 (35)	104 (30)	132 (34)	96 (28)	--
Water	85 (22)	69 (20)	77 (20)	73 (21)	--
Filter	56 (15)	43 (12)	42 (11)	51 (15)	--
Drug mix	46 (12)	34 (10)	46 (12)	37 (11)	--
None	219 (57)	220 (63)	233 (59)	222 (64)	--
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	304 (79)	292 (83)	303 (77)	291 (83)	--
Yes	75 (20)	54 (15)	84 (21)	54 (15)	--
Not reported	4 (1)	5 (1)	7 (2)	4 (1)	--
<b>Source of needle acquisition</b>					
Needle Syringe Program	353 (92)	323 (92)	358 (91)	314 (90)	--
Chemist/Pharmacy	86 (22)	63 (18)	61 (15)	63 (18)	--
Personal sources	46 (12)	51 (15)	50 (13)	53 (15)	--
Dispensing/Vending Machine	47 (12)	53 (15)	90 (23)	68 (19)	--
Other sources	6 (2)	11 (3)	21 (5)	13 (4)	--

**Table 8.1.4 Number (percentage) of respondents by treatment for drug use and survey year**

Victoria	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=423	N=380	N=437	N=375	--
<b>Ever any treatment/therapy for drug use (%)</b>					
No	51 (12)	44 (12)	54 (12)	53 (14)	-- --
Yes	367 (87)	335 (88)	385 (88)	320 (85)	-- --
Not reported	5 (1)	1 (<1)	1 (<1)	2 (1)	-- --
<b>History of methadone maintenance treatment (%)</b>					
Currently	128 (30)	123 (32)	139 (32)	143 (38)	-- --
Previously	153 (36)	156 (41)	155 (35)	114 (30)	-- --
Never	122 (29)	97 (26)	134 (31)	109 (29)	-- --
Not reported	20 (5)	4 (1)	9 (2)	9 (2)	-- --
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	45 (11)	31 (8)	33 (8)	25 (7)	-- --
Previously	166 (39)	161 (42)	170 (39)	146 (39)	-- --
Never	197 (47)	181 (48)	229 (52)	194 (52)	-- --
Not reported	15 (4)	7 (2)	5 (1)	10 (3)	-- --
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	55 (13)	51 (13)	57 (13)	27 (7)	-- --
Previously	150 (35)	150 (39)	159 (36)	149 (40)	-- --
Never	209 (49)	175 (46)	216 (49)	193 (51)	-- --
Not reported	9 (2)	4 (1)	5 (1)	6 (2)	-- --

**Table 8.1.5 Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year**

Victoria	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=423	N=380	N=437	N=375	--
<b>Previous HIV test (%)</b>					
Yes, ever	356 (84)	331 (87)	364 (83)	306 (82)	-- --
Yes, last year	222 (52)	223 (59)	226 (52)	206 (55)	-- --
>1 year ago	134 (32)	108 (28)	138 (32)	100 (27)	-- --
Never tested	51 (12)	33 (9)	57 (13)	54 (14)	-- --
Not reported	16 (4)	16 (4)	16 (4)	15 (4)	-- --
<b>Previous HCV test (%)</b>					
Yes, ever	362 (86)	317 (83)	363 (83)	309 (82)	-- --
Yes, last year	252 (60)	234 (62)	243 (56)	218 (58)	-- --
>1 year ago	110 (26)	83 (22)	120 (27)	91 (24)	-- --
Never tested	18 (4)	19 (5)	30 (7)	23 (6)	-- --
Not reported	43 (10)	44 (12)	44 (10)	43 (11)	-- --
<b>Lifetime treatment for HCV (%)#</b>					
<b>N° self-reported HCV diagnosis</b>	N=166	N=149	N=150	N=131	--
Antiviral treatment	35 (21)	70 (50)	86 (57)	87 (66)	-- --
No antiviral treatment	130 (78)	78 (52)	63 (42)	44 (34)	-- --
Not reported	1 (1)	1 (1)	1 (1)	0 (0)	-- --
<b>Treatment for HCV in past 12 months (%)**</b>					
<b>N° self-reported HCV diagnosis</b>	N=161	N=140	N=121	N=100	--
Antiviral treatment	25 (16)	56 (40)	53 (44)	48 (48)	-- --
No antiviral treatment	135 (84)	83 (59)	67 (55)	52 (52)	-- --
Not reported	1 (1)	1 (1)	1 (1)	0 (0)	-- --

# among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 8.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

Victoria	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=423	N=380	N=437	N=375	--
<b>Sex with a regular partner last month (%)</b>					
No	223 (53)	217 (57)	253 (58)	212 (57)	-- --
Yes	186 (44)	146 (38)	173 (40)	147 (39)	-- --
Not reported	14 (3)	17 (4)	11 (3)	16 (4)	-- --
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=186	N=146	N=173	N=147	--
Never	136 (73)	109 (75)	126 (73)	102 (69)	-- --
Sometimes	20 (11)	17 (12)	23 (13)	20 (14)	-- --
Every time	17 (9)	15 (10)	10 (6)	13 (9)	-- --
Not reported	13 (7)	5 (3)	14 (8)	12 (8)	-- --
<b>Sex with other partner(s) last month (%)</b>					
No	341 (81)	301 (79)	355 (81)	297 (79)	-- --
Yes	60 (14)	52 (14)	58 (13)	54 (14)	-- --
Not reported	22 (5)	27 (7)	24 (5)	24 (6)	-- --
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=60	N=52	N=58	N=54	--
Never	22 (37)	15 (29)	22 (38)	25 (46)	-- --
Sometimes	20 (33)	23 (44)	18 (31)	14 (26)	-- --
Every time	18 (30)	10 (19)	15 (26)	11 (20)	-- --
Not reported	0 (0)	4 (8)	3 (5)	4 (7)	-- --
<b>Sex work last month (%)</b>					
No	370 (87)	335 (88)	378 (87)	325 (87)	-- --
Yes	26 (6)	18 (5)	29 (7)	30 (8)	-- --
Not reported	27 (6)	27 (7)	30 (7)	20 (5)	-- --
<b>Condom used at last sex work (%)</b>					
Yes	16 (62)	14 (78)	22 (76)	17 (57)	-- --

**Table 8.1.7 Number (percentage) of respondents by COVID-19 related behaviours in 2020**

Victoria				
N° surveyed	Not applicable			
<b>More difficult to access sterile needles and syringes</b>			<b>Start or increase takeaway dose of methadone/bupe/suboxone</b>	
Yes	-- --		Yes	-- --
No	-- --		No	-- --
Not applicable	-- --		Not applicable	-- --
Not reported	-- --		Not reported	-- --
<b>Start depot buprenorphine</b>			<b>Inject own methadone/bupe/suboxone</b>	
Yes	-- --		Yes	-- --
No	-- --		No	-- --
Not applicable	-- --		Not applicable	-- --
Not reported	-- --		Not reported	-- --
<b>Access take home naloxone</b>			<b>COVID-19 test</b>	
Yes	-- --		Yes	-- --
No	-- --		No	-- --
Not applicable	-- --		Don't know	-- --
Not reported	-- --		Not reported	-- --
<b>Change illicit drug use</b>			<b>If YES, what was result (Not applicable)</b>	
Yes, increased	-- --		Positive	-- --
Yes, decreased	-- --		Negative	-- --
No change	-- --		Don't know	-- --
Not reported	-- --		Not reported	-- --

## HIV antibody prevalence

**Table 8.2.1 HIV antibody prevalence by gender and survey year**

Victoria Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2016	266	6 (2.3)	149	2 (1.3)	419	8 (1.9)
2017	243	6 (2.5)	127	1 (0.8)	376	7 (1.9)
2018	289	8 (2.8)	145	1 (0.7)	436	9 (2.1)
2019	234	8 (3.4)	128	1 (0.8)	367	9 (2.5)
2020	--	-- --	--	-- --	--	-- --
X <sup>2</sup> p trend		0.417		0.604		0.580

**Table 8.2.2 HIV antibody prevalence by sexual identity, gender and survey year**

Victoria Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Heterosexual	232	4 (1.7)	94	1 (1.1)	327	5 (1.5)
Bisexual	10	0 (0.0)	34	0 (0.0)	45	0 (0.0)
Homosexual	6	2 (33.3)	6	0 (0.0)	13	2 (15.4)
p value		0.010		1.000		0.029
<b>2017</b>						
Heterosexual	206	3 (1.5)	84	0 (0.0)	290	3 (1.0)
Bisexual	9	0 (0.0)	23	0 (0.0)	34	0 (0.0)
Homosexual	4	2 (50.0)	9	0 (0.0)	16	2 (12.5)
p value		0.004		--		0.037
<b>2018</b>						
Heterosexual	240	5 (2.1)	101	1 (1.0)	341	6 (1.8)
Bisexual	11	1 (9.1)	22	0 (0.0)	33	1 (3.0)
Homosexual	11	2 (18.2)	6	0 (0.0)	18	2 (11.1)
p value		0.022		1.000		0.042
<b>2019</b>						
Heterosexual	194	7 (3.6)	78	1 (1.3)	272	8 (2.9)
Bisexual	11	0 (0.0)	22	0 (0.0)	37	0 (0.0)
Homosexual	6	1 (16.7)	10	0 (0.0)	16	1 (6.3)
p value		0.258		1.000		0.299
<b>2020</b>						
Heterosexual	--	-- --	--	-- --	--	-- --
Bisexual	--	-- --	--	-- --	--	-- --
Homosexual	--	-- --	--	-- --	--	-- --
p value		--		--		--



**Table 8.2.3 HIV antibody prevalence by age group, gender and survey year**

Victoria Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
<25 years	4	1 (25.0)	8	0 (0.0)	13	1 (7.7)
25-34 years	49	3 (6.1)	37	1 (2.7)	86	4 (4.7)
35-44 years	114	0 (0.0)	62	0 (0.0)	177	0 (0.0)
45+ years	99	2 (2.0)	42	1 (2.4)	143	3 (2.1)
p value		0.005		0.384		0.008
<b>2017</b>						
<25 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
25-34 years	39	4 (10.3)	22	0 (0.0)	65	4 (6.2)
35-44 years	107	2 (1.9)	51	0 (0.0)	158	2 (1.3)
45+ years	91	0 (0.0)	50	1 (2.0)	143	1 (0.7)
p value		0.014		0.598		0.081
<b>2018</b>						
<25 years	2	0 (0.0)	6	0 (0.0)	8	0 (0.0)
25-34 years	43	4 (9.3)	30	0 (0.0)	73	4 (5.5)
35-44 years	117	0 (0.0)	57	0 (0.0)	175	0 (0.0)
45+ years	123	4 (3.3)	51	1 (2.0)	175	5 (2.9)
p value		0.013		0.604		0.024
<b>2019</b>						
<25 years	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
25-34 years	32	3 (9.4)	25	0 (0.0)	59	3 (5.1)
35-44 years	97	3 (3.1)	54	0 (0.0)	152	3 (2.0)
45+ years	99	1 (1.0)	45	1 (2.2)	145	2 (1.4)
p value		0.139		0.575		0.387
<b>2020</b>						
<25 years	--	-- --	--	-- --	--	-- --
25-34 years	--	-- --	--	-- --	--	-- --
35-44 years	--	-- --	--	-- --	--	-- --
45+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.2.4 HIV antibody prevalence by last drug injected, gender and survey year**

Victoria Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Heroin	150	4 (2.7)	70	2 (2.9)	221	6 (2.7)
Methamphetamine	76	1 (1.3)	55	0 (0.0)	131	1 (0.8)
Other opioids	20	0 (0.0)	14	0 (0.0)	35	0 (0.0)
Other drugs	20	1 (5.0)	10	0 (0.0)	32	1 (3.1)
p value		0.560		0.651		0.434
<b>2017</b>						
Heroin	151	3 (2.0)	79	0 (0.0)	232	3 (1.3)
Methamphetamine	57	3 (5.3)	33	0 (0.0)	92	3 (3.3)
Other opioids	15	0 (0.0)	7	0 (0.0)	24	0 (0.0)
Other drugs	20	0 (0.0)	8	1 (12.5)	28	1 (3.6)
p value		0.525		0.118		0.426
<b>2018</b>						
Heroin	145	5 (3.5)	77	1 (1.3)	222	6 (2.7)
Methamphetamine	109	3 (2.8)	48	0 (0.0)	158	3 (1.9)
Other opioids	12	0 (0.0)	9	0 (0.0)	22	0 (0.0)
Other drugs	23	0 (0.0)	9	0 (0.0)	32	0 (0.0)
p value		1.000		1.000		0.922
<b>2019</b>						
Heroin	120	5 (4.2)	72	1 (1.4)	194	6 (3.1)
Methamphetamine	78	2 (2.6)	44	0 (0.0)	124	2 (1.6)
Other opioids	11	1 (9.1)	2	0 (0.0)	13	1 (7.7)
Other drugs	22	0 (0.0)	10	0 (0.0)	33	0 (0.0)
p value		0.555		1.000		0.318
<b>2020</b>						
Heroin	--	-- --	--	-- --	--	-- --
Methamphetamine	--	-- --	--	-- --	--	-- --
Other opioids	--	-- --	--	-- --	--	-- --
Other drugs	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.2.5 HIV antibody prevalence by years of injection, gender and survey year**

Victoria Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
<3 years	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
3 to 10 years	30	2 (6.7)	26	1 (3.9)	57	3 (5.3)
11+ years	220	4 (1.8)	110	1 (0.9)	333	5 (1.5)
p value		0.250		0.410		0.150
<b>2017</b>						
<3 years	3	0 (0.0)	3	0 (0.0)	8	0 (0.0)
3 to 10 years	22	1 (4.6)	17	0 (0.0)	39	1 (2.6)
11+ years	218	5 (2.3)	107	1 (0.9)	329	6 (1.8)
p value		0.482		1.000		0.610
<b>2018</b>						
<3 years	12	0 (0.0)	6	0 (0.0)	18	0 (0.0)
3 to 10 years	24	2 (8.3)	24	0 (0.0)	48	2 (4.2)
11+ years	253	6 (2.4)	115	1 (0.9)	370	7 (1.9)
p value		0.171		1.000		0.507
<b>2019</b>						
<3 years	6	0 (0.0)	7	0 (0.0)	13	0 (0.0)
3 to 10 years	23	2 (8.7)	20	0 (0.0)	45	2 (4.4)
11+ years	188	5 (2.7)	93	1 (1.1)	282	6 (2.1)
p value		0.320		1.000		0.492
<b>2020</b>						
<3 years	--	-- --	--	-- --	--	-- --
3 to 10 years	--	-- --	--	-- --	--	-- --
11+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year**

Victoria Receptively shared syringe last month	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
<b>2016</b>						
No receptive sharing	191	3 (1.6)	103	2 (1.9)	298	5 (1.7)
Receptive sharing	48	3 (6.3)	31	0 (0.0)	79	3 (3.8)
p value		0.097		1.000		0.372
<b>2017</b>						
No receptive sharing	181	3 (1.7)	97	0 (0.0)	284	3 (1.1)
Receptive sharing	41	2 (4.9)	14	1 (7.1)	55	3 (5.5)
p value		0.230		0.126		0.056
<b>2018</b>						
No receptive sharing	210	7 (3.3)	110	1 (0.9)	320	8 (2.5)
Receptive sharing	48	1 (2.1)	21	0 (0.0)	70	1 (1.4)
p value		1.000		1.000		1.000
<b>2019</b>						
No receptive sharing	185	6 (3.2)	98	1 (1.0)	286	7 (2.5)
Receptive sharing	29	1 (3.5)	21	0 (0.0)	52	1 (1.9)
p value		1.000		1.000		1.000
<b>2020</b>						
No receptive sharing	--	-- --	--	-- --	--	-- --
Receptive sharing	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year**

Victoria	Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Less than daily	90	1 (1.1)	64	1 (1.6)	156	2 (1.3)
Daily or more	151	5 (3.3)	70	1 (1.4)	223	6 (2.7)
Not last month	18	0 (0.0)	13	0 (0.0)	31	0 (0.0)
p value		0.622		1.000		0.724
<b>2017</b>						
Less than daily	95	1 (1.1)	51	0 (0.0)	148	1 (0.7)
Daily or more	132	5 (3.8)	63	1 (1.6)	199	6 (3.0)
Not last month	15	0 (0.0)	10	0 (0.0)	25	0 (0.0)
p value		0.596		1.000		0.353
<b>2018</b>						
Less than daily	117	3 (2.6)	51	0 (0.0)	169	3 (1.8)
Daily or more	143	5 (3.5)	81	1 (1.2)	224	6 (2.7)
Not last month	24	0 (0.0)	11	0 (0.0)	36	0 (0.0)
p value		0.870		1.000		0.882
<b>2019</b>						
Less than daily	70	1 (1.4)	36	0 (0.0)	107	1 (0.9)
Daily or more	145	6 (4.1)	86	1 (1.2)	235	7 (3.0)
Not last month	17	1 (5.9)	5	0 (0.0)	22	1 (4.6)
p value		0.324		1.000		0.328
<b>2020</b>						
Less than daily	--	-- --	--	-- --	--	-- --
Daily or more	--	-- --	--	-- --	--	-- --
Not last month	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year**

Victoria	Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
No imprisonment	201	6 (3.0)	124	0 (0.0)	328	6 (1.8)
Imprisonment	42	0 (0.0)	16	1 (6.3)	59	1 (1.7)
p value		0.594		0.114		1.000
<b>2017</b>						
No imprisonment	189	5 (2.7)	105	1 (1.0)	300	6 (2.0)
Imprisonment	40	0 (0.0)	10	0 (0.0)	50	0 (0.0)
p value		0.590		1.000		0.600
<b>2018</b>						
No imprisonment	218	7 (3.2)	115	1 (0.9)	334	8 (2.4)
Imprisonment	52	1 (1.9)	23	0 (0.0)	75	1 (1.3)
p value		1.000		1.000		1.000
<b>2019</b>						
No imprisonment	162	5 (3.1)	95	1 (1.1)	261	6 (2.3)
Imprisonment	55	2 (3.6)	26	0 (0.0)	82	2 (2.4)
p value		1.000		1.000		1.000
<b>2020</b>						
No imprisonment	--	-- --	--	-- --	--	-- --
Imprisonment	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year**

Victoria	Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
No condom use	74	2 (2.7)	59	1 (1.7)	134	3 (2.2)
Condom use	24	0 (0.0)	13	0 (0.0)	37	0 (0.0)
p value		1.000		1.000		1.000
<b>2017</b>						
No condom use	62	1 (1.6)	45	0 (0.0)	109	1 (0.9)
Condom use	22	1 (4.6)	9	1 (11.1)	32	2 (6.3)
p value		0.458		0.167		0.129
<b>2018</b>						
No condom use	73	2 (2.7)	53	0 (0.0)	126	2 (1.6)
Condom use	25	1 (4.0)	8	0 (0.0)	33	1 (3.0)
p value		1.000		--		0.505
<b>2019</b>						
No condom use	57	1 (1.8)	42	0 (0.0)	100	1 (1.0)
Condom use	18	0 (0.0)	12	0 (0.0)	32	0 (0.0)
p value		1.000		--		1.000
<b>2020</b>						
No condom use	--	-- --	--	-- --	--	-- --
Condom use	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.2.10 HIV antibody prevalence by sex work last month, gender and survey year**

Victoria	Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
No sex work	242	5 (2.1)	122	0 (0.0)	366	5 (1.4)
Sex work	8	0 (0.0)	17	1 (5.9)	26	1 (3.9)
p value		1.000		0.122		0.339
<b>2017</b>						
No sex work	223	5 (2.2)	103	1 (1.0)	332	6 (1.8)
Sex work	4	0 (0.0)	14	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000
<b>2018</b>						
No sex work	257	8 (3.1)	118	1 (0.9)	377	9 (2.4)
Sex work	13	0 (0.0)	16	0 (0.0)	29	0 (0.0)
p value		1.000		1.000		1.000
<b>2019</b>						
No sex work	210	8 (3.8)	107	1 (0.9)	321	9 (2.8)
Sex work	14	0 (0.0)	14	0 (0.0)	29	0 (0.0)
p value		1.000		1.000		1.000
<b>2020</b>						
No sex work	--	-- --	--	-- --	--	-- --
Sex work	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

<b>Victoria</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Aboriginal and Torres Strait Islander origin</b>	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Non Indigenous	213	2 (0.9)	121	1 (0.8)	337	3 (0.9)
Indigenous	46	4 (8.7)	23	0 (0.0)	70	4 (5.7)
p value		0.010		1.000		0.019
<b>2017</b>						
Non Indigenous	207	4 (1.9)	104	0 (0.0)	316	4 (1.3)
Indigenous	34	2 (5.9)	20	1 (5.0)	55	3 (5.5)
p value		0.201		0.161		0.070
<b>2018</b>						
Non Indigenous	240	4 (1.7)	117	0 (0.0)	358	4 (1.1)
Indigenous	43	4 (9.3)	27	1 (3.7)	71	5 (7.0)
p value		0.021		0.187		0.008
<b>2019</b>						
Non Indigenous	183	4 (2.2)	102	0 (0.0)	289	4 (1.4)
Indigenous	42	4 (9.5)	23	1 (4.4)	65	5 (7.7)
p value		0.042		0.184		0.012
<b>2020</b>						
Non Indigenous	--	-- --	--	-- --	--	-- --
Indigenous	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year**

<b>Victoria</b>	<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Main language spoken at home by parents</b>	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
English speaking	233	6 (2.6)	139	1 (0.7)	376	7 (1.9)
Non-English speaking	30	0 (0.0)	8	0 (0.0)	38	0 (0.0)
p value		1.000		1.000		1.000
<b>2017</b>						
English speaking	203	5 (2.5)	124	1 (0.8)	333	6 (1.8)
Non-English speaking	40	1 (2.5)	3	0 (0.0)	43	1 (2.3)
p value		1.000		1.000		0.576
<b>2018</b>						
English speaking	254	8 (3.2)	136	1 (0.7)	392	9 (2.3)
Non-English speaking	34	0 (0.0)	9	0 (0.0)	43	0 (0.0)
p value		0.602		1.000		0.609
<b>2019</b>						
English speaking	209	7 (3.4)	125	1 (0.8)	338	8 (2.4)
Non-English speaking	23	1 (4.4)	2	0 (0.0)	26	1 (3.9)
p value		0.572		1.000		0.491
<b>2020</b>						
English speaking	--	-- --	--	-- --	--	-- --
Non-English speaking	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.2.13 HIV antibody prevalence by region/country of birth, gender and survey year**

Victoria	Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Australia	225	6 (2.7)	134	1 (0.8)	362	7 (1.9)
Other Oceania	5	0 (0.0)	1	0 (0.0)	7	0 (0.0)
Asia	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)
UK & Ireland	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
Other	13	0 (0.0)	6	0 (0.0)	19	0 (0.0)
p value		1.000		1.000		1.000
<b>2017</b>						
Australia	209	5 (2.4)	116	1 (0.9)	329	6 (1.8)
Other Oceania	5	0 (0.0)	3	0 (0.0)	9	0 (0.0)
Asia	4	1 (25.0)	1	0 (0.0)	5	1 (20.0)
UK & Ireland	8	0 (0.0)	5	0 (0.0)	13	0 (0.0)
Other	17	0 (0.0)	1	0 (0.0)	19	0 (0.0)
p value		0.246		1.000		0.250
<b>2018</b>						
Australia	243	8 (3.3)	127	1 (0.8)	372	9 (2.4)
Other Oceania	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)
Asia	6	0 (0.0)	0	0 (0.0)	6	0 (0.0)
UK & Ireland	8	0 (0.0)	12	0 (0.0)	20	0 (0.0)
Other	21	0 (0.0)	3	0 (0.0)	24	0 (0.0)
p value		1.000		1.000		1.000
<b>2019</b>						
Australia	206	6 (2.9)	119	1 (0.8)	328	7 (2.1)
Other Oceania	2	0 (0.0)	4	0 (0.0)	7	0 (0.0)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)
Other	16	2 (12.5)	3	0 (0.0)	19	2 (10.5)
p value		0.283		1.000		0.234
<b>2020</b>						
Australia	--	-- --	--	-- --	--	-- --
Other Oceania	--	-- --	--	-- --	--	-- --
Asia	--	-- --	--	-- --	--	-- --
UK & Ireland	--	-- --	--	-- --	--	-- --
Other	--	-- --	--	-- --	--	-- --
p value		--		--		--

## HCV antibody prevalence

**Table 8.3.1 HCV antibody prevalence by gender and survey year**

Victoria Survey year	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2016	243	167 (69)	130	85 (65)	377	254 (67)
2017	230	160 (70)	118	85 (72)	353	246 (70)
2018	284	161 (57)	145	81 (56)	431	243 (56)
2019	236	153 (65)	126	76 (60)	367	232 (63)
2020	--	-- --	--	-- --	--	-- --
X <sup>2</sup> p trend		0.061		0.098		0.017

**Table 8.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

Victoria Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heterosexual	214	153 (72)	81	51 (63)	296	204 (69)
Bisexual	9	5 (56)	32	21 (66)	42	27 (64)
Homosexual	5	0 (0)	6	4 (67)	12	4 (33)
p value		0.001		0.944		0.038
<b>2017</b>						
Heterosexual	193	135 (70)	76	52 (68)	269	187 (70)
Bisexual	9	6 (67)	23	19 (83)	34	25 (74)
Homosexual	4	1 (25)	9	6 (67)	16	8 (50)
p value		0.185		0.392		0.217
<b>2018</b>						
Heterosexual	236	136 (58)	101	58 (57)	337	194 (58)
Bisexual	10	4 (40)	22	12 (55)	32	16 (50)
Homosexual	11	7 (64)	6	4 (67)	18	11 (61)
p value		0.471		0.889		0.668
<b>2019</b>						
Heterosexual	196	129 (66)	77	46 (60)	273	175 (64)
Bisexual	11	6 (55)	22	12 (55)	37	20 (54)
Homosexual	6	1 (17)	10	7 (70)	16	8 (50)
p value		0.041		0.737		0.290
<b>2020</b>						
Heterosexual	--	-- --	--	-- --	--	-- --
Bisexual	--	-- --	--	-- --	--	-- --
Homosexual	--	-- --	--	-- --	--	-- --
p value		--		--		--



**Table 8.3.3 HCV antibody prevalence by age group, gender and survey year**

Victoria Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	4	1 (25)	8	5 (63)	13	7 (54)
25-34 years	44	26 (59)	31	19 (61)	75	45 (60)
35-44 years	104	78 (75)	55	41 (75)	160	119 (74)
45+ years	91	62 (68)	36	20 (56)	129	83 (64)
p value		0.058		0.258		0.070
<b>2017</b>						
<25 years	3	0 (0)	4	3 (75)	7	3 (43)
25-34 years	36	22 (61)	20	13 (65)	59	35 (59)
35-44 years	101	70 (69)	47	34 (72)	148	104 (70)
45+ years	87	67 (77)	47	35 (74)	136	103 (76)
p value		0.019		0.899		0.046
<b>2018</b>						
<25 years	2	0 (0)	6	2 (33)	8	2 (25)
25-34 years	43	22 (51)	30	17 (57)	73	39 (53)
35-44 years	115	69 (60)	57	31 (54)	173	101 (58)
45+ years	120	68 (57)	51	31 (61)	172	99 (58)
p value		0.300		0.647		0.294
<b>2019</b>						
<25 years	3	2 (67)	3	0 (0)	6	2 (33)
25-34 years	32	13 (41)	25	17 (68)	59	30 (51)
35-44 years	98	56 (57)	54	30 (56)	153	87 (57)
45+ years	100	79 (79)	43	29 (67)	144	109 (76)
p value		<0.001		0.090		<0.001
<b>2020</b>						
<25 years	--	-- --	--	-- --	--	-- --
25-34 years	--	-- --	--	-- --	--	-- --
35-44 years	--	-- --	--	-- --	--	-- --
45+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

Victoria Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	5	2 (40)	7	2 (29)	12	4 (33)
3 to 10 years	28	15 (54)	23	15 (65)	52	31 (60)
11+ years	200	142 (71)	96	65 (68)	299	208 (70)
p value		0.050		0.139		0.017
<b>2017</b>						
<3 years	3	0 (0)	3	1 (33)	8	1 (13)
3 to 10 years	20	9 (45)	17	12 (71)	37	21 (57)
11+ years	201	147 (73)	93	69 (74)	297	217 (73)
p value		0.001		0.264		<0.001
<b>2018</b>						
<3 years	12	2 (17)	6	0 (0)	18	2 (11)
3 to 10 years	24	13 (54)	24	13 (54)	48	26 (54)
11+ years	233	137 (59)	107	64 (60)	342	202 (59)
p value		0.014		0.013		<0.001
<b>2019</b>						
<3 years	6	1 (17)	7	0 (0)	13	1 (8)
3 to 10 years	23	10 (43)	20	8 (40)	45	19 (42)
11+ years	189	129 (68)	91	62 (68)	281	191 (68)
p value		0.003		<0.001		<0.001
<b>2020</b>						
<3 years	--	-- --	--	-- --	--	-- --
3 to 10 years	--	-- --	--	-- --	--	-- --
11+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

Victoria Receptively shared syringe last month	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	9	3 (33)	251	171 (68)	269	182 (68)
Receptive sharing	2	0 (0)	66	48 (73)	71	50 (70)
p value		1.000		0.472		0.656
<b>2017</b>						
No receptive sharing	6	0 (0)	256	177 (69)	265	180 (68)
Receptive sharing	1	0 (0)	50	39 (78)	53	40 (75)
p value		--		0.209		0.277
<b>2018</b>						
No receptive sharing	14	1 (7)	291	174 (60)	315	180 (57)
Receptive sharing	3	1 (33)	60	39 (65)	70	46 (66)
p value		0.331		0.452		0.188
<b>2019</b>						
No receptive sharing	11	1 (9)	259	169 (65)	285	184 (65)
Receptive sharing	0	0 (0)	44	30 (68)	52	35 (67)
p value		--		0.705		0.703
<b>2020</b>						
No receptive sharing	--	-- --	--	-- --	--	-- --
Receptive sharing	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

Victoria	<3 years		3+ years		Total	
Last drug injected	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	2	1 (50)	189	138 (73)	195	142 (73)
Methamphetamine	7	1 (14)	105	66 (63)	119	73 (61)
Other opioids	2	2 (100)	27	16 (59)	30	19 (63)
Other drugs	1	0 (0)	23	13 (57)	25	14 (56)
p value		0.117		0.124		0.099
<b>2017</b>						
Heroin	3	1 (33)	206	158 (77)	217	165 (76)
Methamphetamine	4	0 (0)	83	49 (59)	88	50 (57)
Other opioids	0	0 (0)	21	15 (71)	21	15 (71)
Other drugs	1	0 (0)	23	15 (65)	24	15 (63)
p value		0.386		0.024		0.008
<b>2018</b>						
Heroin	6	1 (17)	200	134 (67)	216	141 (65)
Methamphetamine	8	1 (13)	142	68 (48)	156	72 (46)
Other opioids	0	0 (0)	19	8 (42)	20	8 (40)
Other drugs	4	0 (0)	22	15 (68)	30	17 (57)
p value		0.704		0.001		0.001
<b>2019</b>						
Heroin	4	1 (25)	177	126 (71)	194	138 (71)
Methamphetamine	9	0 (0)	104	63 (61)	121	69 (57)
Other opioids	0	0 (0)	12	6 (50)	13	7 (54)
Other drugs	0	0 (0)	29	13 (45)	33	16 (48)
p value		0.118		0.017		0.013
<b>2020</b>						
Heroin	--	-- --	--	-- --	--	-- --
Methamphetamine	--	-- --	--	-- --	--	-- --
Other opioids	--	-- --	--	-- --	--	-- --
Other drugs	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

Victoria	<3 years		3+ years		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Less than daily	5	2 (40)	133	90 (68)	140	93 (66)
Daily or more	6	1 (17)	186	131 (70)	202	141 (70)
Not last month	1	1 (100)	25	12 (48)	27	14 (52)
p value		0.343		0.079		0.170
<b>2017</b>						
Less than daily	5	0 (0)	132	95 (72)	139	96 (69)
Daily or more	2	0 (0)	180	127 (71)	186	131 (70)
Not last month	1	1 (100)	21	15 (71)	25	18 (72)
p value		0.125		0.963		0.966
<b>2018</b>						
Less than daily	11	0 (0)	153	89 (58)	168	91 (54)
Daily or more	6	2 (33)	201	125 (62)	220	136 (62)
Not last month	1	0 (0)	31	12 (39)	36	12 (33)
p value		0.209		0.046		0.005
<b>2019</b>						
Less than daily	3	0 (0)	98	58 (59)	107	62 (58)
Daily or more	9	1 (11)	208	142 (68)	234	158 (68)
Not last month	1	0 (0)	17	9 (53)	23	11 (48)
p value		1.000		0.174		0.064
<b>2020</b>						
Less than daily	--	-- --	--	-- --	--	-- --
Daily or more	--	-- --	--	-- --	--	-- --
Not last month	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

Victoria	<3 years		3+ years		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No imprisonment	11	3 (27)	279	176 (63)	298	185 (62)
Imprisonment	0	0 (0)	49	46 (94)	52	49 (94)
p value		--		<0.001		<0.001
<b>2017</b>						
No imprisonment	6	1 (17)	268	183 (68)	283	189 (67)
Imprisonment	2	0 (0)	44	37 (84)	46	37 (80)
p value		1.000		0.033		0.064
<b>2018</b>						
No imprisonment	16	2 (13)	304	165 (54)	332	173 (52)
Imprisonment	2	0 (0)	64	50 (78)	72	53 (74)
p value		1.000		<0.001		0.001
<b>2019</b>						
No imprisonment	11	1 (9)	236	140 (59)	263	152 (58)
Imprisonment	1	0 (0)	69	52 (75)	81	61 (75)
p value		1.000		0.015		0.005
<b>2020</b>						
No imprisonment	--	-- --	--	-- --	--	-- --
Imprisonment	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	197	134 (68)	107	68 (64)	307	204 (66)
Indigenous	39	27 (69)	19	13 (68)	59	40 (68)
p value		0.882		0.683		0.841
<b>2017</b>						
Non Indigenous	195	133 (68)	97	67 (69)	297	201 (68)
Indigenous	33	25 (76)	18	15 (83)	51	40 (78)
p value		0.384		0.269		0.124
<b>2018</b>						
Non Indigenous	237	131 (55)	117	64 (55)	355	195 (55)
Indigenous	42	27 (64)	27	17 (63)	70	45 (64)
p value		0.277		0.435		0.149
<b>2019</b>						
Non Indigenous	185	113 (61)	100	62 (62)	289	177 (61)
Indigenous	42	34 (81)	23	12 (52)	65	46 (71)
p value		0.015		0.385		0.151
<b>2020</b>						
Non Indigenous	--	-- --	--	-- --	--	-- --
Indigenous	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	211	140 (66)	121	79 (65)	336	221 (66)
Non-English speaking	29	24 (83)	7	4 (57)	36	28 (78)
p value		0.075		0.696		0.146
<b>2017</b>						
English speaking	192	130 (68)	115	83 (72)	312	214 (69)
Non-English speaking	38	30 (79)	3	2 (67)	41	32 (78)
p value		0.169		1.000		0.215
<b>2018</b>						
English speaking	249	137 (55)	136	75 (55)	387	213 (55)
Non-English speaking	34	24 (71)	9	6 (67)	43	30 (70)
p value		0.086		0.731		0.065
<b>2019</b>						
English speaking	210	134 (64)	123	73 (59)	337	209 (62)
Non-English speaking	24	19 (79)	2	2 (100)	27	22 (81)
p value		0.134		0.516		0.043
<b>2020</b>						
English speaking	--	-- --	--	-- --	--	-- --
Non-English speaking	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.3.11 HCV antibody prevalence by region/country of birth, gender and survey year**

Victoria	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Australia	204	138 (68)	118	77 (65)	325	216 (66)
Other Oceania	5	5 (100)	1	1 (100)	7	7 (100)
Asia	6	5 (83)	1	0 (0)	7	5 (71)
UK & Ireland	10	5 (50)	3	1 (33)	13	6 (46)
Other	13	9 (69)	4	3 (75)	17	12 (71)
p value		0.391		0.498		0.179
<b>2017</b>						
Australia	196	133 (68)	107	79 (74)	306	212 (69)
Other Oceania	5	3 (60)	3	2 (67)	9	6 (67)
Asia	4	3 (75)	1	0 (0)	5	3 (60)
UK & Ireland	8	7 (88)	5	3 (60)	13	10 (77)
Other	17	14 (82)	1	0 (0)	19	14 (74)
p value		0.587		0.180		0.936
<b>2018</b>						
Australia	238	132 (55)	127	72 (57)	367	205 (56)
Other Oceania	9	4 (44)	3	1 (33)	12	5 (42)
Asia	6	5 (83)	0	0 (0)	6	5 (83)
UK & Ireland	8	3 (38)	12	6 (50)	20	9 (45)
Other	21	16 (76)	3	2 (67)	24	18 (75)
p value		0.140		0.826		0.121
<b>2019</b>						
Australia	207	133 (64)	117	71 (61)	327	205 (63)
Other Oceania	2	2 (100)	4	1 (25)	7	4 (57)
Asia	3	2 (67)	0	0 (0)	3	2 (67)
UK & Ireland	6	5 (83)	1	1 (100)	7	6 (86)
Other	16	11 (69)	3	2 (67)	19	13 (68)
p value		0.855		0.485		0.802
<b>2020</b>						
Australia	--	-- --	--	-- --	--	-- --
Other Oceania	--	-- --	--	-- --	--	-- --
Asia	--	-- --	--	-- --	--	-- --
UK & Ireland	--	-- --	--	-- --	--	-- --
Other	--	-- --	--	-- --	--	-- --
p value		--		--		--

## HCV RNA prevalence

**Table 8.4.1 HCV RNA prevalence by gender and survey year \***

Victoria	Male		Female		Total	
Survey year	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2016	203	102 (50)	115	41 (36)	321	143 (45)
2017	137	51 (37)	70	22 (31)	210	74 (35)
2018	198	46 (23)	99	20 (20)	299	66 (22)
2019	219	49 (22)	117	23 (20)	341	73 (21)
2020	--	-- --	--	-- --	--	-- --
X <sup>2</sup> p trend (4 year)		<0.001		0.002		<0.001

\* Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

**Table 8.4.2 HCV RNA prevalence by sexual identity, gender and survey year \***

Victoria	Male		Female		Total	
Sexual identity	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Heterosexual	174	93 (53)	73	24 (33)	248	117 (47)
Bisexual	8	2 (25)	26	12 (46)	34	14 (41)
Homosexual	3	0 (0)	4	1 (25)	8	1 (13)
p value		0.059		0.340		0.107
<b>2017</b>						
Heterosexual	115	43 (37)	43	15 (35)	158	58 (37)
Bisexual	6	3 (50)	12	3 (25)	19	7 (37)
Homosexual	1	1 (100)	4	0 (0)	6	1 (17)
p value		0.313		0.366		0.627
<b>2018</b>						
Heterosexual	163	41 (25)	71	16 (23)	234	57 (24)
Bisexual	8	0 (0)	15	3 (20)	23	3 (13)
Homosexual	6	2 (33)	4	0 (0)	10	2 (20)
p value		0.222		0.548		0.325
<b>2019</b>						
Heterosexual	183	42 (23)	71	15 (21)	254	57 (22)
Bisexual	9	2 (22)	20	2 (10)	33	6 (18)
Homosexual	6	0 (0)	10	5 (50)	16	5 (31)
p value		0.394		0.045		0.604
<b>2020</b>						
Heterosexual	--	-- --	--	-- --	--	-- --
Bisexual	--	-- --	--	-- --	--	-- --
Homosexual	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.4.3 HCV RNA prevalence by age group, gender and survey year \***

Victoria Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	2	1 (50)	6	3 (50)	9	4 (44)
25-34 years	32	14 (44)	26	9 (35)	59	23 (39)
35-44 years	93	51 (55)	48	21 (44)	142	72 (51)
45+ years	75	36 (48)	34	8 (24)	110	44 (40)
p value		0.735		0.150		0.224
<b>2017</b>						
<25 years	2	0 (0)	3	1 (33)	5	1 (20)
25-34 years	24	8 (33)	10	3 (30)	36	11 (31)
35-44 years	68	25 (37)	32	11 (34)	100	36 (36)
45+ years	43	18 (42)	25	7 (28)	68	25 (37)
p value		0.668		0.988		0.866
<b>2018</b>						
<25 years	2	0 (0)	5	3 (60)	8	3 (38)
25-34 years	23	5 (22)	23	5 (22)	47	10 (21)
35-44 years	86	25 (29)	34	7 (21)	121	32 (26)
45+ years	84	15 (18)	35	4 (11)	120	20 (17)
p value		0.295		0.077		0.131
<b>2019</b>						
<25 years	2	0 (0)	3	0 (0)	5	0 (0)
25-34 years	30	6 (20)	22	3 (14)	53	9 (17)
35-44 years	92	20 (22)	51	12 (24)	144	31 (22)
45+ years	92	22 (24)	40	8 (20)	134	31 (23)
p value		0.814		0.656		0.493
<b>2020</b>						
<25 years	--	-- --	--	-- --	--	-- --
25-34 years	--	-- --	--	-- --	--	-- --
35-44 years	--	-- --	--	-- --	--	-- --
45+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--



**Table 8.4.4 HCV RNA prevalence by years since first injection, gender and survey year \***

Victoria Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	5	2 (40)	4	2 (50)	9	4 (44)
3 to 10 years	14	6 (43)	17	8 (47)	33	14 (42)
11+ years	175	90 (51)	90	31 (34)	266	121 (45)
p value		0.727		0.673		0.897
<b>2017</b>						
<3 years	2	0 (0)	2	0 (0)	5	0 (0)
3 to 10 years	15	3 (20)	9	3 (33)	24	6 (25)
11+ years	115	47 (41)	56	19 (34)	173	66 (38)
p value		0.167		0.622		0.139
<b>2018</b>						
<3 years	5	0 (0)	4	1 (25)	9	1 (11)
3 to 10 years	11	3 (27)	13	6 (46)	24	9 (38)
11+ years	170	39 (23)	77	12 (16)	248	51 (21)
p value		0.442		0.092		0.243
<b>2019</b>						
<3 years	6	1 (17)	7	0 (0)	13	1 (8)
3 to 10 years	20	6 (30)	19	3 (16)	40	10 (25)
11+ years	175	37 (21)	85	20 (24)	261	57 (22)
p value		0.639		0.290		0.398
<b>2020</b>						
<3 years	--	-- --	--	-- --	--	-- --
3 to 10 years	--	-- --	--	-- --	--	-- --
11+ years	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year \***

Victoria Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	148	70 (47)	80	26 (33)	231	96 (42)
Receptive sharing	31	20 (65)	22	12 (55)	54	33 (61)
p value		0.092		0.046		0.012
<b>2017</b>						
No receptive sharing	99	36 (36)	58	19 (33)	160	55 (34)
Receptive sharing	32	14 (44)	5	1 (20)	37	15 (41)
p value		0.407		0.604		0.430
<b>2018</b>						
No receptive sharing	141	33 (23)	71	12 (17)	212	45 (21)
Receptive sharing	36	9 (25)	18	8 (44)	55	18 (33)
p value		0.761		0.005		0.065
<b>2019</b>						
No receptive sharing	174	38 (22)	91	16 (18)	269	55 (20)
Receptive sharing	25	7 (28)	19	5 (26)	45	13 (29)
p value		0.549		0.358		0.225
<b>2020</b>						
No receptive sharing	--	-- --	--	-- --	--	-- --
Receptive sharing	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.4.6 HCV RNA prevalence by last drug injected, gender and survey year \***

Victoria Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	109	54 (50)	48	20 (42)	157	74 (47)
Methamphetamine	59	30 (51)	46	10 (22)	105	41 (39)
Other opioids	17	7 (41)	12	7 (58)	30	14 (47)
Other drugs	10	5 (50)	8	3 (38)	20	8 (40)
p value		0.923		0.086		0.568
<b>2017</b>						
Heroin	93	37 (40)	44	16 (36)	139	53 (38)
Methamphetamine	27	11 (41)	17	5 (29)	46	16 (35)
Other opioids	3	1 (33)	4	1 (25)	8	2 (25)
Other drugs	12	2 (17)	3	0 (0)	15	2 (13)
p value		0.606		0.615		0.369
<b>2018</b>						
Heroin	111	25 (23)	55	9 (16)	167	34 (20)
Methamphetamine	65	16 (25)	27	8 (30)	93	24 (26)
Other opioids	7	1 (14)	6	0 (0)	14	1 (7)
Other drugs	12	4 (33)	7	3 (43)	19	7 (37)
p value		0.800		0.187		0.199
<b>2019</b>						
Heroin	115	19 (17)	67	12 (18)	183	30 (16)
Methamphetamine	69	19 (28)	38	9 (24)	109	29 (27)
Other opioids	11	11 (100)	2	0 (0)	13	5 (38)
Other drugs	19	5 (26)	10	2 (20)	31	7 (23)
p value		0.088		0.814		0.092
<b>2020</b>						
Heroin	--	-- --	--	-- --	--	-- --
Methamphetamine	--	-- --	--	-- --	--	-- --
Other opioids	--	-- --	--	-- --	--	-- --
Other drugs	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year \***

Victoria	Male		Female		Total	
Frequency of injection last month	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Less than daily	69	32 (46)	51	18 (35)	122	50 (41)
Daily or more	111	60 (54)	51	20 (39)	163	80 (49)
Not last month	16	5 (31)	11	2 (18)	27	7 (26)
p value		0.202		0.407		0.067
<b>2017</b>						
Less than daily	47	16 (34)	29	8 (28)	77	24 (31)
Daily or more	84	34 (40)	36	13 (36)	121	47 (39)
Not last month	5	1 (20)	4	1 (25)	9	2 (22)
p value		0.596		0.856		0.475
<b>2018</b>						
Less than daily	70	14 (20)	33	6 (18)	104	20 (19)
Daily or more	107	28 (26)	57	14 (25)	164	42 (26)
Not last month	19	4 (21)	8	0 (0)	27	4 (15)
p value		0.538		0.219		0.186
<b>2019</b>						
Less than daily	65	13 (20)	32	6 (19)	96	19 (20)
Daily or more	135	33 (24)	91	15 (16)	220	50 (23)
Not last month	17	2 (12)	5	2 (40)	22	4 (18)
p value		0.409		0.490		0.742
<b>2020</b>						
Less than daily	--	-- --	--	-- --	--	-- --
Daily or more	--	-- --	--	-- --	--	-- --
Not last month	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year \***

Victoria	Male		Female		Total	
Imprisonment last year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No imprisonment	157	71 (45)	95	32 (34)	254	104 (41)
Imprisonment	26	20 (77)	13	7 (54)	40	27 (68)
p value		0.002		0.184		0.002
<b>2017</b>						
No imprisonment	109	39 (36)	57	17 (30)	168	56 (33)
Imprisonment	22	11 (50)	5	1 (20)	27	12 (44)
p value		0.203		0.687		0.239
<b>2018</b>						
No imprisonment	148	34 (23)	81	15 (19)	229	49 (21)
Imprisonment	33	8 (24)	13	4 (31)	46	12 (26)
p value		0.691		0.333		0.370
<b>2019</b>						
No imprisonment	156	27 (17)	90	18 (20)	250	46 (18)
Imprisonment	48	16 (33)	22	4 (18)	71	20 (28)
p value		0.030		0.865		0.058
<b>2020</b>						
No imprisonment	--	-- --	--	-- --	--	-- --
Imprisonment	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year \***

Victoria	Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	164	80 (49)	95	31 (33)	262	111 (42)
Indigenous	33	19 (58)	17	8 (47)	50	27 (54)
p value		0.370		0.305		0.149
<b>2017</b>						
Non Indigenous	114	42 (37)	55	14 (25)	171	56 (33)
Indigenous	22	8 (36)	14	7 (50)	37	15 (41)
p value		0.911		0.049		0.305
<b>2018</b>						
Non Indigenous	159	38 (24)	80	17 (21)	240	55 (23)
Indigenous	37	7 (19)	19	3 (16)	57	10 (18)
p value		0.417		0.840		0.411
<b>2019</b>						
Non Indigenous	175	34 (19)	91	18 (20)	270	53 (20)
Indigenous	39	14 (36)	23	5 (22)	61	19 (31)
p value		0.035		0.801		0.066
<b>2020</b>						
Non Indigenous	--	-- --	--	-- --	--	-- --
Indigenous	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year \***

Victoria	Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	177	85 (48)	109	40 (37)	289	125 (43)
Non-English speaking	23	15 (65)	5	0 (0)	28	15 (54)
p value		0.125		0.091		0.289
<b>2017</b>						
English speaking	112	41 (37)	70	22 (31)	185	63 (34)
Non-English speaking	25	10 (40)	0	0 (0)	25	10 (40)
p value		0.715		--		0.537
<b>2018</b>						
English speaking	172	36 (21)	94	18 (19)	267	54 (20)
Non-English speaking	26	10 (38)	5	2 (40)	31	12 (39)
p value		0.061		0.097		0.013
<b>2019</b>						
English speaking	195	44 (23)	114	21 (18)	313	66 (21)
Non-English speaking	23	5 (22)	2	2 (100)	26	8 (31)
p value		0.891		0.004		0.274
<b>2020</b>						
English speaking	--	-- --	--	-- --	--	-- --
Non-English speaking	--	-- --	--	-- --	--	-- --
p value		--		--		--

**Table 8.4.11 HCV RNA prevalence by region/country of birth, gender and survey year \***

Victoria	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Australia	173	90 (52)	102	38 (37)	276	128 (46)
Other Oceania	3	1 (33)	0	0 (0)	5	1 (20)
Asia	6	3 (50)	1	0 (0)	7	3 (43)
UK & Ireland	8	2 (25)	5	0 (0)	13	2 (15)
Other	8	3 (38)	6	2 (33)	14	5 (36)
p value		0.535		0.313		0.184
<b>2017</b>						
Australia	119	46 (39)	64	20 (31)	186	66 (35)
Other Oceania	3	1 (33)	2	1 (50)	5	2 (40)
Asia	2	1 (50)	0	0 (0)	2	1 (50)
UK & Ireland	4	1 (25)	3	1 (33)	7	2 (29)
Other	8	2 (25)	0	0 (0)	8	2 (25)
p value		0.947		0.757		0.921
<b>2018</b>						
Australia	168	34 (20)	84	14 (17)	254	48 (19)
Other Oceania	6	2 (33)	3	1 (33)	10	3 (30)
Asia	3	3 (100)	0	0 (0)	3	3 (100)
UK & Ireland	4	0 (0)	9	3 (33)	13	3 (23)
Other	15	7 (47)	3	2 (67)	18	9 (50)
p value		0.004		0.249		0.001
<b>2019</b>						
Australia	192	42 (22)	109	21 (19)	304	64 (21)
Other Oceania	2	1 (50)	3	1 (33)	6	3 (50)
Asia	3	0 (0)	0	0 (0)	3	0 (0)
UK & Ireland	6	2 (33)	1	1 (100)	7	3 (43)
Other	15	4 (27)	3	0 (0)	18	4 (22)
p value		0.690		0.155		0.248
<b>2020</b>						
Australia	--	-- --	--	-- --	--	-- --
Other Oceania	--	-- --	--	-- --	--	-- --
Asia	--	-- --	--	-- --	--	-- --
UK & Ireland	--	-- --	--	-- --	--	-- --
Other	--	-- --	--	-- --	--	-- --
p value		--		--		--

## Western Australia

Table 9.1.1 Number (percentage) of respondents by demographic characteristics and survey year

Western Australia	2016	2017	2018	2019	2020*
<b>Number of sites</b>	4	4	4	4	4
<b>N° surveyed</b>	N=425	N=508	N=521	N=528	N=399
<b>Response rate (%)</b>	75%	72%	71%	78%	57%
<b>Gender (%)</b>					
Male	274 (64)	340 (67)	309 (59)	309 (59)	246 (62)
Female	148 (35)	166 (33)	211 (41)	211 (41)	152 (38)
Other*	2 (<1)	1 (<1)	1 (<1)	1 (<1)	1 (<1)
Not reported	1 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)
<b>Sexual identity (%)</b>					
Heterosexual	336 (79)	421 (83)	408 (78)	415 (79)	311 (78)
Bisexual	33 (8)	32 (6)	48 (9)	39 (7)	37 (9)
Gay/Lesbian	14 (3)	9 (2)	16 (3)	12 (2)	13 (3)
Other	-- --	-- --	-- --	-- --	13 (3)
Not reported	42 (10)	46 (9)	49 (9)	62 (12)	25 (6)
<b>Aboriginal and Torres Strait Islander origin (%)</b>					
No	326 (77)	397 (78)	367 (70)	374 (71)	258 (65)
Yes	76 (18)	106 (21)	139 (27)	146 (28)	123 (31)
Not reported	23 (5)	5 (1)	15 (3)	8 (2)	18 (5)
<b>Region/country of birth (%)</b>					
Australia	358 (84)	423 (83)	427 (82)	457 (87)	336 (84)
Other Oceania	17 (4)	9 (2)	21 (4)	14 (3)	14 (4)
Asia	4 (1)	7 (1)	11 (2)	4 (1)	4 (1)
UK & Ireland	19 (4)	45 (9)	33 (6)	31 (6)	24 (6)
Other	13 (3)	16 (3)	23 (4)	21 (4)	14 (4)
Not reported	14 (3)	8 (2)	6 (1)	1 (<1)	7 (2)
<b>Main language spoken at home by parents (%)</b>					
English	388 (91)	484 (95)	489 (94)	509 (96)	381 (95)
Non-English	22 (5)	21 (4)	26 (5)	17 (3)	15 (4)
Not reported	15 (4)	3 (1)	6 (1)	2 (<1)	3 (1)
<b>Age and time since first injection (years)</b>					
<i>Median age</i>	41	42	41	41	43
<i>Age range</i>	20-68	18-70	18-69	15-70	18-74
<i>Age group (%)</i>					
<25 years	14 (3)	19 (4)	30 (6)	22 (4)	13 (3)
25+ years	408 (96)	484 (95)	490 (94)	505 (96)	385 (96)
Not reported	3 (1)	5 (1)	1 (<1)	1 (<1)	1 (<1)
<i>Median age first injection</i>	18	18	19	19	19
<i>Age range</i>	10-57	10-53	11-59	10-66	10-57
<i>N° not reported</i>	21	33	20	31	11
<i>Median yrs since first injection</i>	21	21	20	21	22
<i>Range</i>	<1-51	<1-54	<1-51	<1-55	<1-52
<i>Years since first injection</i>					
<3 years	25 (6)	31 (6)	35 (7)	28 (5)	16 (4)
3+ years	379 (89)	444 (87)	465 (89)	467 (88)	372 (93)
Not reported	21 (5)	33 (7)	21 (4)	33 (6)	11 (3)
<b>Imprisonment last year (%)</b>					
No	348 (82)	386 (76)	404 (78)	429 (81)	329 (82)
Yes	52 (12)	71 (14)	80 (15)	69 (13)	54 (14)
Not reported	25 (6)	51 (10)	37 (7)	30 (6)	16 (4)
<b>N° in prison</b>	N=52	N=71	N=80	N=69	N=54
Injected in prison	13 (25)	20 (28)	25 (31)	23 (33)	12 (22)

\* Implementation of the 2020 ANSPS was impacted by the COVID-19 pandemic, see page 1 for more information

**Table 9.1.2 Number (percentage) of respondents by last drug injected, frequency of injecting and survey year**

Western Australia	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=425	N=508	N=521	N=528	N=399
<b>Drug last injected (%)</b>					
Cocaine	0 (0)	0 (0)	1 (<1)	0 (0)	1 (<1)
Methamphetamine	256 (60)	275 (54)	357 (69)	352 (67)	254 (64)
Heroin	65 (15)	113 (22)	80 (15)	104 (20)	73 (18)
Pharm. opioids	30 (7)	24 (5)	18 (3)	17 (3)	12 (3)
Methadone	8 (2)	28 (6)	8 (2)	7 (1)	11 (3)
Buprenorphine	14 (3)	8 (2)	9 (2)	5 (1)	10 (3)
Buprenorphine/naloxone	8 (2)	9 (2)	6 (1)	8 (2)	8 (2)
PIEDs	9 (2)	6 (1)	4 (1)	7 (1)	4 (1)
More than one	27 (6)	35 (7)	33 (6)	21 (4)	20 (5)
Other	8 (2)	6 (1)	3 (1)	6 (1)	1 (<1)
Not reported	0 (0)	4 (1)	2 (<1)	1 (<1)	5 (1)
<b>Ever injected opioids</b>					
No	128 (30)	142 (28)	187 (36)	181 (34)	137 (34)
Yes	297 (70)	363 (71)	330 (63)	341 (65)	261 (65)
Not reported	0 (0)	3 (1)	4 (1)	6 (1)	1 (<1)
<b>Frequency of injection last month (%)</b>					
Not last month	27 (6)	40 (8)	28 (5)	26 (5)	32 (8)
Less than weekly	65 (15)	57 (11)	55 (11)	70 (13)	84 (21)
Weekly not daily	89 (21)	109 (21)	104 (20)	124 (23)	91 (23)
Daily or more	234 (55)	292 (57)	321 (62)	298 (56)	189 (47)
Not reported	10 (2)	10 (2)	13 (3)	10 (2)	3 (1)
<b>Present when someone injected for the first time in the last 12 months (%)</b>					
No	326 (77)	363 (71)	372 (71)	401 (76)	317 (79)
Yes	82 (19)	118 (23)	125 (24)	104 (20)	77 (19)
Not reported	17 (4)	27 (5)	24 (5)	23 (4)	5 (1)
<b>Overdosed in last 12 months</b>					
No	344 (81)	368 (72)	390 (75)	409 (77)	346 (87)
Yes	61 (14)	112 (22)	107 (21)	96 (18)	47 (12)
Not reported	20 (5)	28 (6)	24 (5)	23 (4)	6 (2)

**Table 9.1.3 Number (percentage) of respondents by injecting behaviour in the last month and survey year**

<b>Western Australia</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° injected last month</b>	<b>N=388</b>	<b>N=458</b>	<b>N=480</b>	<b>N=492</b>	<b>N=364</b>
<b>Places injected last month (%)</b>					
All private	179 (46)	207 (45)	193 (40)	217 (44)	169 (46)
Any public	209 (54)	247 (54)	286 (60)	274 (56)	194 (53)
Not reported	0 (0)	4 (1)	1 (<1)	1 (<1)	1 (<1)
<b>Use of new and sterile needles and syringes last month (%)</b>					
All injections	228 (59)	275 (60)	278 (58)	322 (65)	244 (67)
Most of the time	130 (34)	140 (31)	146 (30)	124 (25)	96 (26)
Half of the time	16 (4)	22 (5)	31 (6)	24 (5)	9 (2)
Some of the time	6 (2)	10 (2)	14 (3)	16 (3)	10 (3)
Not last month	4 (1)	4 (1)	5 (1)	1 (<1)	2 (1)
Not reported	4 (1)	7 (2)	6 (1)	5 (1)	3 (1)
<b>Re-used someone else's used needle &amp; syringe last month (%)</b>					
None	280 (72)	331 (72)	330 (69)	354 (72)	276 (76)
Once	23 (6)	33 (7)	56 (12)	39 (8)	30 (8)
Twice	33 (9)	28 (6)	27 (6)	48 (10)	22 (6)
3-5 times	25 (6)	33 (7)	32 (7)	22 (4)	27 (7)
>5 times	20 (5)	23 (5)	31 (6)	21 (4)	9 (2)
Not reported	7 (2)	10 (2)	4 (1)	8 (2)	0 (0)
<b>Number of people needle &amp; syringe was re-used after last month (%)</b>					
None	280 (72)	331 (72)	330 (69)	354 (72)	276 (76)
One	41 (11)	51 (11)	62 (13)	72 (15)	39 (11)
Two	10 (3)	14 (3)	14 (3)	14 (3)	8 (2)
Three to five	10 (3)	10 (2)	15 (3)	7 (1)	6 (2)
More than five	7 (2)	3 (1)	8 (2)	8 (2)	4 (1)
Don't know	22 (6)	25 (5)	18 (4)	20 (4)	21 (6)
Not reported	18 (5)	24 (5)	33 (7)	17 (3)	10 (3)
<b>Relationship to people needle &amp; syringe was used after last month (%) [more than one could be selected]</b>					
Regular sex partner	41 (11)	41 (9)	58 (12)	56 (11)	39 (11)
Casual sex partner	3 (1)	4 (1)	7 (1)	7 (1)	6 (2)
Close friend	30 (8)	40 (9)	47 (10)	25 (5)	16 (4)
Acquaintance	17 (4)	16 (3)	17 (4)	15 (3)	15 (4)
Other	5 (1)	12 (3)	14 (3)	15 (3)	11 (3)
<b>Equipment used after someone else last month (%) [more than one could be selected]</b>					
Spoon	74 (19)	107 (23)	91 (19)	94 (19)	56 (15)
Water	95 (24)	113 (25)	132 (28)	115 (23)	86 (24)
Filter	35 (9)	56 (12)	59 (12)	32 (7)	21 (6)
Drug mix	29 (7)	52 (11)	63 (13)	47 (10)	36 (10)
None	261 (67)	273 (60)	284 (59)	304 (62)	230 (63)
<b>Injected by someone after that person injected themselves or others last month (%)</b>					
No	302 (78)	345 (75)	361 (75)	379 (77)	304 (84)
Yes	83 (21)	104 (23)	110 (23)	105 (21)	60 (16)
Not reported	3 (1)	9 (2)	9 (2)	8 (2)	0 (0)
<b>Source of needle acquisition</b>					
Needle Syringe Program	313 (80)	363 (79)	374 (78)	398 (81)	293 (80)
Chemist/Pharmacy	138 (36)	157 (34)	185 (39)	177 (36)	138 (38)
Personal sources	65 (17)	60 (13)	72 (15)	72 (15)	49 (13)
Dispensing/Vending Machine	9 (2)	12 (3)	11 (2)	15 (3)	3 (1)
Other sources	11 (3)	24 (5)	21 (4)	23 (5)	10 (3)



**Table 9.1.4** Number (percentage) of respondents by treatment for drug use and survey year

Western Australia	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=425	N=508	N=521	N=528	N=399
<b>Ever any treatment/therapy for drug use (%)</b>					
No	163 (38)	189 (37)	239 (49)	225 (43)	177 (44)
Yes	250 (59)	316 (62)	277 (53)	303 (57)	222 (56)
Not reported	13 (3)	3 (1)	5 (1)	0 (0)	0 (0)
<b>History of methadone maintenance treatment (%)</b>					
Currently	48 (11)	71 (14)	56 (11)	68 (13)	42 (11)
Previously	88 (21)	96 (19)	72 (14)	83 (16)	55 (14)
Never	255 (60)	324 (64)	373 (72)	365 (69)	295 (74)
Not reported	34 (8)	17 (3)	20 (4)	12 (2)	7 (2)
<b>History of buprenorphine (Subutex®) treatment (%)</b>					
Currently	14 (3)	35 (7)	28 (5)	34 (6)	19 (5)
Previously	63 (15)	83 (16)	88 (17)	93 (18)	51 (13)
Never	329 (77)	379 (75)	388 (74)	399 (76)	323 (81)
Not reported	19 (4)	11 (2)	17 (3)	2 (<1)	6 (2)
<b>History of buprenorphine-naloxone (Suboxone®) treatment (%)</b>					
Currently	20 (5)	24 (5)	30 (6)	41 (8)	17 (4)
Previously	55 (13)	71 (14)	80 (15)	87 (16)	52 (13)
Never	328 (77)	397 (78)	393 (75)	394 (75)	327 (82)
Not reported	22 (5)	16 (3)	18 (3)	6 (1)	3 (1)

**Table 9.1.5** Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year

Western Australia	2016	2017	2018	2019	2020
<b>N° surveyed</b>	N=425	N=508	N=521	N=528	N=399
<b>Previous HIV test (%)</b>					
Yes, ever	327 (77)	384 (76)	389 (75)	391 (74)	303 (76)
Yes, last year	203 (48)	226 (44)	252 (48)	253 (48)	179 (45)
>1 year ago	124 (29)	158 (31)	137 (26)	138 (26)	124 (31)
Never tested	75 (18)	84 (17)	99 (19)	106 (20)	83 (21)
Not reported	23 (5)	40 (8)	33 (6)	31 (6)	13 (3)
<b>Previous HCV test (%)</b>					
Yes, ever	322 (75)	397 (78)	397 (76)	396 (75)	315 (79)
Yes, last year	210 (49)	252 (50)	273 (52)	264 (50)	188 (47)
>1 year ago	112 (26)	145 (29)	124 (24)	132 (25)	127 (32)
Never tested	53 (12)	51 (10)	64 (12)	73 (14)	52 (13)
Not reported	50 (12)	60 (12)	60 (12)	59 (11)	32 (8)
<b>Lifetime treatment for HCV (%)#</b>					
<b>N° self-reported HCV diagnosis</b>	N=92	N=97	N=99	N=103	N=87
Antiviral treatment	26 (28)	34 (35)	42 (42)	60 (58)	45 (52)
No antiviral treatment	65 (71)	62 (64)	55 (56)	42 (41)	41 (47)
Not reported	1 (1)	1 (1)	2 (2)	1 (1)	1 (1)
<b>Treatment for HCV in past 12 months (%)**</b>					
<b>N° self-reported HCV diagnosis</b>	N=86	N=90	N=93	N=76	N=64
Antiviral treatment	14 (16)	20 (22)	28 (30)	25 (33)	12 (19)
No antiviral treatment	71 (83)	69 (77)	63 (68)	50 (66)	51 (80)
Not reported	1 (1)	1 (1)	2 (2)	1 (1)	1 (2)

# among people who tested HCV antibody positive and did not report spontaneous clearance

\* excludes people who reported treatment induced clearance more than 12 months previously

**Table 9.1.6 Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year**

<b>Western Australia</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>	<b>2019</b>	<b>2020</b>
<b>N° surveyed</b>	N=425	N=508	N=521	N=528	N=399
<b>Sex with a regular partner last month (%)</b>					
No	208 (49)	240 (47)	235 (45)	252 (48)	209 (52)
Yes	193 (45)	228 (45)	256 (49)	249 (47)	181 (45)
Not reported	24 (6)	40 (8)	30 (6)	27 (5)	9 (2)
<b>Condom used with regular partner last month (%)</b>					
<b>N° surveyed</b>	N=193	N=228	N=256	N=249	N=181
Never	132 (68)	157 (69)	195 (76)	174 (70)	141 (78)
Sometimes	35 (18)	35 (15)	37 (14)	42 (17)	16 (9)
Every time	18 (9)	25 (11)	15 (6)	23 (9)	13 (7)
Not reported	8 (4)	11 (5)	9 (4)	10 (4)	11 (6)
<b>Sex with other partner(s) last month (%)</b>					
No	324 (76)	385 (76)	390 (75)	414 (78)	329 (82)
Yes	72 (17)	78 (15)	99 (19)	82 (16)	59 (15)
Not reported	29 (7)	45 (9)	32 (6)	32 (6)	11 (3)
<b>Condom used with other partner(s) last month (%)</b>					
<b>N° surveyed</b>	N=72	N=78	N=99	N=82	N=59
Never	30 (42)	37 (47)	50 (51)	44 (54)	33 (56)
Sometimes	23 (32)	27 (35)	25 (25)	24 (29)	16 (27)
Every time	15 (21)	13 (17)	20 (20)	9 (11)	8 (14)
Not reported	4 (6)	1 (1)	4 (4)	5 (6)	2 (3)
<b>Sex work last month (%)</b>					
No	372 (88)	435 (86)	446 (86)	460 (87)	364 (91)
Yes	24 (6)	24 (5)	35 (7)	27 (5)	20 (5)
Not reported	29 (7)	49 (10)	40 (8)	41 (8)	15 (4)
<b>Condom used at last sex work (%)</b>					
Yes	18 (75)	15 (63)	23 (66)	11 (41)	5 (25)

**Table 9.1.7 Number (percentage) of respondents by COVID-19 related behaviours in 2020**

<b>Western Australia</b>			
<b>N° surveyed</b>	<b>N=399</b>		
<b>More difficult to access sterile needles and syringes</b>		<b>Start or increase takeaway dose of methadone/bupe/suboxone</b>	
Yes	52 (13)	Yes	22 (6)
No	289 (72)	No	209 (52)
Not applicable	30 (8)	Not applicable	132 (33)
Not reported	28 (7)	Not reported	36 (9)
<b>Start depot buprenorphine</b>		<b>Inject own methadone/bupe/suboxone</b>	
Yes	11 (3)	Yes	40 (10)
No	238 (60)	No	195 (49)
Not applicable	114 (29)	Not applicable	130 (33)
Not reported	36 (9)	Not reported	34 (9)
<b>Access take home naloxone</b>		<b>COVID-19 test</b>	
Yes	56 (14)	Yes	77 (19)
No	202 (51)	No	265 (66)
Not applicable	106 (27)	Don't know	26 (7)
Not reported	35 (9)	Not reported	31 (8)
<b>Change illicit drug use</b>		<b>If YES, what was result (N=77)</b>	
Yes, increased	21 (5)	Positive	2 (3)
Yes, decreased	181 (45)	Negative	73 (95)
No change	161 (40)	Don't know	1 (1)
Not reported	36 (9)	Not reported	1 (1)

## HIV antibody prevalence

**Table 9.2.1 HIV antibody prevalence by gender and survey year**

Western Australia Survey year	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2016	270	2 (0.7)	146	2 (1.4)	419	5 (1.2)
2017	310	3 (1.0)	154	2 (1.3)	466	5 (1.1)
2018	299	6 (2.0)	207	4 (1.9)	507	10 (2.0)
2019	320	4 (1.3)	198	3 (1.5)	520	7 (1.4)
2020	239	3 (1.3)	152	2 (1.3)	392	5 (1.3)
X <sup>2</sup> p trend		0.525		0.970		0.790

**Table 9.2.2 HIV antibody prevalence by sexual identity, gender and survey year**

Western Australia Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Heterosexual	228	1 (0.4)	103	2 (1.9)	331	3 (0.9)
Bisexual	7	1 (14.3)	24	0 (0.0)	33	2 (6.1)
Homosexual	9	0 (0.0)	5	0 (0.0)	14	0 (0.0)
p value		0.058		1.000		0.118
<b>2017</b>						
Heterosexual	265	2 (0.8)	116	2 (1.7)	382	4 (1.1)
Bisexual	10	1 (10.0)	22	0 (0.0)	32	1 (3.1)
Homosexual	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
p value		0.162		1.000		0.401
<b>2018</b>						
Heterosexual	249	4 (1.6)	148	2 (1.4)	397	6 (1.5)
Bisexual	16	1 (6.3)	31	2 (6.5)	47	3 (6.4)
Homosexual	10	1 (10.0)	5	0 (0.0)	16	1 (6.3)
p value		0.102		0.230		0.037
<b>2019</b>						
Heterosexual	264	2 (0.8)	145	2 (1.4)	409	4 (1.0)
Bisexual	15	2 (13.3)	23	0 (0.0)	39	2 (5.1)
Homosexual	9	0 (0.0)	3	0 (0.0)	12	0 (0.0)
p value		0.019		1.000		0.135
<b>2020</b>						
Heterosexual	195	1 (0.5)	111	2 (1.8)	306	3 (1.0)
Bisexual	16	1 (6.3)	18	0 (0.0)	35	1 (2.9)
Homosexual	10	1 (10.0)	3	0 (0.0)	13	1 (7.7)
p value		0.058		1.000		0.142

**Table 9.2.3 HIV antibody prevalence by age group, gender and survey year**

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
<25 years	5	0 (0.0)	8	0 (0.0)	14	0 (0.0)
25-34 years	60	0 (0.0)	38	0 (0.0)	98	0 (0.0)
35-44 years	100	1 (1.0)	52	0 (0.0)	152	1 (0.7)
45+ years	103	1 (1.0)	47	2 (4.3)	152	4 (2.6)
p value		1.000		0.279		0.376
<b>2017</b>						
<25 years	14	0 (0.0)	5	0 (0.0)	19	0 (0.0)
25-34 years	53	0 (0.0)	38	0 (0.0)	92	0 (0.0)
35-44 years	114	0 (0.0)	59	0 (0.0)	174	0 (0.0)
45+ years	127	3 (2.4)	49	2 (4.1)	176	5 (2.8)
p value		0.323		0.231		0.064
<b>2018</b>						
<25 years	15	0 (0.0)	13	0 (0.0)	28	0 (0.0)
25-34 years	54	1 (1.9)	58	0 (0.0)	112	1 (0.9)
35-44 years	99	1 (1.0)	78	0 (0.0)	178	1 (0.6)
45+ years	131	4 (3.1)	57	4 (7.0)	188	8 (4.3)
p value		0.822		0.031		0.081
<b>2019</b>						
<25 years	10	0 (0.0)	11	0 (0.0)	22	0 (0.0)
25-34 years	54	1 (1.9)	49	0 (0.0)	103	1 (1.0)
35-44 years	124	1 (0.8)	79	1 (1.3)	203	2 (1.0)
45+ years	131	2 (1.5)	59	2 (3.4)	191	4 (2.1)
p value		0.847		0.560		0.718
<b>2020</b>						
<25 years	3	0 (0.0)	9	0 (0.0)	12	0 (0.0)
25-34 years	37	0 (0.0)	32	1 (3.1)	70	1 (1.4)
35-44 years	80	1 (1.3)	60	0 (0.0)	140	1 (0.7)
45+ years	118	2 (1.7)	51	1 (2.0)	169	3 (1.8)
p value		1.000		0.412		0.870

**Table 9.2.4 HIV antibody prevalence by last drug injected, gender and survey year**

Western Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
Heroin	43	0 (0.0)	20	1 (5.0)	64	1 (1.6)
Methamphetamine	148	2 (1.4)	101	1 (1.0)	251	4 (1.6)
Other opioids	46	0 (0.0)	14	0 (0.0)	60	0 (0.0)
Other drugs	33	0 (0.0)	11	0 (0.0)	44	0 (0.0)
p value		1.000		0.523		1.000
<b>2017</b>						
Heroin	72	0 (0.0)	32	1 (3.1)	105	1 (1.0)
Methamphetamine	166	2 (1.2)	83	1 (1.2)	249	3 (1.2)
Other opioids	41	1 (2.4)	22	0 (0.0)	63	1 (1.6)
Other drugs	31	0 (0.0)	17	0 (0.0)	49	0 (0.0)
p value		0.647		0.711		1.000
<b>2018</b>						
Heroin	48	0 (0.0)	31	1 (3.2)	79	1 (1.3)
Methamphetamine	204	5 (2.5)	144	3 (2.1)	348	8 (2.3)
Other opioids	23	0 (0.0)	17	0 (0.0)	40	0 (0.0)
Other drugs	24	1 (4.2)	15	0 (0.0)	40	1 (2.5)
p value		0.508		0.769		1.000
<b>2019</b>						
Heroin	66	1 (1.5)	38	1 (2.6)	104	2 (1.9)
Methamphetamine	201	2 (1.0)	142	2 (1.4)	344	4 (1.2)
Other opioids	29	0 (0.0)	8	0 (0.0)	37	0 (0.0)
Other drugs	24	1 (4.2)	10	0 (0.0)	34	1 (2.9)
p value		0.286		0.633		0.511
<b>2020</b>						
Heroin	44	1 (2.3)	27	1 (3.7)	71	2 (2.8)
Methamphetamine	150	1 (0.7)	100	1 (1.0)	250	2 (0.8)
Other opioids	26	0 (0.0)	14	0 (0.0)	41	0 (0.0)
Other drugs	17	1 (5.9)	10	0 (0.0)	27	1 (3.7)
p value		0.161		0.563		0.180

**Table 9.2.5 HIV antibody prevalence by years of injection, gender and survey year**

Western Australia Years of injection	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
<3 years	14	0 (0.0)	11	0 (0.0)	25	0 (0.0)
3 to 10 years	31	1 (3.2)	24	0 (0.0)	56	1 (1.8)
11 + years	209	0 (0.0)	106	2 (1.9)	317	3 (1.0)
p value		0.177		1.000		0.599
<b>2017</b>						
<3 years	20	0 (0.0)	10	0 (0.0)	30	0 (0.0)
3 to 10 years	38	0 (0.0)	24	0 (0.0)	62	0 (0.0)
11 + years	252	3 (1.2)	120	2 (1.7)	374	5 (1.3)
p value		1.000		1.000		1.000
<b>2018</b>						
<3 years	15	1 (6.7)	17	0 (0.0)	32	1 (3.1)
3 to 10 years	46	0 (0.0)	46	0 (0.0)	92	0 (0.0)
11 + years	238	5 (2.1)	144	4 (2.8)	383	9 (2.4)
p value		0.309		0.698		0.259
<b>2019</b>						
<3 years	18	0 (0.0)	10	0 (0.0)	28	0 (0.0)
3 to 10 years	36	0 (0.0)	50	1 (2.0)	87	1 (1.2)
11 + years	248	4 (1.6)	124	2 (1.6)	372	6 (1.6)
p value		1.000		1.000		1.000
<b>2020</b>						
<3 years	7	0 (0.0)	9	0 (0.0)	16	0 (0.0)
3 to 10 years	39	0 (0.0)	30	1 (3.3)	70	1 (1.4)
11 + years	187	3 (1.6)	108	1 (0.9)	295	4 (1.4)
p value		1.000		0.462		1.000

**Table 9.2.6 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year**

Western Australia Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
<b>2016</b>						
No receptive sharing	176	2 (1.1)	98	1 (1.0)	276	4 (1.5)
Receptive sharing	68	0 (0.0)	31	0 (0.0)	100	0 (0.0)
p value		1.000		1.000		0.577
<b>2017</b>						
No receptive sharing	197	2 (1.0)	105	2 (1.9)	304	4 (1.3)
Receptive sharing	73	1 (1.4)	32	0 (0.0)	105	1 (1.0)
p value		1.000		1.000		1.000
<b>2018</b>						
No receptive sharing	193	4 (2.1)	130	3 (2.3)	323	7 (2.2)
Receptive sharing	85	0 (0.0)	58	0 (0.0)	143	0 (0.0)
p value		0.317		0.554		0.106
<b>2019</b>						
No receptive sharing	208	3 (1.4)	139	2 (1.4)	348	5 (1.4)
Receptive sharing	85	1 (1.2)	43	0 (0.0)	128	1 (0.8)
p value		1.000		1.000		1.000
<b>2020</b>						
No receptive sharing	175	2 (1.1)	94	2 (2.1)	270	4 (1.5)
Receptive sharing	46	1 (2.2)	42	0 (0.0)	88	1 (1.1)
p value		0.505		1.000		1.000

**Table 9.2.7 HIV antibody prevalence by frequency of drug injection last month, gender and survey year**

Western Australia		Male		Female		Total	
Frequency of injection	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
Less than daily	101	1 (1.0)	51	0 (0.0)	153	2 (1.3)	
Daily or more	148	1 (0.7)	80	1 (1.3)	230	2 (0.9)	
Not last month	16	0 (0.0)	10	1 (10.0)	26	1 (3.9)	
p value		1.000		0.137		0.398	
<b>2017</b>							
Less than daily	103	2 (1.9)	48	1 (2.1)	152	3 (2.0)	
Daily or more	172	1 (0.6)	92	1 (1.1)	265	2 (0.8)	
Not last month	26	0 (0.0)	13	0 (0.0)	39	0 (0.0)	
p value		0.663		1.000		0.591	
<b>2018</b>							
Less than daily	101	2 (2.0)	56	2 (3.6)	157	4 (2.6)	
Daily or more	179	2 (1.1)	134	2 (1.5)	313	4 (1.3)	
Not last month	12	2 (16.7)	15	0 (0.0)	27	2 (7.4)	
p value		0.016		0.693		0.093	
<b>2019</b>							
Less than daily	130	2 (1.5)	61	2 (3.3)	192	4 (2.1)	
Daily or more	169	2 (1.2)	123	1 (0.8)	292	3 (1.0)	
Not last month	15	0 (0.0)	11	0 (0.0)	26	0 (0.0)	
p value		1.000		0.375		0.615	
<b>2020</b>							
Less than daily	111	1 (0.9)	61	1 (1.6)	173	2 (1.2)	
Daily or more	110	2 (1.8)	75	1 (1.3)	185	3 (1.6)	
Not last month	17	0 (0.0)	14	0 (0.0)	31	0 (0.0)	
p value		0.697		1.000		1.000	

**Table 9.2.8 HIV antibody prevalence by imprisonment last year, gender and survey year**

Western Australia		Male		Female		Total	
Imprisonment last year	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
No imprisonment	218	1 (0.5)	123	1 (0.8)	343	3 (0.9)	
Imprisonment	38	1 (2.6)	13	0 (0.0)	51	1 (2.0)	
p value		0.275		1.000		0.427	
<b>2017</b>							
No imprisonment	232	2 (0.9)	123	2 (1.6)	356	4 (1.1)	
Imprisonment	48	0 (0.0)	16	0 (0.0)	65	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2018</b>							
No imprisonment	227	3 (1.3)	168	3 (1.8)	396	6 (1.5)	
Imprisonment	51	3 (5.9)	28	0 (0.0)	79	3 (3.8)	
p value		0.077		1.000		0.176	
<b>2019</b>							
No imprisonment	252	1 (0.4)	168	3 (1.8)	421	4 (1.0)	
Imprisonment	50	1 (2.0)	19	0 (0.0)	69	1 (1.5)	
p value		0.304		1.000		0.533	
<b>2020</b>							
No imprisonment	191	2 (1.1)	131	2 (1.5)	323	4 (1.2)	
Imprisonment	40	1 (2.5)	13	0 (0.0)	53	1 (1.9)	
p value		0.436		1.000		0.534	



**Table 9.2.9 HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year**

Western Australia		Male		Female		Total	
Condom use at last sex	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
No condom use	75	1 (1.3)	53	0 (0.0)	129	1 (0.8)	
Condom use	33	0 (0.0)	20	0 (0.0)	53	0 (0.0)	
p value		1.000		--		1.000	
<b>2017</b>							
No condom use	88	0 (0.0)	54	0 (0.0)	142	0 (0.0)	
Condom use	35	0 (0.0)	21	0 (0.0)	56	0 (0.0)	
p value		--		--		--	
<b>2018</b>							
No condom use	103	2 (1.9)	91	1 (1.1)	194	3 (1.6)	
Condom use	28	0 (0.0)	21	0 (0.0)	49	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2019</b>							
No condom use	86	1 (1.2)	86	0 (0.0)	172	1 (0.6)	
Condom use	40	0 (0.0)	24	1 (4.2)	64	1 (1.6)	
p value		1.000		0.218		0.470	
<b>2020</b>							
No condom use	75	1 (1.3)	63	1 (1.6)	138	2 (1.5)	
Condom use	20	1 (5.0)	8	0 (0.0)	28	1 (3.6)	
p value		0.378		1.000		0.428	

**Table 9.2.10 HIV antibody prevalence by sex work last month, gender and survey year**

Western Australia		Male		Female		Total	
Sex work last month	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
No sex work	239	2 (0.8)	125	2 (1.6)	366	5 (1.4)	
Sex work	11	0 (0.0)	12	0 (0.0)	24	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2017</b>							
No sex work	265	3 (1.1)	131	2 (1.5)	398	5 (1.3)	
Sex work	13	0 (0.0)	8	0 (0.0)	21	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2018</b>							
No sex work	262	5 (1.9)	174	2 (1.2)	436	7 (1.6)	
Sex work	15	0 (0.0)	18	0 (0.0)	33	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2019</b>							
No sex work	279	4 (1.4)	174	3 (1.7)	454	7 (1.5)	
Sex work	14	0 (0.0)	12	0 (0.0)	26	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2020</b>							
No sex work	223	3 (1.4)	133	1 (0.8)	357	4 (1.1)	
Sex work	10	0 (0.0)	10	1 (10.0)	20	1 (5.0)	
p value		1.000		0.135		0.240	

**Table 9.2.11 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Western Australia		Male		Female		Total	
Aboriginal and Torres Strait Islander origin	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
Non Indigenous	216	1 (0.5)	104	1 (1.0)	320	2 (0.6)	
Indigenous	39	1 (2.6)	35	1 (2.9)	76	2 (2.6)	
p value		0.283		0.442		0.168	
<b>2017</b>							
Non Indigenous	248	0 (0.0)	116	1 (0.9)	364	1 (0.3)	
Indigenous	59	3 (5.1)	36	1 (2.8)	97	4 (4.1)	
p value		0.007		0.419		0.008	
<b>2018</b>							
Non Indigenous	225	3 (1.3)	137	1 (0.7)	362	4 (1.1)	
Indigenous	67	2 (3.0)	65	2 (3.1)	132	4 (3.0)	
p value		0.324		0.243		0.219	
<b>2019</b>							
Non Indigenous	238	2 (0.8)	131	1 (0.8)	369	3 (0.8)	
Indigenous	76	2 (2.6)	66	2 (3.0)	144	4 (2.8)	
p value		0.248		0.260		0.101	
<b>2020</b>							
Non Indigenous	165	1 (0.6)	87	1 (1.2)	252	2 (0.8)	
Indigenous	65	2 (3.1)	57	1 (1.8)	122	3 (2.5)	
p value		0.193		1.000		0.335	

**Table 9.2.12 HIV antibody prevalence by main language spoken at home by parents, gender and survey year**

Western Australia		Male		Female		Total	
Main language spoken at home by parents	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
English speaking	247	2 (0.8)	133	2 (1.5)	382	5 (1.3)	
Non-English speaking	14	0 (0.0)	7	0 (0.0)	22	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2017</b>							
English speaking	294	3 (1.0)	147	2 (1.4)	443	5 (1.1)	
Non-English speaking	14	0 (0.0)	6	0 (0.0)	20	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2018</b>							
English speaking	282	6 (2.1)	196	3 (1.5)	478	9 (1.9)	
Non-English speaking	15	0 (0.0)	9	0 (0.0)	25	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2019</b>							
English speaking	306	4 (1.3)	194	3 (1.6)	502	7 (1.4)	
Non-English speaking	13	0 (0.0)	3	0 (0.0)	16	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2020</b>							
English speaking	227	3 (1.3)	147	2 (1.4)	375	5 (1.3)	
Non-English speaking	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)	
p value		1.000		1.000		1.000	

**Table 9.2.13 HIV antibody prevalence by region/country of birth, gender and survey year**

Western Australia		Male		Female		Total	
Region/country of birth	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	
<b>2016</b>							
Australia	231	2 (0.9)	119	2 (1.7)	353	5 (1.4)	
Other Oceania	11	0 (0.0)	6	0 (0.0)	17	0 (0.0)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)	
Other	6	0 (0.0)	7	0 (0.0)	13	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2017</b>							
Australia	251	3 (1.2)	135	2 (1.5)	388	5 (1.3)	
Other Oceania	5	0 (0.0)	3	0 (0.0)	8	0 (0.0)	
Asia	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)	
UK & Ireland	33	0 (0.0)	10	0 (0.0)	43	0 (0.0)	
Other	13	0 (0.0)	1	0 (0.0)	14	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2018</b>							
Australia	238	6 (2.5)	180	3 (1.7)	418	9 (2.2)	
Other Oceania	12	0 (0.0)	8	0 (0.0)	20	0 (0.0)	
Asia	7	0 (0.0)	4	0 (0.0)	11	0 (0.0)	
UK & Ireland	26	0 (0.0)	6	0 (0.0)	32	0 (0.0)	
Other	14	0 (0.0)	7	0 (0.0)	22	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2019</b>							
Australia	273	4 (1.5)	175	3 (1.7)	450	7 (1.6)	
Other Oceania	7	0 (0.0)	7	0 (0.0)	14	0 (0.0)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	19	0 (0.0)	11	0 (0.0)	30	0 (0.0)	
Other	17	0 (0.0)	4	0 (0.0)	21	0 (0.0)	
p value		1.000		1.000		1.000	
<b>2020</b>							
Australia	190	3 (1.6)	139	2 (1.4)	330	5 (1.5)	
Other Oceania	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)	
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)	
UK & Ireland	18	0 (0.0)	6	0 (0.0)	24	0 (0.0)	
Other	12	0 (0.0)	2	0 (0.0)	14	0 (0.0)	
p value		1.000		1.000		1.000	

## HCV antibody prevalence

**Table 9.3.1 HCV antibody prevalence by gender and survey year**

Western Australia	Male		Female		Total	
Survey year	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2016	263	125 (48)	143	42 (29)	409	169 (41)
2017	296	140 (47)	153	57 (37)	451	198 (44)
2018	297	115 (39)	204	72 (35)	502	188 (37)
2019	320	149 (47)	197	76 (39)	519	225 (43)
2020	239	114 (48)	151	63 (42)	391	177 (45)
X <sup>2</sup> p trend		0.935		0.038		0.355

**Table 9.3.2 HCV antibody prevalence by sexual identity, gender and survey year**

Western Australia	Male		Female		Total	
Sexual identity	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heterosexual	221	105 (48)	100	26 (26)	321	131 (41)
Bisexual	7	4 (57)	24	12 (50)	33	17 (52)
Homosexual	9	3 (33)	5	0 (0)	14	3 (21)
p value		0.673		0.025		0.155
<b>2017</b>						
Heterosexual	252	117 (46)	116	41 (35)	369	158 (43)
Bisexual	10	6 (60)	21	9 (43)	31	15 (48)
Homosexual	6	0 (0)	3	0 (0)	9	0 (0)
p value		0.039		0.421		0.020
<b>2018</b>						
Heterosexual	249	94 (38)	147	57 (39)	396	151 (38)
Bisexual	16	8 (50)	30	5 (17)	46	13 (28)
Homosexual	10	3 (30)	5	3 (60)	16	7 (44)
p value		0.552		0.024		0.366
<b>2019</b>						
Heterosexual	264	120 (45)	144	55 (38)	408	175 (43)
Bisexual	15	6 (40)	23	6 (26)	39	12 (31)
Homosexual	9	1 (11)	3	1 (33)	12	2 (17)
p value		0.113		0.665		0.078
<b>2020</b>						
Heterosexual	196	95 (48)	110	42 (38)	306	137 (45)
Bisexual	16	8 (50)	18	11 (61)	35	19 (54)
Homosexual	9	3 (33)	3	2 (67)	12	5 (42)
p value		0.193		0.227		0.283

**Table 9.3.3 HCV antibody prevalence by age group, gender and survey year**

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	5	0 (0)	7	1 (14)	13	2 (15)
25-34 years	59	16 (27)	38	8 (21)	97	24 (25)
35-44 years	98	53 (54)	51	12 (24)	149	65 (44)
45+ years	99	55 (56)	46	21 (46)	147	77 (52)
p value		<0.001		0.040		<0.001
<b>2017</b>						
<25 years	14	3 (21)	5	0 (0)	19	3 (16)
25-34 years	52	23 (44)	37	9 (24)	90	33 (37)
35-44 years	109	46 (42)	59	21 (36)	169	67 (40)
45+ years	119	66 (55)	49	25 (51)	168	91 (54)
p value		0.041		0.022		0.001
<b>2018</b>						
<25 years	14	5 (36)	13	4 (31)	27	9 (33)
25-34 years	53	19 (36)	57	16 (28)	110	35 (32)
35-44 years	99	30 (30)	77	26 (34)	177	57 (32)
45+ years	131	61 (47)	56	25 (45)	187	86 (46)
p value		0.086		0.311		0.022
<b>2019</b>						
<25 years	10	2 (20)	11	2 (18)	22	4 (18)
25-34 years	54	13 (24)	49	18 (37)	103	31 (30)
35-44 years	124	55 (44)	78	28 (36)	202	83 (41)
45+ years	131	79 (60)	59	28 (47)	191	107 (56)
p value		<0.001		0.258		<0.001
<b>2020</b>						
<25 years	3	0 (0)	9	4 (44)	12	4 (33)
25-34 years	37	15 (41)	32	9 (28)	70	24 (34)
35-44 years	80	43 (54)	59	29 (49)	139	72 (52)
45+ years	118	55 (47)	51	21 (41)	169	76 (45)
p value		0.220		0.281		0.089

**Table 9.3.4 HCV antibody prevalence by years since first injection, gender and survey year**

Western Australia Years of injection	Male		Female		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
<3 years	14	1 (7)	11	1 (9)	25	2 (8)
3 to 10 years	31	8 (26)	23	3 (13)	55	12 (22)
11+ years	203	107 (53)	104	35 (34)	309	143 (46)
p value		<0.001		0.053		<0.001
<b>2017</b>						
<3 years	19	0 (0)	10	0 (0)	29	0 (0)
3 to 10 years	38	11 (29)	24	5 (21)	62	16 (26)
11+ years	225	119 (53)	104	44 (42)	330	163 (49)
p value		<0.001		0.005		<0.001
<b>2018</b>						
<3 years	15	2 (13)	17	1 (6)	32	3 (9)
3 to 10 years	45	11 (24)	45	15 (33)	90	26 (29)
11+ years	227	96 (42)	135	52 (39)	363	149 (41)
p value		0.009		0.019		<0.001
<b>2019</b>						
<3 years	18	2 (11)	10	0 (0)	28	2 (7)
3 to 10 years	36	8 (22)	50	17 (34)	87	25 (29)
11+ years	248	132 (53)	123	51 (41)	371	183 (49)
p value		<0.001		0.021		<0.001
<b>2020</b>						
<3 years	7	0 (0)	9	0 (0)	16	0 (0)
3 to 10 years	39	11 (28)	30	11 (37)	70	22 (31)
11+ years	187	97 (52)	107	49 (46)	294	146 (50)
p value		0.001		0.014		<0.001

**Table 9.3.5 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year**

Western Australia Receptively shared syringe last month	<3 years		3+ years		Total	
	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No receptive sharing	16	0 (0)	241	94 (39)	269	102 (38)
Receptive sharing	6	2 (33)	90	45 (50)	99	49 (49)
p value		0.065		0.071		0.045
<b>2017</b>						
No receptive sharing	25	0 (0)	251	110 (44)	292	123 (42)
Receptive sharing	2	0 (0)	92	54 (59)	102	59 (58)
p value		--		0.015		0.006
<b>2018</b>						
No receptive sharing	17	2 (12)	296	100 (34)	320	105 (33)
Receptive sharing	9	1 (11)	125	63 (50)	141	69 (49)
p value		1.000		0.001		0.001
<b>2019</b>						
No receptive sharing	19	1 (5)	309	140 (45)	348	151 (43)
Receptive sharing	8	0 (0)	111	51 (46)	128	54 (42)
p value		1.000		0.908		0.814
<b>2020</b>						
No receptive sharing	14	0 (0)	247	113 (46)	268	118 (44)
Receptive sharing	1	0 (0)	85	43 (51)	88	45 (51)
p value		--		0.441		0.246

**Table 9.3.6 HCV antibody prevalence by last drug injected, years since first injection and survey year**

Western Australia Last drug injected	<3 years		3+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	1	0 (0)	57	37 (65)	60	38 (63)
Methamphetamine	17	2 (12)	218	72 (33)	244	79 (32)
Other opioids	0	0 (0)	53	28 (53)	56	30 (54)
Other drugs	6	0 (0)	29	14 (48)	39	17 (44)
p value		0.638		<0.001		<0.001
<b>2017</b>						
Heroin	3	0 (0)	86	57 (66)	96	64 (67)
Methamphetamine	20	0 (0)	209	69 (33)	241	76 (32)
Other opioids	1	0 (0)	55	33 (60)	62	35 (56)
Other drugs	5	0 (0)	33	16 (48)	42	19 (45)
p value		<0.001		<0.001		<0.001
<b>2018</b>						
Heroin	0	0 (0)	76	40 (53)	78	41 (53)
Methamphetamine	29	3 (10)	294	93 (32)	337	105 (31)
Other opioids	0	0 (0)	40	20 (50)	40	20 (50)
Other drugs	3	0 (0)	33	17 (52)	37	17 (46)
p value		0.558		0.001		0.001
<b>2019</b>						
Heroin	1	1 (100)	95	67 (71)	100	71 (71)
Methamphetamine	23	1 (4)	293	99 (34)	339	109 (32)
Other opioids	1	0 (0)	34	20 (59)	37	21 (57)
Other drugs	3	0 (0)	29	19 (66)	34	20 (59)
p value		0.004		<0.001		<0.001
<b>2020</b>						
Heroin	1	0 (0)	69	51 (74)	71	52 (73)
Methamphetamine	15	0 (0)	226	76 (34)	247	80 (32)
Other opioids	0	0 (0)	40	27 (68)	41	28 (68)
Other drugs	0	0 (0)	24	12 (50)	26	14 (54)
p value		--		<0.001		<0.001

**Table 9.3.7 HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year**

Western Australia	<3 years		3+ years		Total	
Frequency of injection last month	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	14	1 (7)	134	60 (45)	152	63 (41)
Daily or more	8	1 (13)	204	84 (41)	223	93 (42)
Not last month	2	0 (0)	19	7 (37)	24	8 (33)
p value		1.000		0.714		0.726
<b>2017</b>						
Less than daily	10	0 (0)	130	56 (43)	148	62 (42)
Daily or more	18	0 (0)	219	111 (51)	254	123 (48)
Not last month	1	0 (0)	34	8 (24)	39	9 (23)
p value		--		0.010		0.010
<b>2018</b>						
Less than daily	11	2 (18)	143	53 (37)	157	57 (36)
Daily or more	16	1 (6)	280	112 (40)	308	120 (39)
Not last month	5	0 (0)	20	5 (25)	27	6 (22)
p value		0.734		0.381		0.217
<b>2019</b>						
Less than daily	13	2 (15)	170	81 (48)	192	88 (46)
Daily or more	15	0 (0)	255	113 (44)	292	122 (42)
Not last month	0	0 (0)	26	11 (42)	26	11 (42)
p value		0.206		0.753		0.675
<b>2020</b>						
Less than daily	7	0 (0)	161	70 (43)	173	74 (43)
Daily or more	8	0 (0)	171	86 (50)	183	89 (49)
Not last month	1	0 (0)	30	11 (37)	32	12 (38)
p value		--		0.256		0.359

**Table 9.3.8 HCV antibody prevalence by imprisonment last year, years since first injection and survey year**

Western Australia	<3 years		3+ years		Total	
Imprisonment last year	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	19	1 (5)	298	119 (40)	333	129 (39)
Imprisonment	4	1 (25)	43	24 (56)	51	28 (55)
p value		0.324		0.049		0.029
<b>2017</b>						
No imprisonment	25	0 (0)	298	129 (43)	345	142 (41)
Imprisonment	1	0 (0)	56	30 (54)	62	35 (56)
p value		--		0.156		0.025
<b>2018</b>						
No imprisonment	26	3 (12)	357	137 (38)	392	146 (37)
Imprisonment	4	0 (0)	69	28 (41)	79	31 (39)
p value		1.000		0.731		0.738
<b>2019</b>						
No imprisonment	24	1 (4)	373	163 (44)	420	175 (42)
Imprisonment	3	0 (0)	58	30 (52)	69	34 (49)
p value		1.000		0.253		0.236
<b>2020</b>						
No imprisonment	14	0 (0)	299	134 (45)	321	140 (44)
Imprisonment	2	0 (0)	49	26 (53)	54	29 (54)
p value		--		0.283		0.168



**Table 9.3.9 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year**

Western Australia Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	209	103 (49)	102	31 (30)	311	134 (43)
Indigenous	39	16 (41)	34	8 (24)	75	26 (35)
p value		0.343		0.444		0.184
<b>2017</b>						
Non Indigenous	235	99 (42)	115	44 (38)	350	143 (41)
Indigenous	58	38 (66)	36	12 (33)	96	51 (53)
p value		0.001		0.593		0.032
<b>2018</b>						
Non Indigenous	224	76 (34)	136	42 (31)	360	118 (33)
Indigenous	66	36 (55)	64	28 (44)	130	64 (49)
p value		0.002		0.075		0.001
<b>2019</b>						
Non Indigenous	238	107 (45)	131	49 (37)	369	156 (42)
Indigenous	76	40 (53)	65	27 (42)	143	67 (47)
p value		0.243		0.576		0.349
<b>2020</b>						
Non Indigenous	165	66 (40)	86	32 (37)	251	98 (39)
Indigenous	65	40 (62)	57	26 (46)	122	66 (54)
p value		0.003		0.316		0.006

**Table 9.3.10 HCV antibody prevalence by main language spoken at home by parents, gender and survey year**

Western Australia Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	240	113 (47)	130	35 (27)	372	149 (40)
Non-English speaking	14	6 (43)	7	4 (57)	22	11 (50)
p value		0.758		0.101		0.356
<b>2017</b>						
English speaking	281	132 (47)	146	54 (37)	429	187 (44)
Non-English speaking	13	7 (54)	6	3 (50)	19	10 (53)
p value		0.628		0.672		0.437
<b>2018</b>						
English speaking	280	107 (38)	194	68 (35)	474	175 (37)
Non-English speaking	15	7 (47)	9	4 (44)	25	12 (48)
p value		0.512		0.723		0.265
<b>2019</b>						
English speaking	306	140 (46)	193	75 (39)	501	215 (43)
Non-English speaking	13	9 (69)	3	1 (33)	16	10 (63)
p value		0.154		1.000		0.120
<b>2020</b>						
English speaking	227	110 (48)	146	60 (41)	374	170 (45)
Non-English speaking	11	4 (36)	4	3 (75)	15	7 (47)
p value		0.543		0.310		0.926

**Table 9.3.11 HCV antibody prevalence by region/country of birth, gender and survey year**

<b>Western Australia</b>		<b>Male</b>		<b>Female</b>		<b>Total</b>	
<b>Region/Country of birth</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	<b>N° tested</b>	<b>N° with HCV (%)</b>	
<b>2016</b>							
Australia	224	106 (47)	116	31 (27)	343	139 (41)	
Other Oceania	11	7 (64)	6	2 (33)	17	9 (53)	
Asia	4	2 (50)	0	0 (0)	4	2 (50)	
UK & Ireland	11	5 (45)	7	2 (29)	18	7 (39)	
Other	6	1 (17)	7	4 (57)	13	5 (38)	
p value		0.506		0.382		0.856	
<b>2017</b>							
Australia	240	110 (46)	134	49 (37)	376	160 (43)	
Other Oceania	4	0 (0)	3	2 (67)	7	2 (29)	
Asia	3	2 (67)	2	2 (100)	5	4 (80)	
UK & Ireland	32	17 (53)	10	2 (20)	42	19 (45)	
Other	12	7 (58)	1	0 (0)	13	7 (54)	
p value		0.275		0.166		0.414	
<b>2018</b>							
Australia	236	84 (36)	178	64 (36)	414	148 (36)	
Other Oceania	12	5 (42)	8	0 (0)	20	5 (25)	
Asia	7	4 (57)	4	4 (100)	11	8 (73)	
UK & Ireland	26	12 (46)	6	1 (17)	32	13 (41)	
Other	14	9 (64)	7	3 (43)	22	13 (59)	
p value		0.158		0.008		0.018	
<b>2019</b>							
Australia	273	126 (46)	174	66 (38)	449	192 (43)	
Other Oceania	7	2 (29)	7	4 (57)	14	6 (43)	
Asia	4	1 (25)	0	0 (0)	4	1 (25)	
UK & Ireland	19	10 (53)	11	5 (45)	30	15 (50)	
Other	17	10 (59)	4	0 (0)	21	10 (48)	
p value		0.587		0.318		0.878	
<b>2020</b>							
Australia	190	93 (49)	139	60 (43)	330	153 (46)	
Other Oceania	10	4 (40)	4	1 (25)	14	5 (36)	
Asia	4	1 (25)	0	0 (0)	4	1 (25)	
UK & Ireland	18	8 (44)	5	1 (20)	23	9 (39)	
Other	12	6 (50)	2	1 (50)	14	7 (50)	
p value		0.909		0.711		0.809	

## HCV RNA prevalence

Table 9.4.1 HCV RNA prevalence by gender and survey year \*

Western Australia	Male		Female		Total	
Survey year	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
2016	16	4 (25)	8	1 (13)	24	5 (21)
2017	171	52 (30)	77	16 (21)	249	68 (27)
2018	67	17 (25)	48	10 (21)	115	27 (23)
2019	313	63 (20)	138	23 (17)	453	86 (19)
2020	215	57 (27)	136	29 (21)	351	86 (25)
X <sup>2</sup> p trend		0.241		0.874		0.345

\* Weighted for gender and HCV antibody status

Totals include respondents where gender was reported as other or not reported

Table 9.4.2 HCV RNA prevalence by sexual identity, gender and survey year \*

Western Australia	Male		Female		Total	
Sexual identity	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Heterosexual	13	3 (23)	6	0 (0)	20	3 (15)
Bisexual	0	0 (0)	2	1 (50)	2	1 (50)
Homosexual	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.748		0.105		0.475
<b>2017</b>						
Heterosexual	147	41 (28)	62	12 (19)	210	53 (25)
Bisexual	6	5 (83)	11	4 (36)	17	9 (53)
Homosexual	4	0 (0)	1	0 (0)	5	0 (0)
p value		0.010		0.535		0.039
<b>2018</b>						
Heterosexual	56	15 (27)	35	8 (23)	91	24 (26)
Bisexual	2	1 (50)	6	0 (0)	8	1 (13)
Homosexual	4	0 (0)	1	0 (0)	5	0 (0)
p value		0.311		0.355		0.362
<b>2019</b>						
Heterosexual	261	50 (19)	102	16 (16)	363	65 (18)
Bisexual	15	2 (13)	18	3 (17)	34	4 (12)
Homosexual	11	1 (9)	1	0 (0)	12	1 (8)
p value		0.479		0.909		0.443
<b>2020</b>						
Heterosexual	174	47 (27)	98	26 (27)	272	73 (27)
Bisexual	16	5 (31)	15	1 (7)	31	6 (19)
Homosexual	9	2 (22)	3	0 (0)	12	2 (17)
p value		0.831		0.271		0.537

**Table 9.4.3 HCV RNA prevalence by age group, gender and survey year \***

Western Australia Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<25 years	0	0 (0)	1	0 (0)	1	0 (0)
25-34 years	4	1 (25)	1	1 (100)	5	2 (40)
35-44 years	5	1 (20)	5	0 (0)	11	1 (9)
45+ years	6	1 (17)	1	0 (0)	7	1 (14)
p value		0.953		0.082		0.446
<b>2017</b>						
<25 years	10	2 (20)	1	0 (0)	11	2 (18)
25-34 years	32	11 (34)	22	5 (23)	54	16 (30)
35-44 years	56	19 (34)	30	5 (17)	87	24 (28)
45+ years	71	19 (27)	24	6 (25)	95	26 (27)
p value		0.685		0.783		0.877
<b>2018</b>						
<25 years	1	0 (0)	2	1 (50)	3	1 (33)
25-34 years	7	0 (0)	15	5 (33)	22	5 (23)
35-44 years	27	5 (19)	21	2 (10)	48	7 (15)
45+ years	32	12 (38)	10	2 (20)	42	14 (33)
p value		0.134		0.461		0.294
<b>2019</b>						
<25 years	13	1 (8)	10	2 (20)	24	3 (13)
25-34 years	65	8 (12)	35	5 (14)	99	13 (13)
35-44 years	117	21 (18)	51	7 (14)	168	27 (16)
45+ years	117	33 (28)	42	10 (24)	160	43 (27)
p value		0.017		0.617		0.009
<b>2020</b>						
<25 years	3	0 (0)	9	3 (33)	12	3 (25)
25-34 years	32	7 (22)	26	3 (12)	58	10 (17)
35-44 years	72	26 (36)	54	14 (26)	126	40 (32)
45+ years	107	24 (22)	46	9 (20)	154	33 (21)
p value		0.122		0.385		0.095

**Table 9.4.4 HCV RNA prevalence by years since first injection, gender and survey year \***

Western Australia Years of injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 10 years	2	0 (0)	0	0 (0)	2	0 (0)
11+ years	12	4 (33)	8	1 (13)	20	5 (25)
p value		0.361		--		0.464
<b>2017</b>						
<3 years	11	0 (0)	6	0 (0)	17	0 (0)
3 to 10 years	23	6 (26)	12	5 (42)	35	11 (31)
11+ years	133	43 (32)	52	7 (13)	186	50 (27)
p value		0.067		0.072		0.040
<b>2018</b>						
<3 years	2	0 (0)	4	2 (50)	6	2 (33)
3 to 10 years	9	1 (11)	10	3 (30)	19	4 (21)
11+ years	55	14 (25)	34	5 (15)	89	20 (22)
p value		0.519		0.291		0.795
<b>2019</b>						
<3 years	24	1 (4)	6	0 (0)	30	2 (7)
3 to 10 years	42	7 (17)	36	9 (25)	80	16 (20)
11+ years	229	50 (22)	86	11 (13)	315	61 (19)
p value		0.219		0.140		0.156
<b>2020</b>						
<3 years	6	0 (0)	7	0 (0)	13	0 (0)
3 to 10 years	36	8 (22)	27	5 (19)	63	12 (19)
11+ years	169	46 (27)	97	24 (25)	266	70 (26)
p value		0.262		0.294		0.072

**Table 9.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year \***

Western Australia Receptively shared syringe last month	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
No receptive sharing	12	3 (25)	3	0 (0)	15	3 (20)
Receptive sharing	2	1 (50)	2	1 (50)	4	2 (50)
p value		0.946		0.289		0.572
<b>2017</b>						
No receptive sharing	121	31 (26)	55	15 (27)	176	46 (26)
Receptive sharing	32	16 (50)	14	1 (7)	46	18 (39)
p value		0.008		0.221		0.109
<b>2018</b>						
No receptive sharing	44	7 (16)	36	7 (19)	80	14 (18)
Receptive sharing	17	8 (47)	4	2 (50)	21	10 (48)
p value		0.018		0.178		0.005
<b>2019</b>						
No receptive sharing	199	48 (24)	94	14 (15)	294	62 (21)
Receptive sharing	89	12 (13)	33	8 (24)	122	20 (16)
p value		0.040		0.207		0.261
<b>2020</b>						
No receptive sharing	158	38 (24)	80	18 (23)	238	56 (24)
Receptive sharing	38	15 (39)	41	9 (22)	79	24 (30)
p value		0.045		0.835		0.239

**Table 9.4.6 HCV RNA prevalence by last drug injected, gender and survey year \***

Western Australia Last drug injected	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Heroin	4	1 (25)	2	0 (0)	6	1 (17)
Methamphetamine	11	3 (27)	6	1 (17)	17	4 (24)
Other opioids	0	0 (0)	0	0 (0)	0	0 (0)
Other drugs	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.474		0.672		0.413
<b>2017</b>						
Heroin	49	18 (37)	23	7 (30)	73	25 (34)
Methamphetamine	89	20 (22)	41	7 (17)	131	28 (21)
Other opioids	17	7 (41)	4	0 (0)	21	7 (33)
Other drugs	14	7 (50)	8	1 (13)	23	8 (35)
p value		0.122		0.371		0.176
<b>2018</b>						
Heroin	17	3 (18)	9	2 (22)	26	5 (19)
Methamphetamine	38	11 (29)	28	4 (14)	66	15 (23)
Other opioids	7	2 (29)	4	1 (25)	11	3 (27)
Other drugs	3	0 (0)	5	3 (60)	8	3 (38)
p value		0.657		0.251		0.849
<b>2019</b>						
Heroin	50	19 (38)	22	8 (36)	71	27 (38)
Methamphetamine	209	37 (18)	100	13 (13)	311	50 (16)
Other opioids	27	6 (22)	7	1 (14)	34	7 (21)
Other drugs	23	1 (4)	8	2 (25)	30	3 (10)
p value		0.002		0.048		<0.001
<b>2020</b>						
Heroin	40	12 (30)	25	9 (36)	65	22 (34)
Methamphetamine	135	26 (19)	85	13 (15)	221	39 (18)
Other opioids	22	12 (55)	14	3 (21)	37	14 (38)
Other drugs	15	5 (33)	9	4 (44)	24	9 (38)
p value		0.007		0.047		0.002

**Table 9.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year \***

Western Australia	Male		Female		Total	
Frequency of injection last month	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
Less than daily	7	2 (29)	5	0 (0)	12	2 (17)
Daily or more	7	2 (29)	2	1 (50)	9	3 (33)
Not last month	0	0 (0)	1	0 (0)	2	0 (0)
p value		0.844		0.351		0.511
<b>2017</b>						
Less than daily	62	15 (24)	21	6 (29)	83	22 (27)
Daily or more	93	34 (37)	49	10 (20)	143	44 (31)
Not last month	15	2 (13)	7	0 (0)	22	2 (9)
p value		0.092		0.269		0.105
<b>2018</b>						
Less than daily	15	5 (33)	16	4 (25)	31	9 (29)
Daily or more	46	11 (24)	24	3 (13)	70	14 (20)
Not last month	5	1 (20)	6	2 (33)	11	3 (27)
p value		0.820		0.554		0.579
<b>2019</b>						
Less than daily	130	25 (19)	44	11 (25)	175	36 (21)
Daily or more	164	36 (22)	85	11 (13)	249	47 (19)
Not last month	14	2 (14)	8	1 (13)	22	3 (14)
p value		0.591		0.155		0.571
<b>2020</b>						
Less than daily	103	24 (23)	56	12 (21)	159	36 (23)
Daily or more	93	30 (32)	65	14 (22)	158	44 (28)
Not last month	18	2 (11)	13	3 (23)	31	5 (16)
p value		0.113		0.998		0.255

**Table 9.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year \***

Western Australia	Male		Female		Total	
Imprisonment last year	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HCV (%)
<b>2016</b>						
No imprisonment	13	3 (23)	6	0 (0)	19	3 (16)
Imprisonment	3	1 (33)	0	0 (0)	3	1 (33)
p value		0.277		--		0.140
<b>2017</b>						
No imprisonment	131	37 (28)	64	12 (19)	195	49 (25)
Imprisonment	27	11 (41)	8	2 (25)	35	13 (37)
p value		0.245		0.447		0.129
<b>2018</b>						
No imprisonment	52	13 (25)	41	8 (20)	93	21 (23)
Imprisonment	11	4 (36)	4	2 (50)	15	6 (40)
p value		0.696		0.181		0.289
<b>2019</b>						
No imprisonment	236	47 (20)	114	19 (17)	351	66 (19)
Imprisonment	55	12 (22)	16	3 (19)	71	14 (20)
p value		0.816		1.000		0.765
<b>2020</b>						
No imprisonment	171	44 (26)	117	25 (21)	288	69 (24)
Imprisonment	37	10 (27)	12	4 (33)	49	13 (27)
p value		0.987		0.397		0.618

**Table 9.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year \***

Western Australia Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
Non Indigenous	14	3 (21)	5	1 (20)	19	4 (21)
Indigenous	2	1 (50)	0	0 (0)	2	1 (50)
p value		0.715		--		0.633
<b>2017</b>						
Non Indigenous	142	38 (27)	58	10 (17)	200	48 (24)
Indigenous	27	11 (41)	18	6 (33)	45	17 (38)
p value		0.104		0.163		0.049
<b>2018</b>						
Non Indigenous	53	11 (21)	30	6 (20)	83	17 (20)
Indigenous	13	6 (46)	16	3 (19)	29	9 (31)
p value		0.097		0.760		0.334
<b>2019</b>						
Non Indigenous	234	46 (20)	86	16 (19)	319	62 (19)
Indigenous	73	16 (22)	51	7 (14)	126	23 (18)
p value		0.610		0.366		0.794
<b>2020</b>						
Non Indigenous	146	34 (23)	73	17 (23)	219	51 (23)
Indigenous	61	19 (31)	55	10 (18)	115	30 (26)
p value		0.187		0.567		0.587

**Table 9.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year \***

Western Australia Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<b>2016</b>						
English speaking	13	4 (31)	6	1 (17)	19	5 (26)
Non-English speaking	2	0 (0)	0	0 (0)	2	0 (0)
p value		0.335		--		0.405
<b>2017</b>						
English speaking	162	49 (30)	73	15 (21)	235	64 (27)
Non-English speaking	8	2 (25)	3	1 (33)	11	3 (27)
p value		0.770		0.474		0.896
<b>2018</b>						
English speaking	64	15 (23)	46	10 (22)	110	26 (24)
Non-English speaking	3	1 (33)	1	0 (0)	4	1 (25)
p value		0.567		0.597		0.798
<b>2019</b>						
English speaking	299	58 (19)	134	22 (16)	434	81 (19)
Non-English speaking	14	4 (29)	3	1 (33)	16	5 (31)
p value		0.280		0.453		0.178
<b>2020</b>						
English speaking	204	55 (27)	132	27 (20)	336	82 (24)
Non-English speaking	10	2 (20)	4	2 (50)	14	4 (29)
p value		0.605		0.195		0.785



**Table 9.4.11 HCV RNA prevalence by region/country of birth, gender and survey year \***

Western Australia		Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	
<b>2016</b>							
Australia	11	3 (27)	5	1 (20)	16	4 (25)	
Other Oceania	1	1 (100)	1	0 (0)	2	1 (50)	
Asia	1	0 (0)	0	0 (0)	1	0 (0)	
UK & Ireland	1	0 (0)	0	0 (0)	2	0 (0)	
Other	0	0 (0)	0	0 (0)	0	0 (0)	
p value		0.640		0.754		0.773	
<b>2017</b>							
Australia	136	38 (28)	67	14 (21)	204	52 (25)	
Other Oceania	2	0 (0)	2	1 (50)	4	1 (25)	
Asia	3	2 (67)	1	0 (0)	4	2 (50)	
UK & Ireland	19	6 (32)	5	1 (20)	24	7 (29)	
Other	9	4 (44)	0	0 (0)	9	4 (44)	
p value		0.431		0.644		0.714	
<b>2018</b>							
Australia	54	12 (22)	41	9 (22)	95	21 (22)	
Other Oceania	1	0 (0)	2	0 (0)	3	0 (0)	
Asia	0	0 (0)	1	0 (0)	1	0 (0)	
UK & Ireland	9	2 (22)	1	1 (100)	10	3 (30)	
Other	3	2 (67)	2	0 (0)	5	2 (40)	
p value		0.227		0.306		0.565	
<b>2019</b>							
Australia	266	53 (20)	119	20 (17)	388	73 (19)	
Other Oceania	8	2 (25)	5	1 (20)	13	3 (23)	
Asia	5	1 (20)	0	0 (0)	5	1 (20)	
UK & Ireland	19	3 (16)	9	2 (22)	27	5 (19)	
Other	15	3 (20)	3	0 (0)	18	3 (17)	
p value		0.995		0.829		1.000	
<b>2020</b>							
Australia	171	42 (25)	127	27 (21)	298	70 (23)	
Other Oceania	10	2 (20)	4	1 (25)	14	3 (21)	
Asia	4	0 (0)	0	0 (0)	4	0 (0)	
UK & Ireland	15	6 (40)	4	1 (25)	19	7 (37)	
Other	12	5 (42)	1	0 (0)	13	5 (38)	
p value		0.344		0.966		0.393	

## Appendix A: Participating NSP services

Year	'16	'17	'18	'19	'20
Number of NSP sites	50	52	53	54	38
<b>Australian Capital Territory</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>1</b>
Directions Health, Canberra	✓	✓	✓	✓	✓
<b>New South Wales</b>	<b>17</b>	<b>18</b>	<b>19</b>	<b>18</b>	<b>12</b>
ACON Hunter	✓	✓	✓	✓	✓
Ballina Harm Reduction Services	✓	✓	✓	✓	
Blacktown HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Byron/Tweed Harm Reduction Services	✓	✓	✓	✓	
Canterbury Harm Minimisation Program	✓	✓	✓	✓	✓
Clinic 180 (formerly K2), Kings Cross	✓	✓	✓	✓	
Coffs Harbour/Grafton Harm Reduction Services	✓	✓	✓	✓	
First Step Program, Port Kembla	✓	✓	✓	✓	
Health ConneXions, Liverpool			✓		✓
Hunter Harm Reduction Services	✓	✓	✓	✓	✓
Kelly Close Needle Syringe Program, Mt Druiitt	✓	✓	✓	✓	✓
Kirketon Road Centre	✓	✓	✓	✓	✓
KRC South, Sutherland		✓	✓	✓	✓
Nimbin/Lismore Harm Reduction Services	✓	✓	✓	✓	
NSW Users and AIDS Association (NUAA)	✓	✓	✓	✓	✓
Parramatta HIV/Hepatitis C Prevention Service	✓	✓	✓	✓	✓
Redfern Harm Minimisation Program	✓	✓	✓	✓	✓
Royal Prince Alfred Hospital, Camperdown	✓	✓	✓	✓	
South Court Primary Care NSP	✓	✓	✓	✓	✓
<b>Northern Territory</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>	<b>3</b>
Northern Territory AIDS & Hepatitis Council, Alice Springs	✓	✓	✓	✓	✓
Northern Territory AIDS & Hepatitis Council, Darwin	✓	✓	✓	✓	✓
Northern Territory AIDS & Hepatitis Council, Palmerston	✓	✓	✓	✓	✓
<b>Queensland</b>	<b>8</b>	<b>9</b>	<b>9</b>	<b>10</b>	<b>7</b>
Biala Community Alcohol and Drug Services, Brisbane	✓	✓	✓	✓	✓
Cairns ATODS NSP	✓	✓	✓	✓	
Kobi House, Toowoomba	✓	✓	✓	✓	✓
Queensland Injectors Health Network, Brisbane	✓	✓	✓	✓	✓
Queensland Injectors Health Network, Gold Coast	✓	✓	✓	✓	✓
Queensland Injectors Health Network, Sunshine Coast	✓	✓	✓	✓	✓
Rockhampton AODS NSP				✓	
Townsville ATODS NSP	✓	✓	✓	✓	✓
West Moreton Sexual Health Service	✓	✓	✓	✓	
Youth Link, Cairns		✓	✓	✓	✓

<b>Year</b>	<b>'16</b>	<b>'17</b>	<b>'18</b>	<b>'19</b>	<b>'20</b>
Number of NSP sites	50	52	53	54	38
<b>South Australia</b>	<b>7</b>	<b>7</b>	<b>7</b>	<b>8</b>	<b>7</b>
Anglicare Salisbury (formerly SAVIVE – Shopfront)	✓	✓	✓		
Community Access & Services SA (CASSA)			✓	✓	✓
Drug Arm Australasia	✓	✓	✓	✓	
Hindmarsh Centre	✓	✓			
Kurlana Tampawardli, Hendon				✓	✓
Noarlunga Primary Health (formerly SAVIVE Noarlunga)	✓	✓	✓	✓	✓
Nunkuwarrin Yunti Community Health Centre	✓	✓	✓	✓	✓
Streetlink Youth Services	✓	✓	✓	✓	✓
Watto Purrinna, Port Adelaide (formerly SAVIVE Port Adelaide)	✓	✓	✓	✓	✓
West Coast Youth, Port Lincoln				✓	✓
<b>Tasmania</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>4</b>
Burnie NSP Service	✓				
Clarence Integrated Care Centre	✓	✓	✓	✓	✓
Glenorchy NSP Service	✓	✓	✓	✓	✓
Hobart NSP Service	✓	✓	✓	✓	✓
Salvation Army Launceston		✓	✓	✓	✓
<b>Victoria</b>	<b>6</b>	<b>6</b>	<b>6</b>	<b>6</b>	<b>0</b>
Barwon Health Drug and Alcohol Services	✓	✓	✓	✓	
Innerspace, Collingwood	✓	✓	✓	✓	
Health Works, Footscray	✓	✓	✓	✓	
SHARPS, Frankston	✓	✓	✓	✓	
North Richmond NSP Services	✓	✓	✓	✓	
Health Information Exchange, St Kilda	✓	✓	✓	✓	
<b>Western Australia</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>4</b>	<b>4</b>
Peer Based Harm Reduction Western Australia (formerly WASUA)	✓	✓	✓	✓	✓
HepatitisWA	✓	✓	✓	✓	✓
Peer Based Harm Reduction Western Australia (formerly WASUA)	✓	✓	✓	✓	✓
WA AIDS Council Mobile Exchange	✓	✓	✓	✓	✓

## Appendix B: Methodological notes

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using the Murex 1.2.0 ELISA (Diasorin). Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France). A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 3 EIA, Biorad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

Between 2016 and 2020, HCV RNA was detected and quantified on the Hologic Panther™ using the Aptima™ HCV Quant Dx assay (Hologic, Inc. San Diego, Calif) which has a limit of quantitation (LOQ) 10 IU/mL and an upper limit of quantitation of  $10^8$  IU/mL in plasma. An offboard DBS elution protocol was applied prior to sampling. To correct for haematocrit, all post run DBS VL results on the Aptima assay were multiplied by a plasma conversion factor of 36.36. This calculation was based on the following assumptions: 45% haematocrit average per DBS, 50uL DBS volume and 1000ul Aptima transport media volume. A qualitative result of <10IU/mL detected (trace/equivocal) was applied to samples <400IU/mL (plasma equivalency).

Data presented in this report were analysed using Stata, Version 14 (Stata Corporation, College Station TX). Temporal changes in HIV/HCV antibody and HCV RNA prevalence were assessed using the  $\chi^2$  test for linear trend. Associations between demographic and behavioural variables and HIV/HCV antibody and HCV RNA prevalence were assessed using the  $\chi^2$  test or Fisher's exact test where frequencies were less than five. It should be noted that a sub-sample of respondents had sufficient DBS sample for HCV RNA testing. While sample yield has increased over time (from 35% tested in 2016 to 89% tested in 2020), HCV RNA tables were weighted to account for sample bias with respect to HCV antibody status and gender. Weights were applied to national data and to each individual jurisdiction, such that jurisdictional HCV RNA results will not necessarily add to data presented at the national level. Results with small sample size, particularly at the jurisdictional level, should be interpreted with caution.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as other. Time since first injection was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection. Tables reporting HIV antibody prevalence stratified by demographic and drug use characteristics are not included in this report for states and territories or survey years where the number of HIV antibody positive participants was less than 5 in all years.

Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". The symbol "--" shown in some tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. The vast majority of survey questions were consistent over all survey years.

NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey period and this data was used to assess response rates. Some clients visited the site more than once during the survey week, and only one attendance per person was included in the response rate denominator. Ethical approvals for the study were obtained from Human Research Ethics Committees associated with the investigators and participating sites. Verbal rather than written informed consent was obtained to assure the anonymity of participants.

## Appendix C: List of tables

### 1. Demographic characteristics and drug use

Table 1.1.1	Number (percentage) of respondents by demographic characteristics and survey year
Table 1.1.2	Number (percentage) of respondents by last drug injected, frequency of injecting and survey year
Table 1.1.3	Number (percentage) of respondents by injecting behaviour in the last month and survey year
Table 1.1.4	Number (percentage) of respondents by treatment for drug use and survey year
Table 1.1.5	Number (percentage) of respondents by testing for HIV and HCV, HCV treatment by survey year
Table 1.1.6	Number (percentage) of respondents by sexual behaviour in the month prior to survey and survey year
Table 1.1.7	Number (percentage) of respondents by COVID-19 related behaviours in 2020

### 2. HIV antibody prevalence

Table 1.2.1	HIV antibody prevalence by gender and survey year
Table 1.2.2	HIV antibody prevalence by sexual identity, gender and survey year
Table 1.2.3	HIV antibody prevalence by age group, gender and survey year
Table 1.2.4	HIV antibody prevalence by last drug injected, gender and survey year
Table 1.2.5	HIV antibody prevalence by years of injection, gender and survey year
Table 1.2.6	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and survey year
Table 1.2.7	HIV antibody prevalence by frequency of drug injection last month, gender and survey year
Table 1.2.8	HIV antibody prevalence by imprisonment last year, gender and survey year
Table 1.2.9	HIV antibody prevalence by condom use at last sex with regular partner, gender and survey year
Table 1.2.10	HIV antibody prevalence by sex work last month, gender and survey year
Table 1.2.11	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.2.12	HIV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.2.13	HIV antibody prevalence by region/country of birth, gender and survey year

### 3. HCV antibody prevalence

Table 1.3.1	HCV antibody prevalence by gender and survey year
Table 1.3.2	HCV antibody prevalence by sexual identity, gender and survey year
Table 1.3.3	HCV antibody prevalence by age group, gender and survey year
Table 1.3.4	HCV antibody prevalence by years since first injection, gender and survey year
Table 1.3.5	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, years since first injection and survey year
Table 1.3.6	HCV antibody prevalence by last drug injected, years since first injection and survey year
Table 1.3.7	HCV antibody prevalence by frequency of drug injection last month, years since first injection and survey year
Table 1.3.8	HCV antibody prevalence by imprisonment last year, years since first injection and survey year
Table 1.3.9	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year
Table 1.3.10	HCV antibody prevalence by main language spoken at home by parents, gender and survey year
Table 1.3.11	HCV antibody prevalence by region/country of birth, gender and survey year

**4. HCV RNA prevalence**

Table 1.4.1 HCV RNA prevalence by gender and survey year

Table 1.4.2 HCV RNA prevalence by sexual identity, gender and survey year

Table 1.4.3 HCV RNA prevalence by age group, gender and survey year

Table 1.4.4 HCV RNA prevalence by years since first injection, gender and survey year

Table 1.4.5 HCV RNA prevalence by re-use of someone else's used needle and syringe last month, gender and survey year

Table 1.4.6 HCV RNA prevalence by last drug injected, gender and survey year

Table 1.4.7 HCV RNA prevalence by frequency of drug injection last month, gender and survey year

Table 1.4.8 HCV RNA prevalence by imprisonment last year, gender and survey year

Table 1.4.9 HCV RNA prevalence by Aboriginal and Torres Strait Islander origin status, gender and survey year

Table 1.4.10 HCV RNA prevalence by main language spoken at home by parents, gender and survey year

Table 1.4.11 HCV RNA prevalence by region/country of birth, gender and survey year

